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ABSTRACT 
Key components of the innate immune response to infections are the Toll-like receptors 
(TLRs), which are able to detect invading pathogens and subsequently generate inflammatory 
responses. Many details of the signalling pathways of TLRs have emerged from gene targeted 
mice or inhibition studies in transformed cell lines. However, the signalling pathways activated 
in primary human cells and disease tissues are less well understood. Previous studies identified 
differences in TLR signalling between human cells of myeloid- and non-myeloid origin. While 
over-expression of a dominant negative construct of the TLR adaptor molecule MyD88 
inhibited TLR4 signalling in HUVECs it had no effect on TLR4 signalling in macrophages. 
Based on this observation, this thesis examined the function of MyD88 in primary human 
monocyte derived dendritic cells (DCs). Unexpectedly, over-expression of MyD88 dn resulted 
in the activation of DCs. Subsequent experiments, provided evidence for a DC specific 
inhibitory mechanism, which depends on endogenous MyD88 and is disrupted by TIR domain 
over-expression. To further investigate the mechanism, the function of SIGIRR in human DCs 
was examined. SIGIRR is a member of the TIR domain containing receptor family that has 
been shown to be expressed in murine and human DCs but not macrophages. However, results 
in this thesis show that SIGIRR is expressed by human DCs as well as macrophages. While 
SIGIRR has been studied in murine models, nothing is known about its function in primary 
human cells. Therefore, an adenoviral construct encoding wild-type SIGIRR was generated and 
over-expressed in DCs and macrophages, which impaired TLR2, TLR3, TLR4, TLR5, TLR7/8 
and IL-1R but not TNFα signalling. In accordance with these results, siRNA knock down of 
SIGIRR in macrophages led to an increase of TLR3, TLR4, TLR7/8 and IL-1R but not TNFα 
induced cytokine production. Therefore, SIGIRR seems to be an inhibitor of TIR domain 
dependent signalling, affecting the MyD88 dependent as well as the TRIF dependent signalling 
pathway. Furthermore, immunoprecipitation studies of SIGIRR with MyD88 suggest, that 
SIGIRR interacts with MyD88 constitutively through TIR domain interaction, indicating that 
SIGIRR inhibits TLR/IL-1R signalling by sequestering MyD88. Given the potency of SIGIRR 
to inhibit TLR/IL-1R signalling in human DCs and macrophages, this thesis further 
investigated its role in rheumatoid arthritis disease models. Over-expression of SIGIRR wt in 
human RA synovial membrane cultures inhibited the spontaneous secretion of cytokines by 
those cells. In contrast, SIGIRR deficient mice were resistant to collagen induced arthritis 
(CIA). SIGIRR null mice immunised with CIA showed a loss in IgG2a anti-collagen antibody 
production as well as reduced Th1 and Th17 immune responses but increased Th2 immunity. 
Subsequent results indicated that SIGIRR is able to regulate CD4+ T cell development through 
the inhibition of ST2/IL-33 signalling. Therefore, while SIGIRR inhibits pro-inflammatory 
cytokine release during the progression stages of RA, it may also regulate the development of 
Th2 development, thereby reducing CIA incidence. These studies highlight the importance of 
investigating signalling pathways in physiologically relevant cells in order to fully understand 
the roles TLRs and specific signalling molecules play in the human immune system and human 
disease process. 
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1.1 Immunity and inflammation 
The immune system evolved as a mechanism to protect organisms from infections with 
pathogenic organisms and other harmful substances. In general the immune system is capable 
of recognising invading pathogens and their products as well as endogenous danger signals 
(Gallucci and Matzinger, 2001; Janeway, 2001). This recognition results in the initiation of an 
immune response, which will, under normal circumstances, eliminate the insult without further 
damage to the host. However, it is now well recognised that defects in regulating inflammation 
can lead to an excessive response to infectious agents e.g. sepsis or autoinflammatory diseases 
including, rheumatoid arthritis (RA). The molecular pathways leading to inflammation as well 
as the mechanisms underlying its regulation are part of this study. 
Primitive versions of an immune system can already be observed in non-vertebrates, such as the 
horseshoe crab Limulus polyphemus, whose blood cells contain a clotting agent that attaches to 
endotoxins produced by gram-negative bacteria. Moreover, the fruit fly Drosophila 
melanogaster was, and still is, extensively used as a model organism to investigate mechanisms 
of the immune system (Agaisse, 2007). In mammals the immune system is more highly 
developed and can be subdivided into an innate and adaptive immune system. 
The innate and the adaptive immune system, although different in their mechanisms of action, 
are interlinked and can influence each other. The innate immune system is an immediate and, 
compared to the adaptive immune response, a rather unspecific response to an infection or cell 
damage. Upon infection or injury, cells of the innate immune system recognise pathogens or 
their products, also termed pathogen associated molecular patterns (PAMPs), using germ line-
encoded receptors e.g. pattern recognition receptors (PRR). These receptors are able to 
recognise a broad range of different pathogens and molecule families, thereby giving rise to the 
“inflammatory response” and the subsequent elimination of the pathogen. Furthermore, the 
activation of the innate immune response induces the adaptive immune system through the 
presentation of characteristic parts of the pathogen, or antigen, to cells of the adaptive immune 
system. In contrast to the innate immune system the adaptive immune response is highly 
specific to a certain pathogen. On the other hand it is delayed in its onset and can take days 
after an initial infection to develop. At the same time the adaptive immune response gives rise 
to an immunological memory, which results in a faster response to future infections with 
similar pathogens. Subsequently, the host is immune to repeated infections with the same 
pathogen. 
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1.1.1 The inflammatory response 
When the physical barrier, e.g. the skin or the mesoderm, is breached by invading microbes, a 
local infection is established leading to tissue damage. A major aspect of the immune response 
to infection or injury is the initiation of the inflammatory reaction (Figure 1.1). This is 
necessary in order to restrict tissue damage, neutralise and destroy foreign material, to alert the 
adaptive immune response and to induce healing of the injured tissue. As a result of 
inflammation, serum proteins e.g. complement proteins and leukocytes, are able to migrate 
from the blood to the infected extra vascular tissue. This is achieved by the sequential release of 
vasoactive and chemotactic mediators, which as a consequence contribute to the cardinal signs 
of inflammation, e.g. heat, redness, swelling and pain. 
 
Figure 1.1: Simplified overview of mediators involved in the inflammatory response to injury and 
infection. See text for details. Abbreviations: DC (dendritic cell), EC (endothelial cell), F (Fibroblast), 
MC (mast cell), MO (monocyte), MØ (macrophage), NK (natural killer cell), PMN (neutrophil), Tc (T 
cell), PRR (pattern recognition receptor). 
 
Tissue resident phagocytes, such as macrophages, are the first cells to encounter an invading 
pathogen. These cells use manifold receptors, termed PRRs, to constantly monitor their 
surrounding environment. Ultimately the pathogen is recognised by those receptors and its 
elimination initialised. Beside the ability of the PRRs to recognise non-self molecules, they can 
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also bind degradation products of the extracellular matrix and endogenous cell contents 
secreted upon cell necrosis. Since the release of this family of molecules is a direct result of 
infection or tissue injury they are termed danger signals or DAMPs (Danger associated 
molecular patterns). The activation of cells through PRRs not only results in the phagocytosis 
of the microbe but also the release of inflammatory mediators, which subsequently activate 
neighbouring cells as well as induce the recruitment of additional effector cells to the site of 
infection. As a consequence of their activation, endothelial cells upregulate their expression of 
adhesion molecules and the release of chemotactic factors. This in turn facilitates the adherence 
of circulating cells to the vascular endothelium and their migration into the affected area. 
The immediate inflammatory response is characterised by the initial recruitment of neutrophils 
followed by monocytes, which subsequently differentiate into macrophages at the site of 
inflammation. The later stages of inflammation involve the adaptive immune system through 
the recruitment of lymphocytes. These are activated in regional lymph nodes either through 
antigen presentation by dendritic cells (DCs) that have migrated from the site of inflammation 
or by antigens drained from the infected area via the lymphatics. The chemotactic gradient, 
established during the initial stages of inflammation, leads to the recruitment of B cells as well 
as T cells. Once at the site of inflammation they contribute to the clearance of the pathogen by 
antibody-mediated phagocytosis, T cell-dependent macrophage activation or lysis by cytotoxic 
T cells. 
The specific characteristics of a pathogen define the mechanisms employed to initiate an 
appropriate response for elimination of the microbe. Extracellular pathogens and their products, 
e.g. most bacteria and toxins, are phagocytosed by macrophages and neutrophils or opsonised 
by antibodies and complement proteins, which coat the pathogenic products making them more 
readily phagocytosed. Intracellular pathogens, on the other hand, e.g. viruses and mycobacteria, 
are cleared by increased intracellular destruction by phagocytes stimulated by T helper cells or 
lysis of the infected cell by cytotoxic effector cells, such as natural killer (NK) cells and 
cytotoxic T cells. 
1.1.2 Cellular components of inflammation 
The effectiveness of an immune response depends on two mechanisms: the recognition of a 
pathogen and/or danger signal, and the elimination of it. Macrophages and DCs are specialised 
in uptake and recognition of a pathogen through PRRs, which results in antigen presentation 
and the expression of inflammatory mediators, which direct and regulate the subsequent 
adaptive immune response. While T cells become activated through antigen presenting DCs in 
the lymph node, nearly all B cell responses depend on the support of effector T cells and occur 
after antigen presentation. In addition, “non-professional” immune cells, e.g. endothelial cells 
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and fibroblasts, can influence the movement and the direction of the migration of immune cells 
and are therefore considered as gate keepers and amplifiers of an inflammatory reaction. 
1.1.2.1 Cells of the innate immune system 
1.1.2.1.1 Macrophage activation and effector function 
Circulating monocytes, which originate in the bone marrow from the common myeloid 
progenitor and are released into the peripheral blood, give rise to tissue resident macrophages. 
Macrophages display a great degree of heterogeneity and display distinct properties depending 
on the tissue they reside in (Gordon and Taylor, 2005). In vitro, macrophages can be 
differentiated from monocytes using macrophage colony stimulating factor (M-CSF) or 
granulocyte macrophage colony stimulating factor (GM-CSF) or interferon (IFN)γ (Barreda et 
al., 2004; Zicari et al., 1992). Macrophages common feature, however, is their capability to 
monitor their environment for pathogens, to phagocytose microbes and to produce large 
amounts of inflammatory mediators to direct the inflammatory response. 
Macrophage activation is achieved by multiple mechanisms, including phagocytosis and the 
recognition of foreign particles but not apoptotic cells. Following the encounter with a pathogen 
PRRs expressed by the macrophage recognise PAMPs. This leads to the production of pro-
inflammatory cytokines, including tumour necrosis factor (TNF)α, which on their own are able 
to activate macrophages to produce inflammatory mediators. An alternative mechanism to 
activate macrophages is through cytokines produced by antigen-primed T cells, which results in 
increased endocytic activity and increased tissue repair (Mosser, 2003). The heterogeneity of 
activated macrophages and their ability to produce pro- as well as anti-inflammatory cytokines 
allows for a diverse and pathogen adjusted immune response. 
1.1.2.1.2 Dendritic cell function and maturation 
Similar to macrophages, DCs are derived from myeloid progenitor cells and migrate from the 
bone marrow to the peripheral tissue where they are present in almost every organ (Figure 1.2). 
Consequently these resident DCs are classified according to the tissue they are found in, e.g. 
Langerhans cells located in the epidermis, interstitial DCs in the dermis, splenic marginal zone 
DCs, T-zone interdigitating DCs, germinal centre DCs, thymic DCs, liver DCs and blood DCs 
(Shortman and Naik, 2007).  
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Figure 1.2: Differentiation of DCs from haematopoietic progenitor cells.  See text for details. 
Abbreviations: TGFβ (transforming growth factor β), GM-CSF (granulocyte macrophage colony 
stimulating factor), FLT-3L (Fms-related tyrosine kinase 3 ligand). 
 
DCs act as the major bridge between the innate and adaptive immune system and are therefore 
essential for the induction of an antigen specific immune response (Steinman, 1991). The 
initiation of a T cell response poses several challenges: the frequency of microbe-specific T 
cells is very low, infected cells express only very few peptide-major histocompatibility 
complex (MHC) complexes recognised by specific T cells and infected cells do not express co-
stimulatory molecules required to induce T cell clonal expansion. These tasks are accomplished 
by DCs, which undergo distinct developmental stages. In their immature state, DCs act as 
sentinels monitoring their environment, which is achieved by a high endocytic/phagocytic 
activity. DCs become activated by numerous agents including PAMPs, danger signals and 
mediators secreted from innate as well as adaptive immune cells (Ueno et al., 2007). Following 
their activation DCs undergo a complex process of maturation from an antigen-capturing cell to 
an antigen presenting cell (APC). These changes include the loss of endocytic/phagocytic 
activity, change of morphology, production of chemokines and cytokines and the up-regulation 
of co-stimulatory molecules and peptide-MHC II complexes on their surface (Adams et al., 
2005; Dieu-Nosjean et al., 1999; Ueno et al., 2007) (Figure 1.3). As a consequence of their 
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maturation DCs down-regulate the chemokine receptor CCR5 and up-regulate CCR7, which 
enables them to migrate to the lymph node. Once there, they provide the three signals necessary 
for T cell clonal expansion: the antigen, co-stimulatory molecules and the cytokine 
environment (Adams et al., 2005; Banchereau et al., 2000) (Figure 1.3). While macrophages 
and B cells have been shown to function as APCs, DCs are considered the most potent APC as 
they are able to stimulate naïve T cells (Adams et al., 2005). 
 
Figure 1.3: Differentiation and maturation of DCs from peripheral blood derived monocytes. See 
text for details. Abbreviations: GM-CSF (granulocyte macrophage colony stimulating factor), PAMP 
(pathogen associated molecular pattern), MHC II (major histocompatibility complex II). 
 
Beside their role in initiating and directing a T cell response DCs also appear to be essential in 
maintaining immunological tolerance in the thymus as well as in the periphery (Steinman et al., 
2003). In the thymus, high affinity auto-reactive T cells are eliminated upon encountering self 
MHC peptide. Evidence suggests that thymic epithelial cells as well as mature DCs in the 
thymus are involved in this process (Hengartner et al., 1988). Because this mechanism of 
central tolerance is imperfect, peripheral immature DCs were shown to continuously present 
self-antigen to auto-reactive T cells in the absence of co-stimulation, thereby inducing anergy 
or deletion of those T cells (Steinman et al., 2000). Beside this direct influence on potentially 
harmful T cells, mature DCs are also able to expand functional regulatory T cells (Treg), which 
might represent a mechanism of controlling the extent of inflammation (Battaglia et al., 2004; 
Sakaguchi, 2005). The break down of one or more of these mechanisms might contribute to the 
break of tolerance and thereby to the pathogenesis of autoimmune diseases. Therefore, 
increasing interest exists to elucidate the role of DCs in autoimmune diseases, such as systemic 
lupus erythmatosis (SLE) (Ueno et al., 2007). Furthermore, the highly potent antigen presenting 
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function of DCs is utilised in therapies for cancer as well as vaccination procedures 
(Banchereau and Palucka, 2005). 
More recently it became apparent that two distinct subsets of DCs exist; the conventional 
myeloid (m)DCs and the plasmacytoid (p)DCs. In vivo both subsets are derived from CD34+ 
haematopoietic progenitor cells but through distinct pathways (McKenna et al., 2005; Shortman 
and Naik, 2007) (Figure 1.2). These subtypes can be differentiated in vitro using GM-CSF and 
interleukin (IL)-4 or TNFα to obtain mDCs and Flt3L to obtain myeloid as well as 
plasmacytoid DCs (Leon et al., 2005; McKenna et al., 2005; Sallusto and Lanzavecchia, 1994). 
Conventional mDCs exist in at least three compartments: peripheral-tissue-resident DCs, 
secondary lymphoid-organ-resident DCs and circulating blood mDCs (Valladeau and Saeland, 
2005). In contrast, plasmacytoid DCs are found in the blood (Ueno et al., 2007). They are 
named after their characteristic plasma cell-like morphology and are able to produce large 
amounts of type I IFN in response to viral and bacterial stimuli. Activated pDCs have the 
ability to influence the activation of numerous cell types, including myeloid DCs, B cells, NK 
cells and T cells (Ueno et al., 2007). However, while pDCs are able to act as APCs in vitro, 
their role in priming T cell responses in vivo is still not fully established. 
1.1.2.1.3 Non-professional immune cells 
Although being “non-professional” immune cells, endothelial cells and fibroblasts play a major 
role during an immune response. Endothelial cells are the barrier between migrating immune 
cells and the infected tissue. Therefore, they are the gate keepers and are responsible for an 
effective movement of immune cells into the tissue (Cook-Mills and Deem, 2005; Pober and 
Sessa, 2007). They achieve this by expressing adhesion molecules, e.g. intercellular adhesion 
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), to which leukocytes 
attach by integrins. This results in a rolling of the leukocytes along the endothelium and 
subsequent arrest on the endothelial wall. The combination of adhesion molecules expressed by 
endothelial cells determines the homing of specific leucocytes to the tissue. Endothelial cells in 
peripheral lymph nodes constitutively express adhesion molecules required for leukocyte 
migration, whereas cells at sites of inflammation require activation to induce or increase 
adhesion molecule expression. This expression is induced by inflammatory mediators or by 
binding of microbial products to the TLRs expressed by endothelial cells (Henneke and 
Golenbock, 2002; Swerlick and Lawley, 1993). In addition, this activation results in the 
expression of chemokines and cytokines, which further contribute to the recruitment of specific 
leukocytes to the site of inflammation. 
Inside the tissue, fibroblasts are the predominant cell type. They are responsible for the 
development and maintenance of the extracellular matrix (ECM). The ECM serves as a scaffold 
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for cells to move through the tissue. During inflammation the ECM is partly degraded in order 
to allow increased movement through the site of infection (Vaday and Lider, 2000). Resident 
fibroblasts also express PRRs, which allows them to sense infections (Colonna, 2004). As a 
result of PRR activation fibroblasts express a broad range of inflammatory mediators including 
chemokines and pro-inflammatory cytokines. This leads to further recruitment and activation of 
leukocytes. Therefore, resident fibroblasts play a role in amplifying and perpetuating the 
immune response. 
1.1.2.2 Cells of the adaptive immune system 
Unlike the immediate innate immune response the adaptive immune response is highly specific. 
Whereas, innate immune cells recognise pathogens through germ-line encoded receptors, the B 
cell- and the T cell receptor (BCR and TCR respectively) are generated through complex 
somatic gene rearrangement processes. This provides the adaptive immune system with a great 
variety of receptors, which are all specific for a single antigen. However, since each receptor is 
only expressed by one cell, clonal expansion is necessary in order to launch an immune 
response. This process results in a delay until the effector response can be mounted. 
The adaptive immune response is further divided into humoral- and cellular responses. The 
humoral response is mediated by B cell recognition of extracellular antigens through the BCR, 
a surface expressed immunoglobulin. Antigen recognition results in the production of 
antibodies, which opsonise the antigen and promote phagocytosis, complement-mediated cell 
lysis and antibody dependent cellular cytotoxicity. The cellular response on the other hand 
involves T cells, which recognise intracellular antigens presented to them as peptides/MHC I 
complexes on APCs via binding to the TCR. This activation of T cells promotes the cytotoxic 
lysis of infected cells. The adaptive immune responses are initiated in organised lymphoid 
tissues close to the site of infections (Janeway, 2001). 
1.1.2.2.1 B lymphocytes 
Immature B cells originate from the haematopoietic stem cell (HSC) in the bone marrow. After 
becoming IgM+, B cells migrate from the bone marrow to the spleen where they complete their 
developmental process. B cells can function as APCs, but unlike other APCs they bind soluble 
antigens directly with their surface BCR. As a result of BCR cross-linking the antigen becomes 
internalised and presented on MHC II (Ollila and Vihinen, 2005). In addition to BCR mediated 
activation of B cells, they can also become activated as a result of PAMP uptake through TLRs 
and subsequent antigen presentation on their MHC II to antigen specific T cells (Ollila and 
Vihinen, 2005; Pasare and Medzhitov, 2004). Moreover, T cells produce cytokines necessary to 
regulate B cell activation. Subsequent to their activation B cells initiate the production of 
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antibodies, which are identical in specificity to the BCR but can differ in the heavy chain. 
Antibodies protect the body through activating the complement cascade, opsonisation for 
phagocytosis and neutralisation of microbial products, e.g. toxins. 
1.1.2.2.2 T lymphocyte development, differentiation and effector functions 
Similar to the B cell, T cells ultimately originate from HSCs. However, unlike the B cells their 
actual differentiation occurs from a small fraction of HSCs, which migrate to the thymus. These 
T cell precursors are negative for the T cell markers CD4 and CD8. As they progress in their 
development TCR rearrangement occurs and they become CD4, CD8 double positive. 
Following positive- as well as negative selection mature T cells migrate as single positive cells 
(either CD4+ or CD8+) from the thymus to the peripheral tissues (Rothenberg et al., 2008). 
CD4 and CD8 are co-receptors for the TCR, which is necessary for antigen recognition. They 
also provide markers for two distinct T cell populations. CD4+ T cells are known as helper T 
(Th) cells, whereas CD8+ T cells are referred to as cytotoxic T lymphocytes (CTL). CTLs 
recognise antigens presented in the context of MHC I molecules expressed on virally infected 
cells. This leads to the cytotoxic lysis of the infected cell. One mechanism of cell lysis is the 
granule-exocytosis pathway, which utilises perforin to channel the pro-apoptotic protein 
granzyme into the target cell and induce programmed cell death. Furthermore, CTLs also 
express Fas ligand that interacts with Fas on the target cell and initiates apoptosis. 
Unlike CTLs, CD4+ Th cells recognise extra-cellular antigens that were 
endocytosed/phagocytosed, processed and presented to them by APCs on MHC II molecules. 
Activation of a naive Th cell in this manner results in the development of specialised subsets of 
Th cells (Figure 1.4). The development of these subtypes depends on the cytokine environment 
provided by the APCs and other inflammatory cells. Furthermore, Th cells are characterised by 
the signalling pathways utilised and by the production of distinct sets of cytokines (Figure 1.4). 
Th1 cell development depends on the presence of IL-12 and they characteristically produce 
IFNγ and IL-2. Th1 cells are involved in promoting cellular immune responses by activating 
macrophages, NK cells and CTL responses. In contrast, Th2 cells require IL-4 for their 
development and typically secrete IL-13, IL-10, IL-5 and IL-4. By doing so, Th2 cells 
contribute to the humoral immune response by promoting B cell activation and antibody 
production (Santana and Rosenstein, 2003). More recently, a third distinct Th subtype has been 
described, which is characterised by its production of IL-17 (Harrington et al., 2005; Langrish 
et al., 2005). Therefore, this subtype was termed Th17 and although the exact conditions for 
Th17 development are not yet defined, IL-6, IL-23 and transforming growth factor (TGF)β 
seem to be essential (Bettelli et al., 2006; Langowski et al., 2006; Mangan et al., 2006). After 
their initial characterisation Th17 cells have been strongly implicated in autoimmune diseases 
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(Langrish et al., 2005; Park et al., 2005). Their natural function, however, seems to be in the 
immune response against extracellular bacteria and fungal infections, where IL-17 was shown 
to be preferentially induced (Mangan et al., 2006). While the initial cytokine environment 
produced by the APCs is detrimental in directing the development of the Th cells, the cytokines 
subsequently produced by differentiated Th cells further determine Th differentiation. In this 
context, it has been shown that the Th1 and Th2 cytokines IFNγ and IL-4 respectively 
negatively regulate Th17 development while IL-4 also inhibits Th1 development and the Th1 
cytokines IL-12 similarly inhibits Th2 differentiation (Bettelli et al., 2006; Mangan et al., 
2006). 
The function of the Th cells described above are regulated by yet another CD4+ T cell, termed 
regulatory T cell (Treg). As a result of the IL-10 and TGFβ production by Tregs an inhibitory 
signal is transmitted, thereby controlling the extent of the inflammatory response (Tang and 
Bluestone, 2008) (Figure 1.4). 
 
Figure 1.4: Differentiation of CD4+ T cells. See text for details. Abbreviations: Th (Helper T cell), 
TGFβ (Transforming growth factor β), IL (Interleukin), STAT (Signal transduction and activator of 
transcription), IFN (Interferon), Foxp-3 (Forkhead box protein-3). 
 
As already mentioned above (see section 1.1.2.1.2), in order to stimulate a T cell response three 
signals are necessary: the antigen, co-stimulation by surface molecules and cytokine 
stimulation. The first two are delivered through the so called immunological synapse where 
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APC and T cell interact. While the antigen is presented on the MHC complex to the TCR, co-
stimulation occurs through interaction with CD80 and CD86 on the APC surface with CD28 
expressed on the T cell. T cells, which bind antigen but do not encounter co-stimulation 
become anergic and cannot further respond to antigen even if co-stimulation is received. Once 
activated, T cells begin to express further surface molecules that either enhance co-stimulation 
or dampen it. CD40 ligand (CD40L) is expressed early by T cells in their activation process and 
sends an additional activation signal to the T cell by binding to CD40 on the APC. Furthermore, 
binding of CD40L to CD40 further promotes activation of APCs themselves (Xu and Song, 
2004). Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) is structurally similar to CD28 
and is able to bind CD80 and CD86 on the APC (Rudd, 2008). Unlike CD28, however, it 
results in the inactivation of the T cell. These combinations of activation and inactivation 
signalling mechanisms are necessary to keep the powerful immune response under control, 
which otherwise would result in tissue destruction. 
1.1.3 Molecular mediators of inflammation 
During the process of inflammation cells communicate with each other using soluble mediators 
(Table 1.1). The immediate responses are mediated by lipid molecules such as arachidonic acid 
metabolites, prostaglandins and leukotrienes, as well as nitric oxide intermediates (Fang, 2004; 
Yoshikai, 2001). These molecules are also partially responsible for the cardinal signs of 
inflammation, e.g. fever, pain, swelling and redness.  
This initial response is followed by the secretion of cytokines at the site of infection as well as 
systemically. Cytokines exert their broad effects through paracrine/autocrine and in some cases 
endocrine mechanisms. This family of signalling molecules encompass a large group of low 
molecular weight peptides, proteins and glycoproteins, which are characterised by their cellular 
source or function (Oppenheim and Feldmann, 2001a). Cytokines are further subdivided into 
interleukins (act as communicators between leukocytes), interferons (with primarily anti-viral 
functions) and chemokines (responsible for establishing a chemotactic gradient). Once secreted, 
cytokines bind to their specific cell surface receptor and induce signalling pathways, which 
ultimately lead to cell-activation, -proliferation and –differentiation (Oppenheim and Feldmann, 
2001b). Due to their specific properties, cytokines are classified as pro- or anti-inflammatory. 
Furthermore, cytokines are involved in negative feedback loops thereby regulating their own 
expression as well as those of other cytokines. As a consequence a coordinated cytokine 
response during an infection results in the appropriate degree of inflammation. However, a 
failure in regulating the cytokine response can lead to delayed wound healing, failure to 
eliminate an infection and in the worst cases, chronic inflammation, organ failure and death 
(Brennan and Feldmann, 1996; Feldmann et al., 1996). 
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Table 1.1: Properties of selected mediators of inflammation 
Mediator Source Effects 
Pro-inflammatory cytokines 
IL-1α MO, MØ, DC Induces production of prostaglandin, MMPs, pro-inflammatory cytokines and acute phase 
proteins, expression of adhesion molecules, lymphocyte activation and regulates hormone 
function. 
TNFα MØ, DC, PMN Same as above, also up-regulates effector functions of MØ and PMN, tumour cytotoxicity 
and induces MHC I expression 
IL-6 MØ, DC, EC, 
fibroblast, T 
cells, B cells 
Induces B cell growth, antibody production, secretion of acute phase proteins, NK 
activation and IFN production 
IL-12/IL-18 MO, MØ, DC Initiates Th1 responses, production of IFNγ by T cells and NK cells 
IFNγ Th1, NK Induces activation of MØ, NK cells, PMN, expression of MHC I and II, CTL 
differentiation, blocks Th2/TH17 activity, inhibits B cell proliferation and IgE production 
IFNα/β Ubiquitous Produced by all virus infected cells, provides early innate immune response against 
viruses, induces expression of MHC I, blocks viral protein synthesis and replication 
through autocrine or paracrine stimulation, enhances activities of CTL, MØ, DC, NK cells 
and B cells 
Anti-inflammatory cytokines 
IL-10 MØ, Th2, B cell Inhibits activation of MØ and DC, inhibits expression of co-stimulatory molecules and 
MHC II, inhibits production of IL-12, TNF, IL-6 and IL-1 
TGFβ Ubiquitous Inhibits proliferation and effector function of T cells, proliferation of B cells, macrophage 
function, promotes tissue repair 
IL-4 Th2, Mast cell Major stimulus for production of IgE and the development of Th2 cells, antagonises the 
effects of IFNγ and inhibits TNFα production 
IL-13 Th2, Mast cell Inhibits production of IgE by B cells, inhibits expression of Th1 polarising cytokines by 
MØ, increases mucus production 
Chemokines 
IL-8 Ubiquitous Induces chemotaxis of neutrophils, basophils, eosinophils, and T cells, proliferation of 
keratinocytes, activation of neutrophils 
IP10 Ubiquitous Induces chemotaxis of MO, NK cells and Th1 cells 
MCP-1 MO, MØ, DC, 
fibroblast 
Induces chemotaxis and activation of MO and basophils 
MIP-1α/β MO, MØ, DC, 
fibroblast 
Induces chemotaxis of MO, T cells and B cells 
RANTES MO, MØ, DC, 
fibroblast 
Induces chemotaxis of MO 
Arachidonic acid metabolites (eicosanoids) 
PGE2, 
PGF2α PGD2 
MØ Induces vasodilatation, edema and pain 
TXA2 MØ Induces vasoconstriction 
LTB4 MØ Induces chemotaxis 
LTC4 MØ Induces vasoconstriction and increased vascular permeability 
Nitrogen and oxygen intermediates 
NO MØ, PMN Induces smooth muscle relaxation, vasodilatation, neurotransmission, tissue homeostasis, 
inhibition of platelet aggregation 
RNI, ROI MØ, PMN Released in response to bacteria, viruses, fungi and parasites, oxidation and nitration of 
proteins, lipids and nucleic acids, regulation of inflammation, viral mutation, cytotoxicity, 
tissue damage, inflammation 
Abbreviations: dendritic cells (DC), endothelial cells (EC), interleukin (IL), leukotriene (LT), macrophage (MØ), macrophage 
inflammatory protein (MIP), monocytes (MO), monocyte chemotactic protein (MCP), matrix metalloproteinases (MMP), nitric 
oxide (NO), prostaglandin (PG), polymorphonuclear cells (PMN), reactive nitrogen intermediates (RNI), reactive oxygen 
intermediates (ROI), T helper lymphocyte (Th), thromboxane (TX). 
Chapter 1 Introduction 
 14
1.2 Pattern recognition receptors and the detection of 
infection 
The innate immune system is responsible for the early detection and destruction of invading 
microbes. In doing so, it relies on a set of limited germ-line encoded PRRs for detection (Table 
1.2). To initiate an immune response PRRs recognise PAMPs, which are present in pathogens 
but not the host. Subsequently, PRRs induce several extracellular activation cascades such as 
the complement pathways and various intracellular signalling pathways, leading to 
inflammatory responses. In numerous cases several PRRs recognize a given pathogen 
simultaneously or sequentially, activating distinct and shared signalling pathways. This enables 
cross-talk between the pathways as well as with other immunomodulatory signalling events 
generated by a particular inflammatory environment. This interplay between signalling 
pathways eventually determines the specific immune response directed at clearing the 
pathogen. PRRs are present in three different compartments: body fluids, cell membranes and 
cytoplasm. The PRRs in the body fluids play a major role in PAMP opsonisation and the 
activation of complement pathways. PRRs in the cell membrane have diverse functions, such as 
the presentation of PAMPs to other PRRs, the promotion of microbial uptake by phagocytosis 
and the initiation of signalling pathways. Cytoplasmic PRRs can be grouped into two classes: 
The IFN inducible PRRs including the CARD (caspase recruitment domain) family, which are 
involved in antiviral defence and the NLRs (NOD-like receptor), which are mainly involved in 
anti-bacterial immune responses (Lee and Kim, 2007). 
Table 1.2: Selected, non-TLR pattern recognition receptors implicated in microbial 
recognition 
Receptor Type Expression Ligands 
C-type lectins 
MR Type I DC, MØ, EC Mediates antigen uptake of mannose-, fucose-, glucose-, GlcNAc-
containing carbohydrates. Recognises L-selecting to mediate leukocyte 
rolling 
DEC205 Type I DC, EC Ligand unknown 
DC-SIGN Type II DC Mediates antigen uptake of mannose-, fucose-containing 
carbohydrates, viral envelope glycoproteins, glycosylated bacterial 
endotoxin, parasite and fungus. Role in DC migration (ICAM-2) and T 
cell interaction (ICAM-3) 
BDCA-2 Type II DC, MØ, PMN Ligand unknown, ligation of receptor leads to internalisation 
Dectin-1 Type II DC, MØ Recognises zymosan, fungal wall derived β- glucan, live yeast 
Langerin Type II LC specific Recognises mannose-containing carbohydrates. Formation of birbeck 
granules 
DC-ASGPR Type II DC Recognises galactose-containing carbohydrates 
SP-A/D Collectin n/a Surfactant protein. Bind terminal non-reducing carbohydrates 
MBL Collectin n/a Obsonising mannose-containing carbohydrates and apoptotic cells. 
Binds to complement receptor CR1 
table continued on next page… 
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CARD helicases 
RIG-I  ubiquitous (IFN 
inducible) 
Recognises dsRNA, RNA from RNA viruses 
MDA5  ubiquitous (IFN 
inducible) 
Recognises poly I:C, RNA from EMCV 
NOD like receptors 
NOD1  DC, MØ, EC Recognises iE-DAP 
NOD2  DC, MØ Recognises MDP 
NALP1  MØ, PBL   
NALP1b  MØ  - 
NALP2  ubiquitous Ligand unknown 
NALP3  MØ, PBL Recognises bacterial mRNA, extracellular ATP, uric-acid crystals, 
R848, Listeria monocytogenes, Staphylococcus aureus 
NALP12  MØ, eosinophil Ligand unknown 
NAIP5  MØ Recognises Legionella flagellin 
IPAF  MØ Recognises Salmonella flagellin 
Scavenger receptors 
SR-AI/II Class A DC, MØ, EC Recognise LTA, lipid A, CpG-DNA, acytylated and oxidised LDL, 
clearance of apoptotic cells 
MARCO Class A MØ Binds bacteria 
CD36 Class B MØ, EC Recognises oxidised LDL, diacylglycerides, involved in clearance of 
apoptotic cells, collagen and parasitized erythrocytes 
LOX-1 Class D MØ, EC, SMC Binds bacteria, involved in clearance of apoptotic cells 
Complement receptors 
CR3 (Mac-1, 
CD18/CD11b) 
cell surface DC, MØ, NK, 
PMN 
Promotes phagocytosis of targets opsonised by iC3b and non-
opsonising phagocytosis of zymosan, LPS, fibrinogen, heparin sulfate 
and apoptotic cells. Binds ICAM-1/2 
CR4 
(CD18/CD11c) 
cell surface MØ Promotes phagocytosis of targets opsonised by iC3b and non 
opsonising phagocytosis of LPS, fibrinogen. Binds ICAM-1 
CR1 cell surface MØ, B cell, 
PMN 
Promotes phagocytosis of targets opsonised by C1q and MBL. Binds 
C3b and C4b 
C1q soluble n/a Soluble complement component. Opsonise immune complexes, DNA 
and apoptotic cells 
Fc receptors 
FcγR I-III γ DC, MØ, B cell, 
NK, PMN 
Mediate uptake of IgG-, CRP- and SAP-opsonised particles 
FcεR I-III ε DC, MØ, B cell, 
NK, PMN 
Mediate uptake of IgE-opsonised particles 
FcαR I α DC, MØ, B cell, 
NK, PMN 
Mediate uptake of IgA-opsonised particles 
Abbreviations: blood DC antigen (BDCA), complement receptor (CR), C-reactive protein (CRP), dendritic cell specific ICAM-3-
grabbing nonintegrin (DC-SIGN), Dendritic cell-associated C-type lectin-1 (Dectin-1), DC-asialoglycoprotein receptor (DC-
ASGPR), N-acetylglucosamine (GlcNAc), Langerhans-cell-specific C-type lectin (Langerin), lectin-like oxidised LDL-receptor 
(LOX-1), macrophage Ag-1 (Mac-1), macrophage receptor with collagenous structure (MARCO), mannose binding lectin (MBL), 
mannose receptor (MR), serum amyloid P (SAP), smooth muscle cells (SMC), surfactant protein (SP), scavenger receptor (SR), 
nucleotide binding and oligomerisation domain (NOD), NACHT (domain present in NAIP, CIITA, HET-E, TP-1), leucine rich 
repeat and PYD containing (NALP), retinoid inducible gene-I (RIG-I), melanoma differentiation associated gene 5 (MDA5), 
caspase recruitment domain (CARD). 
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1.2.1 Phagocytic, endocytic and scavenger receptors 
The main function of phagocytic PRRs is to internalise self-antigens or microbial components 
resulting in clearance of blood lipoproteins, pathogen elimination as well as enhanced 
processing and presentation by APCs. This group comprises several receptor families, 
including C-type lectins (CLRs), scavenger receptors, Fc receptors and opsonic receptors 
(Table 1.2). In contrast to CARD Helicases, NLRs or TLRs, ligand binding to phagocytic PRRs 
generally does not induce the expression of proinflammatory cytokines. 
CLRs are either expressed as membrane bound receptors or soluble proteins, also termed 
collectins, which are secreted. While the membrane bound CLRs capture pathogens leading to 
their intracellular destruction and antigen loading on MHC molecules, soluble collectins 
opsonise microbes (Haagsman et al., 2008). Following microbe binding, collectins associate 
with cell surface receptors, thereby enhancing phagocytosis of the pathogen by APCs 
(Agramonte-Hevia et al., 2002). In general, CLRs recognise a broad range of carbohydrates, 
which are part of the microbial cell wall as well as being present on endogenous glycoproteins 
(Robinson et al., 2006). 
Scavenger receptors are a structurally unrelated group of receptors. Their common feature is to 
bind and internalise lipoproteins, which allows them to recognise microbes as well as to clear 
apoptotic cells (Peiser et al., 2002). 
The Fc- and complement-receptors (CR) bind antibody- and complement-coated pathogens and 
apoptotic cells, which leads to enhanced uptake and destruction (Gordon, 2002; Underhill and 
Ozinsky, 2002). In addition, several members of the CR family were shown to bind directly to 
carbohydrates on pathogen surfaces and host glycoproteins (Agramonte-Hevia et al., 2002; 
Gasque, 2004). The FcR- and CR-families of receptors also show a certain degree of cross-talk 
to facilitate phagocytosis (Agramonte-Hevia et al., 2002). 
1.2.2 CARD helicases 
Numerous viruses, such as Newcastle disease virus (NDV), enter the cytoplasm of cells directly 
and dsRNA, synthesized during viral replication, is present in the cytoplasm. In order to detect 
this kind of virus cytoplasmic PRRs are essential. The CARD-helicase family consists of RIG-I 
(Retinoid inducible gene I) and MDA5 (Melanoma differentiation associated gene 5) 
(Andrejeva et al., 2004; Yoneyama et al., 2004), which detect viral RNA with the DExD/H 
amino acid sequence (where x can be any amino acid) in their RNA helicase domain. Unlike 
the PRRs described in section 1.2.1 CARD-helicases actively induce a signalling pathway. This 
is achieved through the recruitment of IPS-1 (IFNβ promoter stimulator-1) through CARD 
domains. The localisation of IPS-1 at the mitochondria is essential for downstream signalling 
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and ultimately leads to the induction of pro-inflammatory mediators and type I interferons by 
activation of NF-κB and IRF-3 respectively (Kawai et al., 2005; Meylan et al., 2005; Seth et al., 
2005; Xu et al., 2005). 
LGP2 is a homolog of RIG-I and MDA5. It is, however, lacking the signal transducing CARD 
domains and is suggested to function as inhibitor of CARD-helicases (Rothenfusser et al., 
2005; Yoneyama et al., 2005). 
1.2.3 NOD-like receptor family 
NLRs are a family of cytoplasmic PRRs, which recognise bacterial PAMPs and danger signals 
and subsequently initiate signalling pathways to induce an immune response (Fritz et al., 2006; 
Lee and Kim, 2007; Ting et al., 2006). NLRs consist of a C-terminal leucine rich repeat (LRR) 
domain, which mediates ligand binding, a centrally located NACHT (domain present in NAIP, 
CIITA, HET-E, TP-1) domain, which mediates oligomerisation and activation of the NLRs, and 
an N-terminal effector domain, which initiates downstream signalling. On the basis of the 
effector domains and the phylogenetic history of the NACHT domain, NLRs have been 
grouped into the subfamilies NODs (nucleotide binding and oligomerisation domain), NALPs 
(NACHT, leucine rich repeat and PYD (pyrin domain) containing), CIITA (Class II 
transactivator), IPAF (Ice protease-activating factor) and NAIPs (NLR family, apoptosis 
inhibitory protein). NODs and IPAF contain CARD effector domains, whereas NALPs and 
NAIPs contain PYD and three BIR (Baculoviral IAP Repeats) domains, respectively (Lee and 
Kim, 2007). 
NOD1 and NOD2 were the first mammalian NLRs to be described to sense cytoplasmic 
PAMPs. NOD1 specifically recognises the peptide γ-D-glutamyl-meso-diaminopimelic acid 
and acts as a sensor for gram-negative bacteria, whereas NOD2 binds muramyl dipeptide 
(MDP), a degradation product of peptidoglycan (PGN), and acts as a general sensor for most 
bacteria (Inohara et al., 2005; Strober et al., 2006). The activation of NODs leads to the 
recruitment of the CARD-containing kinase RIP2 (receptor interacting protein 2) to the receptor 
through CARD-CARD interactions, which ultimately leads to the activation of NF-κB and 
MAPKs (Girardin et al., 2001; Inohara et al., 2005; Kobayashi et al., 2005; Strober et al., 
2006). The physiological importance of NODs is demonstrated by the increased susceptibility 
of NOD1 or NOD2 deficient mice to gastrointestinal bacterial infections (Strober et al., 2006). 
In humans NOD2 mutations are linked to Crohn´s disease, however, the pathogenic mechanism 
underlying this association is still unclear (Eckmann and Karin, 2005; Fritz et al., 2006; Strober 
et al., 2006). 
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The NALP family consists of 14 members, which are characterised by their PYD effector 
domain (Tschopp et al., 2003). Although the ligands and function of most of the NALPs is still 
unknown, their critical role in forming an inflammasome upon activation and subsequently 
inducing the production of mature IL-1β and IL-18 has been shown in the case of NALP1 and 
NALP3. Activated NALPs recruit ASC (Apoptosis-associated speck-like protein) via their 
PYD domain, which leads to the recruitment of Caspase-1 and Caspase-5 through CARD-
CARD interactions. The close proximity of the caspases in the inflammasome promotes cross-
activation, thus leading to the maturation of IL-1β and IL-18 (Martinon and Tschopp, 2004). 
The physiological stimulus for NALP1 is unknown. However, cell rupture has been shown to 
be sufficient for inflammasome assembly (Martinon et al., 2002). Numerous stimuli for NALP3 
have recently been described, which include exogenous PAMPs, such as bacterial RNA, DNA 
and the bacteria Staphylococcus aureus and Listeria monocytogenes as well as endogenous 
danger signals including uric acid crystals and extracellular ATP (Kanneganti et al., 2006; 
Mariathasan et al., 2006; Martinon et al., 2006; Muruve et al., 2008). Given this great variety of 
ligands, the hypothesis was formed that NALP3, instead of binding these ligands directly, 
recognises common intracellular changes generated from the multiple inflammasome-activating 
pathways such as lower intracellular K+ concentrations (Mariathasan et al., 2006). It has also 
been shown that TLR stimuli as well as inflammasome activating stimuli interplay for efficient 
IL-1β induction. The importance of NALP3 is demonstrated by the association of NALP3 
mutations with cold-induced autoinflammatory syndrome (Fritz et al., 2006; Ting et al., 2006). 
IPAF has a similar structure to NOD1 and has been shown to be critical for inducing IL-1β 
secretion in response to Salmonella infection (Mariathasan et al., 2004). Flagellin from 
Salmonella, introduced into the cytosol, has been demonstrated to be the key PAMP of IPAF 
(Franchi et al., 2006; Miao et al., 2006). Although, IPAF activation by Salmonella flagellin is 
independent of TLR5 (which is the extracellular PRR for flagellin, see below), it is still unclear 
if IPAF binds flagellin directly. Similar to IPAF, NAIP5 also recognises flagellin, but only if 
derived from Legionella and introduced into the cytosol (Molofsky et al., 2006; Ren et al., 
2006). Therefore, IPAF and NAIP5 seem to control intracellular bacterial growth directly 
through Caspase-1 activation and IL-1β production, whereas TLR5 recognises extracellular 
flagellin to induce an inflammatory response. 
1.2.4 Toll-like receptor family 
TLRs are the most intensively studied PRRs and similar to CARD-Helicases and NLRs, their 
major function is to induce signalling pathways, which lead to an inflammatory response (Akira 
and Takeda, 2004; Lee and Kim, 2007). Unlike NLRs or CARD-Helicases, however, TLRs 
Chapter 1 Introduction 
 19
recognise extracellular PAMPs either directly on the cell surface or in the early endosome 
following endocytoisis/phagocytosis. 
The Toll receptor was discovered in Drosophila melanogaster, where it has originally been 
described to be involved in dorsal/ventral development of the fly (Anderson et al., 1985). Only 
later it was discovered that Toll deficient flies were highly susceptible to fungal infections, 
which suggested an involvement of Toll signalling in the immune response of the fly (Lemaitre 
et al., 1996). Subsequently the discovery and functional analysis of its human homologue, 
TLR4, as well as its ligand, lipopolysaccharide (LPS), demonstrated that it was capable of 
inducing the expression of inflammatory cytokines and co-stimulatory molecules in human cell 
lines (Medzhitov et al., 1997; Poltorak et al., 1998). This observation for the first time provided 
an explanation of how the innate immune system is able to recognise a broad range of microbes 
and induce an immediate inflammatory response. To date, 13 mammalian TLRs have been 
described based on their sequence homology to the Drosophila Toll, and have been shown to 
recognise a wide variety of conserved molecular features of bacteria, fungi and viruses. 10 of 
these TLRs were shown to be expressed in humans. 
1.2.4.1 TLR structure and expression profile 
All TLRs are type I integral membrane glycoproteins that belong to the TLR/IL-1R super 
family, which also includes the receptors for the pro-inflammatory cytokines IL-1 and IL-18 
(Figure 1.5). This super family is characterised by its cytoplasmic TLR/IL-1R homology (TIR) 
domain, which is essential for signal transduction. Despite the similarities in the cytoplasmic 
region, the extracellular portions of the TIR domain receptor family are unrelated to each other. 
While the IL-1R family recognises its ligands using multiple Ig(immunoglobulin)-like domains, 
TLRs contain LRR domains, similar to Drosophila Toll and NODs, to bind their ligands. 
TLRs can be further subdivided by their distribution within the cell. TLR3, TLR7, TLR8 and 
TLR9, which all recognise nucleotide structures, belong to a functional subfamily, which is 
mainly expressed in intracellular compartments and detect PAMPs following 
endosomal/lysosomal acidification (Heil et al., 2003; Latz et al., 2004; Matsumoto et al., 2003). 
TLR1, TLR2, TLR4, TLR5 and TLR6, on the other hand, are located mainly on the cell surface 
and primarily recognise structurally conserved peptides and proteins derived from bacteria and 
fungi. Most TLRs bind their ligands as homodimers, whereas TLR2 heterodimerises with either 
TLR1 or TLR6 or other PRRs, such as Dectin-1, for specific ligand recognition (Lee and Kim, 
2007). 
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Figure 1.5: TLR/IL-1R super family. The members of the TLR/IL-1R family are defined by the 
presence of the cytoplasmic TIR domain and can be divided into two subgroups based on their 
extracellular domains. The TLRs contain leucine-rich repeats (LRRs), whereas the IL-1R family has Ig-
like domains. This group include the IL-1R and the IL-18R and their accessory proteins (IL-1RacP and 
IL-18RacP), as well as ST2 and the orphan receptor SIGIRR. In addition, the super family also includes 
the TIR domain containing TLR/IL-1R adaptors MyD88, Mal, TRIF, TRAM and SARM. 
1.2.4.2 TLR recognition of pathogenic compounds 
1.2.4.2.1 TLR4 
Since TLR4 was described to be the receptor for LPS and the first mammalian TLR to be 
identified in 1997 (Medzhitov et al., 1997) it is also the most extensively studied. Further 
investigations, using two strains of LPS-hyporesponsive mice, which exhibit mutations in the 
TLR4 gene, revealed that TLR4 is a signal transducer for the gram-negative bacterial cell wall 
component LPS. C3H/Hej mice contain a point mutation (P712H) in its TIR domain, whereas 
C57BL/10ScCr mice appear to be null for the TLR4 locus (Poltorak et al., 1998). The role of 
TLR4 as a signal transducer for LPS has been confirmed using TLR4 deficient mice as well as 
in vitro studies in the human embryonic kidney (HEK) cell line HEK293 transfected with 
human TLR4 (Chow et al., 1999; Hoshino et al., 1999). In humans, the TLR4 polymorphism 
Asp299Gly, which alters the LRR domain, results in impaired efficacy of LPS signalling and 
impaired capacity to elicit inflammation (Arbour et al., 2000). 
Although, TLR4 has been established as the essential receptor recognising LPS, several 
additional co-receptors have been shown to be involved in LPS binding. LPS is opsonised by 
the serum protein LPS-binding protein (LBP), which enhances LPS binding to CD14 on the cell 
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surface (Wright et al., 1990). CD14, on the other hand, is a glycosylphosphatidylinositol (GPI)-
anchored cell surface protein that lacks transmembrane- as well as cytoplasmic domains and is 
therefore incapable of signal transduction (Lee et al., 1993). The involvement of CD14 in TLR4 
signalling depends on the LPS chemotype as has been shown in mice containing dysfunctional 
CD14, called the Heedless mutation (Jiang et al., 2005b). LPS consists of a lipid A moiety, a 
core polysaccharide and an O-polysaccharide of variable length. Microbial variants with long 
O-polysaccharide chains form smooth colonies, whereas those that lack an O-polysaccharide 
chain form rough colonies, this led to the designations smooth and rough LPS. While CD14 
defective macrophages still show NF-κB activation in response to rough LPS via the MyD88 
dependent signalling pathway, smooth LPS induced NF-κB activation is impaired (Jiang et al., 
2005b). Moreover, the MyD88 independent signalling pathway was impaired in response to 
both types of LPS. CD14 is also present in the serum as a soluble receptor lacking the GPI-tail 
(Frey et al., 1992). This enables CD14 negative cells, such as endothelial cells, to respond to 
LPS in the absence of membrane bound CD14 (Pugin et al., 1993). In addition to LBP and 
CD14, the secreted molecule MD-2 associates with the LRR domain of TLR4 and thereby 
enhances LPS responsiveness (Akashi et al., 2000; Shimazu et al., 1999; Viriyakosol et al., 
2001). 
Beside the specificity of CD14 in regard to smooth and rough LPS, species specific differences 
have also been demonstrated, depending on the acetylation state of LPS. Pseudomonas 
aeruginosa hexa-acetylates its LPS during adaptation to the cystic fibrosis airway. Whereas the 
LRR domain of human TLR4 is able to recognise hexa-acetylated LPS from Pseudomonas 
aeruginosa, murine TLR4 does not (Hajjar et al., 2002). Moreover, an analogue of lipid A was 
shown to act agonistically on murine TLR4 but not on the human receptor (Akashi et al., 2001). 
This discrimination is attributed to species specific differences in the structure of MD-2. In 
addition, the anti-tumour agent Taxol has been shown to be recognised by TLR4 in murine but 
not human cells (Byrd-Leifer et al., 2001; Kawasaki et al., 2000) (Figure 1.6). 
1.2.4.2.2 TLR1, TLR2 and TLR6 
TLR2 is a unique TLR since it is able to recognise a great variety of bacterial, fungal and even 
virally derived ligands (Figure 1.6). This is achieved by its heterodimerisation with TLR1 or 
TLR6, which are closely related to TLR2, as well as other PRRs such as Dectin-1 (Lee and 
Kim, 2007; Takeuchi et al., 1999). The usage of additional TLRs to recognise ligands enables 
the discrimination of subtle differences in the acylation of lipopeptides derived from microbial 
pathogens. In association with TLR1, TLR2 binds to triacyl lipopeptides (Takeuchi et al., 
2002), whereas TLR2 responds to diacyl lipopeptides in combination with TLR6 (Takeuchi et 
al., 2001). 
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The triacylated lipopeptides recognised by TLR2/1 include the 19 kDa mycobacterial 
lipoprotein (Takeuchi et al., 2002), Borrelia burgdorferi outer membrane lipoprotein A 
(Alexopoulou et al., 2002), the mycobacterial aralipoarabinomannan (Sandor et al., 2003) and 
the synthetic lipoprotein structure Pam3Cys (Pam3Cys-Ser-(Lys)4-trihydrochloride) (Takeuchi 
et al., 2001). TLR2/6 heterodimers, on the other hand, recognise the synthetic diacylated 
lipopeptide macrophage activating lipopeptide-2 (MALP-2) (Takeuchi et al., 2001), phenol-
soluble modulin (PSM) from Staphylococcus epidermidis (Hajjar et al., 2001) and group B 
streptococcal soluble factor (Henneke et al., 2001). A number of ligands appear to be 
recognised by TLR2 homodimers such as Porphyromonas gingivelis LPS (Hirschfeld et al., 
2001) and chlamydial HSP (heat shock protein) 60 (Vabulas et al., 2001). Other ligands seem to 
require the association with the co-receptor CD14 as has been shown in the case of gram-
positive lipoteichoic acid (LTA) (Cleveland et al., 1996; Schwandner et al., 1999) and 
mycobacterial lipoarabinomannan (Means et al., 1999). Furthermore, CD36 has been shown to 
further enable discrimination of TLR2/6 ligands as it contributes to the responses to MALP-2 
but not zymosan (Hoebe et al., 2005) (Figure 1.6). 
The recognition of the fungal cell wall component zymosan occurs in concert with Dectin-1 
(Brown, 2006; Gantner et al., 2003). Moreover, the cooperation of TLR2 with Dectin-1, results 
in a distinct cytokine profile compared to TLR2/6 signalling on its own (Brown, 2006). In 
contrast, TLR2 association with TLR1 or TLR6 increases the spectrum of ligands being 
recognised but it does not seem to lead to differential signalling events. 
In addition to bacterial structures, TLR2 has also been reported to interact with different 
viruses, including hemagglutinin (HA) protein from measles virus and envelope glycoproteins 
of the human cytomegalovirus (CMV) (Bieback et al., 2002). TLR2 has also been described to 
be involved in signalling responses to herpes simplex virus-1 (HSV-1) (Ahmad et al., 2008; 
Kurt-Jones et al., 2004) and lymphocytic choriomeningitis virus (LCMV) (Zhou et al., 2008). 
1.2.4.2.3 TLR3 
Double-stranded (ds) RNA is a product of the replication cycle of numerous viruses inside the 
cell. It was the first viral product to be implicated in antiviral immunity by its ability to induce 
virus-like symptoms (Field et al., 1971). In 2001, dsRNA was described to be the ligand for 
TLR3, which forms homodimers in order to bind its ligand (Alexopoulou et al., 2001; 
Matsumoto et al., 2002). Purified genomic reovirus dsRNA and its synthetic analogue 
polyinosinic-polycytidylic acid (poly I:C) stimulate cells such as myeloid DCs to express type I 
IFNs and inflammatory cytokines. This expression is reduced but not abolished in cells from 
TLR3 deficient mice due to the presence of other dsRNA binding PRRs such as the CARD-
Helicases described above (Section 1.2.2) (Alexopoulou et al., 2001). 
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Although the physiological importance of TLR3 in anti-viral responses has been demonstrated, 
its specific role is still unclear. The effector responses elicited by poly I:C treatment inhibits 
murine γ herpesvirus 68 replication in murine macrophages (Doyle et al., 2002). Similarly, it 
has been shown, that the administration of the synthetic dsRNA poly (I:C12U) protects mice 
against punta toro virus (PTV) infection in a TLR3 dependent manner (Gowen et al., 2007). In 
support of this, the viral load in TLR3 deficient mice inoculated with murine cytomegalovirus 
(MCMV) have been shown to be substantially augmented (Tabeta et al., 2004). However, 
conflicting data shows that the adaptive antiviral immune response to both RNA and DNA 
viruses is equivalent in TLR3-/- and wild type mice (Edelmann et al., 2004). A report by Schulz 
et al. describes a more specific in vivo function of TLR3, which is to promote cross-priming for 
the initiation of a CD8+ T cell response against viruses that do not directly infect DCs (Schulz 
et al., 2005). Moreover, TLR3 has been shown to be expressed by human CD8+ T cells and 
stimulation of these cells using poly I:C led to an increase in IFNγ production (Hervas-Stubbs 
et al., 2007; Tabiasco et al., 2006). In addition, murine TLR3 recognises dsRNA from eggs of 
the parasite Schistosoma mansoni, indicating that TLR3 might also be involved in non-viral- as 
well as viral immune responses (Aksoy et al., 2005) (Figure 1.6). 
1.2.4.2.4 TLR5 
The ligand for TLR5 has been determined to be monomeric flagellin, a structural component of 
flagella, which enables bacteria to be mobile (Hayashi et al., 2001; Smith et al., 2003). TLR5 is 
suggested to be important for microbial recognition at the mucosal surface, since flagellin 
activates intestinal epithelial cells (Gewirtz et al., 2001), human intestinal microvascular 
endothelial cells (Maaser et al., 2004), and lung epithelial cells (Smith et al., 2003). 
Furthermore, stimulation with flagellin has also been reported to lead to maturation of human 
DCs (Means et al., 2003) (Figure 1.6). 
These in vitro results have been confirmed in individuals with a TLR5 polymorphism 
(TLR5392STOP) resulting in a stop codon in the extracellular ligand-binding domain of TLR5 
(Hawn et al., 2003). This mutation leads to an impaired ability to respond to flagellin and an 
increased risk of developing pneumonia due to the flagellated bacteria Legionella pneumophila 
(Hawn et al., 2003). In mice, the role of TLR5 is still unclear. While TLR5 deficiency leads to 
increased susceptibility to Escherichia coli urinary tract infections, it also results in the 
development of spontaneous colitis, suggesting a role for TLR5 in recognising infections as 
well as protective functions in the gut (Andersen-Nissen et al., 2007; Carvalho et al., 2008; 
Vijay-Kumar et al., 2007). 
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1.2.4.2.5 TLR7 and TLR8 
The common ligand for TLR7 and the structurally related TLR8 is single stranded (ss)RNA 
derived from ssRNA viruses such as vesicular stomatitis virus (VSV) (Diebold et al., 2004; 
Heil et al., 2004; Lund et al., 2004). However, there appear to be species specific differences in 
its recognition. Murine, but not human, TLR7 binds ssRNA from VSV and influenza virus 
(Diebold et al., 2004; Lund et al., 2004), as well as guanosine- and uridine (GU)-rich ssRNA 
from human immunodeficiency virus-1 (HIV-1) U5 region (Heil et al., 2004). In contrast, the 
response to GU-rich ssRNA is mediated by TLR8 in humans, whereas this could not be 
observed with murine TLR8 (Heil et al., 2004). TLR7 and TLR8 have also been shown to 
recognise the synthetic anti-viral compounds imidazoquiolines, which are structurally related to 
nucleic acids. Again, these results vary between the human and murine forms of the receptors. 
Both human and murine TLR7 recognise the imidazoquiolines resiquimod (R848), whereas 
R848 only signals from human but not murine TLR8 (Hemmi et al., 2002; Jurk et al., 2002) 
(Figure 1.6). 
TLR7, but not TLR8, is highly expressed by human blood plasmacytoid DCs, which is one 
reason for the secretion of large amounts of type I IFNs following TLR7 stimulation, 
characteristic to those cells (Kawai and Akira, 2006; Liu, 2005). 
1.2.4.2.6 TLR9 
Bacterial DNA exhibits immunostimulatory activity through the presence of the abundantly 
expressed unmethylated deoxycytidylate-phosphate-deoxyguanylate (CpG) motifs, which 
rarely occur in mammalian DNA (Bauer et al., 2001a). The activity of these motifs can be 
mimicked by synthetic DNA oligonucleotides (CpG-DNA or CpG-ODN). Stimulation of TLR9 
deficient mice with CpG-DNA indicated TLR9 as its receptor (Hemmi et al., 2000). This is 
supported by data in primary human cells, where expression of TLR9 correlates with CpG-
DNA responsiveness (Bauer et al., 2001b). The function of TLR9 also seems to be species 
specific, since human and murine TLR9 require distinct CpG motifs for signal initiation (Bauer 
et al., 2001b). However, a recent report challenges the view, that CpG motifs are the defining 
features recognised by TLR9 (Haas et al., 2008; Yasuda et al., 2006). Haas et. al have shown 
that the DNA sugar backbone can activate TLR9 in a sequence independent manner (Haas et 
al., 2008) (Figure 1.6). 
In addition to bacterial DNA, TLR9 has also been shown to recognise viral-derived CpG-DNA 
from genomic HSV-1 and -2 as well as CMV (Krug et al., 2004; Lund et al., 2003; Tabeta et 
al., 2004). Plasmacytoid DCs from TLR9 mutant mice are unable to produce type I IFNs in 
response to treatment with viral DNA, implying a role for TLR9 in anti-viral responses. 
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However, studies also implicated TLR9 independent responses to DNA from HSV-1, providing 
evidence for other PRRs involved in this process (Krug et al., 2004). A recent report identified 
DAI (DNA-dependent activator of IFN-regulatory factors) as a cytosolic PRR recognising 
DNA and subsequently inducing the production of type I IFNs (Takaoka et al., 2007). 
Therefore, DAI represents a new family of cytosolic PRRs, which, similar to RNA recognition 
by CARD-Helicases, provides a mechanism to recognise DNA in the cytosol and inhibit 
bacterial/viral replication. 
Similar to TLR7, TLR9 is highly expressed on pDCs but not on conventional mDCs, therefore 
providing an explanation for the specific role of pDCs in producing large amounts of type I 
IFNs (Kawai and Akira, 2006; Liu, 2005). 
1.2.4.2.7 TLR10-TLR13 
The most recently identified Toll homologues are TLR10 and TLR11, however, their role in 
anti-microbial responses is not yet defined (Chuang and Ulevitch, 2001; Zhang et al., 2004). In 
humans, TLR10 is expressed on B cells and pDCs and although a ligand is still elusive, a 
constitutively active version of TLR10 lead to the expression of inflammatory genes, which 
was dependent on MyD88 (Bourke et al., 2003; Hasan et al., 2005; Hasan et al., 2004; Hornung 
et al., 2002). Although the TLR10 gene is present in mice it is non-functional, due to a partial 
genomic sequence disruption by a retroviral insertion (Hasan et al., 2005). TLR10 is closely 
related to TLR1 and TLR6, the co-receptors of TLR2, and it has been demonstrated, that 
TLR10 dimerises with TLR1 as well as TLR2 (Hasan et al., 2005). Therefore, the hypothesis 
has been formed that TLR10 might cooperate with these receptors for ligand recognition. 
Unlike TLR10, TLR11 has been found to be expressed in murine epithelial cells, whereas no 
TLR11 expression could be observed in humans, due to the presence of a stop codon in the 
genomic sequence (Zhang et al., 2004). Profilin-like molecule from the protozoan parasite 
Toxoplasma gondii has been described as the ligand for murine TLR11 and it has been 
demonstrated that TLR11 is critical for optimal resistance to an infection with this parasite 
(Yarovinsky et al., 2005). Moreover, TLR11 transfected cells specifically respond to 
uropathogenic bacterial lysates and TLR11 deficient mice fail to recognise and respond to 
uropathogenic Escherichia coli (Zhang et al., 2004). 
The sequences of two novel murine TLRs have been identified, based on homology searches to 
the TIR homology domain. These are termed TLR12 and TLR13 but they lack human orthologs 
and their function and ligands are still elusive (Tabeta et al., 2004). 
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Figure 1.6: Selected exogenous and endogenous TLR ligands. See text for details. Abbreviations: HSP 
(heat-shock protein), Malp-2 (macrophage activating lipopeptide-2), CMV (cytomegalovirus), HSV 
(herpes simplex virus), HMGB-1( high mobility group box-1), LCMV (Lymphocytic choriomeningitis 
virus), LTA (lipoteichoic acid), LPS (lipopolysaccharide), TLR (toll-like receptor). 
 
1.2.5 Cross-talk between TLRs with other pattern recognition 
receptors 
TLR induced gene expression together with antigen uptake by phagocytic PRRs is an essential 
part of how innate immunity fights infections. Numerous studies have tried to examine whether 
these mechanisms influence each other. The phagocytic receptors Dectin-1 (Dendritic cell-
associated C-type lectin-1), DC-SIGN (Dendritic cell specific ICAM-3-grabbing nonintegrin) 
and the mannose receptor have all been described to influence TLR signalling (Underhill and 
Gantner, 2004). LPS induced maturation of DCs is blocked by simultaneous stimulation of DC-
SIGN with lipoarabinomannan from Mycobacterium tuberculosis (Geijtenbeek et al., 2003). 
Similarly, cross-linking of the mannose receptor as well as stimulation of it, using Mannose-
capped lipoarabinomannan (ManLAM) from Mycobacterium tuberculosis, has been shown to 
inhibit LPS-induced IL-12 production (Chieppa et al., 2003; Nigou et al., 2001). In contrast, 
Dectin-1 has been reported to collaborate with TLR2 following Zymosan stimulation to 
produce pro-inflammatory cytokines in macrophage cell lines and BMDCs (Brown et al., 2003; 
Gantner et al., 2003; Gross et al., 2006) (Figure 1.7). 
The innate immune system utilises numerous signal inducing PRRs providing the immune 
system with TLR independent mechanisms to induce inflammatory mediators (Figure 1.7). 
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However, TLRs have been shown to interact with them and influence their signalling. This is 
important, since it leads to potential amplification of the inflammatory response. 
NOD1 or NOD2 induced pro-inflammatory cytokine production, was shown to be markedly 
enhanced by stimulation with TLR ligands and mice treated with the NOD2 ligand MDP are 
more susceptible to LPS induced septic shock (Kobayashi et al., 2005; Netea et al., 2005; van 
Heel et al., 2005; Wolfert et al., 2002). This indicates the existence of a synergistic mechanism 
between NOD2 and TLRs. The molecular basis for this mechanism is still unclear. However, it 
has been described, that TLR4 stimulation upregulates NOD2 expression and similarly that 
NOD2 stimulation induces MyD88 expression (Inohara et al., 2005). Furthermore, MDP 
stimulated macrophages induce the transcription of TNFα mRNA, which is not translated into 
protein. Subsequent LPS stimulation, leads to TNFα protein synthesis and its secretion (Wolfert 
et al., 2002). 
Although the CARD-helicase family has only recently been characterised, reports of cross-talk 
between them and TLRs have already been published. The stimulation of TLR3, TLR4, TLR7, 
TLR8 and TLR9 induces the expression of type I IFNs, which consequently results in the 
expression of RIG-I and MDA5, as these are IFN inducible genes, leading to a potentially 
amplified anti-viral response (Kang et al., 2002). In contrast, the LPS induced negative 
regulator A20 has been shown to reduce RIG-I mediated IRF and NF-κB activation (Lin et al., 
2006). 
These results demonstrate that TLR signalling communicates with other PRRs in an amplifying 
as well as inhibitory manner. These mechanisms are part of the regulatory mechanisms, which 
are essential to conduct a successful immune response. 
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Figure 1.7: Recognition of PGN, dsRNA and DNA by TLR-dependent and independent pathways. 
See text for details. Abbreviations: PGN (peptidoglycan), MDP (muramyl dipeptide), ie-DAP 
(diaminopimelic acid containing dipeptide), NOD (nucleotide-binding oligomerisation domain), RIG-I 
(retinoid inducible gene-I), MDA5 (melanoma differentiation associated gene 5), DAI (DNA dependent 
activator of IFN regulatory factors). 
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1.3 Activation of TLRs by danger signals and their role in 
chronic inflammation 
The main role of TLRs is considered to be the recognition and response to microbial pathogens 
but they have also been reported to recognise endogenous ligands. Moreover, the evolutionary 
conserved Toll pathway in Drosophila melanogaster is induced by binding of the endogenous 
ligand Spätzle to Toll (Lemaitre et al., 1996), suggesting that Toll receptors are able to bind 
endogenous ligands. This is an area of TLR research that has recently gained momentum with 
increasing numbers of publications about endogenous TLR ligands (reviewed in (Brentano et 
al., 2005a; Drexler et al., 2006; Marshak-Rothstein, 2006; Marshak-Rothstein and Rifkin, 2007; 
Rifkin et al., 2005; Roelofs et al., 2008; Tsan and Gao, 2004). 
Endogenous ligands are thought to be released during necrotic cell death induced by tissue 
damage, stress factors or infection, which result in the release of cell components that initiate 
an inflammatory response (Searle et al., 1982). Subsequently, these endogenous molecules 
were termed “danger signals” (Gallucci and Matzinger, 2001). The release of these danger 
signals as a result of injury and the consequent stimulation of TLR signalling provides a 
mechanism to alarm the immune system as well as to induce tissue repair. An involvement of 
TLRs in tissue repair and homeostasis has been suggested by the observations in MyD88- and 
TLR4 deficient mice, which show decreased proliferation of epithelial cells in the gut following 
injury (Fukata et al., 2006; Fukata et al., 2005; Rakoff-Nahoum et al., 2004). In accordance 
with these results is the observation that epithelial cells from mice deficient of the TLR 
inhibitor SIGIRR hyperproliferate (Xiao et al., 2007). 
1.3.1 Endogenous ligands for TLR2 and TLR4 
One of the first reported groups of endogenous TLR ligands were the heat shock proteins 
(HSP)s. HSP60 (Vabulas et al., 2001), HSP70 (Vabulas et al., 2002a) and gp96 (glycoprotein 
96) (Vabulas et al., 2002b). Recent studies also suggest HSP22 as a TLR4 ligand, which is able 
to activate monocyte-derived DCs (Roelofs et al., 2006). HSP60, -70 and gp96 have been 
reported to signal through TLR2 and TLR4 in a MyD88- and TRAF6- dependent manner in 
murine DCs and macrophages (Vabulas et al., 2001; Vabulas et al., 2002a; Vabulas et al., 
2002b). 
However, several studies have raised doubts about the ability of HSPs to act as endogenous 
TLR ligands. Highly purified murine liver HSP70 does not induce TNFα release from murine 
macrophages even at high concentrations (Wallin et al., 2002) leading to suggestions that the 
TNFα-inducing activity previously attributed to HSP70 (Vabulas et al., 2002a) has been due to 
endotoxin contamination (Gao and Tsan, 2003). Similarly, other studies using LPS-free 
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preparations of HSP70, HSP60 and gp96 have all suggested that the TLR activity previously 
reported may have been due to LPS contamination (Bausinger et al., 2002; Gao and Tsan, 2003; 
Reed et al., 2003). Other studies using expression of gp96 or addition of gp96 secreting 
fibroblasts into mice have avoided potential contamination. Activation of APCs has been 
observed in these studies but it is unclear if this has been due to a direct effect gp96 (Baker-
LePain et al., 2004; Liu et al., 2003).  
High mobility group box (HMGB)-1 is a molecule released during cell necrosis (Andersson et 
al., 2000). HMGB-1 has been suggested to signal through TLR4 as it shares a similar signalling 
pathway to LPS when stimulating human endothelial cells and neutrophils (Fiuza et al., 2003; 
Park et al., 2003). However, neutrophils lacking TLR4 still respond to HMGB-1 (Park et al., 
2004). A recent study demonstrated a role for TLR2, TLR4 and TLR9 in recognising HMGB-1 
and the subsequent activation of NF-κB, suggesting multiple mechanisms of HMGB-1 
recognition (Ivanov et al., 2007; Park et al., 2006; Tian et al., 2007). 
Another source of endogenous TLR2 and TLR4 ligands is the remodelling and/or destruction of 
the ECM due to tissue damage. This process results in the release of fragments from ECM 
components, which can induce inflammation. Heparan sulphate is associated with the cell 
membrane as well as part of the ECM (Yanagishita and Hascall, 1992) and is only found at low 
levels in healthy tissue. Increased levels of heparan sulphate are detected in the extracellular 
fluid around injuries (Kainulainen et al., 1998), in RA synovium (Lohmander et al., 1989) and 
in urine from patients with infections (Oragui et al., 2000). Hyaluronic acid, a major component 
of the ECM, is rapidly degraded at sites of inflammation (Johnson et al., 2002; Weigel et al., 
1986). Both heparan sulphate and hyaluronic acid have been shown to signal via TLR4. DCs 
from the C3H/HeJ mouse, which expresses a non-functional TLR4, do not respond to either 
stimulus (Johnson et al., 2002; Termeer et al., 2002). Fragments of hyaluronan released during 
injury can also stimulate TLR4 (Jiang et al., 2005a; Taylor et al., 2004) and biglycan a 
ubiquitously expressed proteoglycan in the ECM has been reported to signal through TLR2 and 
TLR4 in macrophages (Schaefer et al., 2005). Fibronectin is released from cells in response to 
tissue damage (George et al., 2000; Hino et al., 1995; Jarnagin et al., 1994; Saito et al., 1999) 
and is able to stimulate synovial cells to release pro-inflammatory cytokines and MMPs (Saito 
et al., 1999). Studies using transfected TLR4 HEK293 cells have shown fibronectin to be a 
ligand for TLR4 (Okamura et al., 2001). 
While HSPs, hyaluronic acid, heparan sulphate and fibronectin are released as a result of cell 
necrosis or ECM damage, other endogenous TLR ligands are a sign of inflammation or 
infection. These include fibrinogen and β-defensins. Fibrinogen is an early hallmark of 
inflammation. It migrates from the vasculature into the extravascular space during 
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inflammation due to increased permeability of endothelial cells (Dvorak et al., 1985). Data 
from macrophage cell lines have shown that fibrinogen-induced secretion of macrophage 
inflammatory protein 1 α (MIP1α), MIP1β and MIP2 requires functional TLR4 (Smiley et al., 
2001). 
Murine β-defensin, an anti-microbial peptide of the innate immune response, has been shown to 
stimulate TLR4 on immature DCs, inducing maturation and up-regulation of co-stimulatory 
molecules (Biragyn et al., 2002). In addition, β-defensin has been shown to act as a 
chemoattractant of immature DCs (Biragyn et al., 2001; Yang et al., 1999) (Figure 1.6). 
1.3.2 Endogenous ligands for TLR3, -7 and -8 
The exogenous ligand for TLR3 is dsRNA (Kariko et al., 2004) but not ssRNA, which is 
instead recognised by TLR7 and TLR8 (Heil et al., 2004). Although cellular RNAs are mainly 
regarded as ssRNA, they can produce hairpin loop formations that act as sources of endogenous 
dsRNA (Panet, 1983). Endogenous dsRNA released from necrotic cells stimulates DCs via 
TLR3 to produce IFNα whereas pre-treatment of necrotic cells with RNase prior to incubation 
with DCs, prevented this response (Kariko et al., 2004). Single stranded RNA-associated 
autoantigens have been reported to activate B cells by combined B cell antigen receptor-TLR7 
engagement in mice, thereby implicating a role for endogenous RNA recognition by TLR7. 
(Lau et al., 2005) (Figure 1.6). 
1.3.3 Endogenous ligands for TLR9 
While non-methylated CpG-motifs in bacterial and viral DNA are recognized by TLR9, 
endogenous DNA on its own is normally inert (Krieg et al., 1995). However, cells from 
autoimmune humans and mice show decreased CpG-methylation (Richardson et al., 1990) yet 
de-methylation of murine DNA does not enable it to stimulate B cells (Sun et al., 1997). Thus, 
the mechanism of activation by bacterial and endogenous DNA appears to be more complex 
than simply methylation. Indeed, a recent report by Wagner and colleagues describes that the 
sugar backbone of DNA is able to activate TLR signalling independent of the base sequence 
(Haas et al., 2008). Given that TLR9 is capable of recognising self-DNA (IgG-chromatin) 
complexes in B-cells (Leadbetter et al., 2002), in situations where necrotic cells are abundant 
the DNA released may form autoantibody immune complexes, which can stimulate TLR9. 
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1.4 The role of TLRs in inflammatory diseases 
TLR activation is a double edged sword as exacerbated TLR signalling can lead to tissue 
damage and chronic inflammation. TLRs are emerging as major factors in many disease 
conditions. While enabling TLRs to respond to tissue injury the recognition of danger signals 
may also have a role in the development of autoimmune disease and chronic inflammatory 
disorders. In contrast to apoptosis, necrotic cell death is typically associated with inflammation. 
This is most likely due to the release of the cell contents into the surrounding environment 
leading to activation of adjacent cells (Edinger and Thompson, 2004). Apoptotic cells retain 
their membrane integrity and are rapidly cleared by macrophages before lysis (Platt et al., 
1998). This has been demonstrated in DCs, which are activated by exposure to necrotic cells 
but not apoptotic cells (Gallucci et al., 1999; Sauter et al., 2000). The contents released from 
necrotic cells may activate TLRs, generating further inflammation and thus more necrosis. This 
cycle of inflammation may explain the chronic inflammatory state found in autoimmune 
diseases such as RA (Figure 1.8). 
 
Figure 1.8: Hypothesis for TLR participation in chronic inflammation. A) The release of 
endogenous TLR ligands (e.g., HMGB-1, RNA) due to cell necrosis, breakdown of extracellular matrix, 
or infections subsequently leads to the activation of TLRs. As a result proinflammatory cytokines and 
chemokines, which induce inflammation, are produced. B) Exogenous TLR ligands from bacterial or 
viral infection may activate TLRs resulting in inflammation. C) The inflammation generated by 
endogenous and/or exogenous ligands may cause cells to undergoing necrotic cell death and the release 
of endogenous TLR ligands. Abbreviations: HMGB (high mobility group box) 
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Several studies emphasize a role for TLRs in the promotion of systemic lupus erythematosus 
(SLE), asthma, Crohn’s disease, multiple sclerosis, type 1 diabetes, and RA (Table 1.3). In this 
chapter I will concentrate on the existing evidence of an involvement of TLRs in RA due to the 
research interests of the Kennedy Institute. 
Table 1.3: Toll-like receptors were shown to be involved in inflammatory diseases and  
      injury 
Disease/Injury Toll-like receptor Potential ligands References 
Systemic Lupus 
Erythematosis (SLE) 
- TLR7 
- TLR8 
- TLR9 
- RNA 
- RNA 
- Immune  
        complexes/dsDNA 
- HMGB-1 
(Lau et al., 2005; Tian et 
al., 2007; Vollmer et al., 
2005)} 
Atherosclerosis - TLR2 
- TLR4 
- Fatty acids 
- Fatty acids 
(Lee et al., 2001; Lee et al., 
2004; Yamashita et al., 
2006) 
Diabetes (type I) - TLR3 
- TLR7 
- TLR9 
- RNA 
- RNA 
- DNA 
(Lang et al., 2005; Wen et 
al., 2004; Zipris et al., 
2007) 
Multiple sclerosis - TLR4 
- TLR9 
- ? 
- ? 
(Ichikawa et al., 2002; 
Kerfoot et al., 2004; Prinz 
et al., 2006; Waldner et al., 
2004) 
Inflammatory bowl 
disease 
- TLR2 
- TLR5 
- TLR9 
- Microbial antigens 
- Microbial antigens 
- Bacterial DNA 
(Fukata et al., 2005; Netea 
et al., 2004; Rakoff-
Nahoum et al., 2004) 
Asthma - TLR2 
- TLR4 
- Hyaluronan  
        fragments 
- Hyaluronan  
        fragments 
(Jiang et al., 2005a) 
Rheumatoid Arthritis 
(RA) 
 
- TLR2 
- TLR3 
- TLR4 
 
 
 
 
- TLR9 
- HMGB-1 
- RNA 
- HMGB-1 
- HSPs 
- Hyaluronan  
        oligosaccharides 
- Fibronectin  
        fragments 
- Bacterial DNA 
- HMGB-1 
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1.4.1 Involvement of TLRs in the pathogenesis of RA 
Rheumatoid arthritis (RA) is one of the most prevalent autoimmune diseases. It affects ~0.5-1% 
of the adult population, with three times more females than males affected. RA is marked by 
persistent inflammatory polyarticular synovitis mainly affecting the small joints. TLRs were 
first suggested to have a role in RA in response to a pathogen initiating the disease (van der 
Heijden et al., 2000). Several animal models use bacterial cell wall components to induce 
experimental arthritis. The injection of streptococcal cell wall (SCW), containing a toxic 
peptidoglycan-polysaccharide fragment, into rats leads to a chronic arthritis comparable to 
human RA (Cromartie et al., 1977). Similar experiments in mice showed that TLR2 knockout 
or MyD88 knockout mice were protected from SCW induced joint inflammation since these 
animals did not develop joint swelling (Joosten et al., 2003). In addition, the intra-articular 
administration of the TLR2 and NOD2 ligand peptidoglycan, also led to the development of 
destructive arthritis in mice (Liu et al., 2001). As well as peptidoglycan, the administration of 
LPS together with arthritogenic serum in IL-1 receptor-deficient mice, but not in MyD88-
deficient mice, resulted in acute paw swelling (Choe et al., 2003), indicating a role for TLR4 in 
murine RA. Furthermore, mice deficient of IL-1RA display uncontrolled IL-1 signalling and 
develop a chronic T cell-driven arthritis (Horai et al., 2000). In contrast, IL-1RA and TLR4 
double knock out mice show a markedly reduced arthritis severity, which has not been 
observed in IL-1RA and TLR2 double knock out mice, suggesting a TLR4 specific function in 
driving RA pathology in this model (Abdollahi-Roodsaz et al., 2008). In support of this study 
are results obtained by blocking TLR4 with a naturally occurring antagonist. In mice 
immunised with collagen induced arthritis (CIA), the administration of TLR4 antagonist led to 
a reduction in disease severity even when administered post disease onset (Abdollahi-Roodsaz 
et al., 2007). Moreover, serum transferred arthritis has been shown to be not sustained in TLR4 
mutant mice compared with controls (Choe et al., 2003). Thus, animal disease models show a 
possible role for TLR2 and TLR4 in RA. However, while bacterial TLR ligands have been 
detected in human RA synovium (van der Heijden et al., 2000), they were also found in 
synovial tissue of healthy donors without any inflammatory response (Schumacher et al., 1999). 
Similarly, reports of bacterial DNA in the synovium of RA patients (Gerard et al., 2001; 
Kempsell et al., 2000; van der Heijden et al., 2000) were called into question by a more 
sensitive study detecting the bacterial marker muramic acid, which did not identify any 
bacterial components in RA patients (Chen et al., 2003b). It has been demonstrated, however, 
that B cells become activated by chromatin-IgG complexes binding to the antigen receptor and 
TLR9 to produce rheumatoid factor (RF) independently of T cells (Leadbetter et al., 2002). 
Moreover, DNase II-/- mice develop chronic polyarthritis due to excessive release of DNA 
following cell death, which might be due to TLR9 activation (Kawane et al., 2006). Therefore, 
the search for the trigger initiating RA has now turned to the involvement of endogenous TLR 
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ligands. Cell necrosis due to tissue damage or inflammation are a major source of endogenous 
danger signals and Hyaluronan oligosaccharides, fibronectin fragments, HSPs, antibody-DNA 
complexes and high mobility group box (HMGB)-1 have all been identified in the RA joint 
(Schett et al., 1998; Scott et al., 1981; Taniguchi et al., 2003; Yu et al., 1997). 
Expression of TLR2, -3, -4, -7 and -9 has been demonstrated in human synovial tissue from RA 
patients (Brentano et al., 2005b; Iwahashi et al., 2004; Radstake et al., 2004; Roelofs et al., 
2005; Seibl et al., 2003). TLR2 expression has been identified in synovial fibroblasts, CD16+ 
monocytes and CD16+ macrophages in the synovium (Iwahashi et al., 2004; Kyburz et al., 
2003; Seibl et al., 2003). Interestingly, expression of TLR2, -3 and -4 was shown to be 
increased in the synovial tissue of RA patients compared with healthy donors or OA samples 
(Brentano et al., 2005b; Radstake et al., 2004). Functional studies have been performed by 
stimulation of TLR2- and TLR9-expressing RA synovial fibroblasts with peptidoglycan, a 
TLR2 ligand, which led to the expression of MMPs and secretion of IL-6 and IL-8 while no 
activation has been observed in response to the TLR9 ligand CpG oligodeoxynucleotides 
(Kyburz et al., 2003). More recently, RNA released from necrotic synovial fluid cells has been 
shown to activate synovial fibroblasts via TLR3 (Brentano et al., 2005b). Interestingly, RA 
synovial fibroblasts were shown to respond to TLR3 stimulation by producing TNFα while 
primary human skin fibroblasts do not (Lundberg et al., 2007). This shows that TLR3 is 
functional in the inflamed synovium but also shows a tissue specific mechanism of TLR 
signalling. In addition, evidence for a TLR4 ligand in the serum and synovial fluid of RA 
patients has been observed. Serum and synovial fluid from RA patients stimulated TLR4 
expressing CHO cells to up regulate CD25 but had no effect on untransfected CHO cells 
(Roelofs et al., 2005). Moreover, conditioned media from RA synovial membrane cultures has 
been shown to activate human macrophages in a MyD88 and Mal dependent manner, further 
strengthening the involvement of an endogenous ligand driving RA pathology (Sacre et al., 
2007a; Sacre et al., 2007b). In support of this data, the over-expression of a dominant negative 
construct of MyD88 or Mal inhibits the spontaneous release of cytokines and MMPs by RA 
synovial membrane cultures (Sacre et al., 2007a; Sacre et al., 2007b). However, no ligand has 
so far been defined. 
A strong candidate for an endogenous TLR ligand involved in RA pathology is the DNA 
binding protein HMGB-1. It exhibits cytokine like properties as it is actively released by LPS, 
TNFα or IL-1 stimulated macrophages as well as passively released during cell necrosis 
(Andersson et al., 2000; Wang et al., 1999). It has been shown to activate NF-κB in human 
endothelial cells and human neutrophils to produce pro-inflammatory cytokines (Fiuza et al., 
2003; Park et al., 2003). Therefore, it can function as a mediator of inflammatory responses. 
RA patients as well as Lewis rats with Mycobacterium tuberculosis-induced adjuvant arthritis 
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contain detectable amounts of HMGB-1 in the synovial fluid (Kokkola et al., 2002). 
Interestingly, HMGB-1 expression is increased in synovial fibroblasts of RA patients compared 
to osteoarthritis patients, which may result in the release of pro-inflammatory cytokines by RA 
synovial fibroblasts (Taniguchi et al., 2003). TLR2 and TLR4 have been described to recognise 
HMGB-1 leading to the subsequent activation of NF-κB (Park et al., 2006). A more recent 
study demonstrated the activation of TLR9 by HMGB-1 and DNA containing immune 
complexes, which require the immunoglobulin family member RAGE (Receptor for advanced 
glycation end products) (Tian et al., 2007). 
Naturally occurring polymorphisms can give clues to the relevance of TLR involvement in 
human RA. However, no association between TLR2 and TLR4 polymorphisms and the 
susceptibility to RA have been found. The amino acid substitution Asp299Gly in the TLR4 
gene results in the disruption of TLR4 signalling and two studies investigating this 
polymorphism found no correlation with susceptibility to RA (Kilding et al., 2003; Lamb et al., 
2004). The polymorphisms Arg677Trp and Arg753Gln in the TLR2 gene and Thr399Ile in the 
TLR4 gene also showed no association with RA (Sanchez et al., 2004). Investigating the TLR 
adaptor Mal, no association between the Mal polymorphism Ser180Leu and the susceptibility 
or severity of RA could be found (Sheedy et al., 2008). 
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1.5 TLR signalling pathways 
The existing evidence of an involvement of TLRs in the pathogenesis of RA and other 
inflammatory diseases makes it necessary to investigate and understand the molecular basis of 
the signalling pathways induced by these receptors. Potentially this research could result in the 
identification of therapeutic targets for the treatment of inflammatory diseases. 
 
 
Figure 1.9: TLR signalling pathways. The IL-1R pathway is solely dependent on the adaptor molecule MyD88 
and induces NF-κB through IRAK-4, IRAK-1 and TRAF-6. In general TLR signalling is induced following binding 
of the ligand and the recruitment of the adaptor molecules MyD88 (Myeloid differentiation primary response gene 
88), Mal (MyD88 adaptor like protein), TRIF (TIR domain containing adaptor inducing interferon β) and TRAM 
(TRIF-related adaptor molecule) are recruited to the TIR domain of the TLR. MyD88-dependent pathway: IRAK 
(IL-1 receptor associated kinase)-4 and IRAK-1 are recruited to the Death Domain (DD) of MyD88, where they 
become phosphorylated and recruit TRAF (TNF receptor associated factor)-6. IRAK-1 and TRAF-6 dissociate from 
the receptor and activate the IKK complex, resulting in the translocation of NF-κB to the nucleus and the up 
regulation of pro-inflammatory genes. Beside the induction of NF-κB, the MyD88-dependent pathway also activates 
the mitogen activated protein kinases p38 and JNK (c-Jun-N-terminal kinase). This pathway is used by TLR1, -2, -4, 
-5, -6, -7 and -9. Mal, a second TIR-domain containing adaptor protein, is involved in the MyD88-dependent 
signalling pathway through TLR2 and TLR4 and acts as a bridging molecule for MyD88 to these receptors. MyD88-
independent pathway: By contrast, TLR3 and TLR4 mediated activation of IRF (interferon regulating factor)-3 and 
the initiation of IFN (interferon)-β are observed in a MyD88-independent manner. The adaptor molecule TRIF is 
essential in this pathway. TRIF recruits and activates RIP-1, which is responsible for a late induction of NF-κB as 
well as TBK-1 and IKKi, which form a complex with TRAF-3 activating IRF-3 and IRF-7 and the induction of type 
I interferons. The fourth adaptor protein TRAM, which is only involved in TLR4 MyD88-independent signalling, 
serves as a bridge between TLR4 and TRIF. 
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Due to their structural relationship TLRs share certain signalling pathways with the IL-1R 
family (Akira and Takeda, 2004) (Figure 1.5). TLR and IL-1R signalling is initiated by ligand 
induced hetero- or homodimerisation of the receptors or association with accessory proteins 
(Wesche et al., 1997b). The signal is transduced by the intracellular TIR domain, present in 
TLRs as well as IL-1Rs, through the recruitment of TIR domain containing adaptor molecules 
(Wesche et al., 1997a). The TLRs use distinct combinations of these adaptors to turn on the 
common TLR/IL-1R pathway as well as pathways unique to TLRs, leading to the activation of 
transcription factors (Figure 1.9). 
1.5.1 TLR adaptor proteins 
IL-1Rs and all TLRs, with the exception of TLR3, share a common signalling pathway which 
depends on the adaptor molecule MyD88 (Myeloid differentiation primary response gene 88), 
the first TLR adaptor to be described (Adachi et al., 1998; Burns et al., 1998; Janssens and 
Beyaert, 2002; Wesche et al., 1997a). It has originally been identified as a protein induced 
during myeloid differentiation (Lord et al., 1990) but has since been shown to be recruited to 
IL-1Rs and most TLRs through its carboxyl-terminal TIR domain (Burns et al., 1998; Wesche 
et al., 1997a). In addition MyD88 contains an amino-terminal death domain (DD), which is 
responsible for the recruitment of downstream signalling mediators, including IRAK (IL-1R 
associated kinase) family members and TRAF6 (TNF receptor associated factor 6), to the 
receptor complex (Burns et al., 1998; Wesche et al., 1997a). Ultimately, this leads to the 
activation of MAPKs as well as NF-κB and the transcription of inflammatory mediators (Akira 
and Takeda, 2004). 
The essential role of MyD88 in IL-1R/TLR signal transduction has been demonstrated in 
MyD88 deficient mice. In response to IL-1R and IL-18R stimulation, MyD88 deficient 
macrophages show a loss in NF-κB and MAPKs activation, as well as TNFα and IL-6 
production (Adachi et al., 1998). This has also been observed for most TLRs, with the 
exception of TLR3 and TLR4 (Hayashi et al., 2001; Heil et al., 2003; Schnare et al., 2000; 
Takeuchi et al., 2000). TLR4 stimulation only led to a reduced production of pro-inflammatory 
cytokines and activation of NF-κB and MAPKs could still be observed with delayed kinetics. In 
contrast, MyD88 deficiency had no effect on TLR3 induced activation of NF-κB and MAPKs 
in macrophages. (Alexopoulou et al., 2001; Kawai et al., 1999). In addition, DCs from MyD88 
deficient mice still showed functional maturation in response to LPS and dsRNA and retained 
their capacity to activate IRF3 (Alexopoulou et al., 2001; Doyle et al., 2002; Kaisho et al., 
2001; Kawai et al., 2001). Together, these results suggested the presence of additional adaptor 
molecules essential for MyD88 independent signalling. 
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TIR domain homology searches led to the discovery of Mal (MyD88 adaptor like protein, also 
termed TIRAP (TIR domain containing adaptor protein)), which at the time was thought to be 
the missing link responsible for MyD88 independent signal transduction (Fitzgerald et al., 
2001; Horng et al., 2001). Studies using HEK293 cells have shown that Mal is required for NF-
κB activation following TLR4 stimulation; while IL-1R, TLR2 and TLR9 induced NF-κB 
activation was unaffected. However, Mal deficient mice, generated by two groups, showed a 
reduction in TLR4 and TLR2 induced NF-κB activation, suggesting species specific differences 
(Horng et al., 2002; Yamamoto et al., 2002). To date Mal is thought to function as a sorting 
adaptor for TLR2 and TLR4, recruiting MyD88 to the receptor complex in the plasma 
membrane, through its ability to interact with phosphatidylinositol-4,5-bisphosphate 
(PtdIns(4,5)P2) (Kagan and Medzhitov, 2006). In addition, Mal has been shown to get 
phosphorylated following TLR2 or TLR4 stimulation, which leads to its interaction with 
SOCS1 and its subsequent degradation (Mansell et al., 2006). This makes Mal part of a 
negative feedback loop to restrict TLR2 and TLR4 induced signalling. 
Three additional TLR adaptor molecules have been described, so far, through TIR domain 
homology searches: TRIF (TIR-domain-containing adapter-inducing interferon-β, also termed 
TICAM-1 (Toll-like receptor adaptor molecule 1)), TRAM (TRIF-related adaptor molecule, 
also termed TICAM2) and SARM (TIR domain-sterile alpha and HEAT/Armadillo motif) 
(O'Neill and Bowie, 2007). Stimulation of cells with dsRNA or LPS (TLR3- and TLR4-ligands 
respectively) results in the recruitment of TRIF, and in case of TLR4 also TRAM (Oshiumi et 
al., 2003a; Oshiumi et al., 2003b; Yamamoto et al., 2003). The dissociation of TRIF leads to 
the activation of IRF-3 and IRF-7 subsequently resulting in the expression of IFN inducible 
genes including IFN-β, IP10 (inducible protein 10) and RANTES (Regulated on activation, 
normal T expressed and secreted) (Akira and Takeda, 2004; Honda and Taniguchi, 2006; 
Kawai et al., 2001) (Figure 1.9). Moreover, TRIF recruitment has also been shown to be 
responsible for the MyD88 independent activation of NF-κB. However, the exact mechanism of 
NF-κB activation by TRIF is still unclear. Studies show that binding of RIP (receptor 
interacting protein)-1 to the RIHM (RIP interacting homology motif) domain of TRIF leads to 
the induction of NF-κB while Covert et al. suggest that an autocrine effect of TNFα, initially 
induced through IRF-3 is responsible for NF-κB activation (Covert et al., 2005; Cusson-
Hermance et al., 2005). 
TRAM is structurally related to Mal and has therefore been suggested to function as a sorting 
adaptor, recruiting TRIF to TLR4 (Kagan and Medzhitov, 2006; Oshiumi et al., 2003b). In this 
context, TRAM has been shown to be recruited to the plasma membrane by myristoylation 
(Rowe et al., 2006). Moreover, a recent study provides evidence that TRAM recruitment is 
subsequent to the endocytosis of the TLR4 complex (Kagan et al., 2008). Therefore, TRAM 
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provides a mechanism, which allows sequential activation of MyD88 dependent signalling 
while TLR4 is located in the plasma membrane, followed by TRIF dependent signalling after 
TLR4 internalisation (Kagan et al., 2008). In addition, studies using primary human synovial 
fibroblasts and HUVECs as well as murine embryonic fibroblasts demonstrate that TRAM is 
involved in TLR2/6 signal transduction (Sacre et al., 2007c 2859). Furthermore, one group 
could show a role for TRAM in IL-1R signalling (Bin et al., 2003). These results might indicate 
a broader and possibly a cell type specific function of TRAM. 
SARM is the least investigated TLR adaptor molecule. So far, no activation function could be 
assigned to it. However, recent data describes SARM as an inhibitor of TRIF dependent 
signalling (Carty et al., 2006). SARM has been shown to interact with TRIF and expression of 
SARM in HEK293 cells led to the inhibition of TRIF dependent but not MyD88 dependent NF-
κB activation (Carty et al., 2006). 
1.5.2 Induction of NF-κB signalling pathways by TLRs 
The transcription factor family NF-κB is involved in numerous cell processes including 
development, apoptosis and inflammation (Karin and Lin, 2002). The NF-κB pathway 
integrates signals from a wide range of stimuli, including cytokines, growth factors, UV-
radiation and PAMPs, and in turn activates numerous cellular responses (Hayden and Ghosh, 
2004). The NF-κB family consists of the five subunits c-Rel (also known as Rel), p65 (also 
known as RelA and NF-κB3), RelB, p50 (also known as NF-κB1) and p52 (also known as NF-
κB2), which all contain the characteristic Rel homology domain (RHD). Three NF-κB family 
members, p65, RelB and c-Rel, contain carboxyl-terminal transcriptional activation domains 
(TAD), which are crucial for their ability to activate gene expression. The other two members, 
p50 and p52, are processed from large precursor proteins, p105 and p100 respectively. Because 
of the lack of a TAD, p50 and p52 are transcriptionally inactive on their own. The most 
common canonical NF-κB dimer consists of p65/p50, however, there are numerous other 
combinations, which can induce transcriptional activation (Table 1.4).  
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Table 1.4: Proposed role of NF-κB dimer 
NF-κB dimers Function 
p65/p50 Classical heterodimer of the canonical NF-κB pathway, involved in 
expression of target genes such as IL-8, IL-6 TNFα and IκBα 
p65/p65 No DNA binding activity 
RelB/p50 or p52 Classical heterodimers of the non-canonical NF-κB pathway, results in 
RelB-mediated transcriptional activation 
p50 or p52/p65 or c-Rel p50 and p52 are derived from processing of p105 and p100, respectively. 
Form transcriptionally active timers with p65 or c-Rel 
p50 and p52 homodimers Are able to bind DNA but cannot induce transcriptional activation on their 
own. Can function by recruiting co-factors to the promoter of target genes or 
by repression the induction of their target genes, such as TNFα and IL-6. 
 
In an inactive state, NF-κB dimers are retained in the cytosol through the interaction with IκB 
(Inhibitor κB) proteins (Hayden and Ghosh, 2004). In order for NF-κB dimers to be able to 
translocate to the nucleus IκBs need to be degraded, which is achieved by IκB phosphorylation 
through the IKK (IκB kinases) complex. NF-κB activation is further divided into a canonical- 
and a non-canonical pathway (Bonizzi and Karin, 2004). The canonical pathway is induced by 
inflammatory signals including TNFα, IL-1, as well as TLR ligands (Kolls and Linden, 2004; 
Martinon and Tschopp, 2005; O'Neill, 2006; Osborn et al., 1989) and leads to the expression of 
inflammatory mediators and the maturation of DCs (Kopp and Medzhitov, 1999). Strong 
inducers of the non-canonical NF-κB pathway are lymphotoxin (LT), CD40L and B 
lymphocyte stimulator (Blys). Activation of the alternative NF-κB pathway plays a major role 
in lymphoid organogenesis and humoral immunity by inducing B cell maturation (Hayden and 
Ghosh, 2004). 
TLR stimulation ultimately results in the translocation of NF-κB transcription factors to the 
nucleus. This signalling pathway is initiated upon the recruitment of the serine-threonine 
kinases IRAK4 and IRAK1 (Cao et al., 1996a; Li et al., 2002; Li et al., 1999b; Suzuki et al., 
2002) as well as the scaffolding protein TRAF6 (Cao et al., 1996b) to the receptor complex 
(Figure 1.9). IRAK4 is recruited via DD-DD interactions with MyD88 and facilitates the 
recruitment of IRAK1. Subsequently, IRAK1 becomes hyperphosphorylated, most likely by 
IRAK4 (Li et al., 2002; Lye et al., 2004; Qin et al., 2004). In mice, IRAK4 deficiency results in 
an ablation of cytokine production in response to IL-1 or LPS while IRAK1 deficiency reduces, 
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but not abolishes, cytokine production (Kanakaraj et al., 1998; Suzuki et al., 2002; Swantek et 
al., 2000; Thomas et al., 1999). Human patients with IRAK4 deficiency do not respond to IL-1 
or IL-18 as well as ligands for TLR2, TLR3, TLR4, TLR5 or TLR9, indicating the crucial role 
of IRAK4 in IL-1R/TLR signalling in primary human cells (Picard et al., 2003). 
Phosphorylated IRAK1 interacts with TRAF6 and dissociates as a complex from the receptor 
(Jiang et al., 2003). Several models have been proposed for TRAF6 dependent activation of the 
IKK complex (Hayden and Ghosh, 2004). TRAF6 has been shown to function as an ubiquitine 
ligase, which, upon oligomerisation, triggers non-classical ubiquitination. This process involves 
TAB2 (TGF-activated kinase 1 binding protein 2) and TAB3 and is catalysed by the 
ubiquitination proteins Ubc13 (ubiquitin-conjugating enzyme E2 13) and Uev1A (ubiquitin-
conjugating enzyme E2 variant 1 isoform A) (Kishida et al., 2005; Wang et al., 2001). TAB2 
and/or TAB3 bind the ubiquitin chains on TRAF6 and recruit the TAK1 (TGF-activated kinase 
1) kinase complex (TAK1/TAB1/TAB2 or TAB3) (Kanayama et al., 2004). TAK1 is activated 
by additional ubiquitination through the TRAF6 complex and is subsequently able to 
phosphorylate IKKβ (Wang et al., 2001). It is suggested, that TAB2 is responsible for enabling 
the interaction with the IKK complex through its ability to associate with IKKα and NEMO 
(Kanayama et al., 2004; Kishida et al., 2005). 
Alternative mechanisms bridging TRAF6 dependent IKK complex activation are suggested to 
involve ECSIT (Evolutionarily conserved signalling intermediate in Toll pathways) or MEKK3 
(Mitogen-activated protein kinase kinase kinase 3) (Huang et al., 2004; Kopp et al., 1999; Xiao 
et al., 2003). Both have been shown to associate with TRAF6 and dominant negative constructs 
of these proteins have been shown to inhibit TRAF6 induced NF-κB activation. In addition the 
ability of MEKK3 to phosphorylate IKKβ and its necessity for IKK complex association with 
IκBα has been described (Schmidt et al., 2003). However, it is still unclear how these signals 
cooperate with the TAK1 kinase complex in mediating NF-κB activation. 
1.5.2.1 The IKK complex 
In order to allow the release of NF-κB dimers IκBs need to become phosphorylated by IKKs 
(Karin and Ben-Neriah, 2000). The IKK complex, inducing the canonical NF-κB pathway, 
consists of the regulatory subunit NEMO (NF-κB essential modulator) and the catalytic 
subunits IKKα and IKKβ (Rothwarf et al., 1998). While NEMO and IKKβ appear to be 
essential for NF-κB activation, cells lacking IKKα still show normal levels of NF-κB DNA 
binding activity (Chen et al., 2003a; Hu et al., 1999; Hu et al., 2001; Li et al., 1999a; Li et al., 
1999c; Makris et al., 2000). Subsequently, IKKα kinase activity was found to be involved in the 
resolution of inflammation, induced by NF-κB activation, by accelerating the turn-over of NF-
κB and its release from the gene promoter (Lawrence et al., 2005). In addition, IKKα was 
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shown to be an activator of the non-canonical NF-κB pathway (Dejardin et al., 2002; Ghosh 
and Karin, 2002; Senftleben et al., 2001). IKKα homo-dimer complexes induce the processing 
of p100 to p52 and consequently the nuclear translocation of p52/RelB hetero-dimers. The two 
non-canonical IKKs IKKi (also known as IKKε) and TBK-1 (TRAF family member-associated 
NF-κB activator binding kinase 1) have been shown to be involved in the induction of IRF-3 in 
response to the TLR4 ligand LPS and the TLR3 ligand dsRNA (Akira and Takeda, 2004; 
Honda and Taniguchi, 2006). Their role in the activation of NF-κB, however, is still not well 
understood. 
1.5.2.2 IκB proteins 
IκBα is the archetypical NF-κB inhibitor in an evolutionary conserved family consisting of 
IκBβ, IκBε, B cell CLL/lymphoma (Bcl)-3, IκBNS and IκBζ as well as IκBγ, the degradation 
product of p50 and p52 (Baldwin, 1996; Ghosh et al., 1998; Kuwata et al., 2006; Verma et al., 
1995). With the exception of Bcl-3 and IκBζ, these proteins can inhibit the translocation of NF-
κB dimers to the nucleus by interacting with RHD and thereby inactivating the nuclear 
localization signal (NLS). IκBβ resembles IκBα in its primary sequence as well as tertiary 
structure. However, while IκBα degradation leads to a rapid oscillatory NF-κB activation, 
degradation IκBβ results in prolonged NF-κB activation (Ghosh et al., 1998; Thompson et al., 
1995; Tran et al., 1997). This prolonged activation appears to play a role in numerous 
pathological conditions including asthma and cystic fibrosis (Bitko and Barik, 1998; Blackwell 
et al., 2001; DeLuca et al., 1999; Hiscott et al., 2001; Palmer et al., 1997; Stecenko et al., 2001; 
Thompson et al., 1995). The oscillatory propensity in the NF-κB signalling system, caused by 
IκBα, is counteracted by a negative feedback mechanism mediated by IκBε, which is delayed 
and functions in anti-phase to IκBα (Kearns et al., 2006). This indicates that cells have the 
capacity to modulate NF-κB activity depending on cell type and stimuli. Beside the canonical 
inhibitors IκBα, IκBβ and IκBε, the IκB family members IκBNS, Bcl-3 and IκBζ seem to have 
a more multi-facetted role. IκBNS has been shown to be involved in the inhibition of NF-κB 
induced genes including IL-6 and IL-12p40 following TLR stimulation (Kuwata et al., 2006). 
Bcl-3 specifically interacts with the intrinsically inactive NF-κB1 and NF-κB2 homodimers in 
the nucleus and is not degraded following cellular stimulation (Bours et al., 1993; Fujita et al., 
1993; Heissmeyer et al., 1999; Nolan et al., 1993). Depending on its phosphorylation it can 
either act as an inhibitor, dissociating NF-κB1 or NF-κB2 homodimers from DNA, or as a co-
activator that is recruited to the gene promoter by NF-κB1 or NF-κB2 homodimers (Bours et 
al., 1993; Dechend et al., 1999; Franzoso et al., 1992; Fujita et al., 1993; Heissmeyer et al., 
1999; Nolan et al., 1993). The more recently described IκBζ is highly homologous to Bcl-3 
(Kitamura et al., 2000; Yamazaki et al., 2001). Its transcription is rapidly induced upon 
stimulation with TLR ligands and IL-1. Cells from IκBζ deficient mice show a severe 
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impairment of IL-6 production in response to TLR2-, TLR4-, TLR7/8- and TLR9 ligands as 
well as IL-1 but not in response to TNFα (Yamamoto et al., 2004). Similar results were 
obtained using NF-κB1 knock-out mice, which might indicate that IκBζ specifically interacts 
with the NF-κB1 subunit (Yamamoto et al., 2004). 
1.5.3  Mitogen-activated protein kinases 
TLR/IL-1R stimulation also results in the activation of the MAPK signalling pathways, which 
are crucial for a wide range of cellular processes including cell cycle regulation, differentiation 
and inflammation. MAPKs comprise four subfamilies: ERK1/2 (extracellular-signal-regulated 
kinases 1/2), ERK5, JNKs (c-Jun N-terminal kinase) and p38 MAPK (Ashwell, 2006). ERK1/2, 
JNK and p38 MAPK kinases are the most well characterised and are generally considered as 
serine/threonine kinases, although during autophosphorylation they can also transfer phosphates 
to tyrosine residues (Crews et al., 1991). MAPKs are activated by a wide variety of stimuli, but 
in general ERK1/2 are preferentially activated in response to mitogens while JNKs and p38 
MAPK are more responsive to stress stimuli including cytokines and PAMPs (Ashwell, 2006; 
Roux and Blenis, 2004). 
Activation of MAPKs requires dual phosphorylation on tyrosine and threonine residues within 
the activation loop of their kinase domain (Ashwell, 2006; Roux and Blenis, 2004). This is 
achieved by a cascade of numerous kinases, which for simplicity are termed in accordance with 
their order in the cascade. The first (the most membrane proximal) kinases to be activated by a 
stimulus are serine/threonine kinases known as MAPK kinase kinase (MAPKKK). The 
MAPKKKs phosphorylate and activate MAPKKs, which are dual specificity kinases and are 
able to activate MAPKs. Each MAPK has a different set of initiating MAPKKK and MAPKK, 
which results in signal specificity. Activated MAPKs are able to translocate to the nucleus 
where they phosphorylate and regulate numerous substrates including transcription factors and 
MAPK-activated protein kinases (MKs) (Handley et al., 2007a; Handley et al., 2007b; Yang et 
al., 2003) (Figure 1.10). 
Chapter 1 Introduction 
 45
 
Figure 1.10: Selected members of the MAPK signalling cascades leading to the activation of AP-1 
and MKs. The MAPKs are activated via a conserved three-tiered kinase cascade. The MAPKs, ERK1/2, 
JNK and p38 MAPK are activated by dual phosphorylation on Threonine and Tyrosine motifs caused by 
members of the MAPKK group of protein kinases. The MAPKKs are in turn activated by 
phosphorylation mediated by a group of MAPKKKs. The activated MAPKs are then able to 
phosphorylate target proteins such as the AP-1 subunits and the MKs. The regulation of AP-1 is also 
mediated through transcriptional induction of the AP-1 subunits. see text for abbreviations. 
 
MAPKs regulate the activation of the ATF (Activating transcription factor) transcription factor 
family. This family comprises the subunits of AP-1 typically consisting of c-Jun and JunD 
heterodimers along with members of the fos family. Additional regulation is gained through the 
substrate specificity of MAPKs for different members of the AP-1 family (Yang et al., 2003). 
ERK1/2 (p44/p42) is activated by the upstream kinases MEK1/2 and once phosphorylated is 
able to activate transcription factors such as Elk-1 and c-Fos (Kyriakis and Avruch, 2001; Roux 
and Blenis, 2004). JNK is activated by the kinases MEK4/6/7 and has a critical role in the 
regulation of AP-1 transcription activity through phosphorylation and activation of several AP-
1 proteins such as c-Jun and ATF2. The p38 MAPK exists as four isoforms (α, β, γ, δ), from 
which α and β are the best characterised (Lee et al., 1999). p38α was originally identified as a 
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38 kDa protein, which is phosphorylated on tyrosine residues in macrophages stimulated with 
LPS (Han et al., 1994). Moreover, administration of the p38α and β inhibitor SB203580 has 
been shown to have beneficial effects in animal disease models such as CIA and endotoxin-
induced septic shock (Lee et al., 1999). The p38 MAPK pathway is induced by MEK3/6 and 
controls inflammatory response genes at the transcriptional level through AP-1 and NF-κB 
regulation as well as at the post-transcriptional level by stabilising mRNA (Briata et al., 2005; 
Dean et al., 2004; Hitti et al., 2006; Ono and Han, 2000). Post-transcriptional mRNA 
stabilisation is achieved through the activation of the p38 MAPK substrate MK-2 (Clark et al., 
2003). P38 MAPK and its substrate activate several proteins, which bind to adenosine- and 
uridine-rich elements (ARE), incorporated in the 3´ untranslated region (UTR) of mRNAs, and 
regulate their degradation. Through this mechanism, p38 is able to control the production of 
several proinflammatory mediators by reducing or prolonging protein expression. 
1.5.3.1 MAPK activation by TLR signalling pathways 
Although it has been known for a long time that TLR/IL-1R signalling results in the activation 
of MAPKs, the signalling mediators involved are not as well characterised as for the NF-κB 
pathway. The divergence of the TIR signalling pathway, leading to MAPK activation, is still 
under debate and there are numerous reports describing possible linking proteins. 
To date the accepted pathway suggests a linear cascade, with the NF-κB and MAPK pathway 
bifurcating at the level of the TRAF6/TAK-1 complex (Figure 1.9). Beside being able to 
phosphorylate IKKβ, TAK-1 has also been shown to act as a MAPKKK by phosphorylating 
MEK6, which in turn stimulates JNK and p38 MAPK, leading to c-Jun and AP-1 activation 
(Wang et al., 2001). The RING-finger and zinc-finger domains of TRAF6 have been shown to 
be essential for MAPKs activation, although it is unclear if this is due to interactions with 
TAK-1 or other proteins such as ECSIT and MEKK3 (Kobayashi et al., 2001). ECSIT bound to 
TRAF6 activates MEKK1, which subsequently activates AP-1 (Kopp et al., 1999). The crucial 
role for MEKK3 in TLR/IL-1R induced JNK and p38 MAPK activation has been demonstrated 
in MEKK3 deficient mice (Huang et al., 2004). Furthermore, evidence from other studies have 
revealed the existence of alternative pathways diverging upstream of TAK-1 as IRAK-1 has 
been shown to be able to activate JNK (Li et al., 2001). More recently, ASK-1 (Apoptosis 
signal-regulating kinase 1) has been described to specifically induce p38 MAPK activation 
following LPS stimulation, which is dependent on reactive oxygen species, via association with 
TRAF6 (Matsuzawa et al., 2005). In addition, small GTPase Ras, activated by IL-1, associates 
with the IRAK-1/TRAF6/TAK-1 complex and induces phosphorylation of MEK3 and MEK6, 
the MAPKKs upstream of p38 MAPK (McDermott and O'Neill, 2002). Moreover, it has been 
demonstrated that mixed lineage kinases (MLKs) function as MAPKKKs in DCs and are 
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necessary for TLR3 and TLR4 induced JNK and p38 MAPK activation (Handley et al., 2007a; 
Handley et al., 2007b) 
Evidence suggests a high degree of cross-talk between the pathways leading to the activation of 
NF-κB and MAPKs. Using macrophages from Tpl-2 (tumour progression locus-2) deficient 
mice, this MAPKKK has been shown to participate in LPS induced TNFα production (Dumitru 
et al., 2000). Tpl-2 associates with the IκB protein p105, the precursor of p50, in resting cells 
and is thereby inhibited. Upon LPS stimulation, p105 is proteolysed as a result of IKKβ 
activation (Heissmeyer et al., 1999). Tpl-2 is subsequently released from its inhibitor to 
phosphorylate MEK1, which leads to ERK1/2 activation (Beinke et al., 2004). 
1.5.4 IRF signalling pathways 
Initiation of TLR signalling also results in the expression of type I IFNs as well as IFN 
inducible genes such as IP10 and RANTES. The expression of these genes is regulated by the 
IRF transcription factor family. The mammalian IRF family comprises nine members: IRF1 to 
IRF9. Each IRF is characterised by a highly conserved DNA binding domain, which is located 
at the amino-terminus (Honda and Taniguchi, 2006). The DNA binding domain recognises 
IFN-stimulated response elements (ISREs) in the promoter of their target genes. IRFs have 
distinct roles in the development and function of immune cells, as has been shown by gene-
disruption studies (Honda and Taniguchi, 2006). Four IRF family members have been 
implicated in the induction of type I IFN genes. IRF1 was the first IRF family member that has 
been described to activate expression of type I IFNs (Miyamoto et al., 1988). However, IRF1- 
as well as IRF5-deficient mouse embryonic fibroblasts (MEFs) are still able to induce type I 
IFNs in response to NDV, suggesting redundancy between IRF family members (Matsuyama et 
al., 1993; Takaoka et al., 2005). The structurally related IRF3 and IRF7, on the other hand, 
have gained much attention as essential regulators of type I IFN gene expression. IRF3 is 
constitutively expressed while IRF7 is expressed at low levels in most cells but becomes 
strongly induced in response to type I IFN mediated signalling (Honda and Taniguchi, 2006). 
IRF3 and IRF7 are activated by serine phosphorylation in their carboxyl-terminus upon, which 
they form either homodimers or heterodimers with each other and translocate to the nucleus 
(Lin et al., 1998; Sato et al., 1998; Yoneyama et al., 1998). 
1.5.4.1 IRF activation by TRIF dependent TLR signalling pathways 
TLR4 as well as TLR3 utilise the adaptor molecule TRIF, which is essential for the induction 
of type I IFNs following LPS or poly I:C stimulation, respectively (Akira and Takeda, 2004). 
The expression of IFNβ has been shown to be reduced in IRF3- or IRF7-deficient mice in 
response to poly I:C (Honda and Taniguchi, 2006). However, while IRF3 deficiency also leads 
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to an abrogated IFNβ response following LPS stimulation, IRF7 deficiency has almost no effect 
suggesting a predominant role for IRF3 in TLR4 induced IFN production (Hoebe et al., 2003; 
Honda et al., 2005b; Sakaguchi et al., 2003). Interestingly pre-treatment of IRF3 deficient DCs 
with IFNβ, which leads to the up-regulation of IRF7, restores IFNβ expression in response to 
LPS (Sakaguchi et al., 2003). This might suggest that IRF7 is able to participate in TLR4 
signalling. In addition to IRF3 and IRF7, the induction of nitric oxide synthase (NOS)2 by 
macrophages in response to LPS has been shown to depend on IRF1 (Kamijo et al., 1994). 
Following TLR3 or TLR4 stimulation, TIRF forms a complex with IKKi, TRAF3 and TBK-1, 
which subsequently leads to the phosphorylation of IRF3 and IRF7 by TBK-1 (Figure 1.9) 
(Hacker et al., 2006; Hemmi et al., 2004; Oganesyan et al., 2006; Perry et al., 2004; Sasai et al., 
2005). TRAF6 has also been described to associate with the amino-terminal region of TRIF but 
studies using TRAF6 deficient mice indicate that it is dispensable for the TLR4 and TLR3 
induced TRIF pathway (Gohda et al., 2004). In addition TRAF1 and TRAF4 have been shown 
to function as negative regulators of TRIF dependent IFNβ expression, however, the 
mechanisms are so far unclear (Su et al., 2006; Takeshita et al., 2005). 
1.5.4.2 IRF activation by MyD88 dependent TLR signalling pathways 
Plasmacytoid DCs are characterised by their ability to produce large amounts of type I IFNs in 
response to viral infections (McKenna et al., 2005). TLR7 and TLR9, which are localised in the 
endosome, are the TLRs used by pDCs to detect viruses and induce type I IFNs. Splenic pDCs 
from IRF7-deficient mice show a defect in type I IFN production following stimulation with the 
TLR7 or TLR9 ligands ssRNA or CpG-DNA respectively (Diebold et al., 2004; Heil et al., 
2004; Klinman, 2004). Since TLR7 and TLR9 do not utilise TRIF, the pathways induced are 
distinct from TLR3 and TLR4. MyD88 has been shown to specifically interact with IRF7, but 
not IRF3, at the endosomal compartment through its DD (Honda et al., 2005a; Honda et al., 
2004; Kawai et al., 2004). Furthermore, pDCs deficient in MyD88 or IRAK1 or IRAK4 or 
IKKα do exhibit a defect in IFNα expression following TLR9 stimulation (Honda et al., 2004; 
Hoshino et al., 2006; Uematsu et al., 2005). These data suggests, that TLR9 and TLR7 utilise a 
similar pathway to NF-κB activation leading to the phosphorylation of IRF7 in murine pDCs 
(Figure 1.9). 
In addition to IRF7, IRF5 also seems to be utilised by the MyD88 dependent pathway of 
numerous TLRs. The induction of TNFα, IL-6 and IL12p40 by macrophages and myeloid DCs 
from IRF5-deficient mice is impaired in response to TLR4, TLR5, TLR7 and TLR9 stimulation 
(Schoenemeyer et al., 2005; Takaoka et al., 2005). Interaction between IRF5 and MyD88 as 
well as TRAF6 has been described but unlike IRF7, IRF5 binds the intermediary domain and 
part of the TIR domain of MyD88 (Negishi et al., 2005; Takaoka et al., 2005). However, the 
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function of IRF5 in the MyD88 pathway is far from understood and seems to be cell type 
specific, as B cells from IRF5 deficient mice do show normal pro-inflammatory cytokine 
production and NF-κB as well as MAPKs in response to TLR stimulation (Takaoka et al., 
2005). IRF4 has also been shown to form complexes with MyD88 (Negishi et al., 2005). 
Similar to IRF5, IRF4 binds the central region of MyD88 and is suggested to compete with 
IRF5 for binding (Negishi et al., 2005). Indeed, peritoneal macrophages from IRF4 deficient 
mice show increased cytokine production induced by TLR2, TLR3, TLR4 and TLR9 
stimulation (Negishi et al., 2005). Due to its restricted expression pattern, being highly 
expressed in B- and T cells, IRF4 might provide a cell type specific mechanism for the 
inhibition of MyD88 dependent gene induction (Lohoff and Mak, 2005). 
Beside the induction of the TLR signalling pathways described above, emerging evidence 
suggest that numerous other signalling pathways are activated following TLR stimulation. 
These include the phosphoinositide 3-kinase (PI3K) pathway, which is generally thought to 
inhibit TLR induced pro-inflammatory cytokine expression (Hazeki et al., 2007; Ruse and 
Knaus, 2006), as well as the tyrosine kinase families Tec and Src, which become activated at 
the receptor proximal level and have been shown to take part in TLR induced cytokine 
production (Horwood et al., 2003; Palmer et al., 2008; Smolinska et al., 2008). However, since 
these pathways are not the subject of this study they will not be discussed in further detail. 
1.5.5 Negative regulation of TLR signalling 
As described in section 1.5 TLR signalling induces a strong inflammatory response in 
macrophages and DCs. While inflammation is important for clearing infections and tissue 
repair, excessive inflammation can lead to chronic inflammatory diseases (see section 1.4). In 
order to keep an inflammatory response in check the signalling pathways inducing it must be 
tightly regulated. Regulatory mechanisms, inhibiting TLR signalling, have been described at all 
levels of signal transduction (Figure 1.11) (Lang and Mansell, 2007; Liew et al., 2005). 
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Figure 1.11: Negative regulation of the TLR signalling pathway. See text for details. Abbreviations: 
SIGIRR (single immunoglobulin IL-1R related), ST2 (suppressor of tumorigenicity 2), RP105 
(radioprotective 105), MyD88 (myeloid differentiation primary response gene 88), TOLLIP (toll-
interacting protein), IRAK (IL-1R associated kinase), TRAF (TNF-receptor associated factor). 
 
1.5.5.1 Extracellular TLR inhibitors 
Soluble decoy receptors, including IL-1RA, are well established negative regulators, which are 
able to prevent acute inflammatory responses by directly interacting with the ligand and/or 
receptor (Colotta et al., 1994). In case of TLR signalling soluble decoy receptors have been 
described for TLR2 and TLR4. Although, the TLR4 gene is present as one copy several mRNA 
products have been identified in mice and humans, which indicates the existence of TLR4 
isoforms (Qureshi et al., 1999). The screening of a mouse macrophage cDNA library described 
a 122 amino acid long, soluble form of TLR4, which corresponds largely to the extracellular 
domain of TLR4 (Iwami et al., 2000). This soluble isoform has been shown to inhibit LPS 
induced activation of NF-κB and the production of TNFα in macrophages (Iwami et al., 2000). 
While the mechanism is still unclear the same study suggested that soluble TLR4 might block 
the interaction between TLR4 and co-receptors such as MD-2 and CD14. Similarly, soluble 
isoforms of TLR2 have been identified in human milk and plasma (LeBouder et al., 2003). It 
has been demonstrated, that soluble TLR2 directly binds the TLR2 ligand peptidoglycan, 
thereby inhibiting the production of IL-8 and TNFα from peptidoglycan stimulated monocytes 
(Iwaki et al., 2002).  
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1.5.5.2 Transmembrane TLR inhibitors 
Negative regulators of TLR signalling located in the transmembrane are generally thought to 
function by either sequestering ligands and/or signalling transducers or by blocking access to 
the receptor (Figure 1.11). 
Described transmembrane inhibitors include the IL-1R family members SIGIRR (Single 
immunoglobulin IL-1R related protein) and ST2 (suppressor of tumoigenicity 2) as well as the 
TLR4 homologue RP105 (radioprotective 105). Unlike SIGIRR and ST2, RP105 does not 
posses an intracellular TIR domain. Although, this suggests that RP105 is unable to signal, LPS 
induced phosphorylation of CD19 in murine B cells has been shown to depend on RP105 while 
being TLR4 independent (Yazawa et al., 2003). Contrary to this report, studies using HEK293 
cells reported that RP105 interacts with TLR4 and MD-2 following LPS stimulation, thereby 
inhibiting TLR4 signalling through blocking access of the ligand to TLR4 (Divanovic et al., 
2005b). In addition, RP105 has been shown to require the co-receptor MD-1 in order to be able 
to associate with the TLR4/MD-2 complex (Divanovic et al., 2005a). 
The IL-1R family member ST2 exists in two isoforms, membrane bound ST2L and soluble 
sST2, which corresponds to the extracellular region of ST2L (Bergers et al., 1994; Kropf et al., 
2003; Tominaga, 1989). ST2L has been originally described as an orphan receptor specifically 
expressed on Th2 but not Th1 or Th17 cells and has been shown to be essential for Th2 
development and function (Coyle et al., 1999; Lohning et al., 1999; Lohning et al., 1998; Nakae 
et al., 2007; Townsend et al., 2000; Xu et al., 1998). In addition, ST2L has been described to 
specifically inhibit the MyD88 dependent TLR signalling pathway in murine macrophages and 
HEK293 cells by sequestering MyD88 and Mal through its TIR domain (Brint et al., 2004). 
Subsequently, its ligand, IL-33, has been discovered, which has the capability to drive Th2 
associated cytokine expression in vivo as well as in vitro through initiating the recruitment of 
MyD88, IRAK1, IRAK4 and TRAF6 to ST2 (Schmitz et al., 2005). The function of sST2 is not 
yet defined. However, it has been shown to be up-regulated in inflammatory diseases and to 
down-regulate mRNA expression of TLR1 and TLR4 in LPS stimulated macrophages in vitro 
(Kumar et al., 1997; Kuroiwa et al., 2001; Oshikawa et al., 2001; Saccani et al., 1998; Sweet et 
al., 2001; Tajima et al., 2003; Weinberg et al., 2002). Furthermore, administration of sST2 to 
LPS stimulated macrophages suppresses the production of pro-inflammatory cytokines and 
attenuates septic shock (Sweet et al., 2001). Interestingly, sST2 also shows significant efficacy 
in reducing CIA pathology, which has been hypothesised to be due to blocking macrophage 
activation by binding to a so far unidentified receptor (Leung et al., 2004). However, contrary 
to that report, administration of sST2 in a murine asthma model reduced the production of IL-4, 
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IL-5 and IL-13 by IL-33 stimulated splenocytes (Hayakawa et al., 2007), suggesting that 
soluble ST2 binds IL-33 and/or ST2L, thereby acting as an antagonist. 
Similar to ST2, SIGIRR (also known as Toll/IL-1R8 (TIR8)) is a member of the IL-1R family. 
Unlike other IL-1R family member it consists of a single Ig like extracellular domain and an 
uncharacteristic long cytoplasmic tail, which includes a TIR domain. In addition, SIGIRR has 
been shown to have a highly specific expression pattern, being expressed in epithelial cells and 
immature DCs but not in macrophages (Polentarutti et al., 2003). To date no activation function 
of SIGIRR has been described and SIGIRR deficient mice display increased inflammation in 
the DSS-induced colitis model and a higher susceptibility to septic shock, indicating an 
inhibitory function of SIGIRR on the immune system (Garlanda et al., 2004; Wald et al., 2003; 
Xiao et al., 2007). Further in vitro studies confirmed a role for SIGIRR in regulating TLR/IL-
1R signalling. BMDCs from SIGIRR deficient mice display enhanced cytokine production in 
response to LPS or CpG-DNA but not poly I:C, indicating a MyD88 specific function 
(Garlanda et al., 2004). Furthermore, over-expression of SIGIRR in Jurkat cells stimulated with 
IL-1 or IL-18 led to the inhibition of NF-κB (Wald et al., 2003). Its mode of action has been 
suggested to be as a blocking receptor, as it interacted with IL-1R, TLR4, MyD88, IRAK1 and 
TRAF6 in HEK293 cells following IL-1 or LPS stimulation, thereby inhibiting IL-1R and 
TLR4 signalling (Qin et al., 2005). Furthermore, SIGIRR has been shown to exhibit cell type 
specific functions as it is upregulated by resident intrarenal myeloid cells but down regulated by 
tubule epithelial cells in response to LPS (Lech et al., 2007). While no general ligand for 
SIGIRR has been described yet, there is evidence emerging for SIGIRR acting as a signal 
transducing receptor. Costelloe and colleagues described that IL-1F5 induced IL-4 production 
in the brain is dependent on SIGIRR, however, so far this dependency of IL-1F5 on SIGIRR 
has not been observed in other systems and needs to be further investigated (Costelloe et al., 
2008). Indications for an involvement of SIGIRR in human diseases come from expression 
studies, which demonstrated altered expression patterns of SIGIRR mRNA. SIGIRR has been 
shown to display reduced expression in psoriatic arthritis patients compared to rheumatoid 
arthritis (RA) (Batliwalla et al., 2005). Furthermore, reduced expression of SIGIRR has been 
demonstrated in children with asymptomatic bacteriuria while increased expression in 
monocytes from septic patients has been observed (Adib-Conquy et al., 2006; Ragnarsdottir et 
al., 2007). However, to date no association of SIGIRR polymorphisms with diseases could be 
identified (Nakashima et al., 2006). 
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1.5.5.3 Cytoplasmic TLR inhibitors 
Intracellular inhibitors of TLR signalling target all levels of signal transduction. Therefore, the 
specificity of an inhibitor increases the more receptor proximal it functions. Numerous 
intracellular TLR inhibitors are described, which include highly specific ones such as MyD88s 
and SARM as well as more general inhibitors such as A20 (Lang and Mansell, 2007; Liew et 
al., 2005). In general, these TLR inhibitors function by inducing the degradation of their target, 
e.g. TRIAD3A, sequestering their target, e.g. IRAK-M, or blocking access for essential signal 
transducers, e.g. MyD88s. 
MyD88s is a short splice version of MyD88, which lacks the intermediate domain between TIR 
domain and DD (Janssens et al., 2002; Janssens et al., 2003). Over-expression of MyD88s leads 
to an impairment of NF-κB activation in LPS- but not TNFα-stimulated monocytes (Janssens et 
al., 2002). Furthermore, MyD88s has been shown to be up-regulated in response to LPS and to 
form heterodimers with MyD88 (Burns et al., 2003). These heterodimers are preferentially 
recruited to the TLR instead of MyD88 homodimers, which leads to an ablation of IRAK4 
recruitment and subsequently to an inhibition of IRAK1 phosphorylation (Janssens et al., 
2003). 
SARM is the most recently identified TLR adaptor protein but until recently its function has 
been elusive. However, a report by Carty and colleagues provide evidence for an inhibitory role 
of SARM, which is specific for TRIF dependent TLR signalling (Carty et al., 2006). Over-
expression studies as well as siRNA knock down of SARM in HEK293 cells and monocytes 
describe a specific effect on TLR3 and TLR4 induced NF-κB activation and cytokine 
production. Furthermore, LPS treatment of monocytes induces the expression of SARM, 
suggesting a negative feedback loop of TRIF dependent TLR signalling by SARM (Carty et al., 
2006).  
IRAK-M is a member of the IRAK family; however, unlike other family members IRAK-M 
possesses no phosphorylation capability (Janssens and Beyaert, 2003). The expression of 
IRAK-M is highly restricted, being specifically expressed in monocytes and macrophages, 
indicating a specific inhibitory function (Wesche et al., 1999). IRAK-M deficient mice show 
elevated inflammatory responses to bacterial ligands (Kobayashi et al., 2002). Furthermore, in 
vitro studies have shown that IRAK-M prevents the dissociation of IRAK-4/IRAK-1 complexes 
from the TLR, thereby preventing further downstream signalling (Kobayashi et al., 2002). 
Toll-interacting protein (Tollip) interacts with the IL-1R accessory protein and has been 
described to be involved in recruiting IRAKs to the TLR complex (Burns et al., 2000). Tollip 
exists as three isoforms from, which Tollip-1 has been shown to interact with TLR2 and TLR4 
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(Zhang and Ghosh, 2002). Over-expression of Tollip-1 in HEK293 cells leads to the inhibition 
of TLR2 and TLR4 induced NF-κB activation (Zhang and Ghosh, 2002). Interaction of Tollip 
with IRAK-1 results in increased Tollip phosphorylation and the release of Tollip from the 
complex. Consequently, IRAK-1 becomes ubiquitinated and degraded, thereby terminating 
signal transduction (Zhang and Ghosh, 2002).  
TRIAD3A is a zinc RING finger protein that acts as an E3 ubiquitin protein ligase (Chuang and 
Ulevitch, 2004). Using a yeast-two-hybrid system, TRIAD3A has been identified to interact 
with TIR domain containing proteins. Over-expression of TRIAD3A leads to the ubiquitination 
of TLR4 and TLR9, but not TLR2 or TLR3, and subsequent decreased signal transduction 
(Chuang and Ulevitch, 2004). Supporting these observations are siRNA knock down studies of 
TRIAD3A, which leads to an increase in TLR4 and TLR9 but not TLR2 signalling (Chuang 
and Ulevitch, 2004). In addition, evidence suggests that TRIAD3A targets additional TIR 
domain containing molecules for degradation, including RIP-1 and Mal, thereby modulating 
immune responses (Fearns et al., 2006). 
The SOCS family of proteins consists of eight members, which are part of a negative feedback 
regulation in response to cytokine signalling (Endo et al., 1997; Naka et al., 1997; Starr et al., 
1997). Recent data suggests that SOCS-1 is involved in TLR signalling regulation as SOCS-1 
has been shown to associate with phosphorylated Mal thereby targeting it for ubiquitination and 
subsequent degradation (Mansell et al., 2006). Since Mal is utilised by TLR2 and TLR4, it has 
been demonstrated that the removal of SOCS-1 leads to increased NF-κB activation and IL-6 
production induced by these TLRs in macrophages (Mansell et al., 2006). 
A20 is a zinc RING finger domain protein whose expression is rapidly increased in response to 
LPS but also TNFα, indicating a general role in regulating inflammatory responses (Krikos et 
al., 1992; Opipari et al., 1990). Furthermore, A20 was identified to inhibit the MyD88 
dependent as well as the TRIF dependent TLR signalling pathways as A20 deficient mice show 
increased production of pro-inflammatory cytokines in response to TLR2, TLR3 and TLR9 
stimulation (Boone et al., 2004). Regulation of TLR signalling by A20 has been shown to be 
the result of the de-ubiqutination function of A20, which leads to the cleavage of polyubiquitin 
chains on TRAF6, rendering it inactive (Boone et al., 2004). 
Defects in the regulatory mechanisms described above can lead to excessive inflammation and 
tissue destruction and ultimately to the initiation of inflammatory diseases. 
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1.5.5.4 Pathogenic TLR inhibitors 
Interestingly, the TLR pathways are also targeted by several viruses and bacteria in order to 
suppress host immunity. The NS3 protein from hepatitis C virus (HCV) and the N1L proteins 
from vaccinia virus (VV) block the antiviral response by interacting with TBK-1, thereby 
inhibiting IRF3 activation (DiPerna et al., 2004; Otsuka et al., 2005). Moreover, the N1L 
protein and the proteins A46R and A52R from VV down-regulate IL-1/TLR induced activation 
of NF-κB (Bowie et al., 2000; Stack et al., 2005). TIR domain containing proteins (Tcp) have 
been identified in virulent strains of Escherichia coli and Brucella melitensis (Bowie et al., 
2000; Harte et al., 2003). These Tcps have been shown to inhibit TLR signaling through 
binding MyD88, thereby sequestering MyD88 from the TLR (Cirl et al., 2008). The fact that 
TLR signaling pathways are controlled endogenously, as well as being targeted by pathogens, 
further highlights their importance in the initiation of the immune response. 
Chapter 1 Introduction 
 56
1.6 Aims 
Extensive research into the involvement of TLRs in the immune response has indicated that 
they might play a role in the initiation and/or propagation of chronic inflammatory diseases 
such as RA. Although the TLR signalling pathways have been widely investigated, the majority 
of these studies have been performed in cells from gene deficient mice or inhibition 
experiments in transformed cell lines that are genetically abnormal. However, results obtained 
in our laboratory before this study suggested differences between these systems and primary 
human cells. Andreakos and colleagues could show that expression of dominant negative 
MyD88 inhibits TLR4 signalling in HUVECs but not in primary human macrophages 
(Andreakos et al., 2004). In order to better understand the roles TLRs play in human immune 
regulation and disease processes, I further investigated the function of MyD88 in primary 
human DCs. As a consequence of those results, the role and function of the TLR inhibitor 
SIGIRR was further examined in primary human cells as well as disease models, such as CIA. 
The specific objectives of this project were: 
- To determine the function of the TLR adaptor molecules in monocyte derived DCs and 
macrophages by using adenoviral gene transfer of wild-type as well as dominant 
negative constructs of those molecules. 
- As the project evolved, to characterise the role of SIGIRR as an inhibitor of TLR 
signalling in monocyte derived DCs and macrophages using adenoviral gene transfer as 
well as siRNA knock down techniques. 
- To determine the role and function of SIGIRR in RA disease models including human 
RA synovial membranes and CIA and to investigate SIGIRR as possible target for RA 
treatment. In order to achieve this, adenoviral-gene transfer techniques as well as 
SIGIRR deficient mice have been used. 
The characterisation of TLR signalling pathways and specific regulatory components in human 
cells as well as disease models is crucial in order to establish their potential as targets to treat or 
prevent inflammatory diseases such as RA. 
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2.1 Materials  
All general laboratory reagents and chemicals were purchased from Sigma-Aldrich, Dorset, 
UK, or BDH Chemicals, Dorset, UK, unless otherwise stated.  
2.1.1 Cytokines  
Human recombinant cytokines used for cell culture and as concentration standards are listed in 
Table 2.1. 
Table 2.1: Human/murine Recombinant Cytokines 
Cytokine Concentrations Use Source 
GM-CSF* 50 ng/ml Tissue culture Behringerwerke AG, Marburg, 
Germany 
M-CSF* 100 ng/ml Tissue culture Genetics Institute Inc., MA, USA 
IL-4* 10 ng/ml Tissue culture Novartis Pharma AG, Basel, 
Switzerland 
TNFα 10,000-13.71 pg/ml ELISA/Tissue 
culture 
BD Biosciences, Oxford, UK 
IL-6 10,000-13.71pg/ml ELISA BD Biosciences, Oxford, UK 
IL-8 10,000-13.71 pg/ml ELISA BD Biosciences, Oxford, UK 
IL-10 10,000-13.71 pg/ml ELISA BD Biosciences, Oxford, UK 
IP10 10,000-13.71 pg/ml ELISA R&D, Minneapolis, USA 
IL-1α 20 ng/ml Tissue culture R&D, Minneapolis, USA 
IL-1β 10,000-13.71 pg/ml ELISA BD Biosciences, Oxford, UK 
GM-CSF** 20 ng/ml Tissue culture PeproTech, London, UK 
IL-1α** 20 ng/ml Tissue culture PeproTech, London, UK 
IL-33** 20 ng/ml Tissue culture PeproTech, London, UK 
TNFα** 10,000-13.71 pg/ml ELISA BD Biosciences, Oxford, UK 
IL-10** 10,000-13.71 pg/ml ELISA BD Biosciences, Oxford, UK 
IL-5** 10,000-13.71 pg/ml ELISA R&D, Minneapolis, USA 
IL-17** 10,000-13.71 pg/ml ELISA BD Biosciences, Oxford, UK 
IFNγ** 10,000-13.71 pg/ml ELISA PeproTech, London, UK 
* gifted reagent, ** murine 
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2.1.2 Antibodies 
Capture and detecting antibodies used for enzyme linked immunosorbent sandwich assay 
(ELISA) are listed in Table 2.2. Primary antibodies used for western blotting (WB), flow 
cytometry and immunoprecipitation (IP) are listed in Table 2.3. Secondary antibodies used for 
WB are listed in Table 2.4. The concentrations/titres for the antibodies used were in accordance 
with the company’s recommendation. Preliminary experiments were performed to determine 
the optimal titre if data was unavailable. 
Table 2.2: ELISA antibodies 
Specificity Concentration Antibody  Source 
TNF 4 µg/ml Coat BD Biosciences, Oxford, UK 
 0.5 µg/ml Detect BD Biosciences, Oxford, UK 
IL-6 1 µg/ml Coat BD Biosciences, Oxford, UK 
 0.5 µg/ml Detect BD Biosciences, Oxford, UK 
IL-8 2 µg/ml Coat BD Biosciences, Oxford, UK 
 0.5 µg/ml Detect BD Biosciences, Oxford, UK 
IL-10 1 µg/ml Coat BD Biosciences, Oxford, UK 
 1 µg/ml Detect BD Biosciences, Oxford, UK 
IP10 4 µg/ml Coat R&D, Minneapolis, USA 
 100 ng/ml Detect R&D, Minneapolis, USA 
IL-1β 2 µg/ml Coat BD Biosciences, Oxford, UK 
 0.2 µg/ml Detect BD Biosciences, Oxford, UK 
IL-10* 4 µg/ml Coat BD Bioscience, Oxford, UK 
 0.25 µg/ml Detect BD Bioscience, Oxford, UK 
TNFα* 1 µg/ml Coat BD Bioscience, Oxford, UK 
 0.25 µg/ml Detect BD Bioscience, Oxford, UK 
IL-5* 2 µg/ml Coat BD Bioscience, Oxford, UK 
 1 µg/ml Detect BD Bioscience, Oxford, UK 
IL-17* 1 µg/ml Coat BD Bioscience, Oxford, UK 
 1 µg/ml Detect BD Bioscience, Oxford, UK 
IFNγ* 4 µg/ml Coat BD Bioscience, Oxford, UK 
 1 µg/ml Detect BD Bioscience, Oxford, UK 
Streptavidin-HRP 1:400 n.a. R&D, Minneapolis, USA 
* murine 
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Table 2.3: Western blotting, flow cytometry and immunoprecipitation antibodies 
Specificity (human) Species Use Concentration Source 
SIGIRR  Goat flow cytometry 1:1000 R&D, Minneapolis, USA 
TLR4 Mouse flow cytometry 1:1000 Imgenex, San Diego, USA 
TRAM Rabbit WB 1:1000 Made in house 
MyD88 Rabbit WB 1:1000 Abcam Ltd, Cambridge, UK 
α-Tubulin Mouse WB 1:10,000 Sigma, Poole, Dorset, UK 
Flag Mouse WB/IP 1:1000 Sigma, Poole, Dorset, UK 
HA Mouse WB/IP 1:2000/5µg/ml Covance, California, USA 
IRF3 Mouse WB 1:2000 Santa Cruz Biotechnology, 
Santa Cruz, CA USA 
phospho IκBα Mouse WB 1:1000 New England Biolabs, 
Ipswich, MA, USA 
phospho JNK Rabbit WB 1:1000 New England Biolabs, 
Ipswich, MA, USA 
phospho p38 
(Thr180/Tyr182) 
Rabbit WB 1:1000 Cell Signaling Technology, 
Beverley, MA, USA 
total p38 MAPK Rabbit WB 1:2000 Prof. J. Saklatvala, Imperial 
College London, UK 
Vimentin-Biotinylated Mouse flow cytometry 1:1000 Neo Markers, CA, USA 
CD3-FITC Mouse flow cytometry 1:1000 BD Bioscience, Oxford, UK 
CD3-PECy5 Mouse flow cytometry 1:1000 BD Bioscience, Oxford, UK 
CD14-PE Mouse flow cytometry 1:1000 BD Bioscience, Oxford, UK 
CD14-FITC Mouse flow cytometry 1:1000 BD Bioscience, Oxford, UK 
CD86-PE Mouse flow cytometry 1:1000 BD Bioscience, Oxford, UK 
IgG1-PE Mouse flow cytometry 1:1000 BD Bioscience, Oxford, UK 
IgG2a-PE Mouse flow cytometry 1:1000 BD Bioscience, Oxford, UK 
IgG1-FITC Mouse flow cytometry 1:1000 BD Bioscience, Oxford, UK 
IgG2a-FITC Mouse flow cytometry 1:1000 BD Bioscience, Oxford, UK 
IgG-Biotinylated Goat flow cytometry 1:1000 Abcam Ltd, Cambridge, UK 
* gifted reagent, 
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Table 2.4: Western blotting secondary antibodies 
Specificity Species Dilution Source 
Anti mouse IgG F (ab)2 
HRP conjugate 
Sheep 1:3000 Amersham Biosciences, Little 
Chalfont, UK 
Anti goat IgG HRP 
conjugate 
Rabbit 1:3000 DAKO, Glostrup, Denmark 
Anti rabbit IgG F (ab)2 
HRP conjugate 
Donkey 1:3000 Amersham Biosciences, Little 
Chalfont, UK 
2.1.3 TLR ligands 
Toll-like receptor ligands used for cell stimulation are listed in Table 2.5. 
Table 2.5: TLR ligands 
Receptor(s) Ligand Description Source 
TLR 2/6 Malp-2 Macrophage-activating 
lipopeptide-2 
Alexis, Nottingham, UK 
TLR3 Poly I:C Synthetic analogue of 
double stranded RNA 
Amersham Biosciences, Little 
Chalfont, UK 
TLR 4 LPS Lipopolysaccharide from 
Escherichia coli 
Alexis, Nottingham, UK 
TLR 5 Flagellin From S. typhimurium Alexis, Nottingham, UK 
TLR7/8 R848 Small antiviral molecules Invivogen, San Diego, CA, USA 
Abbreviations: Lipopolysaccharide (LPS), Macrophage-activating lipopeptide-2  (MALP-2), Pam3Cys-
Ser-(Lys)4 . trihydrochloride (Pam3Cys), polyinosinic- polycytidylic acid (poly I:C) 
 
2.1.4 Inhibitors 
Enzyme inhibitors used in cell lysis buffer are listed in Table 2.6. RNA oligonucleotides for 
RNA interference (RNAi) used in this project are listed in. 
Table 2.6: Enzyme inhibitors 
Inhibitor Cellular Target Source 
Protease Inhibitor Cocktail  Sigma, Poole, Dorset, UK 
 AEBSF (104 mM) Serine proteases  
 Aprotinin (80 µM) Serine proteases  
 Leupeptin (2.1 mM) Serine and cysteine proteases  
 Bestatin (3.6 mM) Aminopeptidases  
 Pepstatin A (1.5 mM) Acid proteases  
 E-64 (1.4 mM) Cysteine proteases  
Sodium Fluoride Protein phosphatases Sigma, Poole, Dorset, UK 
Sodium Orthovanadate Protein phosphatases Sigma, Poole, Dorset, UK 
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Table 2.7: RNAi oligonucleotides 
Target Type Catalogue Number Source 
Non targeting siControlTM D-001206-13 Dharmacon, Illinois, USA 
Human SIGIRR SMARTpool M-008082-00 Dharmacon, Illinois, USA 
 
2.1.5 Molecular biology reagents 
One-Step RT-PCR Taqman® reagents and fluorescent probes were purchased from Applied 
Biosystems, California, USA and are listed in Table 2.10. Enzymes and reagents used in virus 
production are described in the Table 2.8 and Table 2.9. The nuclear acid isolation and 
purification kits were obtained from Qiagen Ltd., Crawley, West Sussex, UK. 
Table 2.8: Restriction enzymes and DNA modifying enzymes 
Enzymes Function Buffer Source 
EcoR I/ Not I Restriction 
enzymes 
Provided 
buffer  
New England Biolabs, MA, USA 
Sma I Restriction 
enzymes 
NEB4 New England Biolabs, MA, USA 
Pac I Restriction 
enzyme 
Provided 
buffer  
Q-biogene, Cambridge, UK 
T4 DNA ligase DNA Ligase Provided 
buffer 
New England Biolabs, MA, USA 
Polishing kit PFU polymerase Provided 
buffer 
Stratagene, TX, USA 
Gateway LR clonase 
enzyme mix 
homologous 
recombination 
Provided 
buffer 
Invitrogen, Paisley, UK 
shrimp alkaline 
phosphatase 
phosphatase Provided 
buffer 
Promega, Southampton, UK 
Abbreviations: New England Biolabs (NEB) 
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Table 2.9: Molecular biology reagents and competent bacteria 
Reagents  Use Source 
Agarose electrophoresis grade 1% (w/v) Invitrogen, Paisley, UK 
Antibiotics:                 
- Ampicillin 100 mg /ml Sigma, Poole, UK 
- Kanamycin 30 mg/ml Invitrogen, Paisley, UK 
- Chloramphenicol 34 mg/ml Sigma, Poole, UK 
Competent bacteria:     
- E. coli strain XL-I 
Blue 
n.a. Stratagene, Cambridge, UK 
- E. coli strain TOP10 n.a. Invitrogen, Paisley, UK 
SYBR Green II 1:10.000 Molecular probes, Eugene, Oregon, USA 
EZ Load 100bp, 500bp or 1 
kb molecular ruler 
 
8 µl/ gel Bio-Rad Laboratories, Hercules, CA, USA 
Ethidium bromide 0.1 µg/ml Sigma, Poole, UK 
LB Agar 32 g/ litre Invitrogen, Paisley, UK 
LB Broth base 20 g/ litre Invitrogen, Paisley, UK 
Abbreviations: not applicable (n.a.). 
 
Kits were obtained from Qiagen Ltd., Hilden, Germany. 
Table 2.10: Primers 
Specificity Sequence (5’-3’) Use 
GAPDH forward n.a.-proprietary information by company Taqman PCR Applied 
Biosystems, CA, USA 
GAPDH reverse n.a.-proprietary information by company Taqman PCR Applied 
Biosystems, CA, USA 
SIGIRR forward n.a.-proprietary information by company Taqman PCR Applied 
Biosystems, CA, USA 
SIGIRR reverse n.a.-proprietary information by company Taqman PCR Applied 
Biosystems, CA, USA 
T7 forward CATTATGCTGAGTGATATCCCG Sequencing 
T3 reverse TTAATTGGGAGTGATTTCCC Sequencing 
Abbreviations: not applicable (n.a.). 
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2.1.6 Reagents used for viral purification and titre determination 
Seaplaque GTG-agarose and 2x MEM were obtained from Sigma and Gibco, Invitrogen, 
California, USA, respectively. The polyallomer ultracentrifuge tubes were purchased from 
Sorvall, Connecticut, USA, and the PD10 columns from Amersham Biosciences, UK. Adeno-
XTM Rapid titre kit was obtained from BD Biosciences, New Jersey, USA.  
2.1.7 Tissue culture reagents and cell lines 
Roswell Park Memorial Institute 1640 medium (RPMI) containing 25 mM L-glutamine, 
Dulbecco’s modified Eagle’s Medium (DMEM) with Glucose and L-Glutamine, Hank’s 
Balanced Salt Solution (HBSS), Penicillin/Streptomycin (P/S), and Trypsin/EDTA were 
obtained as sterile solutions from Cambrex, Nottingham, UK. Heat inactivated (HI) foetal calf 
serum (FCS) was purchased from Biowest, East Sussex, UK. Cell dissociation solution was 
purchased from Sigma. MTT (3-[4,5-Dimethylthiazol-2yl]-2,5-diphyltetrazolium bromide3-
[4,5-Dimethylthiazol-2yl]-2,5-diphyltetrazolium bromide) (for use in cell viability assays) were 
obtained from Sigma. Lymphocyte®-H Solution was purchased from Cedarlane Laboratories 
Limited, Ontario, Canada.   
Cell culture was performed in FalconTM plastics obtained from BD Biosciences, Oxford, UK. 
Cell lines used in this project are listed in Table 2.11. 
Table 2.11: Cell lines 
Cell Line Description Source 
AD-293 Human embryonic kidney (HEK293)-
derived AD-293 cells producing the 
adenovirus E1 gene in trans, allowing 
production of infectious virus particles from 
∆E1 
Stratagene, California, USA 
HSF Human foreskin fibroblast Prof J. Saklatvala Imperial 
College London, UK 
 
2.1.8 Transfection reagents 
Monocytes were transfected with RNAi oligonucleotides using the Human Monocyte 
Nucleofector® Kit (Amaxa Biosystems, Cologne, Germany). All transfections were performed 
according to the manufacturer’s instructions.  
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2.1.9 Biochemical reagents 
All other reagents used for western blotting, immunoprecipitation, flow cytometry, ELISA, and 
luciferase reporter assays are listed in Table 2.12. 
Table 2.12: Biochemical reagents 
Reagent Source 
Full range Rainbow molecular weight 
marker RNP800 
Amersham Biosciences, Little Chalfont, UK 
HyperfilmTM  Amersham Biosciences, Little Chalfont, UK 
PVDF transfer membrane Perkin Elmer Life Sciences Inc., Massachusetts, 
USA 
Midi-gel Bio-Rad, Hercules, CA, USA 
Streptavidin PE conjugated BD Bioscience, Oxford, UK 
Saponin Sigma, Poole, UK 
ECLTM Western blotting detection reagent Amersham Biosciences, Little Chalfont, UK 
BCATM Protein assay kit Pierce, Illinois, USA 
TMB (3,3’,5,5’-tetramethylbenzinide) 
peroxidase substrate and peroxidase 
substrate solution 
KPL Inc., Maryland, USA 
Re-Blot Western Blot recycling kit (acid 
strip buffer) 
Chemicon International Inc, California, USA 
MaxisorbTM ELISA plates Nunc A/S, Roskilde, Denmark 
Bright-GloTM Luciferase Assay System Promega, Southampton, UK 
γ-32P-ATP GE Healthcare, BioSciences AB, Upsalla, 
Sweden 
Protein G SepharoseTM GE Healthcare, BioSciences AB, Upsalla, 
Sweden 
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2.1.10 Solutions 
General Buffers  
Phosphate buffered saline (PBS) 4.3 mM Na2HPO4 
 1.4 mM KH2CO3 
 1.4 mM KCL 
 137 mM NaCl 
 pH 7.2 
  
Tris buffered saline (TBS) 20 mM Tris/Base 
 137 mM NaCl 
 pH 8.0 
  
Protein Extraction Buffers  
Triton lysis buffer 1% (v/v) Triton-X 100 
 10 mM Tris/Base pH 7.6 
 150 mM NaCl 
 1 mM EDTA 
 100 µM Na2VO3* 
 5 mM NaF* 
 1:100 protein inhibitor cocktail* (Table 2.7.) 
 *added freshly  
  
Sodium orthovanadate stock solution 100 mM Na2OV3 
 0.0001% (v/v) H2O2 
 pH 10.0 
 Boiled for 60-90 min 
 Stored at 4°C 
  
SDS-PAGE and Western Blotting Buffers  
Running buffer 25 mM Tris/Base 
 192 mM Glycine 
 0.1% (w/v) SDS 
  
5x protein gel sample buffer (GSB) 250 mM Tris/HCl pH 6.8 
 10% (w/v) SDS 
 50% (v/v) glycerol 
 12.5% (v/v) β-mercaptoethanol 
 (Add Tris/HCl, SDS & H2O and heat to 50°C. 
Add glycerol, β-mercaptoethanol and 
bromophenol blue) 
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Transfer buffer 25 mM Tris/Base  
 192 mM glycine 
 20% (v/v) methanol 
  
Acid stripping buffer Purchased from Chemicon (Table 1.12) 
  
Washing buffer (TBS/T) 1xTBS 
0.1% (v/v) Tween 20 
  
Blocking buffer (milk) 1x TBS/T 
5% (w/v) skimmed milk 
  
Blocking buffer (BSA) 1x TBS/T 
5% (w/v) BSA 
  
ELISA Buffers  
ELISA buffer 1x PBS 
0.5% (w/v) BSA 
  
ELISA wash buffer (PBS/T) 1x PBS 
 0.01% (v/v) Tween 20 
  
ELISA blocking buffer 1x PBS 
 2% (w/v) BSA 
ELISA substrate solution TMB peroxidase solution (Table 2.13.) 
  
ELISA stop solution 6% (v/v) Sulphuric Acid (H2SO4) 
  
Taqman Buffers  
Master Mix Reagent Purchased from Applied Biosystems (part 
number 4309169) 
  
Adenoviral Purification Buffers  
Saturated CsCl solution ~35 ml 0.01M Tris 
 1 mM EDTA 
 CsCl added until saturated 
  
PBS2+ 1x PBS 
 0.01% (w/v) CaCl2 
 0.01% (w/v) MgCl2 
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1.4g/ml density CsCl 0.534 g CsCl/ml H2O 
  
1.34g/ml density CsCl 212.5 ml of 1.4 g/ml CsCl in 37.5 ml PBS2+ 
  
Luciferase Assay Buffers  
Luciferase assay buffer (LAB) 25 mM Tris phosphate pH 7.8 
 8 mM MgCl2 
 1 mM EDTA 
 1% (v/v) Triton-X 100 
 1 mM DTT* 
 0.5 mM ATP* 
 *Added freshly 
  
Luciferase lysis (CAT) buffer 10 mM Tris/Base pH 8.0 
 1 mM EDTA 
 150 mM NaCl 
 0.65% (v/v) NP-40 
  
MTT Buffer  
SDS solution for MTT assay 10% (w/v) SDS 
 10.15 M HCl 
  
Flow cytometry buffers  
flow cytometry wash buffer 1 x PBS  
1 % (v/v) FCS 
0.02% (v/v) NaNO2 
 
flow cytometry fixing buffer 1 x PBS  
0.02% (v/v) NaNO2 
0.5 % (v/v) paraformaldehyde 
 
Molecular Biology buffers  
Tris EDTA buffer (TE) 10 mM Tris-HCl, pH 8.0 
1 mM EDTA 
 
6 x DNA gel sample buffer 25 mg Bromophenol blue 
25 mg Xylene Cyanole FF 
30 % (v/v) Glycerol 
 
5 x Tris borate EDTA buffer (TBE) 0.44 M Tris base  
0.44 M Orthoboric acid  
10 mM EDTA 
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2.2 Tissue culture 
All cells were cultured at 37°C in 5% CO2 and 95% humidity. 
2.2.1 Endotoxin testing 
Prior to their use, all cell culture reagents were tested for the presence of endotoxin by the 
Limulus Amebocyte assay (LAL) (BioWhittaker, Bershire, UK). A flat-bottomed micro plate 
was equilibrated to 37°C. A solution of endotoxin (0.1 EU/ml equivalent to 100 pg/ml) was 
prepared and serially diluted in LPS-free water. 50 µl of either endotoxin solution, test sample, 
or blank (LPS free water) were added per well.  An additional 50 µl of limulus amebocyte 
lysate were added to each well and the plate was incubated for 10 minutes (min) at 37°C.  100 
µl of provided substrate solution (at 37°C) was added to each well and incubated for a further 6 
min prior to termination of the reaction by addition of 100 µl stop reagent. Absorbance was 
read at 410 nm. The sensitivity of the assay was < 10 pg/ml. All assays were kindly performed 
by Mrs Patricia Green.  
2.2.2 Cell lines 
All cell lines used in this study are listed in Table 2.11. AD-293 cells were maintained in 
DMEM supplemented with 10% FCS and 1% P/S. HSF cells, obtained from circumcision 
specimens, were cultured in DMEM with 5% FCS and 1% P/S. As standard, all cell lines were 
terminated at a passage number of p11 for HSF cells and p20 for AD-293 cells. All long-term 
culture cell lines were regularly screened for mycoplasma infections by Ms Parisa Amjadi.  
2.2.3 Cryopreservation of cells 
Both primary cells and cell lines were stored in liquid N2 as required.  For freezing down of cell 
lines, cells were grown to 90% confluence, harvested and resuspended in ice-cold freezing 
medium consisting of 10% (v/v) dimethylsulfoxide (DMSO) and 90% (v/v) FCS at a 
concentration 5x 106 cells/ml in cryovials.  Primary cells were resuspended at a concentration 
of 10x 106 cells/ml. Cells were initially frozen at -70°C for up to 1 week and then transferred to 
liquid N2 for long-term storage. Cells were thawed quickly and the DMSO removed by washing 
cells in complete medium prior to culture.  
2.2.4 Isolation of human peripheral blood mononuclear cells  
Peripheral blood mononuclear cells (PBMC) were obtained by density centrifugation of single 
donor buffy coats purchased from the North London Blood Transfusion Service, Colindale, 
UK. Heparinised buffy coats were diluted 1:2 in HBSS and layered onto 20 ml Lymphocyte®-
H Solution (Cedarlane Laboratories Limited, Ontario, Canada) and separated at 2200 
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revolutions per minute (rpm) for 25 min.  The layered PBMC were extracted from the interface 
between the two layers and washed twice in HBSS. 
2.2.5 Separation of human peripheral blood monocytes by counter 
flow centrifugation (elutriation) 
Enriched fractions of monocytes were obtained by separation of PBMC by centrifugation at 
2500 rpm in a Beckman JE6 elutriator (Beckman Coulter, High Wycombe, UK) in RPMI 
containing 1% FCS. Elutriation allows separation of cells according to cell size and granularity 
by exposing the cells to two opposing forces of centrifugal force and fluid flow velocity in a 
specialised funnel-shaped chamber placed in the centrifuge (Figure 2.1). 
Figure 2.1: Schematic Representation of Centrifugal Elutriation. Illustration shows a cross section of 
an elutriation chamber, rotating around an axis at 2500 rpm creating a centrifugal force. A peristaltic 
pump creates an opposite flow. The funnel-shaped chamber causes the velocity of the fluid to decrease, 
forming a defined gradient. Cells of different sizes and densities migrate to the point where the two 
opposite forces balance. When the flow rate is increased, cell populations of increasing sizes can be 
eluted with high purity. 
 
As the cell suspension is pumped into the chamber at a constant flow rate, the fluid velocity 
decreases as the chamber gets wider, which creates a velocity gradient from the narrow end of 
the chamber to the widest part. The cells migrate into the chamber under the influence of the 
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two opposing forces of fluid flow and centrifugation, with the former pushing the cells forward 
and the latter pushing them backwards. 
Cells will halt in a relative position in the chamber, where the effects of the two opposing 
forces are balanced – this separates the cells according to size as the smaller cells are under a 
lower centrifugal force than the larger ones, positioning them further within the chamber. Thus, 
the smallest cells exit the chamber first, with the largest cells exiting last, as the fluid flow rate 
is gradually increased by 1 ml/min during the elutriation. Monocyte purity was assessed by 
flow cytometry based on cell size and granularity, with monocyte fractions typically containing 
>80% CD14+ cells.  
2.2.6 Differentiation and culture of human M-CSF and GM-CSF 
macrophages  
Monocytes collected by elutriation (Section 2.2.4) were cultured at 1x 106 cells/ml in T175 
tissue culture flasks in RPMI containing 10% FCS, 1% (v/v) penicillin/streptomycin and 
differentiated by adding 100 ng/ml M-CSF or 50 ng/ml GM-CSF for 4 days. After the 
incubation period, non-adherent cells were removed and adherent cells dissociated from the 
flask by adding 10 ml cell dissociation solution (Sigma) for 30 min at 37°C.  Cell dissociation 
solution was neutralised by adding 20 ml of complete RPMI, and cells were then collected and 
washed in complete medium and plated as appropriate. The concentration of TLR ligands and 
cytokines used to stimulate macrophages are listed in Table 2.13. 
Table 2.13: Concentrations of TLR ligands and cytokines used for stimulation 
Ligands Macrophages Dendritic cells SF 
LPS 10 ng/ml 100 ng/ml 100 ng/ml 
Poly I:C 20 µg/ml 20 µg/ml 20 µg/ml 
Malp-2 10 ng/ml 100 ng/ml n.a 
R848 100 ng/ml 100 ng/ml n.a 
Flagellin 10 ng/ml 100 ng/ml n.a. 
IL-1α 20 ng/ml 20 ng/ml 20 ng/ml 
TNFα 20 ng/ml 20 ng/ml 20 ng/ml 
Abbreviations:  Lipopolysaccharide (LPS), Macrophage-activating lipopeptide-2  (MALP-2), 
Polyinosinic-polycytidylic acid (Poly I:C), Resiquimod (R848) 
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2.2.7 Differentiation and culture of monocyte derived dendritic cells 
Freshly elutriated monocytes were differentiated into DCs with a stable immature phenotype. 
This was achieved by culture of the cells at 1-2 x 106 cells/ml in 10 cm culture dishes in RPMI, 
10% (v/v) FCS, 1% (v/v) penicillin/streptomycin, supplemented with 50 ng/ml GM-CSF and 10 
ng/ml IL-4, as previously described (Sallusto and Lanzavecchia, 1994). The cytokines were 
replenished at day 3, and the non-adherent cells were harvested after 5-7 days. The 
concentration of TLR ligands and cytokines used to induce dendritic cell maturation are listed 
in Table 2.13 in Section 2.2.6. 
2.2.8 Isolation and culture of rheumatoid arthritis synovial 
fibroblasts (RASF) from rheumatoid synovial specimens 
Synovial tissue specimens were obtained from rheumatoid arthritis patients undergoing joint 
replacement surgery at Charing Cross (donor ID SM#), Ravenscourt Park (RPH#), Central 
Middlesex (CM#), Wexham Park/Heatherwood (WP#) and Royal United (Bath) (BU#) 
hospitals. Ethical approval for the use of this tissue was granted to the Kennedy Institute of 
Rheumatology (KIR) (RREC 1752) by the Riverside Research Ethics Committee, Charing 
Cross Hospital, London, UK. Synovial tissue was excised and placed into a tissue culture dish 
containing 10 ml RPMI supplemented with 10% FCS. The tissue was dissected, homogenised 
and strained through a cell strainer. Attached extra cellular matrix (ECM) was removed by 
digestion with collagenase. For the digest, 20 ml RPMI containing 5 mg/ml collagenase and 
0.15 mg/ml DNAse type I were added, and cultured at 37°C for 1 hour.  Debris was removed 
by passing the cells through a cell strainer, after which cells were washed and resuspended in 
RPMI with 10% FCS. 
Collection of synovial membranes and isolation of RA synovial cells was kindly performed by 
Ms Renee Best and Ms Lauren Schewitz at the Kennedy Institute of Rheumatology (KIR). 
Synovial fibroblasts from rheumatoid tissue (RASF) were obtained by culture of mixed cell 
populations derived from synovial membranes. Cells were plated at 0.5x 106 cells/ml in DMEM 
containing 10% FCS, 1% P/S and 10 µM Indomethacin (Sigma). Adherent cells were passaged 
1:2 with Trypsin/EDTA when confluent and used between passages 3-4. The concentration of 
TLR ligands and cytokines used to stimulate the fibroblasts are listed in table in Table 2.13 in 
Section 2.2.6. 
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2.3 Molecular biology techniques 
2.3.1  Restriction enzyme digestion of DNA 
Treatment of DNA with restriction enzymes that cleave DNA at specific nucleotide sequences 
was performed according to the manufacturer’s instructions, using the enzymes buffers 
indicated in Table 2.8 in Section 2.1.5. Where double digestion was carried out, consideration 
toward buffer compatibility were made in order to maximise the activities of both enzymes 
whilst minimising non-specific enzyme star activity.  All digestions were performed with 1 µl 
enzyme in total volume of 10- 20 µl for 1 h at 37°C. 
2.3.2 DNA fragment purification 
Restriction products were resolved on a 1 % (w/v) agarose/TBE gel containing 0.1 µg/ml 
ethidium bromide or 1/10.000 SYBR Green II, used for DNA visualisation under UV light or a 
pure light source (Dark reader transilluminator, model DR88M, BRI, Ltd., UK). The fragment 
of interest was excised from the agarose and purified using a Qiagen gel extraction kit 
according to the manufacturer’s instruction. The purified DNA was eluted with 30 µl double 
distilled (dd)H2O.  
2.3.3 Dephosphorylation of DNA ends 
Alkaline phosphatase is an enzyme, which removes 5' phosphate groups from DNA that has 
been cut with a restriction enzyme. In subsequent ligation reactions, this treatment prevents 
self-ligation of the vector and thereby improves ligation of other DNA fragments into the vector 
(e.g. subcloning).  
In order to dephosphorylate digested DNA, 1 µl of calf intestinal alkaline phosphatase was 
added per µg of digested DNA, together with 3 µl of 10 x enzyme buffer (provided with the 
enzyme). The reaction was carried out in a total volume of 30 µl for 15 min at 37°C, followed 
by heat inactivation of the enzyme at 65°C for 15 min.  
2.3.4 Ethanol precipitation  
The most widely used method for concentrating DNA is precipitation with ethanol. The 
precipitate of DNA that is allowed to form at low temperature is recovered by centrifugation 
and redissolved in an appropriate buffer. The technique is rapid and is quantitative even with 
nanogram amounts of DNA. 
The DNA solution that is to be treated is mixed with 3 volumes of ice-cold 100 % (v/v) ethanol 
and 1/14 dilution of 3 M NaAc pH 5.2. After a 30 min incubation on ice, the sample is 
centrifuges for 10 min at 13,000 rpm (Biofuge Fresco, Kendro Laboratory products Plc, 
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Bishop’s Stortford, UK), and the supernatant is aspirated off. The DNA pellet is then washed 
with 500 µl 70 % (v/v) ice-cold ethanol and resuspended in either ddH2O or TE buffer. 
2.3.5 DNA ligation 
Ligations of restriction digested DNA fragments were carried out using approximated vector to 
insert molar ratios of 1:10 respectively. In general, 1 µl of gel-purified vector was used with 3 
µl of purified insert. To this, 1 µl of 10 x T4 DNA ligase buffer and 1 µl of T4 DNA ligase was 
added and the volume was adjusted to 10 µl with ddH2O. The reaction was carried out at 16°C 
overnight. 
2.3.6 Preparation and transformation of electrocompetent E.coli 
An XL-I Blue E. coli strain was streaked onto an LB-agar plate containing 25 µg/ml 
tetracycline to give distinct colonies after an overnight incubation at 37°C. Two single colonies 
were picked and grown overnight in 2 x 20 ml LB media. 10 ml of the overnight culture were 
each used to inoculate 4 x 500 ml LB cultures that were grown with vigorous shaking until an 
OD600 nm of 0.4-0.6 units was reached. The cells were harvested by centrifugation at 3000 rpm at 
4°C for 15 min (Sorvall RT-7, Kendro Lab products), and washed in 500 ml ice-cold dH2O per 
tube by centrifugation at 3000 rpm at 4°C for 15 min. The pellets were each resuspended in 10 
ml ice-cold ddH2O and combined to two tubes that were each subjected to an additional wash in 
500 ml ice-cold dH2O. Each pellet was further washed with 20 ml of 10 % (v/v) glycerol. The 
electrocompetent cells were resuspended in an equal weight to volume in g/ml of 10 % (v/v) 
glycerol and the suspension was divided into 50 µl aliquots, snap frozen using liquid nitrogen 
and stored at -70°C until use. 
For transformation, 1 µl of mini-prep purified plasmid DNA (see Section 2.3.2) or 2 µl of 
ligation mix was added to 50 µl of electrocompetent cells that was thawed slowly on ice. The 
mixture was added to an ice-cold 0.2 cm electroporation cuvette, which was pulsed (2.5 kV, 
200 Ω, 25 µF) for 5-6 msec using an electro cell manipulator ECM 630 (Qbiogene, Cambridge, 
UK) according to the manufacturers instructions. After a single pulse, the cuvette was removed 
and cell recovery was initiated by adding ~600 µl of LB to the cuvette and the cells were 
transferred to a fresh tube. The cells were incubated at 37°C with gentle shaking for 1 h, 
followed by spreading onto LB agar plate containing appropriate antibiotics (Table 2.8 in 
Section 2.1.5) of one fifth of the transformation mix. The plates were left at 37°C overnight and 
colonies were picked the following day.  
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2.3.7 DNA isolation by mini – and maxi – preps 
Harvesting plasmid DNA transformed into E. coli was performed using mini- and maxi- prep 
kits purchased from QIAGEN, according to the manufacturer’s instructions. Briefly, separation 
of plasmid DNA from bacterial genomic DNA was achieved by alkaline lysis of the bacteria. 
Pre-cleared lysates were adjusted to high salt concentration and purification was achieved by 
adsorption of the plasmid DNA onto a silica gel membrane in the provided column. The 
plasmid DNA was then washed of contaminants, prior to elution into 50 µl ddH2O. The DNA 
yield was routinely determined by UV absorption at 260-280 nm on a photometer (GeneQuant, 
Eppendorf, UK). 
2.3.8 RNA isolation  
Total RNA was isolated from 106 cells using a QiaAmp RNA Blood mini kit (Qiagen GmbH, 
Germany), following the manufacturer’s instruction according to the protocol for isolation of 
total RNA from cultured cells.  
2.3.9 PCR 
Polymerase Chain Reaction (PCR) amplification of DNA was performed with Taq DNA 
polymerase, using a MWG-Biotech Primus thermocycler. Each reaction was carried out in a 
thin walled PCR tube and contained the following: 
     Reagent Amount 
   
 DNA template  5 µl 
 10 x PCR buffer  5 µl 
 MgCl2 (50 mM) 1.5 µl 
 dNTP (1 mM) 1 µl 
 Forward primer (25 pmol/µl) 1 µl 
 Reverse primer (25 pmol/µl) 1 µl 
 Taq DNA polymerase (5 
units/µl) 
0.5 µl 
 ddH2O To a final volume of 50 µl 
 
Typically, the lid temperature was set for 110 °C and the DNA was denatured at 92°C for 5 min 
and then for 30 sec per cycle. Primer annealing temperature was usually set at 55 °C, and was 
carried out over a period of 30 sec. Primer extension was performed at 72 °C and held for 1-4 
min, depending on the length of the template (1 min/ 1 kb DNA). The reaction was then 
subjected to a final 10 min extension at 72°C and held for 4°C with the lid heating off. 
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Typically 30 cycles were used per reaction. The oligonucleotide primers used for PCR are 
described in Table 2.10 in section 0. 
2.3.10 Real-time PCR - TaqMan® 
Real-time PCR is a semi-quantitative variant of polymerase chain reaction (PCR) that measures 
mRNA levels via fluorescence emitted by specific dyes on specifically designed TaqMan® 
probes after excitation by laser scanning technology.  RT-PCR reactions were set up in 10 µl 
reactions, with each well containing 5 µl 2x Univerasl PCR Mastermix, 0.25 µl 40x 
MultiScribeTM and RNase inhibitor Mix, 0.5 µl pre-labelled primer, 2 µl sample mRNA and 
H2O. Samples were run in duplicates using the Rotor-Gene 6 (Corbett Research UK Ltd., 
Cambridge, UK), which was programmed as follows: 
 Reverse Transcription  20 minutes at 48°C 
 Denaturation   10 minutes at 95°C 
 PCR (40 cycles)  
  Denaturation   15 seconds at 95°C 
  Annealing/Extension  40 seconds at 56°C 
 
The number of PCR cycles required for the fluorescence emitted to be greater than the baseline 
fluorescence is termed the threshold cycle (Ct). Differences in mRNA levels present in the 
samples and variations in polymerase efficiency are controlled by normalising each sample to 
the mRNA levels of the housekeeping gene GAPDH.   
Figure 2.2 illustrates an exemplary amplification plot obtained by sequence detector software 
and the method for calculating the relative abundance of template mRNA using the 
comparative ∆∆Ct method.  
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The comparative Ct method is also referred to as the ∆∆Ct method, where 
∆∆Ct = ∆Ct sample - ∆Ct reference
Here, ∆Ct sample is the Ct value for the control  sample normalised to the 
endogenous housekeeping gene GAPDH 
D - A = ∆Ct sample (∆CtD)
and ∆Ct reference, which is the Ct value for a reference (treatment) also 
normalised to GAPDH under the same treatment
E - B = ∆Ct reference (∆CtE)
For the treatments illustrated above,  the ∆∆Ct values are calculated as follows:
∆CtD - ∆CtD = ∆∆CtD 2-∆∆CtD = 1
∆CtE - ∆CtD = ∆∆CtE 2-∆∆CtE = x
∆CtF - ∆CtD = ∆∆CtF 2-∆∆CtF = y
Values are presented as percent relative to ∆∆Ct sample (=100%).
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Real-time PCR-Comparative Ct Method 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.11 RNA interference (RNAi) 
RNA interference was first discovered in plants, and later in the worm Caenorhabditis elegans 
and its mechanism involves short interfering RNA (siRNA) leading to post-transcriptional gene 
silencing (PTGS) (Fire et al., 1998). Briefly, RNAi requires several steps to induce degradation 
of target mRNA and subsequent PTGS. Double stranded RNA (dsRNA) complementary to 
mRNA of the target gene is synthesised in form of long oligonucleotides (this can vary greatly 
between species). Long oligonucleotides of dsRNA are then recognised and cut into 21-23 
nucleotide siRNAs by an endonuclease called Dicer. Next, the siRNAs are recognised by the 
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RNA-induced silencing complex (RISC), which links the antisense strand of the siRNA to the 
specific mRNA. This interaction leads to the subsequent degradation of the target mRNA 
(Milhavet et al., 2003).   
For RNAi in primary human macrophages, freshly elutriated monocytes (typically 5x106 per 
treatment) were transfected with targeting siRNA or controls (Table 2.7) at concentration 
ranges from 100-400 nM using the Human Monocyte Nucleofector® Kit (section 2.1.8) 
according to the manufacturer’s instructions. Monocytes were allowed to rest in recovery media 
(supplied by Amaxa), which was supplemented with 100 ng/ml M-CSF for 24h. After recovery, 
cells were washed and re-suspended in 10% RPMI with 100 ng/ml M-CSF for 2-3 more days. 
Differentiated macrophages were then harvested and plated as appropriate.  
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2.4 Adenoviral production and infection 
Adenoviruses are efficient vehicles for delivering genes to cells both in vitro and in vivo, 
resulting in high levels of expression of the virally encoded transgene (Horwood et al., 2002). 
Adenoviruses used in this thesis are listed in Table 2.14. The viruses were constructed using the 
Gateway® Vector System (Q-BIOgene, CA, USA and Invitrogen, Paisley, UK, respectively) 
through the homologous recombination of the Ad5 genome with a transfer vector containing 
the gene of interest.  Inserts are driven by a CMV promoter followed by a GFP site. Adenovirus 
vectors have their E1 and E3 regions of the viral genome deleted, which prevents replication 
and removes the adenoviral genes known to subvert intracellular signalling (Hayder and 
Mullbacher, 1996).  
2.4.1 Subcloning into transfer vector  
Genes of interest were cloned in to the transfer vector pENTR4.3F (made in house, Figure 2.3), 
by standard molecular techniques (see Section 2.3). Transgene expression was determined in 
HEK293 cells by lipofectamine mediated transfection (see Section 2.4.3) and confirmed by 
SDS-PAGE and Western blotting (see Sections 2.5.4 and 2.6.1). The sequence of the cloned 
cDNA was also confirmed at this stage, by DNA sequencing. 
2.4.2 Recombination of transfer vectors with viral genomic DNA 
Homologous recombination of the pENTR4.3F vector, containing the gene of interest, with the 
genomic vector pAd/PL-DEST was performed using the following reaction mix: 
     Reagent Amount 
   
 300 ng pENTR4.3F 2 µl 
 300 ng pAd/PL-DEST  2 µl 
 LR clonase 2 µl 
 10 x Buffer 2 µl 
 TE-Buffer 2 µl 
 
The reaction was performed over night at 25°C. The products of the recombination event are 
expression clone and a by product, known as the donor vector. The desired expression clone is 
under two forms of selection: antibiotic resistance and negative selection. Selecting for 
ampicillin resistance eliminates the entry vector (pENTR4.3F) and the by product (both of 
which contain kanamycin resistance). The presence of the negative selection marker (ccdB 
gene) eliminates the destination vector (pAd/PL-DEST) and co-integrated molecules. As an 
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extra control there is another negative selection marker in the form of a chloramphenicol 
resistance present on the pAd/PL-DEST vector. The resulting vector was transformed into 
TOP10 E. coli. 50 µl of transformed TOP10 E. coli were spread on Agarose and resulting 
colonies were picked after over night incubation at 37°C. The colonies were grown in 
ampicillin containing LB media and as a control in chloramphenicol media. Vectors from 
colonies growing in ampicillin containing media only were isolated using maxiprep kit from 
Qiagen. 
 
 
Figure 2.3: Cloning strategy of SIGIRR adenovirus. (A) Flag tagged SIGIRR construct (kindly 
provided by Prof X. Li, Lerner Research Institute, OH, USA) was ligated into the vector pENTR4.3F, 
which was cut with the restriction enzyme Sma I. (B) The correct orientation and sequence of the insert 
was confirmed by sequencing. (C) Following homologous recombination of the entry vector pENTR4.3F 
and the gateway vector pAd/PL-DEST through the homologous sites attL1/2 and attR1/2 the gateway 
vector was linearised using Pac I and transfected into HEK293 cells. Flag tagged SIGIRR as well as 
EGFP are transcribed under the control of the CMV promoter. The IRES permits translation of SIGIRR 
and EGFP as a single transcript. Abbreviations: cytomegalovirus promoter (CMV), multiple cloning site 
(MCS), internal ribosome entry site (IRES), enhanced green fluorescent protein (EGFP), Kanamycin 
resistance gene (Kanamycin), Ampicillin resistance gene (Ampicillin), origin of replication (pUC ori), 
homologous recombination cites (attL2, attL1, attR1, attR2), adenovirus genome (wt Ad5) . 
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2.4.3 Transfection of the viral genomic DNA into AD-293 cells 
The AD-293 cell line is a transformed HEK cell line that produces the adenoviral E1 genes in 
trans. The E1 gene products originate from early transcribed regions and are involved in 
mechanisms of viral replication. Transfection of the E1-deleted adenoviral DNA vectors into 
these cells enables the production of infectious viral particles. 
AD-293 cells were seeded per well of a 6 well plate at ~ 90 % confluency (~1 x 106 ) one day 
prior to the transfection. 3-5 µg of the recombinant viral DNA was digested for 5 h using 4 µl 
Pac I in a total volume of 100 µl. The digest was ethanol precipitated by the addition of 7 µl 3 
M NaAc and 300 µl 100 % (v/v) ice-cold ethanol and the mixture was left on ice for 30 min to 
precipitate, prior to a 5 min spin at 13,000 rpm (Biofuge fresco, Kendro Laboratory products 
Plc, Bishop’s Stortford, UK) at 4°C. The supernatant was removed and 500 µl 70 % (v/v) ice-
cold ethanol was added and the pellet was washed by gently tipping the tube. The ethanol was 
aspirated off and 500 µl prewarmed Optimum transfection media was added, and the pellet 
gently suspended prior to a 30 min incubation at 37°C. 20 µl Lipofectamine was added to the 
DNA suspension and a control media, followed by an incubation at room temperature for 20 
min. During this time, the cell media was removed and replaced with 1 ml prewarmed 
Optimum and incubated for an additional 30 min at 37°C. The DNA-lipofectamine complex 
was added drop-wise to the cells, and the transfection was allowed to occur for 2 h at 37°C, 
after, which the media was replaced with complete growth medium. Transfected cells were 
over-laid with DMEM/agarose (see Section 2.4.4) the following day to allow plaque 
development from the production of infectious viruses. 
2.4.4 Agarose/MEM overlay of AD-293 cells 
The process of overlaying AD-293 cells with agarose is central to the production and 
purification of adenoviruses. Overlaying cells with agar provides extra support to the cells, and 
inhibits contact mediated growth, thus prolonging the longevity of the monolayer. In addition, 
translocation of the viral particles is restricted to two dimensions (across the monolayer via cell 
to cell infection). This restriction conferred upon the virus is central to development of plaques, 
caused by progressive lytic infections of the monolayer. A sterile solution of 1.5 % (w/v) 
Seaplaque GTG-agarose was prewarmed to approximately 42°C. The agarose solution was 
mixed 1:1 with 2x MEM media containing 4 % (v/v) FCS and 2 % (v/v) antibiotics (at 37°C), 
and 3 ml was carefully over-laid onto AD-293 cells in one well of a 6-well plate. Care was 
taken to avoid damaging the cell monolayer. The agarose/MEM layer on the cells, was allowed 
to solidify at room temperature for 5 min before continued incubation at 37°C. The cells were 
then incubated for 5-7 days to allow plaque formation to occur. 
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2.4.5 Plaque purification and virus recovery 
Plaque purification is essential in the de novo production of clonal viruses or for the 
maintenance of good viral stocks. Plaques, developed from plaque assay titration or transfection 
of recombinant viral genome, were selected microscopically. Approximately 1-5 µl of media 
from within the plaque was removed using a 10 µl Gilson pipette. The virus containing media 
was diluted into 500 µl of serum free DMEM and left overnight at 37°C in an incubator to 
allow viral dissociation from cellular debris or agar constituents. The 500 µl viral media was 
used to infect one well of a 12-well plate, containing confluent AD-293 cells. Growth media 
was aspirated and the cells were washed once in serum free DMEM before incubation with the 
virus containing media for 2 h at 37°C. At the end of the incubation, 500 µl of DMEM 
containing 4 % (v/v) FCS was added to the cells, to give a final concentration of 2 % (v/v) FCS. 
Depending upon the number of viral particles isolated from the plaque, the 12-well plate would 
exhibit a full cytopathic effect (CPE) 3-5 days post infection. CPE is typified by the 
degeneration of the monolayer, which is caused by cell swelling and detachment due to the 
adenoviral replication. 
2.4.6 Small scale adenoviral amplification 
When the AD-293 cells reached CPE, cell lysates were transferred to an AD-293 monolayer 
with increasing surface area to achieve efficient viral amplification. At full CPE, the media and 
the cells from the 12- well plate stage were harvested and subjected to three freeze-thaw cycles 
using liquid nitrogen. This induces cell lysis to ensure the recovery of a maximum amount of 
viruses in the media. One fifth of this media was diluted to 1 ml with serum free DMEM and 
was used to infect one well of a 6-well plate for 1 h under serum free conditions. At the end of 
the incubation, 1 ml of DMEM containing 4 % (v/v) FCS was added to the cells, to give a final 
concentration of 2 % (v/v) FCS. A reduction in serum concentration was used to reduce the 
proliferation of the AD-293 cells. Full CPE was normally achieved after 2 days culture, and the 
freeze-thaw cycle was repeated. 
At this stage the adenovirus were screened for expression of the recombinant transgene by 
SDS-PAGE and Western blotting (see Sections 2.5.4 and 2.6.1). Once over-expression was 
confirmed, these lysates purified from single-plaques were either used to seed large-scale 
amplifications of the virus, or were stored at -70°C as archives.  
Chapter 2 Materials & Methods 
83 
2.4.7 Large scale adenoviral amplification 
A confluent T75 flask of Ad-293 cells was infected with the crude lysate made up to 5ml of SF 
DMEM and allowed to infect for 1-2h. 
Table 2.14: Adenoviruses 
Adenovirus Insert cDNA Source of cDNA 
Ad GFP Green fluorescent protein Dr. M. Wood, Quantum 
Biotech, Carlsbad, Canada 
Ad MyD88 dn-GFP MyD88 with truncated death 
domain and point mutation F56N 
(Flag-tag) 
Dr. K. Burns, Ludwig, 
Switzerland 
Ad MyD88wt-GFP MyD88 wild type (Flag-tag) Caroline Andrews, KIRD 
Ad Mal wt-GFP Mal wild type (HA-tag) Cloned from human MAL 
image clone purchased from 
MRC gene service, Babraham 
Bioincubator, Cambridge, UK 
Ad Mal dn-GFP Mal with point mutation P125H 
in the TIR domain (HA-tag) 
Cloned from MAL image clone 
purchased from MRC gene 
service, Babraham 
Bioincubator, Cambridge, UK 
Ad Mal (TIR) TIR domain of Mal (HA-tag) T. Bird, J. Sims, Immunex 
Ad TRAM dn-GFP TRAM with point mutation 
C114H in the TIR domain 
Prof K. Fitzgerald, University 
of Massachusetts, MA, USA 
Ad TRAM wt-GFP TRAM wild type Corinne Taylor, KIRD 
Ad TRIF (TIR)-GFP TIR domain of TRIF (HA-tag) Cloned from human TRIF 
image clone purchased from 
MRC gene service, Babraham 
Bioincubator, Cambridge, UK 
Ad SIGIRR-GFP SIGIRR wild type (Flag-tag) Prof X. Li, Lerner Research 
Institute, OH, USA 
AdLux NFκB*  Firefly luciferase gene driven by 
4 tandem repeats of the consensus 
κ enhancer site 
Dr Lynn Williams 
 
Abbreviations: dominant negative (dn); wild-type (wt) 
 
Following infection, 5 ml of 4% DMEM were added to the flask, which was again allowed to 
reach full CPE before freeze-thawing the lysates 3x as before. For the final step of virus 
amplification, 10 T175 flasks of AD-293 cells at no more than 80-90% confluence were 
infected with the crude lysates from the T75 stage made up to 100 ml in SF DMEM (10ml per 
flask) and again allowed to infect for 1-2 h before adding 10 ml of 4% DMEM to each flask.  
At this point, the cells must be harvested before the virus causes them to lyse – they must not 
reach full CPE. Cells were harvested approximately 24-36 h post infection, when they become 
non-adherent.  
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2.4.8 Purification of high titre adenoviral stocks 
Infected, non-adherent AD-293 cells from the T175 flasks were harvested in 50 ml FalconTM 
tubes and washed with SF DMEM.  Virus-containing AD-293 cells were spun at 1000 rpm for 
5 min, supernatants discarded and cells resuspended in 10 ml 0.1 M Tris (pH 8.0) and freeze 
thawed 3x as before. Lysates were transferred to a new 50 ml tube and passed through a 19G 
needle and syringe 3x to shear the chromatin.  Following a further spin at 2000 rpm for 5 min, 
the lysates were collected into a new 50 ml tube and cell debris discarded.  Supernatants 
(containing virus) were made up 11.4 ml with 0.1 M Tris, to which 6.6 ml of saturated CsCl 
solution were added to achieve a final density of 1.34 g/ml, to enable the adenoviral particles to 
concentrate into a band under centrifugal force. The solution was mixed thoroughly and 
transferred into 2 Sorvall ultracentrifuge tubes using a needle and syringe; the tubes were filled 
to the neck, avoiding bubble formation, and collars screwed tight to seal the tubes for 
centrifugation. Virus bands were separated by centrifugation at 60,000 rpm overnight 
(minimum 8 h) at 4°C using the Sorvall RC-M150 GX ultracentrifuge, Kendro Laboratory 
products, UK. Following centrifugation, a band containing adenovirus was visible in the CsCl 
gradient, and was collected using a 19G needle and syringe (Figure 2.4).   
The viral bands from the two tubes were pooled into a new ultracentrifuge tube and filled by 
adding 1.34 g/ml density CsCl solution. Virus was separated through a further 
ultracentrifugation, and virus band recovered as before in <2.5 ml total volume. 
Figure 2.4: Isolation of the mature adenovirus after caesium chloride density-gradient 
centrifugation. Following ultracentrifugation, mature adenovirus bands at a density of 1.43 g/ml, 
separating the virus from cellular debris and non-packaged viral particles. The air-tight seal is broken by 
removing the sealing screw. The viral band was removed form the ultracentrifuge tube using a 5 ml 
syringe and 19-Gauge needle to puncture the soft tube and removing the viral band in less than 2.5 ml 
total volume. 
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CsCl salts were removed from the virus by column chromatography using a PD10 column 
equilibrated in 25 ml PBS2+. The volume of purified virus was adjusted to 2.5 ml by adding 
PBS2+ and was allowed to enter the column by gravity alone. Elution of purified virus from the 
column was achieved by addition of 3.5 ml PBS2+. Sterile glycerol was added to the eluted 
virus to give a final concentration of 10% (v/v), and the virus solution sterilised by passage 
through 0.45 µm and 0.22 µm filters. Sterilised virus was aliquoted and stored at -70°C. The 
concentration (titre) of the virus was obtained using the Adeno-XTM Rapid titre kit (Section 
2.4.9). 
2.4.9 Determination of viral titre with Adeno-XTM 
The Adeno-XTM Rapid titre kit is an antibody based system used to identify infected cells. The 
assay takes advantage of the production of viral Hexon proteins for the quantification of viral 
stocks. Ad-293 cells were seeded in a 12-well plate at 5x 105 cells/well in 1 ml of 10% FCS 
DMEM. A serial dilution was prepared from the viral stock in 2-fold dilutions ranging from 10-
4 to 10-6. 100 µl of the diluted virus was added drop-wise to the freshly seeded cells, plus one 
control well without virus, and cells were allowed to infect for 28 h. On the second day, 
medium was removed and cells allowed to dry before adding 1 ml of ice-cold 100% methanol 
for 10 min at -20°C to fix the cells.  Methanol was removed and cells washed 3x with 1% (w/v) 
bovine serum albumin (BSA) in PBS. Primary mouse anti-Hexon antibody was added 
(1ml/well) at 1:1000 in 1% BSA and incubated at 37°C for 1h. Primary antibody was removed, 
cells washed 3x and 1 ml/well secondary rat anti-mouse antibody added 1:500 in 1% BSA for 1 
h at 37°C. 
Following the incubation, secondary antibody was removed, cells washed 3x and 0.5 ml/well of 
diaminobenzidine tetrahydrochloride (DAB) working solution was added and incubated at RT 
for 10 min. The DAB solution was replaced by 1% BSA and the number of brown (Hexon-
positive stained) cells was counted for each viral dilution. A minimum of 3 fields of view were 
counted using a light microscope with a 20x objective. Each stained cell corresponds to a single 
infectious unit (ifu). The viral titre was calculated as follows: 
(Mean infected cells/field) x (total fields/well*) 
Virus titre (ifu/ml)= 
Volume virus added to the well (ml) x dilution factor (10-N) 
* total fields/well based on 20x objective = 573 fields 
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2.4.10 Assessment of viral replication deficiency 
Replication deficiency of the virus was tested by culturing human skin fibroblasts (Table 2.11) 
in the presence of purified virus for 14 days, after which cell viability was assessed 
microscopically. The cells are infected, but if the virus is replication deficient, the cells will 
remain viable over the incubation period.  
2.4.11 Adenoviral gene transfer into primary human cells 
For adenoviral infection, dendritic cells and macrophages were plated at 1x 106 cells/ml, and 
RASF at 80% confluence. Infections were performed in serum free medium, generally with 
viruses at a multiplicity of infection (m.o.i.) range between 50:1 and 150:1 for dendritic cells, 
macrophages and RASF for 2 h. After infection, the medium was replaced with full serum 
containing RPMI for macrophages and DMEM for RASF.  For double infections, cells were 
infected with adenovirus at an appropriate m.o.i. for 2h, and cells allowed to rest in full medium 
for 4 h prior to secondary infection as before. Cells were left for produce the viral transgenes 
for 24 to 48 h prior stimulation. Figure 2.5 shows white and ultra violet (UV) light images of 
adenoviral infected dendritic cells (Figure 2.5 A and B) and macrophages (Figure 2.5 C and D) 
under a 20x objective. Adenoviral infection efficiency is at ~100%, as assessed by green 
fluorescent protein (GFP) expression under UV.  
 
Figure 2.5: Adenoviral infection efficiency as assessed by GFP expression in primary human 
dendritic cells and macrophages. Primary human dendritic cells (A and B) and macrophages (C and D) 
were infected with AdSIGIRR at an m.o.i. of 100:1 as described in Section 1.4.12 and allowed to express 
adenoviral genes for 24 h. Infection efficiency was estimated by GFP expression under the fluorescent 
light microscope using 20x objective (B and D). Under white light (A and C) dendritic cells and 
macrophages are healthy and not activated.  
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2.4.12 Luciferase reporter gene assay 
Firefly luciferase has been used as an efficient reporter gene for determining the transcriptional 
activity of specific gene control elements for several years. The luciferase enzyme catalyses 
mono-oxygenation of beetle luciferin in the presence of Mg2+ and ATP, resulting in the release 
of photons (fluorescence).  This fluorescence can be measured using a luminometer, and the 
activity of the element regulating the luciferase gene can thereby be quantified. Cells were 
cultured in a 96-well plate and infected with luciferase constructs (Table 2.12) at an m.o.i. of 
50:1, followed by secondary infection with adenovirus (see section 2.4.11), and allowed to 
express viral transgenes as before. Subsequently, cells were stimulated with LPS for 4 h, at 
which point supernatants were removed, and cells lysed in 100 µl CAT lysis buffer. As 
standard, 50 µl of the lysates were mixed with 120 µl LAB containing 1 mM DTT and 0.5 mM 
ATP. 30 µl luciferin was added immediately prior to analysis in the Wallac MicroBeta Tri Lux 
luminometer (GMI Inc., Minnesota, USA).   
Values were recorded as relative luciferase units (RLU), or as a percentage of the values 
compared to a control. 
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2.5 Biochemical techniques 
2.5.1 MTT cytotoxicity assay 
The MTT cell viability assay is based on the principle that living and metabolically active cells 
can reduce tetrazolium salts to coloured water-insoluble formazan crystals. The tetrazolium salt 
is cleaved to formazan by the ‘succinate-tetrazolium reductase’ system in the respiratory chain 
of mitochondria and is only active in viable cells. An increasing number of viable cells results 
in an overall increase in activity of the mitochondrial dehydrogenases. Since a cytotoxic factor 
will reduce the rate of tetrazolium salt cleavage by a population of cells, this assay can be used 
to measure the factor-induced cytotoxicity or non-specific cell death. Cells were tested for 
viability after adenoviral infections (Section 2.4.11). Culture supernatants were harvested and 
100 µl of complete medium containing 5 µg/ml MTT (3-[4,5-Dimethylhiazol-2-y]-2,5-
diphenyltetrazolium bromide) added to each well and cells cultured for a minimum of 4 h at 
37°C.  After the incubation, cells were lysed by the addition of 100 µl of 1% SDS and 
incubated for a further 18 h. Absorbance was read at 620 nm on a Multiskan BiochromaticTM 
plate reader using AscentTM 2.4.2 software (Labsystems, Helsinki, Finland). 
2.5.2 Preparation of whole cell protein extracts 
Preparation of protein extracts was performed in order to investigate events involved in 
intracellular signalling pathways, using procedures such as SDS-PAGE and western blotting 
(Sections 2.5.4and 2.6.1). Generally, 1-2x 106 cells were washed in ice cold PBS, and lysed in 
100 µl lysis buffer containing protease and phosphatase inhibitors (Table 2.6) on ice for 10 min. 
Following lysis, lysates were collected into 1.5 ml tubes, spun, and lysates without cell debris 
transferred to a new 1.5 ml tube. 
5x GSB was added to give a 1x solution, and lysates further denatured at 100°C for 10 min. At 
this point, lysates were stored at -20°C or analysed.  
2.5.3 Protein concentration estimation 
Prior to using the protein extracts from samples with possible high protein variation for any 
further experimental procedure, the protein concentrations were measured using the BCATM 
protein assay kit according to the manufacturer’s instructions. For this assay, 2 µl lysate (prior 
to addition of GSB and denaturation) were diluted in 8 µl H2O and transferred to a 96-well 
Maxisorb plate (Nunc, Denmark) in duplicate, along with a series of BSA concentrations as 
standard. The BCA solutions were mixed at volume ratios of 50:1 (assay reagents A:B) and 200 
µl added to each well.  Samples were incubated for 1 h at 37°C and absorbance was read at 540 
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nm on a Multiskan BiochromaticTM plate reader using AscentTM 2.4.2 software (Labsystems, 
Helsinki, Finland).  
2.5.4 SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is a technique 
commonly used to separate proteins based on their molecular size when an electric field is 
applied to a gel. SDS is an anionic detergent, which denatures proteins and confers a negative 
charge to the polypeptide that is proportional to its length. Because the charge-to-mass ratio is 
nearly the same among SDS-denatured polypeptides, the final separation of proteins is 
dependent almost entirely on the differences in molecular weight of the polypeptides. Samples 
were denatured prior to electrophoresis by the addition of 5 x gel sample buffer (see Section 
2.1.10), and boiling at 95°C for 5 min. A ready to use 10 % Midigel of BioRad was used to 
separate the proteins. The electrophoresis was performed according to the manufacturers’ 
instructions for 1-2 h using a voltage of 150 V. Molecular weights of the separated proteins 
could be estimated by comparison to protein standards with known molecular weights, run in 
parallel to the samples. 
2.5.5 Protein transfer 
Proteins separated by SDS-PAGE can be transferred onto a membrane, which allows them to 
be identified using specific antibodies (Table 2.3). Proteins were transferred onto a 
polyvinylidene difluoride (PVDF) membrane, which was cut to the size of the gel, hydrated in 
100% methanol and equilibrated in transfer buffer (Section 2.1.10). The gel was placed onto 2 
layers of filter paper pre-soaked in transfer buffer, onto which in turn the equilibrated 
membrane was placed, avoiding bubble formation between the layers. The membrane was 
overlaid with further 2 layers of wet filter paper (again, without bubbles), and the assembly 
placed into a transfer cassette (BioRad, UK). Transfer occurred in a transfer tank (BioRad, UK) 
filled with pre-cooled transfer buffer (4°C). The transfer cassette was orientated such that the 
membrane was between the gel and the anode and transfer performed attached to a cooling unit 
at a constant voltage of 100 V for 2 h. 
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2.6 Immunological techniques 
2.6.1 Western blotting 
The membrane containing transferred proteins (Section 2.5.5) was blocked in 5% (w/v) milk 
powder in TBS/T for 1h and incubated with primary antibody (Table 2.3) in 2% (w/v) BSA or 
milk for 1-2 h at RT end over end. Following incubations the membrane was washed 3x with 
TBS/T. After removal of the primary antibody and washing, secondary HRP-conjugated 
antibody (Table 2.4) was added in 2% (w/v) milk at room temperature (RT) for 1h on an orbital 
shaker prior to detection using the chemiluminescent substrate solution ECL. The protein bands 
were visualised using HyperfilmTM. In most experiments, the membranes were re-probed with 
different primary antibodies, after the previous ones had been removed by stripping the 
membrane in mild acid solution (Table 2.12) for 20 min, followed by re-blocking and re-
probing with antibodies.  
2.6.2 Immunoprecipitation 
Immunoprecipitation (IP) allows the extraction of a protein of interest (and any possible 
associated proteins) from whole cell lysates using specific antibodies, and thus more detailed 
analyses of protein-protein interactions and activity (e.g. kinase assays). Protein-antibody 
complexes are removed from solution using beads covered in insoluble antibody binding 
proteins such as protein A or protein G. Precipitated samples are then denatured and separated 
by SDS-PAGE as described in Section 2.5.4.  
Typically, 5 x 106 cells per condition were treated appropriately, washed in ice-cold 1x PBS 
and lysed for 20 min in 1 ml NP-40 lysis buffer (Section 2.1.10) on ice. Samples were spun at 
4°C at 13,000 rpm for 10 min, and 900 µl lysates moved to a fresh pre-cooled 1.5 ml tube. 
Protein G sepharose beads were washed 3x in lysis buffer, and 50 µl added to each sample for 
pre-clearing end over end at 4°C for 30 min.  Following this, samples were spun at 4°C at 
10,000 rpm for 1 min and supernatants removed into new pre-cooled tubes. For further pre-
clearing, 5 µg/ml of isotype control antibody was added to each sample and incubated at 4°C 
end over end for 30 min. Another 50 µl washed beads were added to the samples, which were 
incubated for a further 30 min at 4°C end over end. Samples were spun at 4°C at 10,000 rpm 
for 1 min and supernatants removed into fresh pre-cooled tubes. At this point, lysates should be 
cleared of any particles binding non-specifically to either protein G and/or the antibody isotype. 
Samples were split and immunoprecipitation with 5 µg/ml specific/isotype control antibody 
was allowed to proceed for 1.5 h at 4°C end over end. Washed protein G beads were then added 
to each sample (50 µl each) and samples incubated a further hour at 4°C end over end before 
spinning at 10,000 rpm for 1 min at 4 °C. Supernatants were removed, and beads (with bound 
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antibody-protein complexes) were washed 3x with lysis buffer prior to addition of 500 mM NP-
40 lysis buffer for denaturing and separation from the beads. Samples were separated by SDS-
PAGE as described in Section 2.5.4. 
2.6.3 ELISA 
The concentration of secreted cytokines in the media surrounding stimulated cells was 
measured by enzyme linked immuno-sorbent sandwich assay (ELISA). This technique uses 
specific antibodies to capture and detect cytokines with the use of a colorimetric assay. The 
antibodies used for ELISA are listed in Table 2.2. Between each incubation step, plates were 
washed 3x with PBS/T. 100 µl capture antibodies were coated onto 96-well Maxisorb plates 
(Nunc, Denmark) in PBS and left at 4°C overnight. The wells were then blocked with 2% (w/v) 
BSA in PBS (200 µl) for 1h at RT, and 100 µl of samples loaded in 0.5% (w/v) BSA in 
appropriate dilutions alongside a serial dilution of recombinant cytokine (Table 2.1) and 
incubated at RT for 2 h on an orbital shaker. Minimal levels of detection (LD) for each cytokine 
are ≤ 13,71 pg/ml based on minimum concentration of standards (Table 2.1). Samples were 
removed and plates washed prior to addition of 100µl biotin-conjugated detection antibody in 
0.5% (w/v) BSA for 1 h at RT. Plates were washed again and incubated with 100 µl/well 
Streptavidin-HRP 1:400 in 0.5% BSA for a further hour at RT. Following the washing steps, all 
wells were developed by adding TMB peroxidase substrate. The reaction was stopped with 
H2SO4, and the absorbance read at 450 nm on Multiskan BiochromaticTM plate reader using 
AscentTM 2.4.2 software (Labsystems, Helsinki, Finland).  
2.6.4 Immunofluorescence-staining and flow cytometry 
Flow cytometry is a technique that is commonly used for determining the presence of cell 
surface or intracellular proteins on a single cell basis. Cells labelled with antibodies are passed 
through the light of one or more lasers, both scattering light and emitting fluorescence. The 
light scatter provides some information regarding the morphology of the particles, which can be 
analysed using forward and sideward scatter. The fluorochrome coupled to the secondary 
antibody emits light when excited by a laser, and the light intensity correlates to the amount of 
antigen present on the cell. Antibodies used in this study are summarised in Table 2.3. In these 
studies an IgG isotype control was used, see Table 2.1. 
In this project DCs were harvested using pre-warmed cell dissociation solution, for 20 min at 
37°C. 1x106 cells/condition were then washed in ice-cold flow cytometry wash buffer (see 
Section 2.1.10). To determine the location of the protein of interest, the cells were surface- as 
well as intracellular stained. 
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2.6.5 Surface staining 
Non-specific staining was blocked by incubating the cells in flow cytometry wash buffer 
containing species-specific serum for 20 min on ice. Then cells were incubated with 10 µg/ml 
of the primary antibody (see Table 2.3) for 1 h on ice. In the case of directly conjugated 
antibodies, the cells were washed 3 times with flow cytometry wash buffer and fixed using 
0.5% formaldehyde before analysis. For secondary conjugated antibodies the cells were washed 
3 times with flow cytometry wash buffer and incubated with 2 µg/ml of the secondary antibody 
(Table 2.12) for 30 min on ice. After incubation cells were washed 3 times with flow cytometry 
wash buffer and fixed using 0.5% formaldehyde. 
2.6.6 Intracellular staining 
The cells are fixed by incubation in 0.5 % formaldehyde for 5-10 min on ice followed by triple 
washing with flow cytometry wash buffer. The cells were permeabilized by incubation in flow 
cytometry wash buffer containing 0.1 % saponin. The cell were incubated for 1 h with 10 µg/ml 
of the primary antibody, washed 3 times with flow cytometry wash buffer containing 0.1 % 
saponin and incubated with 2 µg/ml of the secondary antibody. After 3 washing steps in flow 
cytometry wash buffer containing 0.1 % saponin the cells were re-suspended in flow cytometry 
wash buffer and analysed as described in Section 2.6.4. 
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2.7 Mouse techniques 
2.7.1 Induction and assessment of arthritis 
Collagen-induced arthritis is the most widely used animal model for the evaluation of novel 
therapeutic strategies for rheumatoid arthritis. The disease is induced by immunisation of 
genetically susceptible strains of mice or rats with type II collagen in adjuvant. Susceptibility to 
CIA is associated with MHC class II genes, although non-MHC genes also play a role. Both B 
and T lymphocytes are important in the pathogenesis of collagen-induced arthritis, with the 
peak of the T cell response occurring around the time of disease onset. Histopathological 
assessment of the joints of animals with collagen-induced arthritis reveal a proliferative 
synovitis with infiltration of polymorphonuclear and mononuclear cells, the formation of an 
erosive pannus, cartilage degradation, and fibrosis. As in human rheumatoid arthritis, a number 
of both pro- and anti-inflammatory cytokines are expressed in the joints of mice with collagen-
induced arthritis, including TNFα and IL-1β, IL-6, IL-1Ra, IL-10 and TGFβ. 
The type II collagen from cartilage was purified and prepared for injection by Dr. Julia Inglis 
using the method based on the studies of Miller (Miller, 1972) and Herbage et al (Herbage et 
al., 1977). Type II collagen was dissolved at 4 mg/ml in 0.1M acetic acid overnight at 4°C, with 
vigorous stirring. The complete Freund’s adjuvant (CFA) used was produced by grinding M. 
tuberculosis (H37 RA, Difco) with a pestle and mortar to produce a fine powder, followed by 
suspending it in incomplete Freund’s adjuvant (IFA, Difco) (approx. 3 mg M. tuberculosis/ml 
of IFA). The dissolved type II collagen was emulsified with an equal volume of CFA on ice, 
using a syringe. For immunisation, mice were sedated by intraperitoneal injection of 100 µl of 
10% (v/v) Hypnorm®, diluted in distilled water followed by the shaving of the rumps of the 
mice. The emulsion was injected by Dr. Julia Inglis intradermally at 2 sites at the base of the 
tail using a glass syringe or a latex-free syringe and a 27 gauge needle. Each mouse received 
0.1 ml of emulsion in total. The mice were sacrificed on day 14 and lymph node, spleen, bone 
marrow and blood removed or monitored for arthritis every day from day 14 after 
immunisation. The peak time of arthritis onset is around day 30. To compare the clinical 
severity of arthritis a scoring system was used where 0 = normal, 1 = slight swelling and/or 
erythema, 2 = pronounced swelling, 3 = ankylosis. Each limb is graded in this way, giving a 
maximum score of 12 per mouse. In addition, paw swelling was monitored using calipers (Poco 
2T, Kroeplin). To compare histological severity, paws were removed at post mortem, fixed in 
buffered formalin (10% v/v), then decalcified in EDTA in buffered formalin (5.5% w/v). The 
tissues were then embedded in paraffin, sectioned and stained with haematoxylin and eosin. 
The severity of arthritis was graded as mild, moderate or severe based on the following criteria: 
mild = minimal synovitis, cartilage loss and bone erosions limited to discrete foci; moderate = 
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synovitis and erosions present but normal joint architecture intact; severe = synovitis, extensive 
erosions, joint architecture disrupted. 
2.7.2 Measurement of anti-collagen IgG 
Serum levels of anti-collagen IgG provide a marker of the magnitude of the humoral anti-
collagen response whereas levels of IgG1 and IgG2a serve as in vivo markers of Th2 and Th1 
responses, respectively. To measure IgG levels, a stock solution of type II collagen in 0.05M 
Tris-HCl, 0.2M NaCl (pH7.4) at 1 mg/ml was prepared. An ELISA plate was coated with type 
II collagen at 2-5 µg/ml in 0.05M Tris-HCl, 0.2M NaCl (pH7.4) and incubated overnight at 
4oC. Following the coating the plate was blocked for 1h at room temperature with 2% BSA and 
incubated with test sera (diluted in PBS/Tween 20) for 2h at room temperature. The levels of 
anti-collagen IgG can vary enormously between mice and it is important to serially dilute 
samples to ensure that comparisons are made based on the linear portion of the titration curve. 
The starting dilution used was 1/100, with seven three-fold dilution steps. A standard serum 
sample, obtained from pooled serum from collagen-immunised, wild type C57/B6 mice, was 
used on each plate. The plate was washed 6 times with PBS/Tween 20 and the IgG levels 
detected using HRP-conjugated anti-mouse IgG1 or IgG2a (BD Biosciences). Plates were 
developed with TMB substrate, the reaction stopped with 4.5N H2SO4 and read at 450 nm. 
2.7.3 Analysis of T cell responses 
The proliferative responses of T cells were measured by incorporation of [3H]thymidine in 
response to stimulation of lymph node cells and splenocytes with type II collagen and anti-
CD3. Moreover, cytokines in culture supernatants were measured by ELISA. The inguinal 
lymph node and the spleen were removed from collagen-immunised mice at day 14 after 
immunisation. The lymph nodes and the spleen were pushed through cell strainer using a 
syringe plunger followed by three washes in HBSS. The red blood cells in the spleen were 
lysed, using red cell lysis buffer (Sigma Aldrich), for 5 min at room temperature. Cells were 
resuspended at 5 x 106 cells/ml in complete medium (RPM1 1640 containing 10% (v/v) heat-
inactivated foetal calf serum or 1% (v/v) mouse serum, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 2x10-5 M 2-mercaptoethanol and 20 mM L-glutamine) and cultured for 72h in the 
presence or absence of type II collagen (50 µg/ml) or anti-CD3 (100 ng/ml, eBioscience). 
Supernatants were removed for measurement of IL-5, IL-10, IFNγ, TNFα and IL-17 by ELISA 
as described in Section 1.6.3. To determine the rate of T cell proliferation, cells were pulsed 
with [3H]thymidine (Amersham) and cultured for a further 16 h before being harvested and 
incorporated radioactivity assessed. 
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2.7.4 B and T cell purification and activation 
A single cell suspension was prepared from lymph nodes and spleens as described above. B 
cells were positively enriched using anti-IgM MACS micro beads, and T cells using anti-CD4 
MACS micro beads, according to the manufacturer’s guidelines (Miltenyi Biotec, Bergisch 
Gladbach, Germany). Purity was assessed by flow cytometric analysis (B cells >90% CD19+, T 
cells >90% CD4+). Cells were cultured at 1 x 105 cells/ml in 200µl complete RPMI, as 
described above, in a flat bottom 96-well plate and cultured for 72 h. B cells were stimulated 
with IgM (10 µg/ml; BD) or LPS (10 µg/ml, Alexis), and T cells were stimulated with 10 µg/ml 
plate-bound anti-CD3 (eBiosciences) plus 1 µg/ml soluble anti-CD28 (eBiosciences). In 
addition T cells were cultured in the absence or presence of IL-1α (20 ng/ml, PeproTech) or IL-
33 (20 ng/ml, PeproTech). For proliferation assays, 48 hours after stimulation cells were pulsed 
with 1 µCi 3H thymidine per well for 18 h. Cells were then harvested and plates assessed for 
thymidine incorporation. Each assay was performed on a minimum of 2 occasions. IFN-γ, IL-
17 and IL-5 levels were assessed in the 48hr culture medium by ELISA after cells were 
restimulated on Day 5 after culturing with anti-CD3/CD28, with or without IL-1α or IL-33. 
2.7.5 In vitro culture of Bone marrow cells 
In order to obtain bone marrow derived dendritic cells the femurs were removed and the bone 
marrow washed out using a syringe. The cells were cultured for 7 days in complete media 
containing 20 ng/ml GM-CSF (PeproTech). Cells were re-pulsed with 20 ng/ml GM-CSF on 
day 3 of in vitro culture. On day 7 of in vitro culture the floating cells were collected and re-
plated at 1x105 Cells/ml in a 96-well plate. Cells were stimulated with 100 ng/ml LPS or 100 
ng/ml Malp2 for 18 h before supernatants were collected and cytokines measured by ELISA 
(see Section 2.6.3). 
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2.8 Statistical techniques 
Mean, standard deviation (SD) and standard error of the mean (SEM) were calculated using 
GraphPad Prism version 4.03 (GraphPad Software, Inc.). Statistical significance was assessed 
using the Student’s t-test due to small sample sizes, linear regression or two-way ANOVA 
(Grafen 2002).  
Due to donor variation in primary human cells, data cannot generally be pooled unless 
converted into percentage of controls for each set of experiments. For representative data, SD is 
shown for each triplicate. SEM is shown for pooled data of n≥3. Statistical analyses using 
Student’s t-test were performed on pooled percentage values for n≥3, due to donor variation. 
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3.1  Introduction 
In recent years, the TLR signalling pathway has been described to be one of the major inducers 
of inflammatory mediators in response to PAMPs, which are conserved molecular structures 
present in microbes but not the host (Akira and Takeda, 2004). TLR signalling leads to the 
activation of macrophages and DCs. As a consequence macrophages and DCs produce 
cytokines and chemokines and increase their capacity to phagocytose (Leon et al., 2005) (Lee 
and Kim, 2007). In addition DCs become able to present antigens on MHC II complexes on 
their surface. Consequently these antigens are presented to T cells in the lymph node, thereby 
initiating the adaptive immune response (Leon et al., 2005). 
Our current knowledge of TLR signalling mainly stems from two sources; knock out mice and 
cell lines. In these models TLR signalling has been described to be dependent on four adaptor 
molecules. MyD88, the first one to be described, has been shown to be ubiquitously used by all 
TLRs with the exception of TLR3. Mal is used by TLR2 and TLR4, TRIF by TLR3 and TLR4 
and TRAM only by TLR4. A fifth adaptor molecule, SARM, has been implicated as a negative 
regulator of TRIF dependent signalling (Akira and Takeda, 2004; O'Neill, 2006; O'Neill and 
Bowie, 2007). The recruitment of those adaptor molecules is one of the earliest events 
following TLR stimulation. It leads to the induction of a signalling cascade, ultimately resulting 
in the activation of NF-κB, MAPK and IRFs (O'Neill, 2006). The signalling cascades induced 
by TLRs are further divided into MyD88 dependent signalling, leading to an early activation of 
NF-κB, and TRIF dependent signalling, leading to the activation of IRFs and a late induction of 
NF-κB (O'Neill, 2006). 
Until recently, it has been thought these principles of TLR signalling and its regulation apply to 
human and mouse. Differences in the signalling mechanisms between different cell types have 
until recently not been considered. However, our group has reported differences in TLR4 
signalling between cells of human myeloid and non-myeloid origin (Andreakos et al., 2004). 
Investigating the role of MyD88 in primary human myeloid and non-myeloid cells, our group 
found that a dominant negative construct of MyD88 is able to inhibit TLR4 signalling in 
HUVECs but not in macrophages (Andreakos et al., 2004). Given TLR4 is the most complex 
TLR, as it utilises all 4 adaptor molecules, this result led me to investigate the role of MyD88 in 
“simpler” TLR signalling pathways in macrophages. Furthermore, this study investigated the 
effect of dominant negative MyD88 in another myeloid cell, the dendritic cell. 
The findings in this chapter challenge the current belief of a common TLR signalling pathway 
utilised by most cell types and highlight the possibility of cell type specific regulation in 
accordance with the cell type’s function. Moreover, the results presented in this chapter suggest 
a MyD88 dependent mechanism, through which DCs are kept in an immature phenotype. 
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3.2 Results 
3.2.1 Adenoviral constructs encoding TLR adaptor proteins for 
functional investigations were generated at the Kennedy 
Institute 
To begin this study I collected the adenoviral constructs already available at the KIR (Figure 
3.1). In order to investigate the function of the TLR adaptor molecules in primary human cells, 
adenoviral constructs, expressing both wild type (wt) and dominant negative (dn) forms of 
MyD88, Mal and TRAM, have been generated at the KIR (Mrs Brenda Mutch, Dr Anna 
Lundberg) (Figure 3.1). These constructs allow reliable over-expression of the encoded gene in 
primary human cells. This has been a widely used method to study protein function in those 
cells before the advent of siRNA. In addition to wild-type constructs of the adaptors MyD88, 
Mal and TRAM, mutant constructs have been developed. MyD88 dn contains a point mutation 
(Phe56Asn) and a deletion in the DD, which renders it incapable of signal transduction as 
shown before (Andreakos et al., 2004; Burns et al., 1998). Mal dn and TRAM dn contain a 
point mutation of the conserved proline 125 to histidine in the TIR domain and both constructs 
have been shown to inhibit TLR4 signalling in RASF and HUVECs but not human 
macrophages (Andreakos et al., 2004; Sacre et al., 2007c). In addition adenoviral deletion 
constructs, encoding the TIR domain of Mal and TRIF only, have been generated (Figure 3.1). 
 
Figure 3.1: Wild type- (wt), dominant negative- (dn) and deletion-constructs (TIR) of TLR adaptor 
proteins. Murine MyD88 wt is the only TLR adaptor protein containing a death domain (DD). The 
murine dominant negative construct of MyD88 contains an N-terminal deletion of 52 amino acids and 
the point mutation Phe56Asn in the DD. Human Mal dn and human TRAM dn contain a point mutation 
of the conserved proline in the TIR domain (Pro125His). Moreover, constructs consisting of the TIR 
domain only of human Mal and human TRIF have been made (Mal TIR and TRIF TIR). 
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3.2.2 MyD88 dominant negative over-expression inhibits TLR4 and 
IL-1R signalling in RASF 
To further investigate the difference between cells of myeloid and non-myeloid origin this 
study began by confirming previous experiments performed in our laboratory by over-
expressing murine MyD88 dn in RASF stimulated with LPS, IL-1, poly I:C and TNFα. The 
RASF used in this study stain positive for the fibroblast marker Vimentin while no 
contamination with monocytes/macrophages (CD14) or T cells (CD3) could be detected 
(Figure 3.2). 
Figure 3.2: Rheumatoid arthritis synovial fibroblasts (RASF) are Vimentin positive while no 
contaminations with monocytes/macrophages or T cells can be detected. RASF were used from 
passage 3 after expansion in DMEM 10% FCS. Cells were collected using cell dissociation buffer before 
being permeabilized using 0.1% Saponin and stained for Vimentin (Neo Markers, CA, USA), CD14 (BD 
Bioscience) and CD3 (BD Bioscience). Red line, Isotype control; green line, antigen specific staining. 
 
Over-expression of murine MyD88 dn in RASF resulted in a significant inhibition of IL-6 
production in response to LPS or IL-1 but not poly I:C or TNFα (A, Figure 3.3). The vitality of 
the cells, assessed by MTT assay, was unaffected by the over-expression of murine MyD88 dn 
(B, Figure 3.3). 
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Figure 3.3: Murine MyD88 dn inhibits LPS and IL-1 induced cytokine expression in Synovial 
Fibroblasts (LPS p = 0.02, IL-1 p = 0.0298). RASF were used from passage 3 after expansion in 
DMEM 10% FCS (A). Cells were left uninfected, or infected (300:1 m.o.i.) for 1 h in serum-free medium 
with adenoviruses expressing green fluorescent protein (control) or murine MyD88 dn. 24 h post 
infection, cells were stimulated with 10 ng/ml LPS, 20 µg/ml poly I:C, 20 ng/ml IL-1α or 20 ng/ml TNFα 
for 18 h, where after supernatants were collected and IL-6 induction assayed by ELISA. Data are 
expressed as mean ± SEM. n = 3, data represents 3 independent experiments pooled. p ≤ 0.05 *; p ≤ 0.01 
**; p ≤ 0.005 ***. B) After supernatants were collected, cells were incubated with MTT over night, lysis 
performed and OD574 measured. Data is normalised to un-stimulated cells and expressed as mean 
± SEM. n = 3, data represents 3 independent experiments pooled. 
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The impairment of IL-6 production in response to LPS and IL-1 (A, Figure 3.3) is due to an 
inhibition of NF-κB as over-expression of murine MyD88 dn led to a significant inhibition of 
NF-κB in response to LPS or IL-1 as was shown by using an NF-κB luciferase reporter assay 
(Figure 3.4). Although, the efficency of the second infection with MyD88 dn can not be 
quantitated, its effect seems to be specific to LPS and IL-1 as poly I:C as well as TNFα induced 
NF- κB activation is unaffected. 
While this result once more shows that the murine MyD88 dn is functional in non-myeloid 
human cells it is unclear what effect its over-expression has on TLR signalling, other than 
TLR4, in human monocyte derived macrophages. 
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Figure 3.4: Murine MyD88 dn inhibits LPS and IL-1 induced NF-κB activation in Synovial 
Fibroblasts, (LPS p = 0.0001, IL-1 p = 0.03). Cells were left uninfected, or infected (300:1 m.o.i.) for 1 
h in serum-free medium with adenoviruses expressing NF-κB luciferase reporter. After over night 
incubation in DMEM 10% FCS cells were left uninfected, or infected (300:1 m.o.i.) for 1 h in serum-free 
medium with adenoviruses expressing green fluorescent protein (control) or MyD88 dn. 24 h post 
infection, cells were stimulated with 10 ng/ml LPS, 20 µg/ml poly I:C, 20 ng/ml IL-1α or 20 ng/ml TNFα 
for 18 h, where after cells were lysed and assayed for luciferase activity. Data are expressed as mean 
± SEM. n = 4, data represents 4 independent experiments pooled. p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
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3.2.3 MyD88 dominant negative over-expression does not inhibit 
TLR4 signalling in human monocyte derived macrophages but 
does inhibit TLR2, TLR5 and TLR7/8 
In contrast to RASF, macrophages are professional immune cells whose main function is to 
recognise and eliminate pathogens. Macrophages belong to the myeloid cell lineage and 
differentiate from CD34+ haematopoietic progenitor cells. The monocyte derived macrophages 
used in this study express the monocyte/macrophage marker CD14 and show no contamination 
with T cells (CD3) following isolation from peripheral blood mononuclear cells and in vitro 
culture (Figure 3.5). 
Figure 3.5: M-CSF differentiated macrophages stain positive for CD14 while being negative for 
CD3. Macrophages were used at day 4 of in vitro differentiation with 100 ng/ml M-CSF in RPMI 5% 
FCS. Macrophages were collected using cell dissociation buffer before being stained for CD14 (BD 
Bioscience) and CD3 (BD Bioscience). Red line, Isotype control; green line, antigen specific staining. 
 
Over-expression of murine MyD88 dn in macrophages did not result in an inhibition of TLR4 
signalling (A and B, Figure 3.6), which is in accordance with results published before 
(Andreakos et al., 2004). Interestingly, while it has been demonstrated before that TLR4 
signalling is unaffected by murine MyD88 dn over-expression IL-1R signalling has been shown 
to be impaired in human macrophages (Andreakos et al., 2004). Since the IL-1R, unlike TLR4, 
only utilises MyD88 for signal transduction, I further investigated TLRs, which show similar 
signalling characteristics. 
TLR2 (Malp-2) signalling, using MyD88 and Mal, as well as TLR5 (Flagellin) and TLR7/8 
(R848) signalling, utilising only MyD88, were impaired in macrophages over-expressing 
murine MyD88 dn (Figure 3.6). Over-expression of MyD88 dn significantly inhibited the 
Chapter 3 Results 
 
104 
production of TNFα and IL-6 by R848 stimulated macrophages. Furthermore, expression of 
MyD88 dn resulted in an inhibition of TNFα and significant inhibition of IL-6 following 
stimulation with Flagellin (B, Figure 3.6) and Malp2 (B, Figure 3.6). The cell vitality of 
macrophages was not affected by the over-expression of MyD88 dn (C, Figure 3.6). 
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Figure 3.6: Murine MyD88 dn inhibits TLR-2 (IL-6 p = 0.0003), TLR-5 (IL-6 p = 0.0277) and TLR-
7/8 (TNFα p = 0.0083 and IL-6 p = 0.0003) but not TLR4 signalling in primary human monocyte 
derived macrophages. (A and B) Cytokine induction assayed in culture supernatant by ELISA. 
Macrophages were used at day 4 of in vitro differentiation with 100 ng/ml M-CSF in RPMI 5% FCS. 
Cells were left uninfected, or infected (100:1 m.o.i.) for 1 h in serum-free medium with adenoviruses 
expressing β-galactosidase (Ad β-gal), murine MyD88 dn. 24 h post infection, cells were stimulated with 
20 µg/ml Malp2, 10 ng/ml Flagellin or 100 ng/ml R848 for 18 h, where after supernatants were collected 
and TNFα (A) and IL-6 (B) induction measured by ELISA. Data are expressed as mean ± SEM. n = 3, 
this data is 3 independent experiments pooled. p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** C) After 
supernatants were collected for ELISA assay cells were incubated with MTT over night, lysed and 
OD574 measured and data normalised to un-stimulated cells. Data is normalised to un-stimulated cells 
and expressed as mean ± SEM. n = 3, data represents 3 independent experiments pooled.  
 
Although this shows that the murine dominant negative construct of MyD88 is functional in 
human myeloid as well as non-myeloid cells it is intriguing that TLR4 signalling is not 
suppressed in human macrophages. Current knowledge suggests that TLR4 is the TLR with the 
most complex signalling transduction (O'Neill, 2006). It is the only TLR to utilise four of the 
five described adaptor molecules and is part of a multi-receptor complex consisting of CD14, 
MD-2 and LBP. Although the described complexity in TLR4 signalling could be due to the 
simple fact that TLR4 has been the first mammalian TLR to be described, it could also be an 
indication why TLR4 is the only TLR tested in this study, which is not inhibited by the over-
expression of a MyD88 dn. The usage of all four adaptors raises the possibility of redundancy 
between the adaptors especially MyD88/Mal and TRIF/TRAM. However, the combined 
expression of MyD88 dn, Mal dn and TRAM dn performed in our group also resulted in no 
inhibition of TLR4 signalling (Dr. Anna Lundberg, unpublished data). Another explanation 
could be the involvement of co-receptors and the induction of so far elusive signalling 
pathways independent of MyD88. TLR4 is part of a receptor complex. These co-receptors are 
necessary for a complete induction of TLR4 signalling as was shown in case of smooth LPS 
and its dependency on CD14 to signal (Jiang et al., 2005b). It is intriguing, that while RASF are 
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CD14- the human macrophages used in this study are CD14+. Given these differences I further 
investigated the role of MyD88 in TLR4 signalling in a myeloid cell, which does not express 
CD14, the dendritic cell. 
3.2.4 Over-expression of MyD88 dn induces and super-induces IL-6 
and TNFα production in un-stimulated and LPS stimulated 
human dendritic cells 
Characteristic of immature DCs is their ability to up-regulate co-stimulatory molecules in 
response to TLR stimulation, which results in a mature phenotype (Adams et al., 2005). The 
monocyte derived DCs display this ability by up-regulating CD86 in response to LPS (Figure 
3.7). Furthermore, DCs used in this study do not express CD14 (Figure 3.7) and no 
contaminations with residual T cells from the monocyte isolation process could be detected in 
the DC cultures used (Figure 3.7). 
Figure 3.7: Monocyte derived DCs up-regulate co-stimulatory molecule CD86 while staining 
negative for CD14 and CD3. DCs were used at day 5 of in vitro differentiation using 50 ng/ml GM-CSF 
and 10 ng/ml IL-4  in RPMI 5% FCS. DCs were collected and left un-stimulated or stimulated using 10 
ng/ml LPS for 18 h before being stained for CD86 (BD Bioscience), CD14 (BD Bioscience) and CD3 
(BD Bioscience). Red line, Isotype control; green line, staining of un-stimulated cells; blue line, staining 
of stimulated cells. 
 
To confirm that the adenoviruses used in this study over-express the gene of interest in DCs, 
cells were infected and the over-expression examined by western blot. The infection of DCs 
with adenoviruses encoding wild type-, dominant negative- and deletion (TIR)-constructs of 
TLR adaptor proteins (Figure 3.1) resulted in the over-expression of these proteins (Figure 3.8). 
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Figure 3.8: Adenovirus constructs are expressed in DCs at an m.o.i of 100:1. Dendritic cells were 
used at day 5 of in vitro differentiation with  50 ng/ml GM-CSF and 10 ng/ml IL-4 in RPMI 5% FCS. 
Cells were left uninfected, or infected (100:1 m.o.i.) for 2 h in serum-free medium with adenoviruses 
expressing green-fluorescent protein (GFP), murine MyD88 wt, murine MyD88 dn, Mal wt, Mal dn, Mal 
TIR, TRIF TIR, TRAM wt and TRAM dn. 24 h post infection cells were lysed with 1 % Triton X 100 
lysis buffer and cell lysate was separated by SDS-PAGE. Western blot for MyD88 was performed using 
an rabbit anti-MyD88 antibody (abcam, Cambridge, UK). The HA-tagged Mal and TRIF constructs  
were detected using mouse anti-HA (Covance, Berkeley, CA, USA) and TRAM wt and TRAM dn were 
detected using rabbit ant-TRAM antibody (made in house). As a loading control the membranes were 
striped and re-probed for α-tubulin using a mouse anti-α-tubulin antibody (Sigma, Poole, Dorset, UK). 
As a marker the Full range Rainbow molecular weight marker RPN800 from Amersham was used (scale 
in kDa). 
 
Having shown the expression of the TLR adaptor constructs in DCs, the cells were infected 
with murine MyD88 dn and subsequently stimulated with LPS (Figure 3.9). However, murine 
MyD88 dn did not inhibit LPS induced cytokine production. On the contrary, the over-
expression of MyD88 dn significantly induced IL-6 (A, Figure 3.9) and TNFα (B, Figure 3.9) 
production, in the absence of any stimuli. Furthermore, stimulation of MyD88 dn over-
expressing DCs with LPS resulted in significant super-induction of IL-6 (A, Figure 3.10) and 
TNFα (B, Figure 3.10). 
Given this unexpected result, the role of Mal and TRAM was further investigated in TLR4 
signalling by DCs. Therefore, DCs were infected with human Mal dn or human TRAM dn, 
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which did not result in an induction or super-induction of IL-6 (A, Figure 3.9) or TNFα (B, 
Figure 3.9). 
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Figure 3.9: Expressing murine MyD88 dn significantly induces IL-6 (A, p = 0.0029) and TNFα (B, 
p = 0.0079) production in un-stimulated dendritic cells. Cytokine induction assayed in culture 
supernatant by ELISA (IL-6: A, TNFα: B). Dendritic cells were used at day 5 of in vitro differentiation 
with 50 ng/ml GM-CSF and 10 ng/ml IL-4 in RPMI 5% FCS. Cells were left uninfected, or infected 
(100:1 m.o.i.) for 2 h in serum-free medium with adenoviruses expressing GFP (control), MyD88 dn, 
Mal dn and TRAM dn. 32 h post infection supernatants were collected and TNFα and IL-6 induction 
assayed by ELISA. Data are expressed as mean ± SEM. n = 4, data is 4 independent experiments 
pooled. p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
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Figure 3.10: Expressing murine MyD88 dn significantly super-induces IL-6 (A, p = 0.0448) and 
TNFα (B, p = 0.0392) production in LPS-stimulated dendritic cells. Cytokine induction assayed in 
culture supernatant by ELISA (IL-6: A, TNFα: B). Dendritic cells were used at day 5 of in vitro 
differentiation with  50 ng/ml GM-CSF and 10 ng/ml IL-4 in RPMI 5% FCS. Cells were left uninfected, 
or infected (100:1 m.o.i.) for 2 h in serum-free medium with adenoviruses expressing GFP (control), 
MyD88 dn, Mal dn and TRAM dn. 24 h post infection cells were stimulated with 100 ng/ml LPS for 18 
h, where after  supernatants were collected and TNFα and IL-6 induction assayed by ELISA. Data are 
expressed as mean ± SEM. n = 4, data is 4 independent experiments pooled. p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 
0.005 *** 
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To further study the observation of cytokine induction in DCs expressing murine MyD88 dn, 
the cells were infected with adenovirus over-expressing murine MyD88 wt, human Mal wt and 
human TRAM wt. Unlike MyD88 dn, MyD88 wt did not induce IL-6 (A, Figure 3.11) and 
TNFα (B, Figure 3.11) in un-stimulated DCs. However, over-expression of Mal wt and TRAM 
wt led to a significant induction of IL-6 (A, Figure 3.11) and TNFα (B, Figure 3.11). Moreover, 
stimulation with LPS resulted in significant super-induction of IL-6 (A, Figure 3.12) and TNFα 
(B, Figure 3.12) in TRAM wt over-expressing DCs. Although a trend of IL-6 and TNFα super-
induction was observed in Mal wt over-expressing cells it did not reach statistical significance 
due to donor variability and limited number of repeats. 
un
inf
ec
ted
co
ntr
ol
mu
rin
e M
yD
88
 w
t
Ma
l w
t
TR
AM
 w
t
0
2500
5000
7500
unstimulated
*
*
A
IL
-6
 [p
g/
m
l]
 
un
inf
ec
ted
co
ntr
ol
mu
rin
e M
yD
88
 w
t
Ma
l w
t
TR
AM
 w
t
0
500
1000
1500
unstimulated
*
*
B
TN
F-
α 
[p
g/
m
l]
 
Figure 3.11: Over-expressing Mal wt and TRAM wt significantly induces IL-6 (A, p = 0.0164 and p 
= 0.0113 respectively) and TNFα (A, p = 0.0251 and p = 0.0385 respectively) production in un-
stimulated dendritic cells. Cytokine induction assayed in culture supernatant by ELISA (IL-6: A, 
TNFα: B). Dendritic cells were used at day 5 of in vitro differentiation with  50 ng/ml GM-CSF and 10 
ng/ml IL-4 in RPMI 5% FCS. Cells were left uninfected, or infected (100:1 m.o.i.) for 2 h in serum-free 
medium with adenoviruses expressing GFP (control), MyD88 wt, Mal wt and TRAM wt. 32 h post 
infection supernatants were collected and TNFα and IL-6 induction assayed by ELISA. Data are 
expressed as mean ± SEM. n = 4; data is 4 independent experiments pooled. p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 
0.005 *** 
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Figure 3.12: Over-expressing Mal wt and TRAM wt super-induces IL-6 (A, p = 0.0755 and p = 
0.0351 respectively) and TNFα (B, p = 0.0767 and 0.0043 respectively) production in LPS-
stimulated dendritic cells. Cytokine induction assayed in culture supernatant by ELISA  (IL-6: A, 
TNFα: B). Dendritic cells were used at day 5 of in vitro differentiation with  50 ng/ml GM-CSF and 10 
ng/ml IL-4 in RPMI 5% FCS. Cells were left uninfected, or infected (100:1 m.o.i.) for 2 h in serum-free 
medium with adenoviruses expressing GFP (control), MyD88 wt, Mal wt and TRAM wt. 24 h post 
infection cells were stimulated with 100 ng/ml LPS for 18 h, where after  supernatants were collected and 
TNFα and IL-6 induction assayed by ELISA. Data are expressed as mean ± SEM. n = 4; data is 4 
independent experiments pooled. p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
 
Although, the over-expression of MyD88 wt in DCs is low compared to MyD88 dn, which 
could be one reason for the results obtained, MyD88 wt expression is still significantly higher 
compared to background levels (Figure 3.8). 
Another possible explanation for the observations made could lie in the structural differences of 
the constructs used. While human Mal wt and human TRAM wt, containing a wild type TIR 
domain in the absence of a DD, induced and super-induced IL-6 and TNFα in un-stimulated 
and LPS stimulated DCs, Mal dn and TRAM dn, containing a point mutation in the TIR 
domain, did not. These results may suggest an important role of the TIR domain in DC 
activation. Therefore, the effect of over-expressing Mal TIR and TRIF TIR constructs, 
consisting of the TIR domain only, was further investigated (Figure 3.13 and Figure 3.14). 
3.2.5 Expression of a wild type TIR domain induces and super-
induces IL-6 and TNFα in human dendritic cells 
The expression of the TIR domain of Mal and TRIF resulted in the significant induction of IL-6 
(A, Figure 3.13) and in the case of TRIF TIR TNFα (B, Figure 3.13) in un-stimulated DCs. 
As well as inducing IL-6 (A, Figure 3.13) and TNFα (B, Figure 3.13) in un-stimulated DCs, 
stimulation with LPS resulted in the significant super-induction of IL-6 (A, Figure 3.14) and 
TNFα (B, Figure 3.14) in case of Mal TIR. Although a trend of IL-6 and TNFα super-induction 
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was observed in TRIF TIR over-expressing cells it did not reach statistical significance due to 
donor variability and limited number of repeats. 
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Figure 3.13: Expressing Mal TIR and TRIF TIR induces IL-6 (A, p = 0.0298 and p = 0.0217 
respectively) and TNFα (B, p = 0.0758 and p = 0.0087 respectively) production in un-stimulated 
dendritic cells. Cytokine induction assayed in culture supernatant by ELISA (IL-6: A, TNFα: B). 
Dendritic cells were used at day 5 of in vitro differentiation with  50 ng/ml GM-CSF and 10 ng/ml IL-4 
in RPMI 5% FCS. Cells were left uninfected, or infected (100:1 m.o.i.) for 2 h in serum-free medium 
with adenoviruses expressing GFP (control), Mal TIR and TRIF TIR. 32 h post infection supernatants 
were collected and TNFα and IL-6 induction assayed by ELISA. Data are expressed as mean ± SEM. n 
= 4; data is 4 independent experiments pooled. p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
 
un
inf
ec
ted
co
ntr
ol
Ma
l T
IR
TR
IF 
TIR
0
10000
20000
30000
LPS
A
IL
-6
 [p
g/
m
l]
*
 
un
inf
ec
ted
co
ntr
ol
Ma
l T
IR
TR
IF 
TIR
0
10000
20000
LPS
B
TN
F-
α  
[p
g/
m
l]
*
 
Figure 3.14: Expressing Mal TIR (p = 0.0498 and p = 0.044 respectively) and TRIF TIR (p = 0.0873 
and p = 0.061 respectively) super induces IL-6 (A) and TNFα (B) production in LPS-stimulated 
dendritic cells. Cytokine induction assayed in culture supernatant by ELISA (IL-6: A, TNFα: B). 
Dendritic cells were used at day 5 of in vitro differentiation with 50 ng/ml GM-CSF and 10 ng/ml IL-4 in 
RPMI 5% FCS. Cells were left uninfected, or infected (100:1 m.o.i.) for 2 h in serum-free medium with 
adenoviruses expressing GFP (control), Mal TIR and TRIF TIR. 24 h post infection cells were stimulated 
with 100 ng/ml LPS for 18 h, where after supernatants were collected and TNFα and IL-6 induction 
assayed by ELISA. Data are expressed as mean ± SEM. n = 4; data is 4 independent experiments 
pooled. p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
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These results further indicate the importance of a TIR domain in the induction of cytokines in 
un-stimulated DCs. However, since murine MyD88 wt over-expression does not result in 
cytokine induction, although it has an intact TIR domain, it might also suggest a role for the 
death domain. Furthermore, since the MyD88 constructs used, are of murine origin, the 
observations made could be a species related artefact, although they do function in human 
macrophages and RASF as predicted (Figure 3.3, Figure 3.4 and Figure 3.6). 
3.2.6 Human MyD88 death domain leads to the super-induction of 
TNFα in response to LPS 
In order to be able to exclude any species related effects and to further examine the role of the 
death domain, human MyD88 constructs were generated at the KIR (Mrs Brenda Mutch) 
(Figure 3.15). The human MyD88 mutation construct contains a point mutation of the 
conserved proline (Pro200His) in the TIR domain. The MyD88 DD construct is TIR domain 
deleted but still contains the DD as well as the intermediary domain between DD and TIR 
domain (Figure 3.15). 
 
Figure 3.15: Wild type- (wt), point mutated- (Pro200His) and deletion-constructs (DD) of human 
MyD88. Human MyD88 wt is the only construct containing a Toll/Interleukin-1 receptor (TIR) domain. 
The human dominant negative construct of MyD88 contains a point mutation in the conserved praline 
(Pro200His) in the TIR domain. The MyD88 death domain (DD) construct is TIR domain deleted. 
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Figure 3.16: Adenoviral constructs encoding human MyD88 wt, MyD88 Pro200His and MyD88 DD 
are over-expressed in DCs. Dendritic cells were used at day 5 of in vitro differentiation with  50 ng/ml 
GM-CSF and 10 ng/ml IL-4 in RPMI 5% FCS. Cells were left uninfected, or infected (100:1 m.o.i.) for 2 
h in serum-free medium with adenoviruses expressing green-fluorescent protein (GFP), human MyD88 
wt, human MyD88 Pro200His and MyD88 DD. 24 h post infection cells were lysed with 1 % Triton X 
100 lysis buffer and cell lysate was separated by SDS-PAGE. Western blot for MyD88 was performed 
using mouse anti-HA (Covance, Berkeley, CA, USA). As a loading control the membranes were striped 
and re-probed for β-actin using a mouse anti-β-actin antibody (Sigma, Poole, Dorset, UK). As a marker 
the Full range Rainbow molecular weight marker RPN800 from Amersham was used (scale in kDa). 
 
Having confirmed the over-expression of human MyD88 wt, human MyD88 Pro200His and 
human MyD88 DD (Figure 3.16), DCs were infected with MyD88 wt and subsequently 
stimulated with LPS. The over-expression of human MyD88 wt in DCs did not lead to an 
induction or super-induction of TNFα in response to LPS (Figure 3.17). This result is in 
accordance with murine MyD88 wt over-expression and would suggest that a TIR domain 
together with a DD is not able to activate human DCs. 
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Figure 3.17: Over-expressing human MyD88 wild type (wt) does not induce or super-induce 
cytokine production in DCs. TNFα induction assayed in culture supernatant by ELISA. Dendritic cells 
were used at day 5 of in vitro differentiation with  50 ng/ml GM-CSF and 10 ng/ml IL-4 in RPMI 5% 
FCS. Cells were left uninfected, or infected (100:1 m.o.i.) for 2 h in serum-free medium with 
adenoviruses expressing GFP (control), MyD88 wt. 24 h post infection cells were stimulated with 100 
ng/ml LPS for 18 h, where after supernatants were collected and TNFα induction assayed by ELISA. 
Data are expressed as mean ± SEM. n = 5 data is 5 independent experiments pooled. 
 
Consistent with the results using Mal dn and TRAM dn, shown in Figure 3.9 and Figure 3.10, 
the disruption of a TIR domain also does not induce or super-induce TNFα production in DCs 
as was observed using the human MyD88 Pro200His construct (Figure 3.18). 
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Figure 3.18: Over-expressing human MyD88 Pro200His does not induce or super-induce cytokine 
production in DCs. TNFα induction assayed in culture supernatant by ELISA. Dendritic cells were used 
at day 5 of in vitro differentiation with  50 ng/ml GM-CSF and 10 ng/ml IL-4 in RPMI 5% FCS. Cells 
were left uninfected, or infected (100:1 m.o.i.) for 2 h in serum-free medium with adenoviruses 
expressing GFP (control), MyD88 Pro200His. 24 h post infection cells were stimulated with 100 ng/ml 
LPS for 18 h, where after supernatants were collected and TNFα and IL-6 induction assayed by ELISA. 
Data are expressed as mean ± SEM. n = 5; data is 5 independent experiments pooled. 
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Although the over-expression of a DD alone is not sufficient to significantly induce TNFα 
production without stimuli, it is sufficient to significantly super-induce TNFα production in 
LPS stimulated human DCs (Figure 3.19). 
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Figure 3.19: Over-expressing human MyD88 death domain (DD) does significantly super-induce 
cytokine production in DCs (p= 0.048). TNFα induction assayed in culture supernatant by ELISA. 
Dendritic cells were used at day 5 of in vitro differentiation with 50 ng/ml GM-CSF and 10 ng/ml IL-4 in 
RPMI 5% FCS. Cells were left uninfected, or infected (100:1 m.o.i.) for 2 h in serum-free medium with 
adenoviruses expressing GFP (control), MyD88 DD. 24 h post infection cells were stimulated with 100 
ng/ml LPS for 18 h, where after supernatants were collected and TNFα and IL-6 induction assayed by 
ELISA. Data are expressed as mean ± SEM. n = 4; data is 4 independent experiments pooled. p ≤ 0.05 *; 
p ≤ 0.01 **; p ≤ 0.005 *** 
 
These results confirm the observations made using the murine MyD88 constructs. Furthermore, 
they show that similar to a TIR domain the DD is able to increase activation of human DCs 
following TLR4 stimulation. 
3.2.7 MyD88 dn induces the production of TNFα by BMDCs 
Given the unexpected result of human DC specific activation by over-expression of a TIR 
domain this study further investigated if this mechanism exists in mice as well. Therefore, 
murine BMDCs and BMDMs were infected with murine MyD88 wt or MyD88 dn and cytokine 
production measured (Figure 3.20). 
While the over-expression of MyD88 dn significantly induced the production of TNFα in 
BMDCs without stimulation, it had no effect on BMDMs (Figure 3.20). This result is consistent 
with observations made in human DCs, where over-expression of MyD88 dn did induce 
cytokine production without stimulation but had no effect on human macrophages (Figure 3.6 
and Figure 3.9). Furthermore, the over-expression of MyD88 wt had no effect on TNFα 
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induction by BMDCs or BMDMs (Figure 3.20) again reflecting the observations made in 
human DCs (Figure 3.11). Taken together, these results suggest, that the DC specific activation 
by MyD88 dn over-expression is not restricted to humans but is also present in murine models. 
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Figure 3.20: MyD88 dn over-expression significantly induces TNFα production in un-stimulated 
BMDCs (p ≤ 0.0001) but not BMDMs. TNFα induction assayed in culture supernatant by ELISA. 
BMDCs and BMDMs were derived from the femurs of wild-type C57Bl/6 mice. BMDCs were cultured 
for 7 days in vitro in the presence of 20 ng/ml GM-CSF in RPMI 5% FCS. After 7 days non-adherent 
cells were collected and infected with adenoviral constructs. BMDMs were cultured for 7 days in the 
presence of 10 ng/ml GM-CSF in RPMI 5% FCS. Following 7 day culture adherent cells were collected. 
BMDCs and BMDMs were left uninfected, or infected (300:1 m.o.i.) for 2 h in serum-free medium with 
adenoviruses expressing GFP (control), MyD88 dn or MyD88 wt. 32 h post infection supernatants were 
collected and TNFα induction assayed by ELISA. Data are expressed as mean ± SEM. n = 4, data is 4 
independent experiments pooled. p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
 
3.2.8 Co-expression of MyD88 wt reverses the inducing effect of 
MyD88 dn 
It is curious, that while MyD88 wt is not able to induce DC activation, murine MyD88 dn is, as 
both of these constructs contain a wild type TIR domain. Therefore, it is necessary to 
investigate if the activation of human and murine DCs by MyD88 dn is a consequence of an 
inhibition of MyD88 wt activity. In order to examine whether the activation of DCs, by 
expressing murine MyD88 dn, can be reversed by its wild-type form, murine MyD88 dn and 
murine MyD88 wt were co-expressed in human DCs. 
The induction of IL-6 and TNFα as a result of expressing MyD88 dn was significantly 
abrogated by the co-expression of MyD88 wt in un-stimulated cells (A, B, Figure 3.21). In LPS 
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stimulated DCs the levels of IL-6 as well as TNFα super-induced by MyD88 dn expression 
were reduced to the levels produced by uninfected cells. This suggests that at an m.o.i ratio of 
MyD88 dn to MyD88 wt of 1:2, MyD88 wt is indeed reversing the activating effect of MyD88 
dn (A, B, Figure 3.21). These results may suggest that the over-expression of a TIR domain 
disrupts an inhibitory signal, which is dependent on MyD88. 
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Figure 3.21: Expression of murine MyD88 wt significantly abrogates murine MyD88 dn induced 
IL-6 (A)(un-stimulated p = 0.0243 and p = 0.0418; stimulated p = 0.0061 and p = 0.0109) and TNFα 
(B) (un-stimulated p = 0.0143 and p = 0.0208; stimulated p = 0.0084) production in human DCs. IL-
6 (A) and TNFα (B) induction assayed in culture supernatant by ELISA. Dendritic cells were used at day 
5 of in vitro differentiation with  50 ng/ml GM-CSF and 10 ng/ml IL-4 in RPMI 5% FCS. Cells were left 
uninfected, or infected (100:1 m.o.i.) for 2 h in serum-free medium with adenoviruses expressing GFP 
(control), murine MyD88 wt, murine MyD88 dn or combinations of them. A m.o.i. of 100 was used for 
each virus when used at a ratio of 1. 24 h post infection cells were stimulated with 100 ng/ml LPS for 18 
h, where after supernatants were collected and TNFα and IL-6 induction assayed by ELISA. Data are 
normalised to MyD88 dn only infected cells and are expressed as mean ± SEM. n = 3; data is 3 
independent experiments pooled. p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
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3.3 Conclusions 
The results presented in this chapter suggest a so far unknown unique role of TLR4 signalling 
in human macrophages as over-expression of MyD88 impairs TLR2, TLR5 and TLR7/8 
signalling in those cells but not TLR4. Furthermore, the data presented here indicate a DC 
specific inhibitory mechanism that depends on MyD88 and keeps immature DCs in an inactive 
state. 
When investigating the role of the TLR adaptor molecules in RASFs, HUVECs and human 
macrophages, it became apparent that there are differences between cells of myeloid and non-
myeloid origin (Andreakos et al., 2004). While, murine MyD88 dn, which was reported to 
inhibit TLR signalling, diminished TLR4 and IL-1 signalling in RASFs as expected, TLR4 
signalling was unaffected in human macrophages. This supports data published by our group, 
which compared HUVECs and macrophages and found similar results (Andreakos et al., 2004). 
Further investigation of TLR signalling in macrophages showed that TLR4 signalling in 
macrophages is exceptional, since TLR2, TLR5 and TLR7/8 driven cytokine induction could be 
inhibited by over-expressing murine MyD88 dn. This observation is still part of ongoing 
investigations in our laboratory. A possible explanation could be redundancy between the 
adaptor molecules, as TLR4 has been shown to be the only TLR to use all four adaptor 
molecules. However, unpublished work from our group shows that neither Mal dn, TRAM dn 
nor TRIF dn expression nor the expression of a combination of all four dn adaptor constructs 
can inhibit TLR4 signalling in human macrophages (unpublished results, Dr. Anna Lundberg). 
Therefore, TLR adaptor molecules are utilised differently in murine systems, cell lines and 
primary human cells. This is in accordance with a recent study describing TRAM as an adaptor 
of TLR4 as well as TLR2 in RASF, while no involvement of TRAM in any TLR signalling 
pathway could be observed in human macrophages (Sacre et al., 2007c). While the possibility 
of redundancy between TLR adaptor molecules in human macrophages has been excluded by 
co-expression of the dominant negative adaptor constructs, the possibility of alternative 
signalling transducers being utilised remains. CD14 is a well established co-receptor, necessary 
for TLR4 signalling. However, recent studies described that functions of CD14 are specific to 
the chemotype of LPS (Jiang et al., 2005b). This might indicate that CD14 has a more 
predominant function in TLR4 regulation than previously thought. Since RASFs used in this 
study do not express CD14 and TLR4 signalling is inhibited by MyD88 dn and in contrast 
human macrophages express CD14 but TLR4 signalling is unaffected by MyD88 dn, this study 
further investigated TLR4 signalling in a myeloid cell type, which is CD14 negative, the DC. 
Unexpectedly the over-expression of murine MyD88 dn in DCs led to an induction of TNFα 
and IL-6 without stimulation. Furthermore, LPS stimulation led to a super-induction of these 
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cytokines. In contrast, Mal dn and TRAM dn had no effect on cytokine production in un-
stimulated and LPS stimulated DCs. This unexpected result led to the investigation of TLR4 
signalling using the wild type constructs of MyD88, Mal and TRAM. However, while murine 
MyD88 dn does induce TNFα and IL-6, murine MyD88 wt does not. Moreover, Mal wt and 
TRAM wt both induce and super-induce these cytokines in DCs. 
The common structural feature of the constructs inducing TNFα and IL-6 without further 
stimuli is a wild type TIR domain (Figure 3.1), which might be responsible for this observation. 
This could be confirmed by using the deletion constructs of Mal and TRIF, which contain the 
TIR domain only. The only exception to this pattern is wild type MyD88, which is the only 
adaptor protein with a wild type death domain. In order to investigate the role of a DD further a 
human wild type, a human point mutation and a human deletion construct of MyD88 were 
generated at the KIR (Ms Brenda Mutch). The results obtained by over-expressing human 
MyD88 wt confirmed previous results using murine MyD88 wt as it does not induce or super-
induce cytokine production in DCs. This excludes the possibility of an effect related to species 
differences. Moreover, the over-expression of human MyD88 Pro200His, with a point mutation 
in its TIR domain, had also no effect on cytokine induction. While over-expression of the DD 
domain on its own super-induces TNFα, it does not lead to a significant induction of TNFα 
without any stimuli. Thus showing that while the DD is able to increase cytokine production in 
LPS stimulated DCs it is not as potent as a TIR domain to induce cytokine production in un-
stimulated DCs. 
3.3.1 Potential models to explain the activation of DCs by TIR 
domains 
TIR domain over-expression leads to induction and super-induction of TNFα and IL-6 in 
human DCs. This unexpected result might be explained by a DC specific negative regulation of 
TLR signalling. Based on this premise I proposed three models to explain this observation 
(Figure 3.22). 
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Figure 3.22: Role of a hypothetical, dendritic cell specific, inhibitory receptor for TLR signalling. 
LPS stimulation of human DCs induces the expression of TNFα and IL-6. Over-expression of a TIR 
domain results in the induction of TNFα and IL-6 without further stimuli implicating a DC specific 
negative regulation of TLR signalling, which is disrupted by the over-expression of an intact TIR 
domain. A) This inhibition could be through a receptor blocking access to the TLR. Over-expression of a 
TIR domain would release the TLR and could induce signalling. B) Another model would propose a TIR 
domain containing receptor acting as a sink and thereby keeping MyD88 away from the TLR. C) A third 
model proposes a TIR domain containing receptor, which constitutively induces an inhibitory signal in 
immature DCs. This signal is dependent on MyD88. Abbreviation: TIR (Toll/IL-1R), DD (death 
domain), TLR (toll-like receptor), NF-κB (nuclear factor κB) 
 
A TLR blocking receptor could restrict access to the TLR, thereby keeping the adaptor proteins 
from interacting with the TLR and impairing the signal. By over-expressing a TIR domain the 
blocking receptor would be replaced and the TLR would be accessible for the adaptor 
molecules. Consequently an activating signal would be induced. This model, however, does not 
explain why over-expression of murine or human MyD88 wt, containing an intact TIR domain, 
do not induce cytokine production (A, Figure 3.22). 
A TIR domain containing molecule could act as a sink thereby sequestering TLR adaptor 
molecules away from the TLR and inhibiting TLR signalling. By over-expressing a TIR 
domain the sequestered adaptor molecules are released and can bind the TLR, consequently 
inducing a signal. However, this model, again, does not explain why over-expression of murine 
and human MyD88 wt does not induce cytokine production (B, Figure 3.22). 
Therefore, a third model proposes a TIR domain containing receptor, which constitutively 
induces an inhibitory signal, which is dependent on MyD88. Over-expression of a TIR domain 
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would displace MyD88 from the inhibitory receptor, thereby impairing the inhibitory signal (C, 
Figure 3.22). Consequently, the immature DC becomes activated and induces cytokine 
production. Over-expression of MyD88 wt would have no effect, since the inhibitory signal is 
dependent on MyD88 (B, Figure 3.23). Over-expression of a DD domain, while being able to 
super-induce cytokine production through blocking the DD domain of MyD88, is not able to 
replace MyD88 from the inhibitory receptor and thus is not potent enough to induce cytokine 
production without further stimuli (C, Figure 3.23). 
A prediction from this third model is that MyD88 wt should compete with other TIR domain 
containing molecules for access to the inhibitory receptor when being over-expressed. 
Therefore, the cytokine inducing effect of MyD88 dn should be reversible by co-expression 
with MyD88 wt. That this is the case could be demonstrated in Figure 3.21, where an increase 
in m.o.i. of MyD88 wt leads to a titratable reduction of IL-6 and TNFα induced by the 
expression of murine MyD88 dn. This observation further strengthens the hypothesis of a DC 
specific constitutive inhibitory signal, which is disrupted by the over-expression of a TIR 
domain (Figure 3.23). 
 
Figure 3.23: Characteristics of a constitutive inhibitory signal induced by MyD88 in dendritic cells. 
A) Expression of a wild type TIR domain in dendritic cells leads to the displacement of MyD88 from the 
inhibitory receptor. Consequently the inhibitory signal is impaired and leads to the activation of DCs. B) 
However, over-expression of MyD88 wt in DCs has no effect since it only replaces MyD88 wt with 
MyD88 wt. C) While the expression of the DD domain is able to block the DD domain of MyD88 it is 
not able to displace MyD88 from the inhibitory receptor and therefore, has not the same potency as a TIR 
domain to activate DCs D) The co-expression of MyD88 wt with MyD88 dn is able to gradually reverse 
the induction of cytokines in DCs through competing for the TIR domain of the inhibitory receptor. 
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Several other predictions can be made from this model. The proposed inhibitory receptor must 
be expressed in immature DCs but not in macrophages as no cytokine induction is observed in 
macrophages following the expression of MyD88 dn. Since this constitutive inhibitory signal 
would need to depend on MyD88 it follows that, MyD88 must be bound to the inhibitory 
receptor in a constitutive manner without stimuli present. Besides having an activating function 
in the case of TLR signalling, MyD88 would also need to be able to transduce an inhibitory 
signal. This would require an unexpected functional versatility of MyD88. A recent report 
describing the involvement of MyD88 in IFN-γR signalling would support a multifaceted 
function of MyD88 (Sun and Ding, 2006). Although IFN-γR possesses no TIR domain, IFNγ 
induced stabilization of IP10 mRNA depends on MyD88 to activate p38 MAPK (Sun and Ding, 
2006). Moreover, it has been shown that TIR domain containing adaptor molecules can have 
inhibitory roles instead of signalling inducing functions. A study by Carty et al. describes 
inhibitory functions of SARM, which are specific for TRIF dependent signal induction (Carty 
et al., 2006). 
TLRs recruit adaptor molecules through dimerisation following ligand binding (Akira and 
Takeda, 2004). The model proposed above would suggest that MyD88 binds with a higher 
affinity to the TIR domain of the inhibitory receptor in the un-stimulated state, most likely 
because the inhibitory receptor is constitutively dimerised. Following TLR stimulation, MyD88 
dissociates from the inhibitory receptor and is recruited to the TLR, thereby allowing the 
activation of the DC. 
The model of a constitutive inhibitory signal specific for DCs would propose a mechanism, 
which keeps immature DCs in an inactivated state. This would increase the threshold necessary 
to activate a DC and thereby to activate the adaptive immune response. Such a mechanism 
would control the risk of unwanted and exaggerated inflammatory responses.  
Since TLR signalling leads to a strong inflammatory response it is necessary to be controlled at 
all levels of the signalling pathway (Lang and Mansell, 2007; Liew et al., 2005). Most TLR 
inhibitors described, however, do not show a dendritic cell specific expression pattern. SIGIRR, 
an IL-1R family member, is the exception. SIGIRR was shown to be highly expressed in 
murine and human epithelial cells and immature DCs but not in macrophages (Polentarutti et 
al., 2003). Furthermore, SIGIRR also has been shown to be an inhibitor of TLR signalling in 
mice (Garlanda et al., 2004; Qin et al., 2005; Wald et al., 2003). This makes SIGIRR a possible 
candidate for the model proposed in this chapter and therefore, became the focus of my 
investigation. 
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4.1 Introduction 
Based on the results obtained in Chapter 3, an inhibitory mechanism specific for DCs has been 
proposed, which is disrupted by the over-expression of a TIR domain. This model would 
provide a mechanism that keeps DCs from becoming activated in situations where excessive 
inflammation would be damaging to the host.  
In order to keep a potent inflammatory response in check the signalling pathways inducing it 
must be tightly regulated. Inhibitory mechanisms of TLR signalling have been described at all 
levels of signal transduction. In the case of TLR2 and TLR4, extracellular decoy receptors have 
been shown to function as antagonists, inhibiting the binding of the ligand to the receptor. 
Intracellular inhibitors of TLR signalling include TRIAD3A, MyD88s, IRAK-M, TOLLIP and 
A20 (reviewed in (Lang and Mansell, 2007; Liew et al., 2005)). These inhibitors regulate TLR 
signalling by different mechanisms including the ubiquination and consequent degradation of 
TLRs, e.g. TRIAD3A, blocking access to the TLR, e.g. IRAK-M and TOLLIP, or sequestering 
signalling transducers, e.g. MyD88s. 
Transmembrane inhibitors include the IL-1R family members SIGIRR and ST2 as well as the 
TLR4 homologue RP105. Unlike SIGIRR and ST2, RP105 does not posses an intracellular TIR 
domain. The IL-1R family member ST2 exists in two isoforms, the membrane bound ST2L and 
the secreted sST2 (Lang and Mansell, 2007). ST2L inhibits IL-1R and TLR signalling by 
sequestering MyD88 and Mal through its TIR domain in murine macrophages (Brint et al., 
2004). On the other hand, sST2 has been shown to act as an antagonist to ST2L in T cells by 
sequestering its ligand IL-33 (Hayakawa et al., 2007). Similar to ST2, SIGIRR is also a 
member of the IL-1R family. Its mode of action has been described to be a blocking receptor, 
as it interacted with IL-1R, TLR4, MyD88, IRAK1 and TRAF6 in HEK293 cells, thereby 
inhibiting IL-1R and TLR4 signalling (Qin et al., 2005). In addition to containing a TIR 
domain, SIGIRR, unlike all the above described inhibitors, has been shown to have a very 
specific expression pattern, being expressed in murine and human monocytes and immature 
DCs but not in macrophages (Polentarutti et al., 2003).This makes SIGIRR a candidate for the 
inhibitory mechanism proposed in chapter 3. 
So far, investigations on SIGIRR have concentrated on its expression and function in mice 
models. In order to investigate SIGIRR in primary human cells this chapter examines the 
expression pattern in primary human myeloid and non-myeloid cells. Furthermore it 
investigates the function of SIGIRR in human monocyte derived DCs as well as macrophages 
and describes the signalling pathways regulated by SIGIRR. The results in this chapter describe 
SIGIRR as an inhibitor of the MyD88-dependent as well as MyD88-independent TLR 
signalling pathway in primary human cells. 
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4.2 Results 
4.2.1 SIGIRR mRNA is expressed in primary human monocytes and 
dendritic cells but is differentially expressed in macrophage 
subtypes 
The first prediction of the inhibitory mechanism proposed in Chapter 3 is a dendritic cell 
specific expression of a TLR inhibitory molecule. In case of SIGIRR this expression pattern has 
been described in murine as well as human cell systems in a study by Polentarutti et al. 
(Polentarutti et al., 2003). To confirm these results, real-time PCR was performed on mRNA 
extracted from primary human monocytes, M-CSF differentiated macrophages, GM-CSF 
differentiated macrophages, DCs, RASF and human skin fibroblasts (Figure 4.1). 
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Figure 4.1: SIGIRR is expressed in primary human monocytes, M-CSF differentiated 
macrophages and DCs and expression is significantly reduced in GM-CSF differentiated 
macrophages (p = 0.0378), RASF (p = 0.0473) and HSF (p = 0.0315). Monocytes were isolated from 
peripheral blood mononuclear cells by elutriation. mRNA from 5x106 purified monocytes was extracted. 
The remaining monocytes were differentiated into macrophages using 100 ng/ml M-CSF or 50 ng/ml 
GM-CSF for 4 days or dendritic cells using 50 ng/ml GM-CSF and 10 ng/ml IL-4 for 5 days in 10% FCS 
RPMI. RASF and HSF were used from passage 3 after expansion in DMEM 10% FCS. mRNA from 
5x106 cells was extracted and Taqman PCR performed using GAPDH as a housekeeping gene. Data is 
normalised to GAPDH and expressed relative to monocytes. Data are expressed as mean ± SEM. n = 4, 
this data is 4 independent experiments pooled p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 ***. Abbreviations: DC, 
dendritic cell; RASF rheumatoid arthritis synovial fibroblast; HSF, human skin fibroblast.  
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The results obtained by Taqman PCR show the already described highly specific expression 
pattern of SIGIRR in myeloid and non-myeloid cells (Figure 4.1). SIGIRR mRNA is expressed 
at high levels in monocytes, to which mRNA levels of the other cells investigated has been 
normalised. The mRNA expression is substantially reduced during differentiation to 
macrophages using M-CSF and to dendritic cells. Therefore, contrary to previous reports, M-
CSF differentiated macrophages used in this study express similar amounts of SIGIRR as DCs. 
Furthermore, macrophages differentiated using GM-CSF show a further significant reduction in 
SIGIRR mRNA expression. Similarly to GM-CSF differentiated macrophages, RASF as well 
as HSF express lower levels of SIGIRR mRNA compared to M-CSF differentiated 
macrophages or DCs (Figure 4.1). 
4.2.2 Western blot does not allow the specific detection of SIGIRR 
protein 
To date the expression pattern of SIGIRR has not been investigated at the protein level. In order 
to confirm the differential expression of SIGIRR mRNA in human cells, western blots were 
performed. 
However, the anti-human SIGIRR antibodies commercially available do not detect SIGIRR 
specifically by western blot (Figure 4.2).  
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Figure 4.2: SIGIRR is not detected by western blot in whole cell lysate of HEK293. HEK293 cells 
were transfected with 1 µg and 2 µg of pENTR4.3F plasmid encoding Flag tagged SIGIRR. Cells were 
left for 24 h, where after they were lysed in 1% Triton X 100, the protein concentration measured by 
BCA assay and lysate separated by SDS-PAGE. A total amount of 50 µg of protein was loaded per 
condition. As a marker the Full range Rainbow molecular weight marker RPN800 from Amersham was 
used (scale in kDa). Membrane was stained using polyclonal anti-human SIGIRR antibody AF990 
(R&D, Minneapolis, USA). Membrane was stripped and counter-blotted for Flag (Sigma, Poole, Dorset, 
UK) and as a loading control α-tubulin (Sigma Poole, Dorset, UK). 
 
HEK293 cells were transfected with 1 µg or 2 µg of pENTR4.3F vector encoding Flag tagged 
SIGIRR (kindly provided by Prof X. Li, Lerner Research Institute, OH, USA). After 24 h of 
over-expression the cells were lysed and proteins separated by SDS-PAGE. The membrane was 
stained using a polyclonal anti-human SIGIRR antibody. However, no specific band was 
detected using this antibody (Figure 4.2). By counter-blotting the membrane, using an anti-Flag 
antibody, the over-expression of SIGIRR in these cells could be confirmed (Figure 4.2). 
Therefore, this antibody, as well as others tested, does not detect SIGIRR by western blot. 
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Triton X 100 as well as RIPA lysis buffer was used to lyse the cells. Using PVDF or 
nitrocellulose membranes to transfer the protein also showed no improvement in the quality of 
the western blot. Beside the polyclonal anti-SIGIRR antibody AF990, the following antibodies 
could also not specifically detect SIGIRR by Western Blot (data not shown): 
- anti-SIGIRR, ProSci, Poway, California, USA, Cat. No. 3367 
- anti-TIR8, Abcam, Cambridge, UK, Cat. No. ab22053 
- anti-SIGIRR, Abcam, Cambridge, UK, Cat. No. ab13717 
- anti-SIGIRR, R and D, Minneapolis, Minnesota, USA, Cat. No. MAB990 
Although, one publication does show the detection of SIGIRR protein in HEK293 cells by 
using the polyclonal anti-SIGIRR antibody AF990, I was not able to reproduce these results 
(Qin et al., 2005). 
4.2.3 SIGIRR protein expression can be specifically detected by 
Flow cytometry and confirms mRNA expression pattern  
Flow cytometry is another method to examine protein expression. Unlike western blots, flow 
cytometry requires the recognition of the natural epitope by the antibody. Therefore, it is 
possible that while some antibodies do not detect the denatured epitope, they are able to detect 
a protein specifically by Flow cytometry. 
Monocytes, M-CSF as well as GM-CSF differentiated macrophages and DCs were stained for 
SIGIRR on the cell surface. This did not result in a positive staining (Figure 4.3). Therefore, 
cells were permeabilized and stained for SIGIRR intra-cellular. Interestingly, permeabilization 
of monocytes, M-CSF differentiated macrophages and DCs resulted in a positive staining for 
SIGIRR while there was no SIGIRR expression detectable in permeabilized GM-CSF 
differentiated macrophages (Figure 4.3). These results are in accordance with the expression of 
SIGIRR mRNA detected by TaqMan PCR (Figure 4.1). 
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Figure 4.3: Monocytes and M-CSF differentiated macrophages as well as DCs express SIGIRR intra-cellular. Monocytes were isolated from peripheral blood 
mononuclear cells by elutriation. Cells were stained using BAF990 anti-SIGIRR antibody (R&D, Minneapolis, USA). The remaining monocytes were differentiated 
into macrophages using 100 ng/ml M-CSF or 50 ng/ml GM-CSF for 4 days or dendritic cells using 50 ng/ml GM-CSF and 10 ng/ml IL-4 for 5 days in 10% FCS 
RPMI. Cells were stained for SIGIRR using, polyclonal antibody BAF990. Red line, unstained cells; Green line, isotype control stained cells; blue line, SIGIRR 
stained cells. Experiment shown is representative of 3 independent experiments. 
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Although, the Isotype control used in this experiment did not indicate unspecific staining and 
the GM-CSF macrophages stained negative for SIGIRR, there is still the possibility of 
unspecific binding of the SIGIRR antibody used, which would lead to false positive results. 
This can be especially the case in permeabilized cells. 
To exclude the possibility of unspecific staining an adenovirus expressing Flag-tagged, wild 
type, human SIGIRR was generated to over-express SIGIRR in DCs and macrophages (Figure 
4.5). 
 
Figure 4.4: DCs over-express SIGIRR wt after adenoviral infection at an m.o.i of 100:1. Dendritic 
cells were used at day 6 of in vitro differentiation with  50 ng/ml GM-CSF and 10 ng/ml IL-4 in RPMI 
5% FCS. Cells were left uninfected (cells), or infected for 2 h in serum-free medium with adenoviruses 
expressing GFP and SIGIRR wt (25:1, 50:1, or 100:1 m.o.i.). 24 h post infection cells were lysed with 1 
% Triton X 100 lysis buffer and cell lysate was separated by SDS-PAGE. Western blot was performed 
using a mouse anti-Flag antibody (SIGMA, Poole, Dorset, UK). As a loading control the membranes 
were striped and re-probed for α-tubulin using a mouse anti-α-tubulin antibody (Sigma, Poole, Dorset, 
UK). As a marker the Full range Rainbow molecular weight marker RPN800 from Amersham was used 
(scale in kDa). 
 
Infection of DCs with an adenovirus expressing SIGIRR wt led to a titratable over-expression 
of SIGIRR in these cells as observed by Western Blot for Flag (Figure 4.4). In order to assess 
anti-SIGIRR antibody specificity, flow cytometry of SIGIRR over-expressing DCs was 
performed (Figure 4.5). 
DCs over-expressing SIGIRR were surface stained for SIGIRR using BAF990 antibody, which 
resulted in a small fraction of SIGIRR over-expressing DCs being stained positive for SIGIRR 
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(Figure 4.5). However, permeabilization of the cells followed by SIGIRR staining, showed, that 
the majority of DCs over-express SIGIRR intra-cellular (Figure 4.5). 
 
Figure 4.5: Anti-human SIGIRR antibody BAF990 recognises SIGIRR specifically. SIGIRR is 
expressed in DCs intracellularly. DCs were used at day 5 of in vitro differentiation using 50 ng/ml GM-
CSF and 10 ng/ml IL-4  in RPMI 5% FCS. Cells were left uninfected, or infected (100:1 m.o.i.) for 2 h in 
serum-free medium with adenoviruses expressing GFP (control) or SIGIRR wt. Cells were left for 24 h 
before being stained for SIGIRR using biotynulated, polyclonal antibody BAF990 (R&D, Minneapolis, 
USA). Red line, SIGIRR over-expressing, unstained cells; Green line, SIGIRR over-expressing, isotype 
control stained cells; blue line, control virus infected, SIGIRR stained cells; brown line, SIGIRR over-
expressing, SIGIRR stained cells. Experiment shown is representative of 2 independent experiments. 
 
The expression pattern of SIGIRR protein and mRNA described in this chapter might exclude 
SIGIRR as a DC-specific TLR inhibitor since it is expressed in M-CSF differentiated 
macrophages (Figure 4.1 and Figure 4.3). However, several interesting questions arise, which 
have so far not been answered in the literature. Does SIGIRR function as a TLR inhibitor in 
primary human cells? Does the cellular localisation have any influence on the function of 
SIGIRR as a TLR inhibitor in these cell types? Since an adenoviral construct expressing 
SIGIRR wt has been generated, it was possible to address these questions for the first time in 
primary human cells. 
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4.2.4 SIGIRR wt over-expression inhibits TLR and IL-1R signalling 
in DCs 
SIGIRR has already been shown to inhibit TLR and IL-1R signalling in vivo in mice as well as 
in vitro in cell lines (Garlanda et al., 2004; Wald et al., 2003). In order to examine if SIGIRR 
functions as an inhibitor of TLR signalling in primary human cells, an adenoviral vector, over-
expressing SIGIRR wt, was infected into primary human DCs (Figure 4.7 and Figure 4.8). The 
over-expression of SIGIRR wt at m.o.i. of 25, 50 and 100 has been assessed (Figure 4.3) and 
subsequently DCs were infected at an m.o.i. of 50 and 100. At these m.o.i. adenoviral infection 
of DCs had no effect on cell viability as assessed by MTT assay (Figure 4.6). 
un
inf
ec
ted
co
ntr
ol
SIG
IR
R 
50
 m
.o.
i.
SIG
IR
R 
10
0 m
.o.
i.
un
inf
ec
ted
co
ntr
ol
SIG
IR
R 
50
 m
.o.
i.
SIG
IR
R 
10
0 m
.o.
i.
0
10
20
30
40
50
60
70
80
90
100
110
120
LPS
unstimulated
vi
ta
lit
y 
[%
]
 
Figure 4.6: SIGIRR over-expressing DCs show no reduced vitality. Dendritic cells were used at day 5 
of in vitro differentiation with 50 ng/ml GM-CSF and 10 ng/ml IL-4 in RPMI 5% FCS. Cells were left 
uninfected, or infected (50:1 or 100:1 m.o.i.) for 2 h in serum-free medium with adenoviruses expressing 
GFP (control) or SIGIRR wt. 24 h post infection cells were stimulated with 100 ng/ml LPS. After further 
18 h cells were incubated with MTT over night, lysis performed and OD574 measured. Data are 
normalised to uninfected cells and expressed as mean ± SEM. n = 3, data is 3 independent experiments 
pooled. 
 
SIGIRR wt over-expression in human DCs significantly inhibits the production of TNFα (A, 
Figure 4.7) as well as IL-10 (B, Figure 4.7) at an m.o.i. of 100 in response to LPS, MALP-2, 
Flagellin and R848. Although a trend of inhibition of TNFα induced by Flagellin or IL-1α was 
observed it did not reach statistical significance due to donor variability and limited number of 
repeats. No significant levels of TNFα or IL-10 were being produced by human DCs in 
response to poly I:C (A and B, Figure 4.7). The inhibition of TNFα production in response to 
TLR stimuli as well as IL-1 is titratable. Furthermore, while TLR and IL-1R signalling is 
inhibited by SIGIRR over-expression, TNFα induced IL-10 production is unaffected, 
suggesting functional specificity of SIGIRR inhibition (B, Figure 4.7). 
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Figure continued on next page... 
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Figure 4.7: SIGIRR wt inhibits TLR4, TLR2, TLR5, TLR-7/8 and IL-1R signalling in primary human monocyte derived DCs. Cytokine induction assayed in 
culture supernatant by ELISA (TNFα, A; IL-10, B). Dendritic cells were used at day 5 of in vitro differentiation with 50 ng/ml GM-CSF and 10 ng/ml IL-4 in RPMI 
5% FCS. Cells were left uninfected, or infected (50:1 or 100:1 m.o.i.) for 2 h in serum-free medium with adenoviruses expressing GFP (control) or SIGIRR wt. 24 h 
post infection cells were stimulated with 100 ng/ml LPS, 20 µg/ml poly I:C, 100 ng/ml MALP-2, 100 ng/ml Flagellin, 100 ng/ml R848, 20 ng/ml IL-1α or 20 ng/ml 
TNFα. After further 18 h supernatants were collected and TNFα and IL-10 induction assayed by ELISA. Data are expressed as mean ± SEM. n = 5, data is 5 
independent experiments pooled. p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
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Induction of TNFα and IL-10 is dependent on the MyD88 induced pathway, whereas IP-10 
induction depends on TRIF induced signalling, which is utilised by TLR3 and TLR4. In order 
to investigate if SIGIRR over-expression also inhibits the TRIF pathway, IP10 levels were 
measured in cell supernatants (Figure 4.8). 
As well as inhibiting the MyD88 dependent pathway, SIGIRR over-expression in DCs also 
inhibited the TRIF dependent pathway (Figure 4.8). LPS and poly I:C induced production of 
IP10 was significantly inhibited by the over-expression of SIGIRR in a titratable manner 
(Figure 4.8). As expected, no significant levels of IP10 were produced in response to MALP-2, 
Flagellin, R848, IL-1 and TNFα. 
These results, for the first time, show, that SIGIRR is an inhibitor of the MyD88 dependent 
TLR signalling pathway in primary human cells, thereby, confirming published data in mice. 
Moreover, they also show an inhibitory function of SIGIRR in the TRIF dependent pathway.
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Figure 4.8: SIGIRR wt inhibits TLR3 and TLR4 induced IP10 production in primary human monocyte derived DCs. IP10 induction assayed in culture 
supernatant by ELISA. Dendritic cells were used at day 5 of in vitro differentiation with 50 ng/ml GM-CSF and 10 ng/ml IL-4 in RPMI 5% FCS. Cells were left 
uninfected, or infected (50:1 or 100:1 m.o.i.) for 2 h in serum-free medium with adenoviruses expressing GFP (control) or SIGIRR wt. 24 h post infection cells were 
stimulated with 100 ng/ml LPS, 20 µg/ml poly I:C, 100 ng/ml MALP-2, 100 ng/ml Flagellin, 100 ng/ml R848, 20 ng/ml IL-1α or 20 ng/ml TNFα. After further 18 h 
supernatants were collected and IP10 induction assayed by ELISA. Data are expressed as mean ± SEM. n = 5, data is 5 independent experiments pooled. p ≤ 0.05 *; p 
≤ 0.01 **; p ≤ 0.005 *** 
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4.2.5 SIGIRR wt over-expression inhibits TLR and IL-1R signalling 
in M-CSF macrophages 
To further establish the role of SIGIRR as an inhibitor in primary human cells, SIGIRR wt was 
over-expressed in M-CSF differentiated macrophages, where it was shown to be expressed 
previously (Figure 4.1 and Figure 4.5). Subsequently, M-CSF differentiated macrophages were 
stimulated with LPS, MALP-2, Flagellin, R848, IL-1α or TNFα and the levels of TNFα, IL-10 
and IP10 measured in response to these stimuli (Figure 4.9). 
Similar to the observations made in DCs, SIGIRR inhibits TNFα and IL-10 production in 
response to TLR4 (LPS), TLR2 (Malp-2), TLR5 (Flagellin), TLR7/8 (R848) and IL-1R (IL-1α) 
stimuli in macrophages (Figure 4.9). The inhibition of TNFα production is titratable and is 
significantly inhibited at an m.o.i. of 100 in response to LPS, Flagellin and R848 (A, Figure 
4.9). Moreover, IL-10 production is significantly inhibited at an m.o.i. of 100 in response to 
LPS, Malp-2, Flagellin and R848 (B, Figure 4.9). Although a trend of inhibition of TNFα 
induced by Malp-2 or IL-1α was observed it did not reach statistical significance due to donor 
variability and limited number of repeats. While SIGIRR over-expression inhibits all TLRs 
tested, it does not inhibit TNFα induced IL-10 production (B, Figure 4.9). No significant levels 
of TNFα and IL-10 were produced in response to poly I:C in human macrophages. In order to 
investigate the effect of SIGIRR over-expression on TLR3 signalling, IP10 levels in cell 
supernatants were examined (C, Figure 4.9). Similar to DCs, TLR4 as well as TLR3 induced 
IP10 production was significantly inhibited at an m.o.i. of 100 in SIGIRR over-expressing 
macrophages (C, Figure 4.9). No significant levels of IP10 were produced in response to other 
TLR stimuli demonstrating its dependence on the TRIF dependent pathway (C, Figure 4.9). 
These results suggest that SIGIRR, analogous to its function in human DCs, regulates TLR 
signalling in human M-CSF differentiated macrophages. In order to investigate this observation 
further, I established siRNA knock down of SIGIRR in M-CSF differentiated macrophages.
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Figure continued on next page... 
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Figure continued on next page... 
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Figure 4.9: SIGIRR wt inhibits TLR4, TLR2, TLR5, TLR-7/8 and IL-1R signalling in primary human monocyte derived macrophages. Cytokine induction 
was assayed in culture supernatant by ELISA (A, TNFα; B, IL-10; C, IP10). Macrophages were used at day 4 of in vitro differentiation with 100 ng/ml M-CSF in 
RPMI 5% FCS. Cells were left uninfected, or infected (50:1 or 100:1 m.o.i.) for 2 h in serum-free medium with adenoviruses expressing GFP (control) or SIGIRR wt. 
24 h post infection cells were stimulated with 10 ng/ml LPS, 20 µg/ml poly I:C, 10 ng/ml MALP-2, 10 ng/ml Flagellin, 100 ng/ml R848, 20 ng/ml IL-1α or 20 ng/ml 
TNFα. After further 18 h supernatants were collected and TNFα, IL-10 and IP10 induction assayed by ELISA. Data are expressed as mean ± SEM. n = 4, data is 4 
independent experiments pooled. p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
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4.2.6 DCs, but not M-CSF macrophages, show reduced cell viability 
after AMAXA transfection 
So far this study relied on the over-expression of proteins in order to investigate protein 
function. The use of siRNA allows the specific knock down of genes and is therefore a suitable 
alternative to study the role of particular proteins. Until recently siRNA knock down in primary 
human cells has been difficult due to low transfection efficiencies in those cells. The AMAXA 
transfection system provides cell type specific protocols to transfect plasmids as well as oligo-
nucleotides into primary human cells. The monocytes used in this study were isolated from 
PBMCs and transfected using the AMAXA transfection protocol for primary human monocytes 
(see chapter 2 section 2.3.11) to knock down SIGIRR. Using fluorescently labelled oligos, a 
transfection efficiency of around 50% was reached (Figure 4.10). Following transfection, the 
monocytes were left in culture containing the appropriate differentiation cytokines for 48 h in 
order to obtain either macrophages or DCs before experiments were performed (Figure 4.10). 
 
 
Figure 4.10: The transfection efficiency of monocytes, using fluorescently labelled oligos and the 
AMAXA transfection system, reaches 50%. PBMC isolated monocytes were transfected using the 
AMAXA protocol for primary human monocytes in accordance with the manufactures instructions. Cells 
were left for 24 h before cells were washed and amount of transfected cells measured by Flow cytometry. 
Blue: cells cultured in the presence of oligo but untransfected; Green: oligo transfected cells. 
 
In order to establish whether cell vitality is affected by the transfection procedure, MTT assays 
were performed 66 h after transfection (Figure 4.11 and Figure 4.12). 
Monocytes transfected with SIGIRR siRNA and differentiated into DCs using GM-CSF and IL-
4, showed reduced cell viability of up to 50%, 66 h after transfection (Figure 4.11). This loss of 
viability seems not to be a SIGIRR siRNA specific effect since cells transfected with scrambled 
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control oligos also showed reduced cell vitality (Figure 4.11). It rather seems to be due to the 
transfection procedure of AMAXA systems. However, monocytes transfected with scrambled 
control oligos or SIGIRR siRNA and differentiated into macrophages using M-CSF, showed no 
loss of viability (Figure 4.12). 
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Figure 4.11:GM-CSF and IL-4 differentiated DCs show reduced vitality after siRNA transfection. 
PBMC isolated monocytes were left untransfected or transfected with 400 nM of scrambled oligo, 100 
nM SIGIRR siRNA, 200 nM SIGIRR siRNA or 400 nM SIGIRR siRNA using the AMAXA protocol for 
primary human monocytes in accordance with the manufactures instructions. Cells were incubated for 48 
h with 50 ng/ml of GM-CSF and 10 ng/ml of IL-4 before being stimulated with 10 ng/ml of LPS or left 
un-stimulated. Cells were incubated for 18 h before cells were incubated with MTT over night, lysis 
performed and OD574 measured. Data are normalised to untreated cells and expressed as mean ± SD. n 
= 2, data is 2 independent experiments pooled. 
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Figure 4.12: M-CSF differentiated macrophages show no reduced vitality after siRNA transfection. 
PBMC isolated monocytes were left untransfected or transfected with 400 nM of scrambled control 
oligo, 100 nM SIGIRR siRNA, 200 nM SIGIRR siRNA or 400 nM SIGIRR siRNA using the AMAXA 
protocol for primary human monocytes in accordance with the manufactures instructions. Cells were 
incubated with 100 ng/ml of M-CSF for 48 h before being stimulated with 10 ng/ml of LPS or left un-
stimulated. Cells were incubated for 18 h before cells were incubated with MTT over night, lysis 
performed and OD574 measured. Data are normalised to untreated cells and expressed as mean ± SEM. 
n = 4, data is 4 independent experiments pooled. 
 
Due to the loss of cell vitality in GM-CSF and IL-4 differentiated DCs transfected with the 
AMAXA transfection system only M-CSF differentiated macrophages were used in this study 
for further functional experiments. 
4.2.7 SIGIRR siRNA reduces SIGIRR mRNA and Protein expression 
in M-CSF differentiated macrophages 
For further investigations the kinetics and extent of mRNA knock down had to be examined. 
Therefore, SIGIRR mRNA levels were measured using real-time PCR (Figure 4.13). 
Monocytes were transfected with a titration of SIGIRR siRNA ranging from 100 nM to 400 
nM, before being incubated between 24 h and 96 h (Figure 4.13). 
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Figure 4.13: SIGIRR mRNA knock down occurs between 48 h and 72 h after transfection. PBMC 
isolated monocytes were transfected with 400 nM of scrambled control oligo, 100 nM SIGIRR siRNA, 
200 nM SIGIRR siRNA or 400 nM SIGIRR siRNA using the AMAXA protocol for primary human 
monocytes in accordance with the manufactures instructions. Cells were incubated with 100 ng/ml of M-
CSF for 24 h, 48 h, 72 h and 96 h before mRNA from 5x106 cells was extracted. Taqman PCR was 
performed and data was normalised to GAPDH expression. Data is expressed relative to scrambled 
control oligo transfected cells. Data are expressed as mean ± SD. n = 2, this data is 2 independent 
experiments pooled. 
 
Monocytes transfected with SIGIRR siRNA and differentiated using M-CSF, showed a 
reduction of SIGIRR mRNA at 48 h and 72 h after transfection (Figure 4.13). The levels of 
SIGIRR mRNA return to basal levels 96 h after transfection (Figure 4.13). 
Besides showing the knock down of mRNA, it is important to examine that protein levels are 
also affected by reduced mRNA levels at this time point. Moreover, it is important to examine 
off target effects of the siRNA oligos. Therefore, SIGIRR siRNA transfected monocytes were 
stained for SIGIRR and TLR4 48 h after transfection (Figure 4.14). Monocytes transfected with 
100 nM, 200 nM and 400 nM of SIGIRR siRNA show a significant and titratable reduction of 
SIGIRR protein. At the same concentrations TLR4 expression is unaffected (Figure 4.14). At 
400 nM of SIGIRR siRNA the reduction of SIGIRR protein amounts to 50%. 
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Figure 4.14: SIGIRR Protein is knocked down 48 h after transfection of human monocytes. PBMC 
isolated monocytes were transfected with 400 nM of scrambled control oligo, 100 nM SIGIRR siRNA, 
200 nM SIGIRR siRNA or 400 nM SIGIRR siRNA using the AMAXA protocol for primary human 
monocytes in accordance with the manufactures instructions. Cells were incubated with 100 ng/ml of M-
CSF for 48 h before being stained using BAF990 anti-SIGIRR antibody (R&D) or anti-TLR4 antibody 
(BD). p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
 
The use of SIGIRR siRNA in macrophages results in a reliable knock down of SIGIRR mRNA 
and protein of 50% at a concentration of 400 nM siRNA without affecting TLR4 protein. The 
following investigations were performed in transfected monocytes, differentiated using M-CSF 
for 48 h after transfection. 
4.2.8 SIGIRR siRNA knock down super-induces TLR4, TLR3, TLR7/8 
and IL-1R dependent cytokine production 
In order to confirm the role of SIGIRR as an inhibitor of TLR signalling, as shown by over-
expression of SIGIRR wt in DCs and macrophages (Section 4.2.4 and 4.2.5), SIGIRR knock 
down macrophages were stimulated with TLR4, TLR3 and TLR7/8 ligands (Figure 4.15). 
Knock down of SIGIRR in macrophages and subsequent stimulation with LPS, R848 and IL-1 
results in a significant increase of TNFα (A, Figure 4.15) and IL-10 production (B, Figure 
4.15). This increase in cytokine production is titratable dependent on the concentration of 
siRNA used in accordance with the level of SIGIRR protein knock down shown in Figure 4.14. 
While SIGIRR knock down in macrophages results in super-induction of IL-10 in response to 
LPS, R848 and IL-1α it has no effect on TNFα signalling, thereby indicating its specificity (B, 
Figure 4.15). No significant levels of TNFα or IL-10 were produced by macrophages stimulated 
with poly I:C. 
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Figure continued on next page... 
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Figure 4.15: TNFα (A) and IL-10 (B) are super-induced in SIGIRR knock down, M-CSF differentiated macrophages stimulated with TLR ligands. PBMC 
isolated monocytes were left untransfected or transfected with 400 nM of scrambled control oligo, 100 nM SIGIRR siRNA, 200 nM SIGIRR siRNA or 400 nM 
SIGIRR siRNA using the AMAXA protocol for primary human monocytes in accordance with the manufactures instructions. Cells were incubated with 100 ng/ml of 
M-CSF for 48 h before being stimulated with 10 ng/ml LPS, 20 µg/ml poly I:C, 100 ng/ml R848, 20 ng/ml IL-1α or 20 ng/ml TNFα. After further 18 h supernatants 
were collected and TNFα (A) and IL-10 (B) induction assayed by ELISA. Data are expressed as mean ± SEM. n = 4, data is 4 independent experiments pooled. p ≤ 
0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
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Beside the investigation of the effect of SIGIRR knock down on TNFα and IL-10 production, 
which are both dependent on MyD88 transduced signalling, this study also examined the 
production of IP10 (Figure 4.16). In response to LPS as well as poly I:C the expression of IP10 
was significantly increased in SIGIRR knock down macrophages (Figure 4.16). In the case of 
TLR3 signalling this increase, similar to TNFα and IL-10 induction, is titratable dependent on 
the amount of siRNA transfected into the cells. No detectable levels of IP10 were produced in 
response to TLR7/8 and IL-1R signalling, which do not utilise the TRIF dependent signalling 
pathway (Figure 4.16). 
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Figure 4.16: IP10 is super-induced in SIGIRR knock down, M-CSF differentiated macrophages 
stimulated with TLR ligands. PBMC isolated monocytes were left untransfected or transfected with 
400 nM of scrambled control oligo, 100 nM SIGIRR siRNA, 200 nM SIGIRR siRNA or 400 nM 
SIGIRR siRNA using the AMAXA protocol for primary human monocytes in accordance with the 
manufactures instructions. Cells were incubated with 100 ng/ml of M-CSF for 48 h before being 
stimulated with 10 ng/ml LPS, 20 µg/ml poly I:C, 100 ng/ml R848, 20 ng/ml IL-1α or 20 ng/ml TNFα. 
After further 18 h supernatants were collected and TNFα (A) and IL-10 (B) induction assayed by ELISA. 
Data are expressed as mean ± SEM. n = 8, data is 8 independent experiments pooled. p ≤ 0.05 *; p ≤ 
0.01 **; p ≤ 0.005 *** 
 
The use of siRNA to knock down SIGIRR in macrophages suggests a role of SIGIRR as an 
inhibitor of signalling pathways utilising TIR domains for signal transduction. TLR as well as 
IL-1R signalling are affected by SIGIRR knock down in these cells while TNFα signalling is 
unaffected. 
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4.2.9 SIGIRR knock down super-induces NF-κB, MAPKs and IRF3 
While the induction of cytokine production is a general indication of TLR activation, the 
activation of specific signal transducers allows a more detailed examination of the TLR 
signalling pathways. Therefore, further investigations of the signalling pathways affected by the 
inhibition of SIGIRR were performed by examining the activation of NF-κB, the MAPKs JNK, 
ERK1/2 and p38 MAPK as well as IRF3 in SIGIRR knock down macrophages. Therefore, 
SIGIRR knock down macrophages were stimulated over a time course of 120 min and the 
phosphorylation of IκBα, as an indication for NF-κB activation, as well as the phosphorylation 
of the MAPKs were examined by Western Blot (Figure 4.17). 
Treatment of macrophages with scrambled oligo control resulted in an activation of NF-κB, 
JNK, ERK and p38 MAPK similar to untreated cells as was shown before in our laboratory. 
The knock down of SIGIRR in macrophages resulted in an increased phosphorylation of IκBα, 
in particular, after 5 min of LPS stimulation but also after 40 min and 60 min of stimulation 
compared to macrophages transfected with a scrambled control oligo. However, while JNK and 
ERK also showed increased phosphorylation in response to LPS in SIGIRR knock down cells, 
p38 MAPK seems to be unaffected by SIGIRR knock down (Figure 4.17). The increase in 
phosphorylation of IκBα, JNK and ERK1/2 was not accompanied by a change in the kinetics of 
phosphorylation of these proteins (Figure 4.17). 
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Figure 4.17: NF-κB, JNK and ERK1/2 are super-activated in response to LPS in SIGIRR knock 
down macrophages. PBMC isolated monocytes were left untransfected or transfected with 400 nM of 
scrambled control oligo or 400 nM SIGIRR siRNA using the AMAXA protocol for primary human 
monocytes in accordance with the manufactures instructions. Cells were incubated with 100 ng/ml of M-
CSF for 48 h before being stimulated with 10 ng/ml LPS over a time course of 120 min. Thereafter, cells 
were lysed in 1% Triton X 100 and lysate separated by SDS-PAGE. Specific protein was detected by 
blotting with ani-phospho IκBα- (New England Biolabs), anti-phospho JNK-(New England Biolabs), 
anti-phospho ERK1/2 (New England Biolabs) or anti-phospho p38 antibody (Cell Signalling 
Technology, Beverly, MA, USA).As a marker the Full range Rainbow molecular weight marker RPN800 
from Amersham was used (scale in kDa). Membrane was stripped and counter-blotted using stripping 
buffer. As a loading control anti-total p38 was used (made in house). Experiment shown is representative 
of 2 independent experiments. 
 
The super-induction of IP10 by LPS and poly I:C in SIGIRR knock down cells indicates, that 
the TRIF dependent pathway is also regulated by SIGIRR. However, it is still unclear, whether 
IP10 production is a secondary effect resulting from type I interferons produced in response to 
LPS and poly I:C or directly induced by the TRIF pathway (Honda and Taniguchi, 2006). 
Therefore, the activation of IRF3, the main transcription factor directly activated by the TRIF 
pathway was further examined. IRF3 becomes phosphorylated, dimerises and consequently 
translocates to the nucleus (Honda and Taniguchi, 2006). In order to asses IRF3 activation in 
response to LPS, nuclear proteins were extracted and nuclear IRF3 detected by western blot 
over a time period of 30 min (Figure 4.18). After 20 min of LPS stimulation IRF3 was 
detectable in the nucleus, which further increased 30 min after LPS stimulation (Figure 4.18). 
In SIGIRR knock down cells there was an additional increase in the amount of IRF3 
translocated to the nucleus at the 20 min and 30 min time points compared to scrambled control 
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oligo transfected cells (Figure 4.18). This would indicate an increased activation of IRF3. As a 
loading control βActin and αTubulin were used. The nuclear extraction blot stains negative for 
αTubulin, excluding possible contaminations with cytosolic proteins (Figure 4.18). 
 
 
 
Figure 4.18: Increased IRF3 nuclear translocation in response to LPS in SIGIRR knock down 
macrophages. PBMC isolated monocytes were left untransfected or transfected with 400 nM of 
scrambled control oligo or 400 nM SIGIRR siRNA using the AMAXA protocol for primary human 
monocytes in accordance with the manufactures instructions. Cells were incubated with 100 ng/ml of M-
CSF for 48 h before being stimulated with 10 ng/ml LPS over a time course of 30 min. Thereafter, 
nuclear- and cytosolic cell compartments were lysed and proteins separated by SDS-PAGE. Specific 
protein was detected by blotting with ani-IRF3 antibody (Santa Cruz Biotechnology, Santa Cruz, CA 
USA). As a marker the Full range Rainbow molecular weight marker RPN800 from Amersham was used 
(scale in kDa). Membrane was stripped and counter-blotted using stripping buffer. As a loading control 
anti-βActin and anti-αTubulin were used (Sigma, Poole, Dorset, UK). Experiment shown is 
representative of 2 independent experiments. 
 
These results indicate, that SIGIRR inhibition acts upstream of IκBα, JNK and ERK 
phosphorylation as well as IRF3 activation. SIGIRR has already been shown to interact with 
TLR proximal signal transducing molecules, including MyD88, in HEK293 cells in a transient 
manner after LPS stimulation (Qin et al., 2005). Based on the results obtained in HEK293 cells, 
SIGIRR has been proposed to act as a blocking receptor. 
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4.2.10 SIGIRR wt interacts with MyD88 wt in un-stimulated  
 human DCs 
In order to investigate whether SIGIRR interacts with MyD88 in primary human DCs and to 
investigate the character of this interaction, co-immunoprecipitation studies of SIGIRR and 
MyD88 were performed. Therefore, DCs were infected with SIGIRR and either human MyD88 
wt, human MyD88 Pro220His or human MyD88 DD (Chapter 3 Figure 3.15). After 24 h of 
over-expression SIGIRR was immunoprecipitated using an anti-Flag antibody. The proteins 
were separated by SDS-PAGE and MyD88 constructs detected by western blot using an anti-
HA antibody (Figure 4.19). 
While MyD88 wt co-immunoprecipitated with SIGIRR the interaction was significantly 
reduced with MyD88 Pro200His, which contains a point mutation in its TIR domain (Figure 
4.19). MyD88 DD, which is TIR domain deleted, completely lost the ability to interact with 
SIGIRR (Figure 4.19). 
These results suggest that SIGIRR interacts with MyD88 through TIR domain interactions in 
primary human DCs. This interaction is not dependent on any stimuli, which would suggest that 
a constitutive interaction occurs between SIGIRR and MyD88 in primary human DCs. This 
would strengthen the hypothesis of SIGIRR acting as a sink and thereby inhibiting TLR and IL-
1R signalling. 
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Figure 4.19: SIGIRR interacts with MyD88 through TIR domain interactions in un-stimulated 
primary human DCs. DCs were used at day 4 of in vitro differentiation with 50 ng/ml of GM-CSF and 
10 ng/ml of IL-4 in RPMI 5% FCS. Cells were left uninfected, or double infected (100:1 m.o.i.) for 2 h 
in serum-free medium with adenoviruses expressing SIGIRR wt and GFP (control), human MyD88 wt, 
human MyD88 Pro200His (point mutation of AS200 Pro to His) or human MyD88 DD (TIR domain 
deleted. Cells were left over-expressing for 24 h before being lysed. SIGIRR was immuno-precipitated 
using an anti-Flag antibody (Sigma, Poole, Dorset, UK) and MyD88 constructs were detected by western 
blot using an anti-HA antibody (Covance, California, USA). Experiment shown is representative of 3 
independent experiments. 
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4.3 Conclusions 
The observation of DC activation by the over-expression of TIR domain, made in chapter 3, 
would suggest a DC specific inhibitory mechanism. This mechanism would require a protein, 
which is expressed in DCs but not in M-CSF differentiated macrophages and shows inhibitory 
functions. Furthermore, since a TIR domain is required for the activation of DCs and the 
mechanism proposed in chapter 3 is dependent on MyD88 recruitment to the inhibitory 
receptor, the elusive protein should contain a TIR domain of its own. 
In recent years, a multitude of TLR inhibitory molecules have been described, however, the 
requirements stated above restrict the candidates to three: MyD88s, a short splice version of 
MyD88, ST2 and SIGIRR, both members of the IL-1R family (Lang and Mansell, 2007). Of 
these three molecules only SIGIRR has been shown before in mice and humans to have a 
restricted mRNA expression pattern, being highly expressed in immature DCs but not in mature 
DCs and macrophages (Polentarutti et al., 2003). This observation makes SIGIRR a promising 
candidate for the hypothesis proposed in chapter 3. 
In this study real-time PCR data could confirm the restricted expression pattern of SIGIRR, 
being expressed in monocytes, M-CSF differentiated macrophages and immature DCs but 
being expressed at only low levels in GM-CSF differentiated macrophages and fibroblasts 
(Figure 4.1). It is intriguing that different macrophage subtypes show a selective expression of 
SIGIRR mRNA. This observation is reflected in the current literature. In mice, freshly isolated 
macrophages do not express SIGIRR while bone marrow derived macrophages start expressing 
it after 5 days in M-CSF containing L929 cell-conditioned media culture and even up-regulate 
it after 7 days (Polentarutti et al., 2003). The same investigation has shown that while the 
macrophage cell line GG2EE does express SIGIRR mRNA, another macrophage cell line 
(J774) does not (Polentarutti et al., 2003). Studies performed in humans used macrophages 
differentiated from monocytes in the presence of human serum. These macrophages showed no 
mRNA expression of SIGIRR (Garlanda et al., 2004). However, the use of human serum 
neither allows the adjustment of accurate culture conditions with differentiation factors nor is it 
clear, which differentiation factors are present. Therefore, the results obtained in human 
macrophages are difficult to interpret. Yet, the results obtained in mice and cell lines support 
the observations made in this study that SIGIRR can be expressed in macrophages dependent 
on the differentiation factor used. However, since M-CSF differentiated macrophages do 
express SIGIRR but are not activated by the over-expression of a TIR domain, SIGIRR might 
be excluded as a possible candidate for the mechanism proposed in chapter 3. 
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Current literature does not describe protein expression patterns of SIGIRR in mice or humans. 
Since the expression of mRNA can differ significantly from the actual expression of protein it 
is important to assess SIGIRR protein expression in human cells. However, the antibodies for 
SIGIRR currently available are not able to specifically detect SIGIRR by western blot. One 
reason for the difficulty to obtain a specific anti-SIGIRR antibody might be due to 
posttranslational modifications of the protein, which might interfere with epitope recognition. 
Previous studies performed in murine kidney cells have shown that SIGIRR is highly 
glycosylated (Lech et al., 2007). Furthermore, the Centre for Biological Sequence Analysis 
(CBS) software predicts 6 N-glycosylation sites and 1 O-glycosylation site for human SIGIRR 
(URL: http://www.cbs.dtu.dk/services/NetOGlyc/). Therefore, another method to detect protein 
has been used in this study. Flow cytometry showed that SIGIRR is expressed in DCs as well as 
monocytes and M-CSF differentiated macrophages but not GM-CSF differentiated 
macrophages, thereby confirming the mRNA expression pattern. Interestingly, it seems that 
SIGIRR is expressed intracellularly in those cells. While these results might exclude SIGIRR as 
a DC specific inhibitor, it would be important to investigate if the TLR and IL-1R inhibitory 
role of SIGIRR, observed in mice and cell lines, can also be observed in primary human cells. 
Moreover, the intracellular expression of SIGIRR could have differential influences on TLRs 
expressed on the surface (e.g. TLR4) compared to TLRs expressed intracellularly (e.g. 
TLR7/8). Examples for such TLR specific mechanism is provided by the endosomal protein 
UC93B, which specifically regulates TLR7, TLR8 and TLR9 signalling (Kim et al., 2008). 
Since an adenovirus encoding SIGIRR, to over-express it in DCs and M-CSF macrophages, 
was available these studies were pursued. 
The over-expression of SIGIRR in primary human DCs as well as M-CSF differentiated 
macrophages resulted in an inhibition of TNFα and IL-10 production in response to TLR2/6, 
TLR4, TLR5, TLR7/8 and IL-1R stimuli but not TNFα. In these cells, SIGIRR does not seem 
to have a differential effect on TLR signalling. The results rather suggest that SIGIRR functions 
as a general inhibitor of TIR domain dependent signalling. This is further indicated by the 
inhibition of IP10 production following TLR4 as well as TLR3 stimulation, which suggests that 
SIGIRR does inhibit the MyD88 dependent as well as the TRIF dependent TLR signalling 
pathway in human DCs and macrophages. So far, studies have investigated the inhibitory role 
of SIGIRR in SIGIRR knock out mice as well as cell lines (Garlanda et al., 2004; Qin et al., 
2005; Wald et al., 2003). In vivo, SIGIRR null mice have been shown to have a reduced 
threshold to lethal endotoxin challenge with LPS (Wald et al., 2003). Investigating specific cell 
types more closely ex vivo, it has been found that BMDCs from SIGIRR knock out mice 
produce increased amounts of IL-6 as well as IP10 in response to LPS (TLR4) or CpG (TLR9) 
but not poly I:C (TLR3) or Candida albicans (stimulating TLR2 as well as Dectin-1) (Garlanda 
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et al., 2004), suggesting TLR specificity of SIGIRR. This has also been shown in HEK293 and 
Hela 229 cell lines using NF-κB luciferase assays, which were inhibited by SIGIRR over-
expression in response to IL-1, LPS (TLR4) or Flagellin (TLR5) but not poly I:C (TLR3) or 
TNFα (Qin et al., 2005). However, in contrast to those reports a TLR specific inhibition has not 
been observed in SIGIRR deficient spleen derived monocytes, which produce increased 
amounts of CCL2 in response to Pam3Cys (TLR2/1), poly I:C (TLR3), LPS (TLR4) and CpG 
(TLR9) (Lech et al., 2007). Results obtained in this study do not support differential effects of 
SIGIRR on TLRs as observed before in mice and cell lines. They are, however, in accordance 
with previous reports suggesting that SIGIRR inhibition is specific to TIR domain signal 
transduction (Wald et al., 2003). 
An alternative approach of studying the function of SIGIRR is by utilising siRNA. While 
siRNA knock down of proteins is commonly used in cell lines, it is still difficult to exploit this 
method in primary human cells due to low transfection efficiencies. Therefore, I evaluated and 
established the AMAXA transfection system for primary human monocytes, which reliably 
allows the transfection of plasmids and oligo nucleotides into primary human cells with 
transfection efficiencies higher than 50%. However, this method includes the electrical pulsing 
of cells, which might influence their vitality, especially in long term cultures. While 
transfection of monocytes and consequent culture of the cells using M-CSF showed no effect 
on cell vitality, cell differentiation using GM-CSF and IL-4 resulted in a loss of vitality of up to 
50%. The loss in vitality of DCs might be a result of the long term experiment performed in this 
study. Other studies have already described the sensitivity of DCs to electroporation comparing 
short term cultures (less then 24 h) with long term cultures of more than 24 h (Lenz et al., 
2003). As a consequence of these results only M-CSF differentiated macrophages were used for 
further functional experiments. 
The kinetics of siRNA knock down differs from gene to gene and depends on the amount of 
gene expression as well as the half life of mRNA as well as protein. Real-time PCR results of a 
time course of SIGIRR knock down show that SIGIRR mRNA levels are reduced by 
approximately 50% at an siRNA concentration of 400 nM, 48 h and 72 h after transfection 
compared to scrambled control oligos. Similar to the reduction in mRNA levels, there is also a 
50% reduced expression of SIGIRR protein at an oligo concentration of 400 nM 48 h after 
transfection. The partial knock down of SIGIRR protein might be explained by the fact that the 
transfection efficiency of the AMAXA system is around 50%. Another possible shortcoming of 
siRNA are off-target effects on structurally related proteins. The intra-cellular region of 
SIGIRR shows high sequence homology to TLR4 (Thomassen et al., 1999) but no effects on 
the TLR4 expression could be observed as a result of SIGIRR knock down. 
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The SIGIRR knock down macrophages show super-induced production of TNFα and IL-10 in 
response to LPS, R848 and IL-1α but not TNFα stimulation compared to untransfected cells 
and scrambled control oligo transfected cells. The super-induction observed in SIGIRR knock 
down macrophages is titratable dependent on the amount of siRNA used. Moreover, IP10 
expression is also super-induced in LPS or poly I:C stimulated SIGIRR knock down 
macrophages. These results are in accordance with the over-expression studies and suggest a 
general role of SIGIRR in inhibiting TLR- as well as IL-1R signalling. Therefore, this is the 
first report showing functional inhibition of SIGIRR in primary human cells in response to a 
variety of TLR stimuli. Moreover, it is the first time that siRNA knock down is being utilised to 
examine the function of SIGIRR in TLR signalling. 
The outcome of TLR signalling is the induction of NF-κB, MAPKs and IRF3. Compared to 
scrambled control oligo transfected cells, SIGIRR knock down macrophages show an increased 
phosphorylation of IκBα at 5 min as well as 40 min to 60 min following LPS stimulation, while 
the kinetics of phosphorylation remain the same. Similar to the increased phosphorylation of 
IκBα there is also an increase in the phosphorylation of JNK and ERK at 20 min after LPS 
stimulation. Interestingly, the phosphorylation of p38 MAPK seems to be unaffected by the 
knock down of SIGIRR in macrophages. While this observation is difficult to explain, one 
reason could be that the partial knock down of SIGIRR of 50% in human macrophages is not 
enough to observe an effect on p38 MAPK phosphorylation. However, it is also intriguing that 
so far, no publication on SIGIRR has presented data on the effect of SIGIRR on p38 MAPK 
activation while its inhibitory role of JNK activation is well documented in mice and cell lines 
(Qin et al., 2005; Wald et al., 2003; Xiao et al., 2007). Current literature suggests that JNK as 
well as p38 MAPK activation is a result of the similar TLR signalling cascades (Ashwell, 2006; 
Lee and Kim, 2007). After TLR stimulation TRAF6 becomes ubiquinated, which results in the 
recruitment of TAK1 (Ashwell, 2006; Lee and Kim, 2007). Consequently, TAK1 activates the 
NF-κB cascade as well as MKK6, which results in the phosphorylation of JNK and p38 MAPK. 
Results in our lab suggest that while the activation of p38 MAPK, following LPS stimulation, is 
Btk dependent the activation of JNK and ERK are not (unpublished data, Dr. Maria 
Smolinska). This observation indicates separate pathways leading to the activation of MAPKs, 
which might be responsible for the differential effect of SIGIRR on MAPK phosphorylation. 
However, the mechanisms that account for the activation of specific MAPKs in response to 
receptor engagement through distinct MAP3Ks are far from being understood. Therefore, the 
observation of a specific involvement of SIGIRR in MAPK activation is still part of ongoing 
investigation in our laboratory. 
Following the observation of a regulation of IP10 production by SIGIRR the activation of IRF3 
in SIGIRR knock down macrophages was further investigated. As a result of TLR4 or TLR3 
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stimulation, TRIF recruits TBK1 and IKKi, which leads to IRF3 phosphorylation (Lee and 
Kim, 2007). Subsequently, IRF3 dimerises and translocates to the nucleus (Honda and 
Taniguchi, 2006). SIGIRR knock down macrophages show increased IRF3 nuclear 
translocation 20 min and 30 min after LPS stimulation compared to scrambled control oligo 
transfected macrophages. Currently, it is still unclear whether IP10 is a secondary product of 
LPS or poly I:C induced type I interferon expression or a direct result of TLR stimulation 
(Honda and Taniguchi, 2006). The increased activation of IRF3 in SIGIRR knock down 
macrophages, however, suggests that SIGIRR inhibits the TRIF signalling pathway directly 
following TLR4 stimulation. 
Taken together these results suggest an involvement of SIGIRR in the MyD88 dependent as 
well as MyD88 independent TLR signalling pathway. Moreover, they indicate that SIGIRR acts 
upstream of the activation of NF-κB, the MAPKs and IRF3. Previous studies in cell lines 
suggest that SIGIRR functions at receptor proximal signalling events, possibly as a blocking 
receptor (Qin et al., 2005). The transient interaction of SIGIRR with TLR4 as well as MyD88, 
IRAK1 and TRAF6, following LPS stimulation, has been previously shown in HEK293 cells 
(Qin et al., 2005). In immature human DCs, SIGIRR interacted with wild type MyD88. This 
interaction was nearly completely lost by co-expression of SIGIRR with MyD88 Pro200His, 
which contains a point mutation in its TIR domain. No interaction could be detected when 
SIGIRR was co-expressed with MyD88 DD, which is TIR domain deleted. Thus, these results 
suggest that a TIR domain is necessary for SIGIRR to interact with MyD88. Moreover, the 
interaction between SIGIRR and MyD88 might be constitutive as it does not depend on the 
stimulation of the DCs. Although, it has to be taken into account that SIGIRR and MyD88 were 
over-expressed in these studies. Nonetheless, SIGIRR possibly acts as a sink, sequestering 
MyD88, and thereby inhibiting TLR as well as IL-1R signalling. Since, this mechanism would 
depend on TIR domain interactions it could explain why TNFα signalling as well as IFNγ 
signalling (Wald et al., 2003) is not regulated by SIGIRR.  
This is the first report describing an involvement of SIGIRR in TLR signalling regulation in 
primary human myeloid cells. It describes a specific expression pattern in human macrophages 
dependent on the differentiation factor used. Moreover, using adenovirus vectors to over-
express SIGIRR as well as siRNA to knock down SIGIRR in M-CSF differentiated 
macrophages reveals a general regulation of TLR signalling by SIGIRR. This regulation might 
be due to SIGIRR acting as a sink, thereby sequestering TLR adaptor molecules. TLR 
signalling is a strong inducer of an inflammatory response. In recent years, it was also 
implicated in the induction and progression of inflammatory diseases including rheumatoid 
arthritis (Drexler et al., 2006; Marshak-Rothstein, 2006). Since this study shows that SIGIRR is 
a potent inhibitor of TLR signalling in cells relevant to inflammatory diseases, further 
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investigations were performed to examine the role of SIGIRR in RA disease models in vivo as 
well as in vitro. 
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5.1 Introduction 
In recent years increasing evidence emerged that TLRs are not only able to detect pathogens 
but also endogenous danger signals (Brentano et al., 2005a; Drexler et al., 2006; Marshak-
Rothstein, 2006; Marshak-Rothstein and Rifkin, 2007; Rifkin et al., 2005; Tsan and Gao, 
2004). These danger signals have been shown to be present in the RA synovial fluid (Schett et 
al., 1998; Scott et al., 1981; Taniguchi et al., 2003; Yu et al., 1997). Therefore, the release of 
endogenous TLR-ligands during inflammation may activate TLRs and perpetuate the disease. 
Evidence in mice as well as humans, support a role of TLR activation by endogenous ligands in 
the destructive process observed in RA (Brentano et al., 2005b; Kawane et al., 2006; Sacre et 
al., 2007a). TLR9 was shown to be activated by endogenous DNA released during the process 
of cell necrosis. Therefore, the escape of genomic DNA during cell death might lead to the 
induction of inflammatory disease. That this might be the case has been demonstrated in DNase 
II -/- mice, which develop chronic polyarthritis that resembles human rheumatoid arthritis 
(Kawane et al., 2006). Furthermore, a study using human synovial membranes from RA 
patients has shown that the spontaneous release of cytokines and MMPs by those cells can be 
inhibited through over-expression of dominant negative constructs of MyD88 or Mal. 
Furthermore, it has been shown that conditioned cell media from RA synovial membranes is 
able to activate human monocyte derived macrophages in a MyD88 and Mal dependent manner 
(Sacre et al., 2007a), thereby indicating the presence of an endogenous TLR ligand in RA 
synovial cell supernatants. 
The role of SIGIRR as an inhibitor of TLR and IL-1R signalling and thereby inhibitor of 
inflammation has been well established. SIGIRR-/- mice have more severe inflammation in the 
DSS-induced colitis model (Garlanda et al., 2004; Xiao et al., 2007) and are more susceptible to 
lethal endotoxin challenges (Wald et al., 2003). Given the potential of TLRs in driving RA, I 
further investigated the role of SIGIRR in suppressing signalling by the TLR and IL-1R 
families in RA disease models. 
This study characterises SIGIRR as a suppressor of spontaneous cytokine release in human RA 
membranes. Therefore the data presented here provides further evidence, which suggests a role 
of TLRs in driving the inflammatory process observed during the progression stage of RA. 
Moreover, this investigation demonstrates the involvement of SIGIRR in regulating the 
adaptive immune response, which could be observed during the induction of CIA in SIGIRR 
deficient animals. 
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5.2 Results 
5.2.1 SIGIRR inhibits spontaneous release of cytokines by human 
RA synovial membranes 
The human RA in vitro model, developed at the Kennedy Institute of Rheumatology, utilises 
RA synovial membranes obtained from patients undergoing joint replacement (Hermann et al., 
1998; Katsikis et al., 1994). This system has been used to establish the potent role of TNFα in 
RA pathogenesis (Brennan et al., 1989a; Brennan et al., 1989b). The RA synovial membranes 
are treated with collagenase to obtain a single cell culture, which consist of synovial fibroblasts, 
lymphocytes as well as macrophages and DCs. The resulting cell cultures spontaneously 
produce cytokines and MMPs without further stimulation, which can be measured as a read out 
in functional assays. Therefore, the function of SIGIRR in an established inflammatory 
environment was investigated using these human RA synovial membrane cultures. 
5.2.1.1 SIGIRR is expressed by macrophages in the human RA synovial 
membrane 
The expression of SIGIRR in human RA synovium was examined by flow cytometry staining 
of synovial membrane cultures (Figure 5.1). RA synovial membranes were co-stained for CD3 
(T cells) or CD14 (monocytes/macrophages) and SIGIRR. However, the cells obtained from 
synovial membranes did show a high degree of unspecific binding, as observed using an 
isotype control antibody (Figure 5.1). Therefore, it is difficult to interpret whether synovial 
macrophages or synovial resident T cells do express SIGIRR. Although it seems that CD14+ 
macrophages did stain positive for SIGIRR, this was not reflected in the percentages (Figure 
5.1). The experiment shown in Figure 5.1 is a representative of three donors. Different 
procedures using a range of different blocking buffers did not improve the quality of the 
staining. Ultimately, other methods to detect SIGIRR expression e.g. flow cytometry on sorted 
cells, real-time PCR or histology, will need to be utilised. 
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Figure 5.1: SIGIRR expression by synovial resident and T cells is difficult to interpret due to a 
high degree of unspecific staining. RA synovial membrane cells from the same donor were examined 
by intracellular flow cytometry staining for the expression of SIGIRR expression. A representative 
histogram plot of 3 donors is shown. Permeabilized cells were incubated with isotype control (BD 
Bioscience) or anti-SIGIRR antibody (BAF990, R&D) and co-stained with either anti-CD3 (BD 
Bioscience) or anti-CD14 (BD Bioscience).  
5.2.1.2 SIGIRR over-expression inhibits the spontaneous release of cytokines 
by RA synovial membrane cultures 
Adenoviral infection of RA synovial cells allows the investigation of the function of SIGIRR in 
an established human inflammatory environment. The protocol of RA synovial cell infection by 
adenoviruses has been established in our laboratory and results in an infection efficiency of 
above 90% (Foxwell et al., 1998). Moreover, the viral infection of RA synovial cells has no 
significant influence on cell vitality as shown in Figure 5.2. 
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Figure 5.2: SIGIRR wt over-expression does not significantly affect the cell vitality of RA synovial 
membranes. RA synovial membrane cells were left uninfected, or infected (100:1 m.o.i.) for 2 h in 
serum-free medium with adenoviruses expressing GFP (control) or SIGIRR wt. 48 h post infection cells 
were incubated with MTT over night, lysis performed and OD574 measured. Data are normalised to 
uninfected cells and expressed as mean ± SEM. n = 4, data is 4 independent experiments pooled. 
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RA synovial cells spontaneously produce cytokines without further stimulation (Sacre et al., 
2007a). Therefore, the effect of SIGIRR on the spontaneous release of cytokines was measured 
by ELISA (Figure 5.3). Over-expression of SIGIRR led to a significant suppression of the 
release of IL-6 and TNFα (Figure 5.3 A and B respectively) as well as a reduction in IL-10 
release (C, Figure 5.3). However, no effect on IL-8 production was observed by SIGIRR over-
expression (D, Figure 5.3). These data would suggest that IL-6, TNFα and IL-10 production in 
the RA synovial membrane is driven by IL-1R and/or TLR signalling. 
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Figure 5.3: SIGIRR wt over-expression inhibits the spontaneous release of IL-6 (p = 0.02), TNFα (p 
= 0.021) and IL-10 (p = 0.059) but not IL-8 by RA synovial membranes. RA synovial membrane cells 
were left uninfected, or infected (100:1 m.o.i.) for 2 h in serum-free medium with adenoviruses 
expressing GFP (control) or SIGIRR wt. 48 h post infection supernatants were collected and A) IL-6, B) 
TNFα C), IL-10 and D) IL-8 levels measured using ELISA. Data are expressed as mean ± SEM. Data is 
n independent experiments pooled. p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
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5.2.2 SIGIRR deficient mice show reduced disease incidence 
following CIA induction 
Given that SIGIRR was shown in this study to inhibit TLR signalling in primary human 
macrophages and DCs as well as to inhibit the spontaneous release of cytokines by RA synovial 
membranes in vitro, I further examined the function of SIGIRR in an in vivo model of RA, 
collagen induced arthritis. In accordance with the UK licensing law for animal experiments the 
mice were immunised by Dr. Julia Inglis. All other experimental procedures were performed by 
me. 
5.2.2.1 SIGIRR deficient BMDCs super induce cytokine production in response 
to TLR stimulation 
Previous studies on SIGIRR deficient BMDCs have shown that those cells hyper-respond to 
TLR stimulation by super-inducing cytokine production (Garlanda et al., 2004). In order to 
confirm these data in our laboratory BMDCs were stimulated with LPS and Malp-2 and 
subsequent TNFα production was measured by ELISA (Figure 5.4). BMDCs from SIGIRR 
deficient mice produce more TNFα in response to LPS and Malp-2 compared to WT animals. 
Also a gene dosage effect can be observed as SIGIRR+/- mice produce intermediate amounts of 
TNFα in response to LPS and Malp-2 compared to WT and SIGIRR-/- animals (Figure 5.4). 
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Figure 5.4: Bone marrow derived DCs of SIGIRR-/- mice produce increased amounts of TNFα 
compared to WT mice following TLR stimulation. TNFα induction was assayed in culture supernatant 
by ELISA. BMDCs were used at day 6 of in vitro differentiation with 100 ng/ml GM-CSF in RPMI 5% 
FCS. Cells were stimulated with 100 ng/ml LPS, 20 µg/ml poly I:C, 10 ng/ml Malp-2. After further 18 h 
supernatants were collected and TNFα induction assayed by ELISA. Data are expressed as mean ± SD. 
n = 2, data is 2 independent experiments pooled. 
Chapter 5 Results 
 
166 
5.2.2.2 SIGIRR-/- mice show reduced incidence and disease severity following 
CIA immunisation 
CIA is a widely-used animal model of human rheumatoid arthritis, which utilises type II 
collagen, expressed exclusively in the articular cartilage of the joint, as an auto antigen (Cho et 
al., 2007). Induction of CIA depends on the proliferation of CD4+ T cells 3 to 5 weeks after 
immunisation (Cho et al., 2007). The SIGIRR-/- mouse used in this study is on the C57Bl/6 
background, which can be immunised using chicken type II collagen and Complete Freund´s 
Adjuvant (CFA) to induce CIA as described before (Inglis et al., 2007). Although, the C57/Bl6 
mice show a milder disease phenotype compared to DBA/1 mice, the disease is more chronic 
with a more pronounced and persistent T cell response (Inglis et al., 2007). Moreover, unlike 
DBA/1 mice, C57/Bl6 mice develop an arthritic disease, which more closely correlates with the 
human disease as they respond to methotrexate treatment, which is a classical treatment in 
humans (Inglis et al., 2007). 
The immunised mice began showing signs of the disease, e.g. paw swelling and paw redness, 
between day 16 and day 20 after immunisation (Figure 5.5). All mice that reached a minimum 
clinical score of 1.5 were considered to be diseased. 29 days post immunisation WT mice 
showed a disease incidence of 91.6% (11/12). In contrast, heterozygous- and homozygous 
SIGIRR-/- mice only showed 77.7% (14/18) and 50% (4/8) incidence respectively (Figure 5.5). 
40 days after immunisation the trial had to be terminated due to the severity of the disease in 
WT mice. By then all mice showing signs of disease reached a minimum of 11 days past 
disease onset (Figure 5.5). 
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Figure 5.5: SIGIRR-/- mice show a lower CIA incidence compared to heterozygous SIGIRR 
deficient mice and WT mice. Mice were immunised with type II collagen in complete Freund's adjuvant 
(n = 12 WT mice, n = 18 SIGIRR+/- mice, n = 8 SIGIRR-/- mice).  Mice with a minimum clinical score of 
1.5 were considered diseased and incidence was recorded. 91.6% of WT mice (11/12), 77.8% of 
SIGIRR+/- mice (14/18) and 50% of SIGIRR-/- mice (4/8) showed disease 29 days post immunisation. 
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Over the period of 11 days the diseased WT animals had significantly increased paw swelling 
as well as clinical score compared to diseased heterozygous- and homozygous SIGIRR-/- mice 
(A and B Figure 5.6). A gene-dosage effect was observed as mice heterozygote for SIGIRR 
developed disease of an intermediate severity between homozygous SIGIRR-/- and WT mice as 
measured by paw swelling and clinical score (A and B Figure 5.6). Paw swelling was 
observable in multiple paws of the WT mice, whereas in most heterozygous and homozygous 
SIGIRR-/- mice only one paw per animal was affected by the disease (Figure 5.7). Histological 
examination of the joints showed only minor signs of inflammation in the joints of SIGIRR-/- 
mice, while there was major cell infiltration into the joint space (JS) and synovium (S) as well 
as cartilage (C) and bone (B) destruction in joints from SIGIRR+/- and WT animals (Figure 5.8). 
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Figure 5.6: SIGIRR-/- mice show a lower clinical score and paw swelling compared to heterozygous 
SIGIRR deficient mice and WT mice during 11 days of CIA. (A) Paw diameter as an average of the 4 
paws and (B) clinical score of the diseased mice were measured for 11 days post disease onset (n = 11 
WT arthritic mice, n = 14 SIGIRR+/- arthritic mice, n = 4 SIGIRR-/- arthritic mice). SIGIRR-/- mice 
showed reduced paw swelling and a lower clinical score compared to SIGIRR+/- mice and WT animals. 
Data are expressed as mean ± SEM. Data is n animals pooled. . p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
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Figure 5.7: CIA induction leads to severe swelling of multiple paws in WT mice whereas 
heterozygous- and homozygous SIGIRR deficient mice have only single paws affected with milder 
swelling.  
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Figure 5.8: SIGIRR-/- mice show a significant lower histological score compared to heterozygous 
SIGIRR deficient mice and WT mice during 11 days of CIA (p = 0.0314). Figure shows proximal 
interphalongeal joint (magnification x20). Arthritic mice were sacrificed 11 days post disease onset. 
Joints were decalcified, paraffin embedded, and sections (10 µm) stained with haematoxylin and eosin by 
David Essex (Department of Histopahtology, Charing Cross Hospital). Joints were classified according 
to the presence or absence of inflammatory cell infiltrates (defined as focal accumulations of leukocytes). 
Histological analysis was performed in a blinded fashion by Dr Richard Williams (KIR). Homozygous 
SIGIRR deficient animals showed low grade inflammation, while SIGIRR+/- and WT animal joints 
showed massive infiltration of mononuclear cells into the joint space as well as cartilage and bone 
erosion. Abbreviations: joint space (JS), cartilage (C), bone (B), synovium (S). Data are expressed as 
mean ± SEM. Data is n animals pooled (n = 11 WT arthritic mice, n = 14 SIGIRR+/- arthritic mice, n = 4 
SIGIRR-/- arthritic mice). p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
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5.2.2.3 SIGIRR-/- mice produce less anti-collagen class IgG2a/c antibodies 
compared to WT animals following CIA induction 
The production of anti-type II collagen antibodies following immunisation is required for the 
development of CIA (Cho et al., 2007). In order to investigate the reason for the less severe 
pathology in SIGIRR-/- mice, antibody production was measured in the serum of mice 11 days 
after disease onset (Figure 5.9). WT mice as well as heterozygote- and homozygous SIGIRR 
deficient mice contained equal titres of IgG1 anti-collagen antibody in their serum (A, Figure 
5.9). In contrast, homozygous SIGIRR-/- mice produced significantly reduced amounts of anti-
chicken collagen IgG2a/c 11 days after disease onset (A, Figure 5.9). Consequently, SIGIRR-/- 
mice showed a decreased ratio of IgG2a/c to IgG1 antibody production, which may indicate a 
reduced Th1- and polarised Th2 response (B, Figure 5.9). 
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Figure 5.9: SIGIRR-/- mice produce significantly less IgG2a/c ant-collagen antibodies compared to 
WT mice (p = 0.0303) and show a reduced Th1/Th2 polarised immune response following CIA 
immunisation. Only mice showing signs of disease were included in this figure. 11 days post disease 
onset mice were sacrificed and their serum levels of IgG1 and IgG2a/c anti-collagen antibody measured 
relative to a pooled standard of serum from CIA induced C57Bl/6 mice. (A) WT as well as SIGIRR+/- 
animals showed an antibody concentration of IgG1 and IgG2a/c characteristic for C57Bl/6 mice 
immunised with chicken collagen, as shown before (Inglis et al., 2007). SIGIRR-/- mice, however, show 
significantly lower levels of IgG2a/c anti-collagen antibodies compared to WT mice (n = 11 WT arthritic 
mice, n = 14 SIGIRR+/- arthritic mice, n = 4 SIGIRR-/- arthritic mice). (B) Consequently, SIGIRR-/- mice 
also show a lower ratio of IgG2a/c/IgG1 compared to WT animals, suggesting a Th2 polarisation in those 
mice. Data are expressed as mean ± SEM. Data is n animals pooled (n = 11 WT arthritic mice, n = 14 
SIGIRR+/- arthritic mice, n = 4 SIGIRR-/- arthritic mice). p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
 
The reduced antibody production in SIGIRR-/- mice does not seem to be due to a general defect 
in B cell activation since only IgG2a/c production is affected. However, to further exclude the 
possibility of an intrinsic defect in B cell activation, naive purified B cells from SIGIRR-/- mice 
were stimulated with IgM or LPS and their proliferation measured (Figure 5.10). 
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Purified spleen B cells from naive SIGIRR deficient mice significantly hyper proliferated 
following stimulation with IgM or LPS compared to WT B cells (Figure 5.10). In the case of 
LPS this is to be expected, given the role of SIGIRR as a TLR4 inhibitor. Therefore, an 
intrinsic defect in the activation of B cells from SIGIRR deficient mice might be excluded as a 
reason for reduced IgG2a/c anti-chicken collagen antibody production. This implicates that the 
reduction in antibody production observed in SIGIRR-/- mice following CIA immunisation may 
be due to the nature of the T helper cell immune response. 
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Figure 5.10: Purified naïve B cells from SIGIRR-/- mice hyper proliferate in response to IgM (p = 
0.0066) and LPS (p = 0.0281) stimulation. A single cell suspension was prepared from spleens. B cells 
were positively enriched using anti-IgM MACS micro beads (Miltenyi Biotec, Bergisch Gladbach, 
Germany). Purity was assessed by flow cytometric analysis (B cells >90% CD19+). Cells were cultured 
at 1 x 105 cells/ml in 200µl complete RPMI in a flat bottom 96-well plate and cultured for 72 h. B cells 
were stimulated with IgM (10 µg/ml; BD) or LPS (10 µg/ml, Alexis). For proliferation assays, 48 hours 
after stimulation cells were pulsed with 1 µCi 3H thymidine per well for 18 h. Cells were then harvested 
and plates assessed for thymidine incorporation. Data are expressed as mean ± SEM. Data is n = 3 
independent experiments pooled. p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
 
5.2.2.4 SIGIRR-/- lymph node cells and splenocytes induce a Th2 associated 
cytokine profile following CIA induction 
The activation of auto reactive T cells and consequently the stimulation of B cells to produce 
auto-antibodies are essential for the onset of CIA. Furthermore, the type of T helper cells 
induced plays a major part in CIA, with Th1 as well as Th17 cells strongly implicated in 
disease onset and progression (Furuzawa-Carballeda et al., 2007).  
In order to investigate the nature of Th cell response induced in SIGIRR-/- mice following CIA 
induction, cytokines produced by lymph node cells and splenocytes were measured 16 days 
after immunisation (Figure 5.11). Lymph nodes and spleens were excised from mice 14 days 
after immunisation and cells cultured in vitro un-stimulated or in the presence of type II 
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collagen or anti-CD3 for 48 h, before supernatants were analysed for cytokine levels (Figure 
5.11). 
 
 
 
Figure 5.11: Examination of Collagen induced arthritis in SIGIRR-/- mice. Mice were immunised by 
injecting CFA and chicken collagen at the base of the tale. 14 days after immunisation the mice were 
sacrificed and lymph nodes as well as spleens removed. Following a 2 day in vitro culture of lymph node 
cells and splenocytes in the presence of anti-CD3 or chicken collagen, cytokine levels in cell 
supernatants were measured by ELISA and proliferation assays performed. 
 
Lymph node cells and splenocytes from SIGIRR-/- mice showed decreased production of IFNγ 
compared to WT cells, indicating a reduced Th1 immune response (A and B, Figure 5.12). 
Moreover, SIGIRR-/- lymph node cells as well as splenocytes produced significantly reduced 
amounts of IL-17 in the presence of type II collagen and anti-CD3 (A and B, Figure 5.13). By 
contrast, the amounts of the traditionally Th2 associated cytokines IL-5 and IL-10 produced by 
SIGIRR-/- lymph node cells and splenocytes showed a reversed pattern (A, B and C, D 
respectively, Figure 5.14). The cytokine profile observed suggest a Th2 polarised immune 
response with a reduction in Th1 as well as Th17 cells present in SIGIRR-/- mice induced with 
CIA.  
Chapter 5 Results 
 
174 
 
WT +/
-
KO WT +/
-
KO WT +/
-
KO
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
unstimulated
type II collagen
anti-CD3
A)
IF
N
γ [
pg
/m
l]
WT +/
-
KO WT +/
-
KO WT +/
-
KO
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
6500
unstimulated
type II collagen
anti-CD3
B)
IF
N
γ [
pg
/m
l]
 
Figure 5.12: Lymph node cells and splenocytes of SIGIRR-/- mice produce less IFNγ compared to 
WT mice after induction of CIA. WT, heterozygous (+/-) and KO littermate mice were immunised with 
CFA and chicken collagen. After 14 days lymph nodes and spleens were removed and cells cultured 
either un-stimulated or in the presence of type II collagen or anti-CD3. After 48 h supernatants from A) 
lymph node cells and B) splenocytes were removed and IFNγ levels measured by ELISA. Data are 
expressed as mean ± SEM. n = 6, data is 6 mice per group pooled. 
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Figure 5.13: Lymph node cells and splenocytes of SIGIRR-/- mice produce less IL-17 compared to 
WT mice after induction of CIA. WT, heterozygous (+/-) and KO littermate mice were immunised with 
CFA and chicken collagen. After 14 days lymph nodes and spleens were removed and cells cultured 
either un-stimulated or in the presence of type II collagen or anti-CD3. After 48 h supernatants from A) 
lymph node cells and B) splenocytes were removed and IL-17 levels measured by ELISA. Data are 
expressed as mean ± SEM. n = 6, data is 6 mice per group pooled. p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
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Figure continued on next page… 
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Figure 5.14: Lymph node cells and splenocytes of SIGIRR-/- mice produce more IL-5 (A and B) and 
IL-10 (C and D) compared to WT mice after induction of CIA. WT, heterozygous (+/-) and KO 
littermate mice were immunised with CFA and chicken collagen. After 14 days lymph nodes and spleens 
were removed and cells cultured either un-stimulated or in the presence of type II collagen or anti-CD3. 
After 48 h supernatants from A and C) lymph node cells and B and C) splenocytes were removed and IL-
5 (A and B) as well as IL-10 (C and D) levels measured by ELISA. Data are expressed as mean ± SEM. 
n = 6, data is 6 mice per group pooled. p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
 
TNFα is a cytokine produced by T cells as well as macrophages and dendritic cells. Its 
expression depends on the activation of NF-κB. Previous studies have shown increased NF-κB 
activation in spleen macrophages from SIGIRR-/- mice in response to LPS (Lech et al., 2007). 
The levels of TNFα produced by SIGIRR-/- lymph node cells and splenocytes in this study were 
significantly increased compared to WT cells, thereby confirming previous studies (A and B, 
Figure 5.15). This further strengthens the observation of a specific influence of SIGIRR on the 
Th1/Th17/Th2 balance after induction of CIA. 
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Figure 5.15: Lymph node cells and splenocytes of SIGIRR-/- mice produce more TNFα (A and B) 
compared to WT mice after induction of CIA. WT, heterozygous (+/-) and KO littermate mice were 
immunised with CFA and chicken collagen. After 14 days lymph nodes and spleens were removed and 
cells cultured either un-stimulated or in the presence of type II collagen or anti-CD3. After 48 h 
supernatants from A) lymph node cells and B) splenocytes were removed and TNFα (A and B) levels 
measured by ELISA. Data are expressed as mean ± SEM. n = 6, data is 6 mice per group pooled. p ≤ 
0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
 
Following these unexpected results, the proliferation of lymph node cells and splenocytes was 
measured (Figure 5.16). 16 days post immunisation lymph node cells as well as splenocytes 
from SIGIRR deficient mice did not show differences in their proliferation in response to 
chicken collagen or anti-CD3 compared to SIGIRR+/- or WT mice. 
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Figure 5.16: Lymph node cells and splenocytes of SIGIRR-/- mice show no differences in 
proliferation compared to WT mice after induction of CIA. WT, heterozygous (+/-) and KO 
littermate mice were immunised with CFA and chicken collagen. After 14 days(A) lymph nodes and (B) 
spleens were removed and cells cultured either un-stimulated or in the presence of type II collagen or 
anti-CD3. After 48 h the proliferation of A) lymph node cells and B) splenocytes was assessed by 3H 
incorporation. Data are expressed as mean ± SEM. n = 6, data is 6 mice per group pooled. 
 
5.2.2.5 SIGIRR inhibits ST2 signalling 
Based on the unexpected result of less severe CIA in SIGIRR deficient mice, the question arises 
as to how SIGIRR can influence the T cell response, since it has not been implicated in T cell 
signalling to this date. The IgG2a/c/IgG1 ratio observed following CIA progression in SIGIRR 
deficient mice may suggest a Th2 polarisation (Figure 5.9). This is supported by the cytokine 
profile induced by lymph node cells and splenocytes from CIA immunised SIGIRR-/- mice 
(Figure 5.12 to Figure 5.15). Therefore, this study further examined the role of SIGIRR on ST2 
signalling. Similar to SIGIRR, ST2 belongs to the IL-1R/TLR family. It is expressed on murine 
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Th2 but not Th1 cells and was shown to be important in the differentiation to and activation of 
Th2 cells (Coyle et al., 1999; Lohning et al., 1999; Lohning et al., 1998; Townsend et al., 2000; 
Xu et al., 1998). More recently, its ligand was described to be the IL-1 family member IL-33 
(Schmitz et al., 2005). The administration of IL-33 in vitro as well as in vivo leads to the 
production of Th2 associated cytokines IL-5 and IL-13 (Schmitz et al., 2005). 
To examine whether SIGIRR is involved in regulating ST2 signalling, purified T cells from 
naïve SIGIRR-/- mice were stimulated with anti-CD28 and anti-CD3 in the absence or presence 
of IL-33. Subsequently, their cytokine production as well as the proliferation of T cells was 
examined (Figure 5.17). IL-33 induced the production of the Th2 cytokine IL-5 by 2 folds in 
WT T cells. SIGIRR-/- T cells, on the other hand, displayed a significant exaggerated induction 
of IL-5 compared to WT T cells (A, Figure 5.17). No differences in IFNγ or IL-17 induction 
were observed between SIGIRR-/- and WT T cells (A, Figure 5.18). Priming of αCD3/αCD28 
stimulated T cells with IL-1α also showed no significant differences between the two groups 
(A, Figure 5.17). The proliferative responses of αCD3/αCD28 stimulated T cells were 
unaffected by either IL-33 or IL-1α in SIGIRR-/- compared to WT cells (B, Figure 5.17). These 
data indicate that the absence of SIGIRR increases ST2 signalling, thereby boosting the Th2 
response. As a Th2-shift would be suppressive on the Th1/Th17 development, this observation 
may account for the in vivo findings described earlier. 
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Figure 5.17: Purified Lymph node T cells from naïve SIGIRR-/- mice show A) a significant increase 
in the production of IL-5 in response to IL-33 compared to WT cells B) while there is no difference 
in proliferation. Lymph node T cells from naive WT and KO littermate mice were isolated by positive 
selection for CD4. The isolated T cells were cultured for 2 days in the presence of anti-CD28, anti-CD3 
and left unprimed or primed with IL-1α or IL-33. After 48 h A) supernatants were collected and IFNγ, 
IL-17 and IL-5 levels measured by ELISA and B) the proliferation of the T cells assessed by 3H 
incorporation. Cytokine concentration data has been normalised to unprimed T cells, which were 
stimulated in the absence of IL-1 or IL-33. Data are expressed as mean ± SEM. n = 9, data is 9 mice per 
group pooled. p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
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In mast cells it has been shown that ST2 signalling depends on MyD88 (Schmitz et al., 2005). 
In order to further investigate a possible mechanism of how SIGIRR regulates ST2 signalling, 
MyD88 deficient purified T cells were stimulated with anti-CD28 and anti-CD3 in the absence 
and presence of IL-33. Subsequently the cytokine production of those cells was measured 
(Figure 5.18). While WT T cells increased the expression of IL-5 by 2 folds in the presence of 
IL-33, this up-regulation was lost in MyD88 deficient T cells (Figure 5.18). 
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Figure 5.18: Purified Lymph node T cells from naïve MyD88-/- mice do not up regulate the 
expression of IL-5 in response to IL-33. Lymph node T cells from naive WT and KO littermate mice 
were isolated by positive selection for CD4. The isolated T cells were cultured for 2 days in the presence 
of anti-CD28 and anti-CD3 and left unprimed or primed with IL-33. After 48 h supernatants were 
collected and IFNγ, IL-17 and IL-5 levels measured by ELISA. Cytokine concentration data has been 
normalised to unprimed T cells, which were stimulated in the absence of IL-1 or IL-33. Data are 
expressed as mean ± SEM. n = 3, data is 3 mice per group pooled. p ≤ 0.05 *; p ≤ 0.01 **; p ≤ 0.005 *** 
 
Chapter 5 Results 
 
183 
5.3 Conclusions 
The production of TNFα is a major factor in driving RA pathogenesis (Feldmann et al., 1996). 
Therefore, great interest exists to identify the pathways leading to TNFα production in RA 
models. TLR signalling is one pathway, which became implicated in this process. This study 
presents data, which indicates SIGIRR as a negative regulator of spontaneously released 
cytokines produced by RA synovial membranes. This is most likely due to the inhibition of IL-
1R and/or TLR signalling by SIGIRR. Furthermore, while the function of SIGIRR as an 
inflammatory inhibitor has been extensively studied in murine cells and human cell lines, no 
data is so far available on the function of SIGIRR in the adaptive immune response (Garlanda 
et al., 2007a; Garlanda et al., 2004; Garlanda et al., 2007b; Qin et al., 2005; Xiao et al., 2007). 
Date from this study implicates SIGIRR in the regulation of CD4+ T cells differentiation 
(Figure 5.19). 
 
Figure 5.19: Simplified overview of mechanisms involved in RA induction and RA progression and 
the possible differential effects of SIGIRR on those disease stages. During the induction of RA the 
development of Th17 and/or Th1 cells from naïve CD4+ T cells as well as the production of auto-
antibodies by B cells are essential mechanisms. At later stages of the disease, the production of pro-
inflammatory cytokines and MMPs by innate immune cells, synovial fibroblasts and T cells drive the 
progression of tissue destruction and chronic inflammation. While SIGIRR is able to block the 
spontaneous release of cytokines by human RA synovial cells it seems to be necessary for Th17 
development and antibody production during the induction of CIA. Abbreviations: DC (dendritic cell), F 
(Fibroblast), MC (monocyte), MØ (macrophage), Tc (T cell), TLR (toll-like receptor), Bc (B cell), MMP 
(matrix metalloproteinase), Th (T helper cell). 
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Given the role of SIGIRR in regulating inflammation this study further investigated its function 
in RA. Although, the aetiology of RA has not yet been fully described, the important role of T 
cells and the subsequent induction of a pathogenic B cell response in initiating the disease has 
been extensively shown (Bugatti et al., 2007; Furuzawa-Carballeda et al., 2007). During the 
progression of RA the continuous production of chemokines, cytokines and MMPs by 
neutrophils, macrophages and synovial fibroblasts drive the chronic inflammation in the joint as 
well as joint destruction (Feldmann et al., 1996). Several studies implicate endogenous TLR 
ligands, so called danger signals released from necrotic cells, in the chronic inflammation and 
joint destruction observed in RA (reviewed in (Drexler et al., 2006; Roelofs et al., 2008)). 
Previous results published on SIGIRR would, therefore, predict a role for it in attenuating the 
chronic inflammation in RA joints.  
In order to investigate the function of SIGIRR in a human disease model, RA synovial 
membranes obtained from patients undergoing joint replacement were used. Expression data of 
SIGIRR, obtained from flow cytometry analysis, are difficult to interpret due to the high 
amount of unspecific binding by a unspecific isotype control. A reason for the high degree of 
unspecific staining of RA membranes could include the treatment of the membranes with 
collagenase in order to obtain a single cell culture. As the expression pattern of SIGIRR in RA 
membranes is of great interest for future research it needs to be further examined by different 
methods, e.g. real-time PCR, or different protocols, e.g. cell sorting. Moreover, future 
experiments need to compare the level of expression between RA- and OA joints. 
Functional studies of SIGIRR by over-expressing it, showed a significant inhibition of IL-6 and 
TNFα, which is spontaneously produced by RA synovial cells. A similar trend was observed 
for IL-10 although it did not reach significance. In contrast, IL-8 was not inhibited by SIGIRR 
over-expression, which may indicate a degree of specificity of SIGIRR. Since SIGIRR has been 
shown to inhibit IL-1R and TLR signalling (Garlanda et al., 2004; Qin et al., 2005; Wald et al., 
2003) the suppression of spontaneous cytokine production by RA membranes, resulting from 
SIGIRR over-expression, is most likely due to the inhibition of IL-1R and/or TLR signalling. 
Sacre et al. already demonstrated, that the spontaneous release of cytokines by RA-membranes 
is dependent on the TLR adaptor molecules MyD88 and Mal (Sacre et al., 2007a). Therefore, it 
is reasonable to assume that SIGIRR inhibits TLR signalling in RA synovial cells by either 
blocking access for MyD88 to the TLR, as was already shown in other models, or by 
sequestering MyD88 (Qin et al., 2005). How SIGIRR accomplishes its specificity, inhibiting 
IL-6 and TNFα but not IL-8, is part of an ongoing investigation. One possible explanation for 
this observation could be the specific regulation of MAPKs by SIGIRR shown in chapter 4. 
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To further confirm the attenuating role of SIGIRR in the pathology of human RA this study 
used an in vivo model of RA, CIA. However, SIGIRR deficient mice showed resistance to CIA. 
Since the incidence of disease as well as its severity was lower in SIGIRR deficient mice, these 
unexpected results would implicate an involvement of SIGIRR in the initiation of CIA. 
The use of anti-CD20 monoclonal antibodies (Rituximab) and CTLA4-Ig fusion proteins 
implicate a role for activated B cells and T cells in the pathology of RA (Edwards et al., 2004). 
In the case of CIA the anti-type II collagen antibodies produced are mainly of the IgG2a/c 
subclass, which have been shown to be increased at the peak of the disease (Cho et al., 2007). 
Furthermore, several reports have shown that the subclass of antibody produced during CIA can 
determine the outcome of the disease (Cho et al., 2007). Since results in this study showed a 
decreased incidence in SIGIRR-/- mice, the anti- type II collagen antibody levels were 
measured. The amounts of IgG1 and IgG2a/c antibodies produced in WT animals is 
characteristic for C57Bl/6 mice immunised with chicken collagen, as has been shown before 
(Inglis et al., 2007). However, SIGIRR-/- mice produce significantly less class IgG2a/c but 
similar levels of class IgG1 antibodies compared to WT mice 11 days after disease onset. 
Moreover, the decreased ratio of IgG2a/c to IgG1 implicates a swing from a Th1 to a Th2 
response in SIGIRR deficient animals, which could be responsible for a reduced incidence and 
severity of CIA observed in these animals. As the development of CIA is related to IgG2a/c 
levels (Cho et al., 2007) the less severe disease in SIGIRR deficient animals might be explained 
by the lower titres of this antibody subclass. A general defect in B cell activation does not seem 
to be the reason for the loss in IgG2a/c antibody production as purified B cells from naïve 
SIGIRR-/- mice show a significant increase in proliferation in response to IgM as well as LPS 
compared to WT mice. 
Since an intrinsic defect in the activation of B cells appeared unlikely and the fact that IgG2a/c 
production are a characteristic of Th1 activity, the nature of the T helper response in SIGIRR-/- 
mice was further investigated. SIGIRR deficient mice showed a reduction in IFNγ as well as 
IL-17 production but increased levels of IL-5 and IL-10 compared to WT cells. This cytokine 
profile may suggest a Th2 polarised immune response and at the same time a reduction in Th1 
and Th17 immunity. CIA is clearly considered to be a Th1 and/or Th17 cell driven disease 
(Cho et al., 2007). It is still under debate; however, whether Th1 and/or Th17 cells are the 
driving force in initiating RA. The importance of Th17 cells in RA pathology has been 
demonstrated in studies using IL-17 deficient mice as well as IL-17 blocking antibodies, which 
showed suppressed induction and severity in murine arthritis models (Koenders et al., 2005; 
Lubberts et al., 2004; Lubberts et al., 2005; Nakae et al., 2003). Similarly, mice lacking IL-23, 
which is necessary for Th17 development, are also protected from developing CIA (Murphy et 
al., 2003). Moreover, Th17 cells have been shown to be preferentially recruited to the inflamed 
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joint of mice and humans through the production of CCL20 by synovial fibroblasts in the 
arthritic joint (Hirota et al., 2007). However, other studies could not confirm an increase in 
Th17 cells in the joints of RA patients compared to healthy donors, while at the same time 
showing increased recruitment of Th1 cells to the inflamed joint (Yamada et al., 2007). These 
differences may as well be due to the model used and/or to the different disease stages 
investigated. In contrast to a Th1 and Th17 immune response, Th2 cells are considered to be 
protective for RA initiation and progression (Cho et al., 2007). The Th2 cytokines IL-4 and IL-
10 inhibit osteoclastogenesis and thereby the destruction of the bone while at the same time IL-
17 enhances osteoclastogenesis (Abu-Amer, 2001; Hong et al., 2000; Kotake et al., 1999). 
Moreover, the anti-inflammatory properties of IL-10 through suppressing pro-inflammatory 
cytokine production have been shown in CIA as well as other inflammatory diseases 
(Walmsley et al., 1996; Williams et al., 2004). Therefore, a reduction in Th1 as well as Th17 
immunity together with the induction of a Th2 polarised immune response might explain the 
reduced incidence and severity of CIA in SIGIRR deficient mice. 
This raises the question of why such an unexpected alteration in the adaptive immune response 
should occur, especially as SIGIRR has not been previously implicated in T cell function. To 
date SIGIRR is seen as a repressive molecule that inhibits TLR and IL-1R signalling by 
blocking access of the signalling adaptor MyD88 to the receptor (Qin et al., 2005). Our present 
understanding of the impact on the T cell compartment of the TLR/IL-1R family is still sparse. 
But what is known would suggest that de-repression of signalling would be pro-inflammatory: 
IL-18 drives IFNγ production (Okamura et al., 1995), whereas TLR8 (in humans) is 
suppressive to regulatory T cell function (Peng et al., 2005). However, recent advances in the 
understanding of ST2, another molecule belonging to the same family as SIGIRR, may provide 
an explanation. Similar to SIGIRR, ST2 is a family member of the TIR domain containing 
receptor family of IL-1Rs and TLRs (Li and Qin, 2005). ST2 is expressed as a soluble version, 
which is secreted, and as a membrane bound receptor, due to alternative splicing (Yanagisawa 
et al., 1993). It has been originally described as an orphan receptor specifically expressed on 
Th2 but not Th1 or Th17 cells and has been shown to be essential for Th2 development and 
function (Coyle et al., 1999; Lohning et al., 1999; Lohning et al., 1998; Townsend et al., 2000; 
Xu et al., 1998). Subsequently, its ligand, IL-33, has been described, which has the capability to 
drive Th2 associated cytokine expression in vivo as well as in vitro through initiating the 
recruitment of MyD88, IRAK1, IRAK4 and TRAF6 to ST2 (Schmitz et al., 2005). Results in 
this study showed that purified T cells from SIGIRR deficient mice increased the production of 
IL-5 in the presence of IL-33 compared to WT T cells. This effect is specific to IL-33 since its 
family member IL-1α does not induce increased T cell cytokine expression in SIGIRR deficient 
T cells. Furthermore, the induction of IL-5 production by IL-33 is dependent on MyD88 as T 
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cells lacking MyD88 do not increase their IL-5 expression in the presence of IL-33. Therefore, 
these results implicate SIGIRR as an inhibitor of IL-33 induced ST2 signalling, which is 
dependent on MyD88. As a consequence mice lacking SIGIRR show increased ST2 signalling, 
thereby skewing the T cell response towards Th2.  
In addition to its role as a Th2 marker, membrane bound ST2 has been described to inhibit TLR 
signalling in murine macrophages and HEK293 cells (Brint et al., 2004). Interestingly, the 
soluble version of ST2 has already been examined as a therapy in the CIA model (Leung et al., 
2004). It showed significant efficacy in reducing CIA after disease onset, which was ascribed to 
blocking macrophage activation through an unknown mechanism (Leung et al., 2004). 
However, its effect on T cells was not further investigated. In a murine asthma model treatment 
with soluble ST2 reduced the production of IL-4, IL-5 and IL-13 by IL-33 stimulated 
splenocytes (Hayakawa et al., 2007). It could be demonstrated that soluble ST2 binds IL-33, 
thereby acting as an antagonist to the membrane bound ST2 (Hayakawa et al., 2007). These 
results imply that soluble ST2 is an inhibitor of IL-33 signalling in T cells as well as TLR 
signalling in macrophages through different mechanisms. Interestingly, IL-33 signalling has 
recently been shown to be protective in other inflammatory conditions. Administration of IL-33 
to atherosclerotic ApoE-/- mice has been shown to reduce disease severity (Miller et al., 2008). 
Similar to soluble ST2, our results describe SIGIRR as a novel inhibitor of membrane bound 
ST2 signalling in T cells while at the same time being an inhibitor of TLR signalling in 
macrophages and DCs. SIGIRR inhibits membrane bound ST2 through blocking access to the 
receptor for downstream signalling transducers, e.g. MyD88. This inhibitory mechanism 
resembles the mechanism used by SIGIRR to inhibit IL-1R and TLR signalling (Qin et al., 
2005). 
The observation of lower incidence and less severe CIA in SIGIRR-/- mice is counterintuitive 
since SIGIRR is an inhibitor of IL-1R as well as TLR signalling (Garlanda et al., 2004; Wald et 
al., 2003). This present study demonstrates a pre-eminence of a pro-inflammatory role on the 
adaptive immune response, through the suppression of Th17 development, over an expected 
pro-inflammatory phenotype on innate immune cells, by SIGIRR (Figure 5.19). Based on the 
human in vitro data, where SIGIRR over-expression inhibits the spontaneous release of 
cytokines in an established disease model we predict that if the adaptive immune response is 
bypassed during CIA induction, a more severe pathology in SIGIRR deficient mice will be 
observed. Therefore, future work will investigate models of arthritis, which bypass the 
initiation stage of the disease and directly depend on TLR stimulation, e.g. streptococcal cell 
wall induced joint inflammation (Joosten et al., 2008). Overall these data highlight the 
intricacies of the relationship between the adaptive and innate immune systems in the 
development and progression of a complex disease such as RA. 
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6.1 Concluding Discussion 
RA is a complex chronic inflammatory disease involving the innate as well as the adaptive 
immune systems. Multiple factors play a role in the initiation and progression of the disease. 
Genetic risk factors are known to contribute to the susceptibility to RA, as do environmental 
factors such as smoking, infections and the release of danger signals (Krause et al., 1996; 
Silman et al., 1996; Stastny, 1978). However, it is still unclear whether these factors contribute 
to the initiation of the disease or are involved in acceleration of pre-existing conditions leading 
to disease progression. 
The initiation of an inflammatory reaction in response to infection is mediated via the 
recognition of microbial products by PRRs. TLRs are the most well established PRR family 
capable of inducing signalling pathways, which ultimately result in the production of pro-
inflammatory mediators and the induction of the adaptive immune response. This study was 
based on the hypothesis that TLRs might participate in the pathogenesis of RA, either through 
the recognition of exogenous pathogenic material, or the detection of endogenous danger 
signals released as a consequence of tissue damage, cell necrosis or infections. 
Our current understanding of TLR function and signalling pathways has emerged from a 
combination of research in gene targeted mice and immortalised cell lines. At present our 
knowledge of the function of TLRs in humans is limited partly as a consequence of multiple 
genetic differences between humans, which cannot be directly related to well controlled 
experiments in inbred mice. Evidence for a role of TLRs in human disease is largely based on 
the analysis of polymorphisms of TLRs themselves or downstream signalling mediators 
(Davidson et al., 2006; Ku et al., 2007; Puel et al., 2004; Schroder and Schumann, 2005). As I 
commenced my studies, the details of TLR biology in humans were obscure. Therefore, the aim 
of this thesis was to examine the function of TLR signalling as well as aspects of its regulation 
in primary human cells, such as DCs and macrophages, with the goal to translate it into disease 
relevant systems to assess therapeutic targets. 
At the start of this project the four TLR adaptor proteins MyD88, Mal, TRAM and TRIF as 
well as the signalling pathways induced by them had been characterised in gene targeted mice 
and cell lines. Experiments performed in our laboratory indicated, however, that there are 
differences not only between those systems and primary human cells, but also between cells of 
myeloid- and non-myeloid origin with regards to TLR adaptor usage. For example, while the 
expression of a MyD88 dominant negative construct in HUVECs and synovial fibroblasts 
reflected the results obtained in cell lines with the inhibition TLR4 and IL-1R but not TLR3 or 
TNFα signalling, the expression of this construct in macrophages had no effect on TLR4 
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signalling. Therefore, the first objective of this study was to assess the utilisation of TLR 
adaptors in another myeloid cell, the DC. My results in chapter 3 demonstrated that the 
expression of a wild-type TIR domain results in the activation of human monocyte 
derived DCs without further stimuli. This observation does not seem to be restricted to 
humans, as BMDCs are also activated by MyD88 dn over-expression. Several other groups 
have shown that TIR domains are able to block TLR signalling, similar to what I observed in 
RASF and macrophages, but none of these studies specifically investigated DCs (Cirl et al., 
2008; Newman et al., 2006; Stack et al., 2005). 
The question still remains of how a TIR domain activates DCs, and why it seems to be specific 
to DCs. DCs are highly specialised innate immune cells and are able to activate the potent 
adaptive immune response. Because of this DCs might require special regulation in order to 
control excessive inflammation. The model of a constitutive inhibitory signal, specific to DCs 
and dependent on MyD88, I proposed in chapter 3, would provide such a mechanism. This 
would keep immature DCs inactive until a high enough threshold of pathogens is reached or an 
infection is not cleared quickly enough. Evidence for such DC specific regulatory mechanisms 
emerged recently. DC immuno-receptor (Dcir), a C-type lectin family member, the absence of 
which leads to exacerbated CIA in mice, is mainly expressed in DCs (Fujikado et al., 2008). 
Furthermore, Dcir deficient mice do show an excessively expanded DC population following 
CIA immunisation, suggesting that an inhibitory role for Dcir, which would be mainly DC 
specific may play a similar role. Moreover, pathogens have evolved sophisticated molecular 
strategies to subvert the host defense (Cirl et al., 2008). One of them is the expression of TIR 
domain orthologs by certain strains of Escherichia coli termed TIR domain containing proteins 
(Tcp) (Cirl et al., 2008). In order to investigate the mechanism underlying the constitutive 
inhibitory signal in DCs it will be interesting to test if the administration of Tcps leads to the 
activation of DCs while having no effect on macrophages. Furthermore, immunoprecipitation 
studies will be necessary to identify MyD88 interacting proteins, which are specific to DCs. 
A possible application for the DC specific activation by TIR domains has recently been shown 
by a colleague at the KIR. Numerous signal transducing molecules have been studied for their 
properties as an adjuvant during vaccination. One of those molecules is NF-κB inducing kinase 
(NIK), which enhances the immune response when over-expressed by activating NF-κB and 
thereby possibly increases the efficacy of vaccinations (Andreakos et al., 2006). A possible 
advantage of MyD88 dn as an adjuvant compared to NIK would be its DC specific activation. 
Mice vaccinated with nucleoprotein and MyD88 dn showed similar viral clearance and weight 
loss in response to influenza x-31 infection compared to mice vaccinated without MyD88 dn 
but increased infiltration of CD8+ T cells into the lung. This would suggest that MyD88 dn 
increases the recruitment of CD8+ T cells possibly through increased DC activation (manuscript 
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in preparation). Moreover, infiltration of other immune cells into the lung as well as 
bronchoalveolar spaces was reduced, indicating a specific effect on T cell recruitment. 
Therefore, using MyD88 dn, or possibly other wild-type TIR domain constructs, as an adjuvant 
in influenza vaccination has the possible advantage of increasing a T cell response while at the 
same time reducing inflammation in the lung itself and thereby reducing tissue damage, which 
is the major concern during influenza infection. 
The hypothesis of a DC specific inhibitory signal allowed several predictions: The inhibitory 
receptor must be expressed in immature DCs but not in macrophages and MyD88 must be 
bound to the inhibitory receptor in a constitutive manner most likely through TIR-TIR 
interactions. This would require a receptor containing a TIR domain and a high degree of 
versatility of MyD88, functioning as a signal transducer as well as inhibitor. Indeed, a recent 
report described an inhibitory function of MyD88. This investigation showed that MyD88 is S-
nitrosylated on a specific cysteine residue in its TIR domain, which results in dysfunctional 
translocation of MyD88 to the cell membrane and the inhibition of TLR4 signalling (Into et al., 
2008). Interestingly, only two other TIR domain containing molecules contain this cysteine 
residue: Mal and SIGIRR (Into et al., 2008). While there are numerous TLR inhibitors 
described, only SIGIRR fits all predictions, having been shown to be expressed in DCs and not 
macrophages and being a TIR domain containing inhibitor of TLRs through binding MyD88. 
This has been shown in mice and cell lines. Therefore, the role and function of SIGIRR in TLR 
signalling in human DCs was investigated in chapter 4. However, SIGIRR can be excluded as a 
DC specific TLR inhibitor as SIGIRR mRNA and protein is expressed by both human DCs 
and macrophages. At the time of this study no signalling functions for SIGIRR has been 
described and the mechanism of TLR inhibition by SIGIRR has not been conclusively shown in 
primary human cells. Therefore, SIGIRR was further investigated in human DCs and 
macrophages. Over-expression of SIGIRR as well as siRNA knock down showed that SIGIRR 
is an inhibitor of the MyD88- and TRIF-dependent TLR signalling pathway in human 
DCs and macrophages.  
The current hypothesis is that SIGIRR inhibits TLR4 signalling by transiently blocking access 
for downstream signalling transducers, including MyD88 (Qin et al., 2005). While the results in 
chapter 4 confirm associations between SIGIRR and MyD88 in DCs through TIR domain 
interactions, these interactions are constitutive without a stimulus present. However, the 
possibility that the interaction observed in this study may be artificial can not be excluded, 
since both proteins were over-expressed. Nonetheless, these results suggest that SIGIRR acts as 
a brake on TLR signalling, thereby increasing the amount of stimuli necessary to activate DCs 
and macrophages. Another possibility could be that SIGIRR is a signal transducing receptor 
using MyD88 as its adaptor, similar to its family members ST2, IL-1R and TLRs. Although no 
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general ligand for SIGIRR has been conclusively described so far, a recent report indicates the 
existence of a SIGIRR ligand. Costelloe and colleagues described that IL-1F5-induced IL-4 
production in the brain is dependent on SIGIRR. However, so far this has not been observed in 
other systems and needs to be further investigated (Costelloe et al., 2008). The hypothesis of 
SIGIRR transducing a signal is further supported by similarities with its family member ST2. 
Similar to SIGIRR, ST2 was described to be an orphan receptor and TLR inhibitor by 
sequestering MyD88 and Mal in macrophages (Brint et al., 2004). However, subsequently its 
ligand, IL-33, has been described (Schmitz et al., 2005). Therefore, cell specific functions can 
not be excluded in the search for the role of SIGIRR. Further investigations will be necessary 
and will include the development of the SIGIRR ecto-domain as a way to investigate its 
possible ligand as well as immunoprecipitation of endogenous SIGIRR with specific antibodies 
to define interacting proteins. Moreover, the effects of post-translational modifications, 
including nitrosylations and glycosylations, on SIGIRR function need to be further examined 
by using adenoviral gene transfer of single nucleotide mutated constructs of SIGIRR. 
Following on from the observation of SIGIRR being an inhibitor of TLR signalling this study 
further investigated the role of SIGIRR in RA disease models. Currently, the most widespread 
and successful RA therapeutics are the biologicals, Infliximab/Enbrel/Humera, (Feldmann and 
Steinman, 2005), which block TNFα, a cytokine produced by innate immune cells such as 
macrophages (Feldmann et al., 1996). Consequently, there has been a great deal of interest in 
elucidating the pathways driving the production of TNFα in RA. An attractive candidate is the 
TLR family. There is increasing evidence that TLRs can also respond to endogenous ligands 
produced during tissue damage associated with chronic inflammation (Drexler et al., 2006). 
This hypothesis is supported by studies showing the upregulated expression of TLRs in human 
RA synovium (Roelofs et al., 2005) and the presence of endogenous TLR ligands in RA 
synovial fluid (Brentano et al., 2005a; Drexler et al., 2006; Sacre et al., 2007b). Various murine 
models of disease have implicated TLR4 (Abdollahi-Roodsaz et al., 2008) or TLR9 (Asagiri et 
al., 2008; Leadbetter et al., 2002) in RA pathogenesis. Given the potential of TLRs in driving 
RA, I further investigated the role of SIGIRR in suppressing signalling by the TLR and IL-1R 
families in RA synovial membranes and CIA. 
Previous studies have shown that conditioned media from RA synovial membranes is able to 
activate human macrophages in a MyD88 and Mal dependent manner. This would support the 
hypothesis of an endogenous TLR ligand driving cytokine production in that tissue (Sacre et al., 
2007a). Furthermore, the dependence of spontaneous cytokine production by RA synovial 
membranes on MyD88 and Mal has been demonstrated (Sacre et al., 2007a). Therefore, I 
hypothesise that SIGIRR is able to inhibit spontaneous cytokine release by RA synovial 
membranes through interfering with TLR signalling pathways. This study shows that over-
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expression of SIGIRR inhibits the spontaneous production of IL-6 and TNFα in RA 
synovial membranes, most likely by sequestering MyD88/Mal. 
Given this inhibitory function of SIGIRR I wanted to further elucidate the function of SIGIRR 
in vivo. Therefore, SIGIRR deficient mice were immunised with CIA. Contrary to my 
expectations based on the previous results, SIGIRR deficient animals show decreased 
incidence and CIA pathology. This is most likely due to SIGIRR regulating the T cell 
response. The cytokine profile observed in SIGIRR deficient mice following CIA induction 
indicates a reduction in Th1 and Th17 immunity and at the same time a Th2 polarised immune 
response. CIA is clearly considered to be a Th1 and/or Th17 cell driven disease (Cho et al., 
2007). In contrast, Th2 immunity is considered to be protective for RA initiation and 
progression (Cho et al., 2007). Therefore, a reduction in Th1 as well as Th17 immunity together 
with an induction of a Th2 polarised immune response leads to a reduction in IgG2a/c antibody 
production. Taken together these studies might explain the reduced incidence and severity of 
CIA in SIGIRR deficient mice.  
Given this unexpected alteration of the adaptive immune response the question arises as to how 
SIGIRR can influence T cell function. Present studies indicate a pro-inflammatory role of 
TLR/IL-1R signalling on the T cell compartment. IFNγ production has been shown to be 
induced by IL-18 (Okamura et al., 1995) and, more recently, stimulation of human TLR8 has 
been demonstrated to suppress regulatory T cell function (Peng et al., 2005). Therefore, the 
attention of this study focused on ST2, which has been known for a long time to drive Th2 
differentiation (Coyle et al., 1999; Lohning et al., 1998; Moritz et al., 1998; Townsend et al., 
2000; Xu et al., 1998). The IL-1R family member ST2 has been described to be specifically 
expressed on Th2 but not on Th1 or Th17 cells (Nakae et al., 2007). Data published recently by 
Miller and colleagues, which show a reduction in atherosclerosis severity as a result of IL-33 
administration, further strengthens the hypothesis that altered ST2 signalling can influence the 
pathogenesis of inflammatory diseases (Miller et al., 2008). 
The reduced incidence and severity of CIA in SIGIRR-/- mice is paradoxical since SIGIRR is an 
inhibitor of IL-1R and TLR signalling (Garlanda et al., 2004; Wald et al., 2003). However, data 
presented here have uncovered a role for SIGIRR in regulating the Th1/Th17-Th2 balance 
through inhibiting the IL-33/ST2 signalling pathway. Since IL-33/ST2 signalling depends 
on MyD88, the mode of action of SIGIRR inhibiting ST2 signalling might be due to MyD88 
sequestration/blocking as observed in case of TLR/IL-1R signalling (Qin et al., 2005). While 
the priming of CD4+ T cells with IL-33 suggests a direct influence of SIGIRR on Th2 
development, other indirect mechanisms may exist. One such possible mechanism includes 
TSLP (thymic stromal lymphopoetin), an IL-7 like cytokine secreted by epithelial cells that 
Chapter 6 Concluding Discussion  
194 
 
primes DCs to drive Th2 polarisation (Liu, 2006). A recent study by Humphreys et al. 
demonstrated that IL-33 is a strong inducer of TSLP in epithelial cells (Humphreys et al., 2008 
3103). Therefore, SIGIRR could act indirectly on T cell development by regulating IL-33 
signalling in epithelial cells and thereby influencing the secretion of mediators such as TSLP. 
The results presented in this study suggest an inhibitory effect of SIGIRR on Th2 cells. 
However, SIGIRR may also be necessary for Th17 development. A recent study provides 
evidence for an involvement of SIGIRR on Th17 polarisation. Bozza and colleagues showed 
that Candida albicans infections in SIGIRR deficient mice elicit an enhanced Th17 response 
due to increased IL-1 and IL-23 production by DCs (Bozza et al., 2008). These results would 
suggest that SIGIRR has an inhibitory function on Th17 development by regulating IL-1R 
signalling in DCs. This may suggest that the regulation of T cell development by SIGIRR and 
the outcome of T cell development depend on the system used and the predominance of 
cytokine pathways specific to these systems. 
Based on results obtained by over-expression of SIGIRR in RA synovial membranes, I 
hypothesise that if the adaptive immune response is bypassed during CIA induction, a more 
severe pathology in SIGIRR deficient mice will be observed. Therefore, streptococcal cell wall 
induced joint inflammation as well as antibody induced arthritis trials will be necessary to test 
this hypothesis (Joosten et al., 2008). Furthermore, the regulation of ST2 signalling by SIGIRR 
needs to be further investigated by administration of IL-33 to CIA induced mice, which should 
resemble the SIGIRR deficient phenotype. Moreover, in vitro experiments, including a time 
course of IL-33 stimulation of SIGIRR deficient T cells using NFAT as a readout, will be 
necessary to further elucidate the inhibitory function of SIGIRR on ST2. Furthermore, there is 
the possibility of other pathways affected by SIGIRR, which have not been explored in this 
present study. 
The results presented in this thesis have revealed the complexities of TLR signal transduction in 
primary human cells. While these observations have raised the question of why these 
differences exist between cell types, they highlight the importance of studying signalling 
pathways in relevant cell types. In order to fully understand the roles TLRs have in the human 
innate as well as adaptive immune response, it is essential to further investigate these 
differences. This knowledge could potentially lead to the development of new and more 
specific approaches for the treatment of inflammatory diseases including RA. 
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Key differences in TLR3/poly I:C signaling and cytokine induction by human
primary cells: a phenomenon absent from murine cell systems
Anna M. Lundberg,1 Stefan K. Drexler,1 Claudia Monaco,1 Lynn M. Williams,1 Sandra M. Sacre,1 Marc Feldmann,1
and Brian M. Foxwell1
1Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College of Science, Technology, and Medicine, London, United Kingdom
TLR3 recognizes double-stranded RNA, a
product associated with viral infections.
Many details of TLR3-induced mecha-
nisms have emerged from gene-targeted
mice or inhibition studies in transformed
cell lines. However, the pathways acti-
vated in human immune cells or cells
from disease tissue are less well under-
stood. We have investigated TLR3-
induced mechanisms of human primary
cells of the innate immune system, includ-
ing dendritic cells (DCs), macrophages
(MØs), endothelial cells (ECs), and syno-
vial fibroblasts isolated from rheumatoid
arthritis joint tissue (RA-SFs). Here, we
report that while these cells all express
TLR3, they differ substantially in their
response to TLR3 stimulation. The key
antiviral response chemokine IP-10 was
produced by all cell types, while DCs and
MØs failed to produce the proinflamma-
tory cytokines TNF and IL-6. Unexpect-
edly, TNF was found secreted by TLR3-
stimulated RA-SF. Furthermore, TLR3
stimulation did not activate NFB, MAPKs,
or IRF-3 in DCs and MØs, but was able to
do so in ECs and RA-SF. These findings
were specific for human cells, thereby
revealing a complexity not previously ex-
pected. This is the first report of such cell
type– and species-specific response for
any TLR stimulation and helps to explain
important difficulties in correlating mu-
rine models of inflammatory diseases and
human inflammation. (Blood. 2007;110:
3245-3252)
© 2007 by The American Society of Hematology
Introduction
The discovery of Toll-like receptors (TLRs) uncovered a key
mechanism used by the immune system to detect infections and
tissue damage.1 There are 10 known human TLRs that recognize
“molecular patterns” produced as a result of pathogenic infections.
TLR3 is a member of this receptor family that is activated by
double-stranded RNA (dsRNA),2 an intermediate formed by most
viruses during their replication. The viral dsRNA functions as a
danger signal released in the extracellular environment from dying
virally infected cells, alerting inflammatory cells and contributing
to systemic disease.3,4 In addition to microbial products, there is
growing evidence that TLRs also recognize endogenous ligands
found at sites of tissue destruction and cell death,5 and TLR3 has
been shown to recognize mRNA released from dying cells.6
Although there are concerns that some of the data on endogenous
ligands could be a result of contamination with microbial products,
the detection of endogenous ligands would be useful in alerting the
host of the presence of tissue injury induced by infection or other
means. However, there is a potential drawback in that the same
endogenous ligands are also found at sites of chronic inflammation
and could further drive the inflammatory response in a TLR-
dependent manner. There is increasing evidence that TLRs could be
associated with chronic inflammatory diseases such as rheumatoid
arthritis (RA).5,7 In this context, TLR3 expression is increased in
the RA synovium,8,9 and the presence of TLR3 ligands might affect
several aspects of the disease by acting on cells within the joint. In
support of this, dsRNA can induce joint inflammation and cause
arthritis in a murine disease model.10
Given the importance of TLRs in regulation of both positive
and negative aspects of the immune response, there has been
much interest in how their activation is controlled. The signaling
pathways initiated by most TLRs are regulated by the adaptor
protein MyD88 (myeloid differentiation factor 88), with some
variations by the additional recruitment of MAL (MyD88
adaptor-like), TRAM (TRIF-related adaptor molecule), and
TRIF (TIR-domain–containing adaptor inducing interferon ).11
However, TLR3 is unique since it does not use MyD88 but
instead recruits only TRIF, which mediates the activation of
NFB and IRF-3. Activation of these pathways results in
expression of various inflammatory mediators including the
cytokines tumor necrosis factor  (TNF) and interleukin-6
(IL-6) and the chemokines IL-8 and IFN-inducible-10 (IP-10).
However, as for most TLRs, little is known about TLR3-induced
signaling and cellular responses in human primary cells. Previ-
ous findings are mainly the result of studies in murine cells,
especially derived from knockout animals, or immortalized cell
lines, which are all model systems of the human immune
system. Furthermore, since many cell lines are of tumor origin,
it is unclear if their responses are representative of the normal
innate immune response. We therefore felt that it was important
to define responses induced by TLR3 in human cell types, and in
particular in cells involved in chronic inflammatory disease such
as RA.
The findings presented here challenge the current beliefs that
signaling pathways initiated by the viral response molecule dsRNA
are mediated by NFB, MAPK, and IRF-3 in all cell types. Our
Submitted February 7, 2007; accepted July 19, 2007. Prepublished online as
Blood First Edition paper, July 27, 2007; DOI 10.1182/blood-2007-02-072934.
The online version of this article contains a data supplement.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked ‘‘advertisement’’ in accordance with 18 USC section 1734.
© 2007 by The American Society of Hematology
3245BLOOD, 1 NOVEMBER 2007  VOLUME 110, NUMBER 9
 For personal use only. at IMPERIAL COLLEGE LONDON on April 30, 2008. www.bloodjournal.orgFrom 
results highlight that responses induced by dsRNA/TLR3 differ
between human cells of separate lineages, as well as between
mouse and human. These are crucial findings for increasing the
understanding of the human immune system and the inflammatory
response to infection.
Materials and methods
Ethical approval for the use of human materials was granted by the
Riverside Research Ethics Committee, London, United Kingdom.
Reagents
Human recombinant granulocyte-macrophage colony-stimulating factor
(GM-CSF) was generously provided by Beheringwerke (Marburg, Ger-
many) and human recombinant IL-4 was from Novartis Pharma (Basel,
Switzerland). Human recombinant macrophage colony-stimulating factor
(M-CSF) and human IL-1 were from Genetics Institute (Madison, NJ).
Escherichia coli (E coli) LPS was obtained from Sigma (St Louis, MO) and
polyinosinic-polycytidylic acid (poly I:C) was from Amersham Life
Science (Buckinghamshire, United Kingdom). Mouse serum was purchased
from Sigma (St Louis, MO); anti–TLR3-FITC (clone 40C1285.6) (raised
against a peptide corresponding to AA 54–71 in the LRR motifs of the
TLR3 receptor extracellular domain) was from Imgenex (Cambridge,
United Kingdom); and the corresponding IgG1-FITC–labeled isotype
control was from Becton Dickinson (Oxford, United Kingdom). Protein
inhibitor cocktail and chloroquine were purchased from Sigma (Poole,
United Kingdom). The IRF-3 antibody was obtained from Santa Cruz
Biotechnology (Santa Cruz, CA); anti-HA, from Covance (Denver, PA);
and anti-Flag, from Sigma (Poole, United Kingdom).
Cell isolation and culture conditions
Human peripheral blood mononuclear cells were isolated and differentiated
for 5 to 7 days with 50 ng/mL GM-CSF, and 10 ng/mL IL-4 for dendritic
cells (DCs), and for 3 to 4 days with 100 ng/mL M-CSF for macrophages
(MØs), as previously described.12,13 When matured, DCs express the
specific marker CD83 and MØs express varied levels of CD14. During
assays, both cells were cultured at 106 cells/mL in RPMI1640 5% FCS,
1% penicillin/streptomycin. Rheumatoid arthritis synovial fibroblasts (RA-
SFs) and human umbilical vein endothelial cells (HUVECs) were isolated
as previously described.14,15 RA-SFs express vimentin at more than 95%
and were cultured at 105 cells/mL in DMEM 10% FCS, 100 U/mL
penicillin/streptomycin, and 200 g/mL indomethacin (Sigma, Poole,
United Kingdom); HUVECs were 99.19% pure16 and were cultured at
105 cells/mL on gelatin in RPMI1640, 10% FCS, 10% newborn calf serum
(Gibco, Auckland, NZ), 1% penicillin/streptomycin, 15 g/mL endothelial
growth supplement (Sigma, Poole, United Kingdom), and 50 IU/mL
heparin (CD Pharmaceutical, Wrexham, United Kingdom). Murine bone
marrow DCs were derived as previously described17 and cultured at
105 cells/mL in DMEM 5% FCS and 1% penicillin/streptomycin.
Reverse transcriptase–polymerase chain reaction
RNA was isolated using the Qiagen RNA Blood isolation kit (Qiagen,
Hilden, Germany). Total RNA was reverse transcribed with Superscript II
RNase H reverse transcriptase (Gibco, Paisley, United Kingdom) and
oligo (dT) primer. The primers used were as follows: 5-GCAAACACAAG-
CATTCGGAATCT-3 and 5-TTGAAGGCTTGGGACCAAGGCA-3 for
TLR3; 5-TGGATACGTTTCCTTATAAG-3 and 5-GAAATGGAGGCAC-
CCCTTC-3 for TLR4; 5-GAAGCTCAGAAGCAGTATTGGTC-3 and
5-GGTTGGTGTAGGATGACAAACTCC-3 for MD-2. Amplification was
performed in a Dyad polymerase chain reaction (PCR) machine (MJ Instru-
ments, Watertown, MA) and consisted of 35 cycles with the annealing
temperature 62°C for TLR3 and 40 cycles with the annealing temperature
54°C for TLR4 and MD-2.
Flow cytometry
Intracellular and extracellular TLR3 expressions were determined using
flow cytometry. Cells fixed with 2% paraformaldehyde were either left
untreated or permeabilized with 1% saponin. The cells were incubated with
mouse antihuman TLR3-FITC or isotype control for 30 minutes on ice in
the presence of 1% mouse serum. The samples were analyzed on a Becton
Dickinson LSR flow cytometer.
Cytokine analysis by enzyme-linked immunosorbent assay
Supernatants were harvested after 18-hour stimulation with LPS (100 ng/
mL) or poly I:C (20 g/mL). Enzyme-linked immunosorbent assay
(ELISA) reagents for measurement of human TNF and IL-6 were from
Pharmingen (San Diego, CA) and human IP-10, murine IL-6, and murine
TNF reagents were obtained from R&D Systems (Abington, United
Kingdom). Absorbance of 450 nm was measured on a spectrophotometric
ELISA plate reader (Labsystems Multiscan Biochromic, Cambridge, United
Kingdom) using the Ascent version 2.4.2 software program (Thermo
Labsystems, Cambridge, United Kingdom). Results are expressed as the
mean concentration of triplicate cultures plus or minus SD.
Mixed lymphocyte reaction
Human DCs were stimulated and cultured in graded doses with 1  105
allogeneic elutriated T cells in quadruplicate. Proliferation was measured on
day 5 by thymidine incorporation after a 16-hour pulse with [3H] thymidine
(0.5 Ci/well [0.0185 MBq]; Amersham Life Science).
TaqMan real-time PCR
Total RNA was extracted using RNeasy Kit (Qiagen) and PCR was
performed using an ABI PRISM 7700 Sequence Detection System and
predeveloped assay reagents (PerkinElmer Applied Biosystems, War-
rington, United Kingdom). The one-step real-time PCRs were run for
40 cycles, and all quantitations were normalized to GAPDH. Relative
quantitation was performed using the comparative Ct method according
to the manufacturer’s instructions.
NFB luciferase reporter assay
Cells were infected for 1 to 2 hours in serum-free media with a recombinant
replication-deficient adenovirus containing an NFB luciferase reporter
gene, which is a modification of the pNFB-Reporter vector (BD Clontech,
Palo Alto, CA) and was kindly provided by Dr Paul McCray (University of
Iowa). DCs and MØs were infected at 100:1 multiplicity of infection (moi);
ECs, at 100:1 at 60% confluence; and RA-SFs, at 500:1, resulting in more
than 90% infection efficiencies, as shown by us and others.12,13,18,19 The
cells were cultured for 24 hours prior to 6-hour stimulation. The luciferase
assay was performed as previously described.20
Western blotting
Nuclear protein fractions were extracted as previously described,21 and
whole-cell lysates were prepared in 1% Triton X100, 10 mM Tris-HCl
(pH 7.6), 150 mM NaCl, 1 mM EDTA, 0.1 mM Na3VO4, 5 mM NaF, 1 mM
DTT, and 1  protein inhibitor cocktail. Equal amounts of proteins were
separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE) on a 10% polyacrylamide gel and transferred to a PVDF
membrane for Western blotting.
Limulus assay
The endotoxin content in all reagents was measured with the Limulus assay
(BioWhittaker, Wokingham, United Kingdom) according to the manufactur-
er’s instruction. Only batches of poly I:C with no detectable levels of
endotoxin were used in this study.
Statistical analyses
Mean and standard deviation (SD) were calculated using GraphPad Prism
version 3.02 (GraphPad Software, San Diego, CA).
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Results
Analysis of TLR3 expression on human immune cells
The effects of TLR3 stimulation on human immune cells were
analyzed due to their key roles in infectious diseases and acute
as well as chronic inflammation. Professional immune cells such
as human primary dendritic cells (DCs) and macrophages
(MØs), and nonprofessional immune cells such as endothelial
cells (ECs) and synovial fibroblasts from RA disease tissue
(RA-SFs) were examined. TLR3 expression was detected at the
RNA level in all the cell types studied (Figure 1A). By
fluorescence-activated cell sorting (FACS), a proportion of the
cells was shown to express TLR3 extracellularly, whereas a
higher level of TLR3 was found expressed intracellularly in all
cell types (Figure 1B).
Differential induction of proinflammatory and interferon
response cytokines by TLR3 stimulation
To evaluate the responses of TLR3 stimulation, the effects of
poly I:C treatment on cytokine production by the different
human immune cells were examined. The TLR4 ligand LPS was
used as a control stimulus, and, as shown in Figure 1A, all cell
types studied also express TLR4 and MD-2. In murine cells,
LPS induces similar pathways as dsRNA, leading to production
of proinflammatory cytokines such as IL-6 and TNF, as well as
expression of IFN-regulated genes (IRGs), such as the chemo-
kine IP-10.2,22 As predicted, poly I:C induced IP-10 production
from DCs to similar levels as LPS-stimulated cells (Figure 2A).
However unlike LPS, poly I:C did not induce TNF, IL-6
(Figure 2A), or IL-8 (data not shown) in human DCs. This was
not due to production of the anti-inflammatory cytokine IL-10,
since it was not induced by poly I:C, whereas IL-10 was
produced after LPS stimulation (Figure S1, available on the
Blood website; see the Supplemental Materials link at the top of
the online article). The induction of IP-10 but not TNF or IL-6
was repeated in poly I:C–stimulated MØs (Figure 2A). This
effect was specific for human cells, since TNF or IL-6 was
produced by murine DCs after poly I:C stimulation (Figure 2B),
confirming previous studies.2,22 As poly I:C was described by
another group to induce TNF and IL-6 mRNA in human DCs,23
we investigated whether stimulation with poly I:C could in-
crease TNF and IL-6 mRNA levels in the absence of increased
protein expression. However, studies of mRNA expression
confirmed our protein studies with poly I:C inducing very little,
if any, TNF and IL-6 mRNA, whereas LPS caused high mRNA
levels of both cytokines (Figure 2C). In addition, we could
detect type I IFN from both poly I:C– and LPS-stimulated
human DCs (data not shown). Stimulation of human DCs with
poly I:C was also previously shown to induce DC activation and
functional maturation.24-26 We could confirm these findings,
since poly I:C stimulation of human DCs resulted in increased
ability to induce an allogenic MLR (Figure 2D) and up-
regulation of the costimulatory markers CD80 and CD86 and the
maturation markers HLA-DR and CD83 (Figure 2D).
Given these unexpected findings in human primary DCs and
MØs, we examined the responses to poly I:C in ECs, which was
previously shown to produce IL-6 mRNA and adhesion molecules
after poly I:C stimulation.27,28 In addition, we analyzed the
responses in RA-SFs, which have also been shown to respond to
poly I:C treatment.29-31 Stimulation of ECs with poly I:C induced
IP-10 secretion, whereas no substantial production could be
observed after LPS treatment (Figure 2E). Furthermore, poly I:C
stimulation of ECs led to the production of IL-6 and IL-8, at levels
comparable with LPS (Figure 2E and data not shown). Similar
results were also observed for poly I:C–stimulated RA-SFs (Figure
2E). An interesting observation made in this study was that poly I:C
could induce TNF secretion by human RA-SFs (Figure 2F). This
effect was specific to poly I:C since TNF levels could not be
detected after LPS stimulation (Figure 2F). It was also found
specific for RA-SF, since poly I:C–stimulated human skin fibro-
blasts (HSFs) produced only IL-6 and not TNF (data not shown).
This is the first report describing the ability of a ligand to induce
TNF production from a human fibroblast population. Overall,
these results indicated that responses induced by poly I:C in human
cells differed depending on the cell lineage and can be divided into
response induced by myeloid cells (DCs and MØs) and nonmy-
eloid cells (ECs and RA-SFs).
Poly I:C stimulation was previously shown to be blocked by
inhibitors of endosomal maturation,32,33 suggesting that the TLR3
signaling is initiated intracellularly. To address this issue, we
investigated if the cell type–specific difference was the result of
TLR3 activation mediated from different locations in myeloid and
nonmyeloid cells. However, in the presence of chloroquine, an
inhibitor of endosomal acidification, IP-10 production was inhib-
ited in both DCs and RA-SFs (Figure 3). This suggests that cells of
both lineages use the intracellular TLR3 and that the distribution of
the receptor is not the cause of these variations.
Cell lineage–specific activation of NFB and MAPKs upon
TLR3 stimulation
The finding that poly I:C induces only proinflammatory cytokines
in certain cell types prompted the examination of downstream
signaling pathways. NFB is involved in regulating TNF and
IL-6 expression, and previous studies have claimed that dsRNA
stimulation can activate NFB.2,34-39 We examined if the cell
Figure 1. TLR3 is expressed on all cell types used in this study. Human DCs
were generated from peripheral blood monocytes after 5- to 7-day culture in the
presence of 10 ng/mL IL-4 and 50 ng/mL GM-CSF. MØs were differentiated from
peripheral blood monocytes for 3 to 4 days in the presence of 100 ng/mL M-CSF. ECs
were isolated from human umbilical veins and were used at passages 2 to 3.
Fibroblasts were isolated from synovial tissue from RA patients undergoing joint
replacement. (A) Total RNA was isolated from each cell type and 1 g was subjected
to reverse transcriptase-PCR and analyzed for TLR3, TLR4, MD-2, or GAPDH
expression with PCR.  indicates PCR-negative control. (B) DCs, MØs, ECs, and
RA-SFs were analyzed for both intracellular and membrane-bound TLR3 by flow
cytometry. Cells stained with isotype control (filled histograms) or anti–TLR3-FITC
antibody (open black histograms) are shown.
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type–specific differences observed with cytokine production were
due to a variation in NFB regulation. Interestingly, in DCs and
MØs, poly I:C was unable to activate NFB, whereas LPS was a
potent activator, as expected (Figure 4A). In contrast, NFB
transcriptional activity in ECs and RA-SFs was induced by poly I:C
to levels comparable with LPS stimulation (Figure 4A). Further-
more, the lack of response in the myeloid cells was again shown to
be a species-specific effect of human cells since poly I:C could
stimulate NFB activity in murine DCs (Figure 4B). The NFB
results were supported by studies of poly I:C–induced IB
degradation. In a similar manner, poly I:C did not induce IB
degradation in either DCs (Figure 5A) or MØs (data not shown).
Conversely, poly I:C stimulation of RA-SFs resulted in IB
degradation, confirming our NFB results (Figure 5B). The poly
I:C–induced IB degradation in RA-SFs occurred with a delayed
kinetics than LPS stimulation, which induced IB degradation in
all cell types, as expected.
The production of proinflammatory cytokines can also be regulated
by the 3 major MAPKs: p38 MAPK, JNK (p46/p54), and ERK
(p42/p44) MAPKs. It was previously reported that poly I:C treatment
induced phosphorylation of the MAPKs in murine cells and
various cell lines.2,35,36,40-44 However in our study, poly I:C
stimulation did not induce phosphorylation of p38, JNKs, or
ERKs at any time point analyzed in either human DCs (Figure
6A) or MØs (data not shown), whereas LPS was found to
potently induce all 3 groups of MAPKs, as expected. Con-
versely, stimulation of RA-SFs by both poly I:C and LPS
resulted in activation of all 3 MAPKs, albeit with different
kinetics (Figure 6B). To elucidate if the late activation of the
MAPK in response to poly I:C was due to an indirect effect, we
stimulated RA-SFs in the presence of brefeldin A, an inhibitor
of the secretory pathway. Brefeldin A had no effect on poly
I:C–induced ERK phosphorylation (Figure S2), indicating that
the activation was not mediated by a secreted autocrine mediator.
Figure 2. Poly I:C–induced expression of IFN-regulated genes but not proinflammatory cytokines is both cell-type and species specific. (A) Human DCs and MØs,
(B) murine DCs, (E) ECs, and (E,F) RA-SFs were stimulated with either 100 ng/mL LPS or poly I:C (in g/mL) as indicated. The supernatants were analyzed for IP-10, IL-6, and
TNF by ELISA. The data are mean values (	 SD) from triplicates and are representative of at least 3 experiments using cells of different donors. (C) Human DCs were
stimulated with either 100 ng/mL LPS or 20 g/mL poly I:C, and total RNA was isolated and assessed for the levels of TNF and IL-6 mRNA by Taqman PCR. The points
correspond to values from 4 different donors (	 SD). (D) Human DCs were stimulated with 20 g/mL poly I:C or 100 ng/mL LPS and cocultured with 105 allogeneic T cells in
quadruplicate. Proliferation was determined on day 5 using [3H] thymidine. Each point represents the mean (	 SEM) from 3 independent experiments on unrelated donors.
Human DCs were also examined for cell surface expression of CD80, CD86, HLA-DR, and CD83 by flow cytometry. Unstimulated DCs (black line) and DCs treated with
20 g/mL poly I:C for 48 hours (gray line) were compared. Cells stained with isotype control (filled histograms) or anti-TLR3 antibody (open black histograms) are shown. One
representative of 3 independent experiments is shown.
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IRF-3 activation in response to poly I:C stimulation is restricted
to cells of nonmyeloid lineage
IRF-3 has been shown to have a critical role in TLR3-induced
responses through the TRIF-dependent pathway leading to IFNs
and IRGs, such as IP-10. We aimed to address the question of
whether the induction of IRF-3 could explain the poly I:C–induced
IP-10 production in DCs and MØs in the absence of NFB and
MAPK activation. IRF-3 is found in the cytoplasm as an inactive
monomer and becomes activated by phosphorylation, followed by
dimerization and translocation to the nucleus.45,46 The involvement
of IRF-3 in poly I:C signaling was examined by measuring the
change in IRF-3 nuclear levels. In this study, we could only detect
IRF-3 nuclear translocation after LPS, but not poly I:C treatment of
DCs (Figure 7A) and MØs (data not shown). Conversely, in both
RA-SFs (Figure 7B) and ECs (data not shown), the results showed
enhanced levels of nuclear IRF-3 after only poly I:C and not LPS
stimulation. These results further confirmed that signaling events
induced by poly I:C are tightly regulated according to the cell type
involved, and differ substantially between professional and nonpro-
fessional immune cells.
Discussion
This study investigated and compared the responses induced by
TLR3 stimulation of human primary DCs, MØs, ECs, and
RA-SFs from disease tissue. These cell types are involved in
responses to infection and both acute and chronic inflammation.
The results in this study have uncovered a considerable selectiv-
ity in the TLR3-induced responses of these cell types, with
substantial differences observed between myeloid cells (DCs
and MØs) and nonmyeloid cells (ECs and RA-SFs). Surpris-
ingly, DCs and MØs were found to produce the IRG IP-10, but
not cytokines such as TNF, IL-6, or IL-8 after poly I:C
stimulation. Studies on mRNA expression of TNF and IL-6 in
human DCs confirmed our protein data showing no poly
I:C–induced cytokine production, whereas we could detect
IFN mRNA, as shown by other groups.25,26 This contradicts a
previously published study that failed to detect IFN but
showed induction of TNF and IL-6 mRNA, although no
protein studies were performed.23 Furthermore, we showed that
poly I:C stimulation of human DCs induced up-regulation of the
maturation markers HLA-DR, CD80, CD86, and CD83, and
T-cell stimulatory capacity, all of which have previously been
demonstrated by other groups.24-26 This is the first report
showing induction of DC maturation and production of IRGs
from human DCs and MØs, but not proinflammatory cytokines,
in response to TLR3 stimulation. Furthermore, of great interest,
this phenotype was shown to be specific for human myeloid
cells since both TNF and IL-6 could be produced by murine
DCs after poly I:C stimulation. Moreover, in contrast to DCs
Figure 3. Poly I:C stimulation is dependent on endosomal maturation in both
human dendritic cells and RA synovial fibroblasts. Human DCs and RA-SFs
were incubated with chloroquine for 1 hour prior to stimulation with 20 g/mL poly I:C
for 18 hours. The supernatants were analyzed by ELISA. The data are mean values
(	 SD) from triplicates.
Figure 4. Poly I:C stimulation induces activation of NFB in endothelial cells
and RA synovial fibroblasts but not in dendritic cells and macrophages.
(A) Human DCs, MØs, ECs, RA-SFs, and (B) murine DCs were infected for 1 hour
with an adenovirus carrying an NFB luciferase reporter gene. The cells were
stimulated for 6 hours with 100 ng/mL LPS or poly I:C (in g/mL) as indicated and
then analyzed for luciferase activity. The data are mean values (	 SD) from triplicates
and are representative of at least 3 experiments using cells of different donors.
Figure 5. Poly I:C stimulation induces degradation of IB in fibroblasts but not
in dendritic cells. (A) DCs and (B) RA-SFs were either left untreated (Un) or
stimulated with poly I:C (20g/mL) or LPS (100 ng/mL). The cell lysates were
examined for the level of IB, -actin, or -tubulin by Western blotting. Representa-
tives of 3 independent experiments per cell type are shown.
CELL TYPE– AND SPECIES-SPECIFIC TLR3 MECHANISMS 3249BLOOD, 1 NOVEMBER 2007  VOLUME 110, NUMBER 9
 For personal use only. at IMPERIAL COLLEGE LONDON on April 30, 2008. www.bloodjournal.orgFrom 
and MØs, the cells of nonmyeloid origin, ECs and RA-SFs,
produced both types of cytokines after poly I:C treatment. This
is a major difference in the behavior of TLR3 signaling between
human and mouse and could affect how we interpret and
extrapolate data between the 2 systems, especially when consid-
ering viral disease models, where TLR3 might have a role, or
where cell necrosis and release of RNA may be involved.
The differences between the myeloid and nonmyeloid cell types
were also reflected in the TLR3 signaling pathways. Unexpectedly,
poly I:C did not induce activation of NFB, MAPKs, or IRF3 in
DCs and MØs, but was able to do so in ECs and RA-SFs. The
inability of poly I:C to activate these pathways in DCs and MØs
could explain the failure to produce TNF, IL-6, and IL-8, since
their expressions are regulated by NFB. Conversely, the activa-
tion of NFB and MAPKs in RA-SFs and ECs would also explain
why poly I:C could induce IL-6 and IL-8 in these cells. Our results
confirm the previously reported observation that poly I:C stimula-
tion regulates NFB in human ECs.27,47
We have previously shown that there are major differences in the
signaling pathways of other TLRs between human cells of myeloid and
nonmyeloid lineages.19,20,48 A possible explanation for our results could
be cell type–specific expression of signaling molecules between cell
lineages, as was shown with IKK
 expression between murine macro-
phages and fibroblasts.49 Such differential expression could account for
IFN and IP-10 production but no NFB activation or secretion of
proinflammatory cytokines in poly I:C–stimulated DCs and MØs. It is
possible that these cells lack a signaling molecule similar to feckless
described by Beutler et al.50 Cells from mice with a feckless mutation fail
to activate NFB or produce TNF in response to dsRNA/TLR3,
although dsRNA is still able to initiate IFN production. Another
possibility is that additional transcription factors, such as other IRFs, are
involved in TLR3 activation in human myeloid cells. As such, we have
evidence that poly I:C induces a rapid and transient nuclear accumula-
tion of IRF-1 in DCs (Figure S3). This is an interesting area that we are
actively pursuing further.
An interesting finding in this study was that poly I:C stimulation
of RA-SFs induced TNF production, which was specific for poly
I:C since LPS treatment failed to induce the same response. The
ability of poly I:C to induce TNF production does not appear to be
Figure 6. Poly I:C treatment does not induce phosphorylation of p38, JNK, and ERK in human dendritic cells but does so in RA synovial fibroblasts. (A) Human DCs
and (B) synovial fibroblasts from RA tissue were either left untreated (Un) or stimulated with LPS (100 ng/mL) or poly I:C (20g/mL). The cell lysates were examined for
phospho-p38, phospho-JNK, phospho-ERK, or -actin by Western blotting. Representatives of 3 independent experiments are shown.
Figure 7. Poly I:C stimulation of RA synovial fibroblasts but not DCs activates
nuclear translocation of IRF-3. (A) Human DCs and (B) RA-SFs were either left
unstimulated (Un) or stimulated with poly I:C (20 g/mL) and LPS (100 ng/mL), and
the nuclear fractions were examined for nuclear IRF-3 and topoisomerase by
Western blotting. Representatives of 3 independent experiments per cell type are
shown.
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a general property of all fibroblast populations. We were unable to
detect TNF production in HSFs in response to poly I:C even
though IL-6 was produced by these cells. This is not the only
difference we have observed between RA-SFs and HSFs, as the
former48 unlike the latter are able to respond to LPS. One could
therefore hypothesize that RA-SFs have an inflammatory pheno-
type, possibly due to their environment. It is interesting to note that
poly I:C induces TNF production in cultures of RA joint synovial
membranes from which RA-SFs are derived (S.M.S. et al, manu-
script in preparation). Furthermore, TNF production by poly
I:C–stimulated RA-SFs is unlikely to be caused by contamination
of MØs or T cells, since we could not detect CD14- or CD3-
expressing cells in our RA-SF cultures. If MØs were present, we
would have observed TNF expression after LPS and not poly I:C
stimulation of these cultures. However, although unlikely, we
cannot completely rule out the presence of other contaminating cell
types. Historically nonmyeloid cells were not believed to be able to
express TNF, however, supporting observations were recently
reported by 2 independent groups in murine embryonic fibroblasts
(MEFs).51,52 They showed that LPS stimulation of MEFs induced
low levels of TNF that was a result of IRF-3 activation. We show
in our human cell systems that there is a correlation between TNF
production and IRF-3 activation. As such, LPS stimulation of DCs
and MØs induces TNF production and IRF-3 activation, whereas
poly I:C does not. The situation is reversed in RA-SFs and it is poly
I:C stimulation and not LPS that induces both TNF and IRF-3.
We have previously shown that NFB is required for LPS-
induced MHC class II and CD80/86 expression and antigen
presentation.53,54 However, since TLR3-induced up-regulation of
these molecules could be observed in the absence of a detectable
NFB activation, their expression appears to be NFB indepen-
dent. Furthermore, IRF-3 is thought to be required for TLR3-
induced type I IFN and IP-10 production. However, since no IRF-3
activation could be seen in DCs and MØs, it is unclear what
regulates the production of IP-10 and type I IFNs in these cell
types. This is the subject of ongoing investigations.
One obvious reason for the variations between the cell types is
that they have very different functions in the immune system. DCs
and MØs are professional antigen-presenting cells involved in
T-cell activation, whereas ECs and RA-SFs are nonprofessional
immune cells. Thus, given their diverse roles in the immune
response, it makes sense that the same ligand would induce
individual cell type–specific responses. For example, stimulation of
DCs and MØs by TLR3 appeared to selectively induce IP-10, a key
chemokine targeting T lymphocytes, hence specifically enhancing
recruitment of T cells to the site of inflammation. In contrast, this
selectivity in cytokine production was not observed with ECs and
RA-SFs. In these cells, TLR3 activation instead induced a broader
range of proinflammatory mediators, suggesting participation of
these cell types to chronic inflammation. We also show that TLR3
stimulation results in DC maturation, favoring increased T-cell
activation. Furthermore, DCs and MØs are capable of inducing
cross-presentation,55,56 and TLR3-stimulated DCs can cross-
present antigens from virally infected cells to promote priming of
virus-specific T cells.57-59 It is therefore possible that TLR3-
stimulated DCs and MØs are involved in recruitment of T cells and
induction of cross-presentation. Interestingly, TLR3 stimulation
also leads to a marked increase in cross-priming toward cell-
associated antigens.60 In this way, peripheral tolerance could be
overcome by dsRNA and thus trigger an autoimmune organ-
specific disease.60
The results presented in this study differ from the literature
using other cell systems, and they indicate that the signaling
pathways induced by poly I:C in human primary cell types and
cells from disease tissue are complex. While these observations
have raised the question of why differences exist between cell types
stimulated with the same ligand, they also highlight the importance
of studying signaling pathways in relevant cell types and the danger
in directly transferring the results observed in cell lines or murine
systems to human systems. By characterizing the pattern of
activation induced by each cell type in response to the TLR3
ligand, this study increases the understanding of the possible
contributions of each cell to the innate host responses to viral
infections or tissue damage. The differences in TLR3 stimulation
between the cell types are subject to further investigation, in order
to fully understand the specific role of TLR3 in the human immune
response.
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In the last decade the development of a number of biological therapies has revolutionised the treatment of
rheumatic diseases. The first and most widely used of these approaches, tumour necrosis factor (TNF)
blockade (infliximab, entanercept, adalimumab), has now been administered to over a million patients.
However, the success of these biological therapies has also highlighted their limitations. None of these
treatments has shown a 100% patient response; normally responses are in the 50–70% range. As proteins,
these drugs cannot be given orally and they are expensive to produce, a cost ultimately borne by the patient/
health provider that can seriously limit the availability of these drugs. Lastly, these treatments, whether
involving the systemic neutralisation of a cytokine (eg, TNF or IL6 receptor blockade (tocilizumab)), the
ablation of a B cell population (anti-CD20, rituximab), or the potential disruption of important cellular
interactions as with CTLA4-Ig (abatacept), can cause major perturbations of the immune system, the long-term
effects of which are still unclear. At present, treatments such as TNF blockade can result in an increased
infectious risk and the reactivation of tuberculosis can be a major issue in certain populations. As with all
therapies, there is an increasing large refractory population over time. Therefore, despite the undoubted
success of these therapies, there is room for improvement. Although it might be too much to expect any new
treatment to affect a ‘‘cure’’ (all the current biological therapies require repeated administrations), there are
definite gains to be made in terms of cost, oral bioavailability and a more selective interference with the
immune–inflammatory response.
A
n important consequence of the success of biological
therapies has been to validate the role of various
cytokines and cells in the pathophysiology of rheumatoid
arthritis (RA). The clinical results obtained with TNF blockade
has confirmed in many ways the preclinical studies that
originally indicated that TNF was a key regulator of the
inflammatory cascade in RA. This includes the production of
other cytokines such as IL6, angiogenesis, adhesion molecules
and consequent cell migration, and the production of matrix
metalloproteinases (MMP) and other factors involved in tissue
destruction.1 2
A consequence of the success of blocking TNF has been to
focus attention on finding suitable ‘‘drugable’’ targets, either
proximal or distal of this cytokine. This quest of ‘‘drugability’’
has focused research on the signalling pathways associated
with cytokine production or action. So far two enzymes have
clearly led the field as potential targets, p38MAPK and IKK2.
Both targets have the perceived benefit of being involved in the
production and actions of TNF. IKK2 is a key enzyme in the
activation of the NF-kB transcription factor that is required for
the production of many other inflammatory factors.3 4
p38MAPK is mainly implicated in the production of TNF
through the post-transcription regulation including the stabi-
lisation of mRNA; it is also involved in the regulation of TNF in
RA.5 However, despite both enzymes being identified some time
ago, IKK2 in 19976 and p38MAPK in 1994,7 no compound has
yet succeeded in the clinic. To our knowledge, the most
advanced p38MAPK inhibitors have reached phase II where
progress has stopped, usually due to toxicity. Whether this
toxicity is target-related or not is unclear, however, deletion of
the a isoform of p38MAPK is embryonically lethal in mice.8 A
clear confirmation of the wealth of published data from in vitro
studies indicate that this enzyme is very widely distributed and
has a role in multiple pathways of physiological importance.9
Similarly, the deletion of IKK2 from mice also leads to
embryonic lethality,10 this may not be so surprising an
observation given that cell survival is among the multiple roles
of NF-kB activation. There is the suspicion therefore that
systemic inhibition of either of these enzymes with an
acceptable toxicity profile may be a difficult goal to achieve.
THE QUEST FOR THE MECHANISMS INDUCING TNF
PRODUCTION IN RA, THE BASIS OF DISEASE
CHRONICITY
Another major question that has arisen from the biological
therapies is that in general they do not achieve a permanent
remission of the disease. Anti-TNF approaches require repeated
administration as much as twice weekly (entanercept) and
once every 8 weeks for the longer-lived antibodies such as
infliximab. The factors that drive TNF production would appear
to be still active and unaffected by these treatments. Therefore
the identification of the pathways driving the production of
TNF would not only move our understanding closer to the
source of the chronicity of RA, but also potentially provide a
better therapeutic target. Inhibiting the inducer(s) of TNF
production would provide a more selective suppression of TNF
than the systemic neutralisation of the cytokine. This should
Abbreviations: MMP, matrix metalloproteinases; PAMPs, pathogen-
associated molecular patterns; RA, rheumatoid arthritis; SLE, systemic lupus
erythematosus; TIR, toll/interleukin 1 receptor; TLR, toll-like receptor; TNF,
tumour necrosis factor
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have benefits in terms of safety. Of course, in RA where there
are likely to be multiple complex interactions between various
cell types and soluble factors, there may be no single stimulus
driving cytokine production in all patients. Previously, studies
from this laboratory suggest that cytokine-activated T cells that
are generated in the milieu of the cytokine-rich environment of
the inflamed joint are capable of inducing TNF production from
macrophages.11 However, other possible candidates are factors
that are normally part of the acute inflammatory response
against infection. This is even more appealing when one
considers that several forms of self-limiting arthritis are
induced by infections such as Lyme disease and chlamydia.12 13
In the last decade there has been a major leap in our
understanding of how the host immune system responds to the
challenge of infection with the identification of the toll-like
receptor (TLR) family. The toll receptors were first discovered in
Drosophila but are now known to be widely expressed in nature
and are even present in plants.14 15 Although the original toll
receptor was originally identified in flies as a developmental
protein, in adults it has a major role in defence against
infection, a function replicated by TLRs in many organisms
including mammals. To date 14 mammalian TLRs have been
identified, 10 of which are found in man. These receptors have
a structural homology of leucine-rich repeats in their extra-
cellular domains, however, they are designed to recognise
different ligands, termed PAMPs (pathogen-associated mole-
cular patterns) (fig 1), that is, molecules that would only be
present in the host as the result of the presence of a pathogenic
infection. The first identified of these was LPS which is
recognised by TLR4.16 Subsequently, TLR2 and the associated
TLRs 1 and 6 were shown to recognise proteoglycans, whereas
TLR2 in conjunction with the non-TLR molecule Dectin 1 binds
the yeast product zymosan.17 Flagellin is the ligand for TLR5
and TLR9 recognises the non-methylated CpG rich DNA of
bacteria. The other TLRs, 3, 7 and 8, appear to be more
concerned with recognising viral infections and, unlike the
other TLRs except TLR9, are predominately located in the
endosomal compartment rather than on the cell surface.15 To
this end, TLR3 and TLR7/8 recognise dsRNA and ssRNA,
respectively. The ligand for TLR10 has not been identified. Like
LPS, the other TLR ligands are also potent stimulators of
inflammation. Normal infection-induced inflammation is self-
limiting and resolves, but there are instances as in septic shock,
acute respiratory distress syndrome and cerebral malaria where
a failure to regulate the inflammatory response leads it to
become part of the pathology.
Figure 1 Toll-like receptors: a link between acute and chronic
inflammation. TLRs can respond to both endogenous and exogenous
ligands leading to the production of inflammatory factors. Damage to cells
caused by inflammation may potentially feed back on to the TLRs through
generation of endogenous ligands, thus initiating a cyclical pattern that
may underlie chronic inflammation.
Figure 2 Overexpression of dnMyD88 inhibits TLR2, 5 and 7/8 signalling in human macrophages. M-CSF-derived human macrophages were infected
with a dominant negative (dn) MyD88 adenovirus (MOI 100:1) for 1 hour in serum-free media and then cultured for 24 hours in normal media. Cells were
then stimulated with media alone or media containing (A) 3 ng/ml Malp-2, (B) 1 ng/ml LPS, (C) 10 ng/ml Pam3Cys, (D) 10 mg/ml Flagellin or (E) 1 mg/ml
R-848 for 6 hours. The supernatants were analysed for IL6 by ELISA. Mean cytokine production (¡SEM) of triplicate cultures from three unrelated donors is
shown. For the statistical analysis, a one-tailed Student t test was used to compare uninfected control cells with recombinant adenovirus-infected cells
(*p,0.05, ***p,0.001).
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COULD TLRS AND THEIR ENDOGENOUS LIGANDS
HAVE A ROLE IN RA?
The discovery that the TLRs also recognise endogenous ligands
has widened our view of what role these receptors may play in
the immune system.18 Most of the ligands identified to date
would be generated as products of tissue injury as cell death
(fig 1). The potential benefits of such a complimentary
activation of the TLR systems are obvious as it would alert
the immune system to breaches of physical barriers such as the
skin where infectious organisms might enter. However, there is
a major downside in that there is the potential for self-
activation of the TLRs. This is possibly the case in sepsis where a
major mediator of the exaggerated inflammatory response is
the nuclear protein HMGB1.19 This protein induces macrophage
activation and TLR2/TLR4 has been implicated in HGMB1
activity.20 Also HMGB1 has been recently shown to bind to
extracellular DNA and therefore act as co-ligand for TLR9.21
This potential of endogenous-produced ligands to activate the
TLRs presents the scenario that inflammation could be driven
independently of any external infection where tissue destruction
is occurring for some other reason as in cases of chronic
inflammation itself (fig 1). Such a possibility has been proposed
in systemic lupus erythematosus (SLE) where there is the
formation of HMGB1/DNA complexes that could drive inflamma-
tion via TLR9.21 In addition to TLR9, TLR7 was also shown to be
involved in the pathology of SLE through the recognition of RNA
immune complexes which leads to B cell activation in synergy
with the B cell receptor.22 Given the amount of tissue destruction
that occurs in RA the possibility exists that the self-generation of
TLR ligands would perpetuate and amplify the inflammatory
process.23 24
STUDIES ON TLR SIGNALLING IN RA
To address whether there was a role of endogenous TLR ligands
in driving inflammation in RA we utilised the human RA
synovial tissue culture model that was originally used to
identify the key role of TNF.25 Rather than attempting to study
each individual TLR, we chose to investigate the TLR signalling
pathways. Studies in knockout mice have shown that all TLRs,
with the exception of TLR3, use the intracellular signalling
adaptor molecule Myd88. This protein contains a TIR (Toll/
interleukin 1 receptor) domain that forms a homotypic
interaction with the TIR domain of the receptor. As the name
suggests, the same domain is also found in the IL1 receptor
family and, as a consequence, both families use very similar
signalling pathways.26 However, there are certain additional
receptor complexities concerning TLR signalling over and above
that of IL1. Although TLRs 5, 7, 8 and 9, like IL1 just use
Myd88, TLR 1/2/6 and 4 also use a related adaptor molecule,
Mal/TIRAP. As a further complexity, TLR4 also engages two
further adaptors, TRAM and TRIF, the latter also being the only
signalling adaptor used by TLR3.26 To address the role of TLR
signalling in RA membranes, we generated the dominant
negative version of Myd88 (dnMyd88) that would neutralise all
TLRs (except TLR3) and IL1 signalling, and dominant negative
Mal (dnMal) that would allow differentiation from IL1
signalling at least in the case of TLR1, 2, 4 and 6. To deliver
these dominant negatives to RA tissue we utilised our
adenoviral vectors as used previously in other studies.27 28
However, before we assessed the role of these molecules in
RA, we investigated the activity of the dominant negatives at
blocking TLR signalling on populations of normal human
monocyte-derived macrophages as the role of these molecules
has generally been assessed in various knockout mice. As
shown in fig 2, dnMyd88 reduced the production of TNF
induced by TLR1/2/6 (MALP2 or Pam3-Cys), TLR5 (Flagellin)
and TLR7/8 (R848), and IL1 (not shown). In contrast, dnMal
only blocked TLR2 signalling and had no effect on TLR5 or
TLR7/8 (fig 3). Unfortunately, these cells do not respond to
TLR9 ligands and TLR3 does not induce inflammatory cytokines
Figure 3 Overexpression of dnMal inhibits TLR2 signalling in human macrophages. M-CSF-derived human macrophages were infected with dominant
negative (dn) Mal adenovirus (MOI 100:1) for 1 hour in serum-free media and then cultured for 24 hours in normal media. Cells were then stimulated with
media alone or media containing (A) 3 ng/ml Malp-2, (B) 1 ng/ml LPS, (C) 10 ng/ml Pam3Cys, (D) 10 mg/ml Flagellin or (E) 1 mg/ml R-848 for 6 hours.
The supernatants were analysed by ELISA for TNF. Mean cytokine production (¡SEM) of triplicate cultures from three unrelated donors is shown. For the
statistical analysis, a one-tailed Student t test was used to compare uninfected control cells with recombinant adenovirus-infected cells (*p,0.05).
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in human macrophages.29 However, as we have shown
previously, TLR4 (LPS) signalling was unimpaired by either
dnMyD88 or dnMal.28 The reasons for this are unclear and
infection with dominant negatives of Mal and TRAM either
alone or in combinations with dnMy88 still failed to inhibit LPS
activity in macrophages.27
Having established the activity of these inhibitory constructs
in a simple TLR system, we applied the same reagents to studies
on culture of primary human synovial tissue. As has been
previously described, these spontaneously produce TNF, other
cytokines, MMPs and other inflammatory mediators in the
absence of any exogenous stimulus.30 The factors driving the
production of TNF are not yet defined. As shown in fig 4,
infecting the cells with a control virus had no effect on the
production of TNF or IL6 compared to uninfected controls. In
contrast, the use of a viral vector encoding IkBa that would
specifically inhibit the NF-kB pathway4 reduced the level of
TNF and other cytokines by 50–70% except for IL6 that was
inhibited by over 90%. Dominant negative Myd88 reduced the
production of both TNF and IL1 by approximately 30%,
although the latter was not significant. IL6 and IL8 production
was reduced by 60–70% and VEGF by approximately 50%.
Studies with dnMal produced similar levels of inhibition of all
these cytokines compared to dnMyD88. We also looked at the
effect of inhibiting TLR signalling on the expression of several
Figure 4 Overexpression of dnMyD88 or dnMal inhibits spontaneous
cytokine and MMP production in rheumatoid synovial membranes.
Rheumatoid synovial membrane cultures were infected with adenoviruses
containing dnMyD88, dnMal and IkBa for 1 hour in serum-free media and
the viruses were removed and replaced with normal media. Supernatants
were collected after 48 hours and levels of (A) TNFa, IL1, VEGF, MMP13;
(B) IL8, IL6, MMP3, and (C) MMP1, MMP2 were measured by ELISA.
Concentration of cytokine production from six to eight unrelated patients is
shown. For the statistical analysis a one-tailed Student t test was used to
compare uninfected control cells with recombinant adenovirus-infected cells
(*p,0.05, **p,0.01).
Figure 5 Spontaneous IL6 production from RA synovial membrane
cultures is not inhibited by TLR2 or TLR4 blocking antibodies. Macrophages
were generated from peripheral blood monocytes in culture with 100 ng/
ml M-CSF for 3 days. (A) Macrophages were left untreated or incubated
for 1 hr with 10 mg/ml isotype control antibody or 10 mg/ml a-TLR2 and
then stimulated with 10 and 100 ng/ml Pam3Cys-Ser-Lys4 for 18 hrs. (B)
Macrophages were left untreated or incubated for 1 hr with 10 mg/ml a-
TLR2 or 10 mg/ml a-TLR4 and then stimulated with 0.5 or 1 ng/ml LPS for
18hrs. (C) RA synovial membrane cells were cultured with 10 mg/ml
isotype control, a-TLR2 or a-TLR4 for 48 hrs, n = 5. Mean cytokine
production (¡SD) of triplicate cultures is shown and is representative of
three independent experiments from unrelated donors in parts A and B,
and five in part C.
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MMPs. As shown in fig 4, dnMyd88 and dnMAL both reduced
the production of all the MMPs by 50–70%. These data would
indicate that there is a role for both the Myd88 and Mal
signalling pathways in the production of TNF and, more so,
IL6 in these RA membranes. While a role for Myd88 would
suggest IL1 as well as the TLRs, the role of Mal would
indicate an important role for TLR signalling, although a
contribution from IL1 signalling might also be present. Given
these results, we investigated whether TLR2 or TLR4 were
involved in driving cytokine production in RA membranes.
Antibodies to TLR2 and TLR4 are able to block the response of
human macrophages to PAM3Cys or LPS, respectively (fig 5A,
B). However, these antibodies were unable to block the spon-
taneous production of cytokines in the synovial membranes
(fig 5C).
Given this result, we next investigated whether these TLR
ligands might exist within the culture supernatants of these
cultures. This is a relatively tricky experiment as the culture
supernatant already contains cytokines. To investigate the
presence of TLR ligands we utilised naive primary human
macrophages that contained an NF-kB luciferase reporter gene
construct. Luciferase activity will be induced in these cells by all
the TLRs except 3 and 9 (data not shown). To ascertain if any
induction of NF-kB by the synovial joint culture supernatants
could be attributable to TLR ligands, the cells were co-infected
with viruses for dnMyd88 or dnMal. As shown in fig 6,
dnMyd88 and, to a lesser degree, dnMal inhibited the
activation of the NF-kB luciferase reporter. As might be
expected for cultures that would also contain IL1 and ligands
for TLRs that do not use Mal, the effect of dnMal was less than
that of dnMyd88. Also neither inhibitor produced a complete
inhibition as also would be expected as these supernatants also
contain other activators of NF-kB such as TNF that do not use
the TLR/IL1 signalling pathway. Therefore, although the
antibodies to TLR2 and TLR4 failed to block the spontaneous
release of cytokines in RA membranes, there clearly are ligands
for TLRs present in these cultures. At present our work is
progressing to discover which TLRs are being activated by these
potential ligands.
CONCLUSIONS
Our data would indicate that there is a potential role for the
TLR system in driving the inflammatory and destructive
processes in RA. It may not be necessary for TLRs to be
involved in the inception of disease (although this could be via
micro-organisms), but they could greatly contribute to chroni-
city through cycles of inflammation, disease destruction and
further inflammation (fig 1). This activity may not be confined
to a single TLR as several could be involved. Ongoing studies in
this group are attempting to define which TLRs might be
involved and the nature of the ligands being recognised. Are
TLRs a therapeutic target? Assuming that a substantial
proportion of the TNF-inducing activity is not spread among
too many TLRs, then inhibition of one or two might produce a
significant enough reduction in TNF to have a therapeutic
benefit. In terms of safety that would potentially be a more
selective suppression of TNF production than is obtained with
TNF blockade, although this cannot really be assessed until
actual human studies with an acceptable TLR inhibitor could be
performed. Moreover, side effects through inhibiting one or
several TLRs may be limited as other pattern recognition
receptors such as nucleotide-binding oligomerisation domains,
C-type lectin receptors and retinoic acid-induced gene I would
still be left intact. A further indication for the feasibility of TLR
inhibition as a therapy in terms of its side effects comes from
humans with a mutation in the irak4 gene. IRAK4 is a common
mediator of TLR signalling and, although individuals with
mutated IRAK4 show severe infections in early childhood, this
phenotype dissipates with age suggesting additional TLR-
independent, protective mechanisms taking over.31–33 TLRs,
unlike many receptor systems, might be amenable to inhibition
by small molecular weight compounds that would have an
advantage over kinase inhibitors in that cell permeability is not
a requirement or even desirable. Therefore the likelihood of off-
target effects could be greatly reduced.
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Rheumatoid arthritis (RA) is one of the most prevalent autoimmune diseases. It is 
characterized by chronic inflammation of the joint leading to its destruction. Although the 
initiating cause remains elusive, environmental factors and genetic background are 
known to contribute to the etiology of RA. The role of Toll-like receptors (TLRs) in innate 
immunity and their ability to recognize microbial products has been well characterized. 
TLRs are able to recognize endogenous molecules released upon cell damage and 
necrosis, and are present in RA synovial fluid. Although it appears unlikely that a pathogen 
underlies the pathogenesis or progression of RA, the release of endogenous TLR ligands 
during inflammation may activate TLRs and perpetuate the disease. An increasing body of 
circumstantial evidence implicates TLR signaling in RA, although, at present, their 
involvement is not defined comprehensively. Targeting individual TLRs or their signaling 
transducers may provide a more specific therapy without global suppression of the 
immune system.
Expert Rev. Clin. Immunol. 2(4), 585–599 (2006)
Pathogenesis of rheumatoid arthritis
Rheumatoid arthritis (RA) affects approxi-
mately 0.5–1% of the adult population, with
three-times more females than males affected.
This condition is marked by a persistent
inflammatory polyarticular synovitis, mainly
affecting the small joints. During the early
stages of RA, synovial lining cells proliferate
and endothelial cells in the RA joint
upregulate the expression of chemokines and
adhesion molecules. This results in neo-
vascularization and in the recruitment of large
numbers of mononuclear cells [1]. As the
disease progresses, the inflamed synovium
(termed pannus) invades cartilage and bone.
This process is mediated by the release of
enzymes, including matrix metalloproteases
(MMPs), aggrecanases and cathepsins, from
activated osteoclasts and macrophages, which
degrade the extracellular matrix (ECM). In the
final stages of RA, bone and tendon damage
eventually lead to deformation of the joints
and functional disability.
Strong evidence suggests a role for activated
inflammatory cells in the initiation and pro-
gression of RA. Macrophages are thought to be
activated by infiltrating, activated CD4+
T cells through cell-to-cell contact [2]. Once
activated, macrophages release chemokines
and cytokines that activate and recruit other
inflammatory cells to the joint, creating a
continuous cycle of inflammation (for a review
see [2]). Autoreactive B cells are present in the
lymphoid tissues of healthy individuals, but
typically remain quiescent. Perturbation of
inactive B cells leads to production of self-
reactive antibodies that can have serious patho-
logical consequences. B cells expressing an
antigen receptor specific for self-immuno-
globulin (Ig)G make rheumatoid factor (RF),
an autoantibody used in the diagnosis and
prognosis of RA.
Current therapies for rheumatoid arthritis
Until relatively recently, management of RA
consisted of nonsteroidal anti-inflammatory
drugs (NSAIDs), glucocorticoids and disease-
modifying antirheumatoid drugs (DMARDs)
(including gold, penicillin and methotrexate).
NSAIDs do not have disease-modifying
properties, but help to reduce joint pain. Low-
level glucocorticoids delay the progression of
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articular disease in RA [3], but have the disadvantage of many
well-characterized adverse reactions, such as, osteoporosis and
hypertension, so are often only used prior to the onset of
DMARD treatment. For decades, DMARDs provided the
most beneficial treatment of patient symptoms. Treatment
often consists of combinations of DMARDs, for example,
using methotrexate, sulphasalazine and hydroxychloroquine [4].
However, not all patients respond to DMARDs. The develop-
ment of humanized antitumor necrosis factor (TNF)-α therapy
has heralded the advent of the biologicals as novel therapies for
RA. New treatments for RA have become available as our
understanding of the role of cytokines in RA has improved.
Targeting the key inflammatory cytokines TNF-α and, to a
lesser degree, interleukin (IL)-1 has been the most beneficial
therapeutic interventions to date. The treatments approved for
use in the clinic are the TNF-α inhibitors, infliximab (Remi-
cade®) [5,6], etanercept (Enbrel®) [7] and adalimumab
(Humira®) [8], and the IL-1 inhibitor anakinra (Kineret®) [9,10].
Therapies targeting other inflammatory factors in the RA joint
are under development, including anti-IL-6 receptor and
anticytotoxic T-lymphocyte-associated antigen (CTLA)-4.
Over production of IL-6 plays a pathological role in RA and
treatment of RA patients with a humanized anti-IL-6 receptor
antibody reduced disease activity in 78% of patients after
3 months [11]. T cells express CTLA-4 transiently, which binds
to CD80 and CD86 on antigen-presenting cells (APCs) as well
as CD28 on T cells. Inhibition of CTLA-4 engagement with
CD28 was shown to impair activation of T cells [12]. Therefore,
CTLA-4 may be a useful target in RA therapy [13]. A human
CTLA-4–IgG1 fusion protein is currently in Phase III trials in
RA patients and has shown positive results in patients with an
inadequate response to either methotrexate or anti-TNF-α
therapy [14–16]. As with most immune system-modifying thera-
pies, targeting inflammatory cytokines has a nonspecific effect
on the whole of the immune system. As a result, immune
function is compromised and infection may occur. Reported
side effects of anti-TNF-α therapies are a lupus-like syndrome,
demyelination syndrome and serious infections, including
bacterial sepsis and reactivation of latent Mycobacterium tuber-
culosis [17]. However, these complications occur rarely. The aim
of new therapies is to provide a less expensive, orally available
treatment (anti-TNF-α is by injection) with a more specific
mechanism of action.
Etiology of rheumatoid arthritis
Similar to other autoimmune diseases, environmental factors,
such as mechanical stress and cigarette smoking, appear to play
a role in RA susceptibility [18]. The initiating cause of RA has
been suggested to be bacterial or viral infection [19]; however, no
infectious pathogen has been identified conclusively in the
inflamed joints of RA patients. With 15% concordance in
identical twins, RA shows the lowest concordance of all
autoimmune disease [20]. Nevertheless, there is a genetic influ-
ence in RA. An association between major histocompatibility
complex (MHC) Class II antigens, which present antigenic
peptides to CD4+ T cells, and RA has been suggested [21]. The
initial immune response of RA might be antigen presentation
of a viral/bacterial pathogen or endogenous antigen through
loss of peripheral tolerance [22]. Endogenous ligands such as
human cartilage glycoprotein 39 [23] or self-DNA (IgG–chro-
matin) complexes [24], are equally capable of eliciting an
immune response as exogenous infectious agents. These endo-
genous antigens might be stimuli in the early stages and main-
tenance of the pathogenesis of RA. However, the definitive
cause of RA still remains elusive.
Signaling pathways of Toll-like receptors
Leukocyte recognize pathogen-associated molecular patterns
(PAMPs) such as double-stranded (ds)RNA, unmethylated
DNA, flagellin and lipopolysaccharide (LPS), through a family of
receptors known as pattern recognition receptors (PRRs). TLRs
are a major family of PRRs. The Toll receptor originally found in
Drosophila melanogaster was first described as a protein involved
in embryonic development and, only later, an additional role in
innate immunity was defined [25,26]. Currently, ten human
orthologs of Toll have been described. TLRs are expressed by
APCs and synovial fibroblast-like cells in the RA synovial joint
[27–29]. Some TLRs are found intracellularly in endosomes. These
TLRs (TLR3, 7, 8 and 9) are the only members of the TLR
family that recognize nucleotides (FIGURE 1) [30,31].
All of the TLRs have a cytoplasmic Toll/IL-1 receptor
(IL-1R; TIR) domain shared with the IL-1R family, but show
differences in their extracellular structure. While IL-1R
possesses Ig domains, TLRs have leucine-rich repeats (LRRs) as
their extracellular domains. With the exception of TLR3, TLRs
and IL-1R family members signal using the adaptor myeloid
differentiation primary response gene 88 (MyD88) [32–34],
IL-1R-associated kinase (IRAK)-1, IRAK-4 [32,33,35] and TNF
receptor-associated factor (TRAF)-6 [36]. The outcome of
sequential activation of these signal components is the activa-
tion of inhibitors of nuclear factor (NF)-κB kinase (IKK)
complex and the transcription factor NF-κB. Many NF-κB-
dependent genes are important in the inflammation associated
with RA, and increased NF-κB activation has been observed in
the rheumatoid synovium [37].
MyD88-knockout mice still show activation of NF-κB after
LPS stimulation [38]. This observation led to the discovery of
the TLR adaptors MyD88 adaptor-like (Mal) [39], also termed
TIR domain-containing adaptor protein (TIRAP) [40], TIR
domain-containing adaptor inducing interferon (IFN)-β
(TRIF) [41] (also referred to as TICAM-1 [42]) and TRIF-related
adaptor molecule (TRAM) [43], also known as TICAM-2 [44].
Stimulation of cells with dsRNA or LPS (TLR3 and 4 ligands,
respectively) results in the recruitment of TRIF, and in case of
TLR4, also TRAM, leading to the formation of a complex includ-
ing IKK-ε, TANK-binding-kinase (TBK)-1 and TRAF-3 [45]. The
dissociation of this complex leads to the activation of IFN regula-
tory factor (IRF)-3 and -7, consequently resulting in the expression
of IFN-inducible genes, including IFN-β, IFN-inducible protein
(IP)-10 and RANTES (FIGURE 1) [46–48]. Moreover, TRIF
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recruitment also leads to a MyD88-independent activation of
NF-κB. However, the exact mechanism of NF-κB activation by
TRIF is still unclear. Studies show that binding of receptor-
interacting protein (RIP)-1 to the RIP interacting homology
motif (RIHM) domain of TRIF leads to the induction of
NF-κB, while Covert and colleagues suggest that an autocrine
effect of TNF-α, initially induced through IRF-3, is responsible
for NF-κB activation [49,50]. Besides the activation of NF-κB and
IRFs, stimulation of TLRs also leads to the activation of the
mitogen-activated protein kinase (MAPK) cascades, including
p38 MAPK, extracellular signal-regulated kinase (ERK) and the
c-Jun N-terminal kinase (JNK).
Each TLR recognizes a specific group of ligands, resulting in
the induction of the signaling pathways described above. The
most well-characterized ligands are of exogenous origin
(reviewed in [46]). However, there is increasing evidence that
TLRs also recognize endogenous ligands released during
inflammation, injury or necrotic cell death.
Figure 1. TLR signaling pathways. The IL-1R pathway is solely dependent on the adaptor molecule MyD88 and induces NF-κB through IRAK-4, IRAK-1 and 
TRAF-6. In general, TLR signaling begins following binding of the ligand and the recruitment of the adaptor molecules MyD88, Mal, TRIF and TRAM to the TIR 
domain of the TLR. MyD88-dependent pathway: IRAK-1 and -4 are recruited to the death domain (DD) of MyD88, where they become phosphorylated and 
recruit TRAF-6. IRAK-1 and TRAF-6 dissociate from the receptor and activate the IKK complex, resulting in the translocation of NF-κB to the nucleus and the 
upregulation of proinflammatory genes. Beside the induction of NF-κB, the MyD88-dependent pathway also activates the MAPKs p38 and JNK. This pathway is 
used by TLR1, 2, 4, 5, 6, 7 and 9. Mal, a second TIR domain-containing adaptor protein, is involved in the MyD88-dependent signaling pathway through TLR2 and 
TLR4, and acts as a bridging molecule for MyD88 to these receptors. MyD88-independent pathway: By contrast, TLR3- and TLR4-mediated activation of IRF-3 
and the initiation of IFN-β are observed in a MyD88-independent manner. The adaptor molecule TRIF is essential in this pathway. TRIF recruits and activates RIP-1, 
which is responsible for a late induction of NF-κB as well as TBK-1 and IKK-ε, which form a complex with TRAF-3 activating IRF-3 and IRF-7 and the induction of 
type I IFNs. The fourth adaptor protein, TRAM, which is only involved in TLR4 MyD88-independent signaling, serves as a bridge between TLR4 and TRIF. 
IKK: Inhibitors of NF-κB kinase; IFN: Interferon; IL: Interleukin; IRAK: IL-1 receptor associated kinase; IRF: IFN regulatory factor; JNK: c-Jun-N-terminal kinase; Mal: 
MyD88 adaptor-like protein; MyD88: Myeloid differentiation factor 88; NF: Nuclear factor; RIP: Receptor-interacting protein; TBK: TANK-binding kinase; 
TLR: Toll-like receptor; TNF: Tumor necrosis factor; TRAM: TRIF-related adaptor molecule; TRAF: TNF receptor-associated factor; TRIF: TIR domain-containing 
adaptor inducing IFN-β.
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Toll-like receptors are also stimulated by endogenous ligands
The main role of TLRs is considered to be the recognition and
response to microbial pathogens, but they have also been
reported to recognize endogenous ligands. The evolutionary
conserved Toll pathway in D. melanogaster is induced by binding
of the endogenous protein Spaetzle. This suggests a role for Toll
in recognizing endogenous as well as exogenous ligands. The
recognition of endogenous ligands by mammalian TLRs has
recently gained momentum with increasing numbers of
publications about endogenous TLR ligands (reviewed in [51–54]).
Endogenous ligands are thought to be released during
necrotic cell death induced by tissue damage, stress factors or
infection, and result in the release of cell components that
initiate an inflammatory response [55]. In contrast to apopto-
sis, necrotic cell death is typically associated with inflamma-
tion. This is probably owing to the release of the cell contents
into the surrounding environment, leading to the activation
of adjacent cells [56]. Apoptotic cells retain their membrane
integrity and are cleared rapidly by macrophages before
lysis [57]. This has been demonstrated with dendritic cells
(DCs) that are activated by exposure to necrotic cells, but not
apoptotic cells [58,59]. However, apoptotic particles are often
present in inflammatory conditions and contain single-
stranded (ss)RNA that is capable of stimulating either TLR7
or TLR8, and by forming hairpin loops, also TLR3 [60]. The
contents released from necrotic cells may
activate TLRs, generating further inflam-
mation and thus more necrosis. This
cycle of inflammation may explain the
chronic inflammatory state found in
autoimmune diseases, such as RA
(FIGURE 2). TLRs known to respond to
endogenous ligands are TLR2, 3, 4, 7, 8
and 9. TLR2 and TLR4 respond to struc-
tural proteins released from damaged
cells, whereas TLR3, 7, 8 and 9 respond
to nucleic acids.
Endogenous ligands for TLR2 & TLR4
One of the first reported groups of endo-
genous TLR ligands were the heat-shock
proteins (HSPs), HSP60 [61], HSP70 [62]
and glycoprotein (gp)96 [63]. Recent stud-
ies also suggest HSP22 as a TLR4 ligand
that is able to activate monocyte-derived
DCs [64]. HSP60, HSP70 and gp96 were
reported to signal through TLR2 and
TLR4 [61–63]. Murine DCs and macro-
phages signal in a MyD88- and TRAF6-
dependent manner when stimulated with
HSPs [61–63]. Signaling of HSP60, HSP70
and gp96 through TLR2 was dependent
on endocytosis, whereas signaling via
TLR4 was dependent on the co-receptor
MD-2, similar to LPS signaling [61–63].
However, recent studies have raised doubts about the ability of
HSPs to act as endogenous TLR ligands. Highly purified murine
liver HSP70 did not induce TNF-α release from murine macro-
phages, even at high concentrations [65], leading to suggestions
that the TNF-α-inducing activity previously attributed to
HSP70 [62] was due to endotoxin contamination [66]. Similarly,
other studies using LPS-free preparations of HSP70, HSP60
and gp96 have all suggested that the TLR activity reported pre-
viously may have been due to LPS contamination [66–68].
Contamination in commercially sourced preparations may
occur owing to the isolation process, since all of these products
are recombinant proteins often from Escherichia coli and there-
fore may be contaminated with lipoproteins as well as LPS.
Other studies using expression of gp96 or addition of gp96-
secreting fibroblasts into mice have avoided potential contami-
nation. Activation of APCs was observed in these studies, but it
was unclear if this was due to a direct effect gp96 [69,70]. High-
mobility group box (HMGB)-1 is a molecule released during
cell necrosis [71]. HMGB-1 has been suggested to signal
through TLR4 as it shares a similar signaling pathway to LPS
when stimulating human endothelial cells and neutrophils
[72,73]. However, neutrophils lacking TLR4 still respond to
HMGB-1 [74]. A recent study demonstrated a role for TLR2
and TLR4 in recognizing HMGB-1 and the subsequent
activation of NF-κB [75].
Figure 2. Hypothesis for TLR participation in rheumatoid arthritis. (A) The release of endogenous TLR 
ligands (e.g., HMGB-1, RNA) due to cell necrosis, breakdown of extracellular matrix or infections 
subsequently leads to the activation of TLRs on the synovial membrane (which mainly consists of synovial 
fibroblasts, macrophages). As a result, proinflammatory cytokines and chemokines that induce 
inflammation are produced. (B) Exogenous TLR ligands from bacterial or viral infection may activate TLRs 
resulting in inflammation. (C) The inflammation generated by endogenous and/or exogenous ligands may 
cause cells to undergo necrotic cell death and release endogenous TLR ligands. 
DC: Dendritic cell; HMGB: High-mobility group box; HSP: Heat shock protein; TLR: Toll-like receptor.
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Another source of endogenous TLR2 and TLR4 ligands is
the remodeling and/or destruction of the ECM due to tissue
damage. This process results in the release of fragments from
ECM components that can induce inflammation. Heparan
sulphate is associated with the cell membrane as well as part of
the ECM [76] and is only found at low levels in healthy tissue.
Increased levels of heparan sulphate are detected in the extra-
cellular fluid around injuries [77], in RA synovium [78] and in
urine from patients with infections [79]. Hyaluronic acid (HA),
a major component of the ECM, is degraded rapidly at sites of
inflammation [80,81]. Both heparan sulphate and HA have been
shown to signal through TLR4. DCs from the C3H/HeJ
mouse, which expresses a nonfunctional TLR4, do not respond
to either stimulus [81,82]. Fragments of hyaluronan released
during injury can also stimulate TLR4 [83] and biglycan, a ubiq-
uitously expressed proteoglycan in the ECM, has been reported
to signal through TLR2 and TLR4 in macrophages [84].
Fibronectin is released from cells in response to tissue damage
[85–88] and is able to stimulate synovial cells to release pro-
inflammatory cytokines and MMPs [87]. Studies using trans-
fected TLR4 human embryonic kidney (HEK)293 cells have
shown fibronectin to be a ligand for TLR4 [89].
While HSPs, HA, heparan sulphate and fibronectin are
released as a result of cell necrosis or ECM remodeling, other
endogenous TLR ligands are a sign of inflammation or infec-
tion. These include fibrinogen and β-defensins. Fibrinogen is
an early hallmark of inflammation. It migrates from the vascu-
lature into the extravascular space during inflammation owing
to increased permeability of endothelial cells [90]. Data from
macrophage cell lines have shown that fibrinogen-induced
secretion of macrophage inflammatory protein (MIP)-1α,
MIP-1β and MIP-2 requires functional TLR4 [91].
Murine β-defensin2, an antimicrobial peptide of the innate
immune response, has been shown to stimulate TLR4 on
immature DCs, inducing maturation and upregulation of
costimulatory molecules [92]. β-defensin can also act as a
chemoattractant of immature DCs [93,94].
Endogenous ligands for TLR3, 7 & 8
The exogenous ligand for TLR3 is dsRNA and not ssRNA [95],
which is instead recognized by TLR7 and TLR8 [96]. Although
cellular RNAs are mainly regarded as ssRNA, they can form
hairpin loop formations that act as sources of endogenous
dsRNA [97]. Endogenous dsRNA released from necrotic cells
stimulates DCs to produce IFN-α, whereas pretreatment of
necrotic cells with RNase prior to incubation with DCs pre-
vented this response [95]. ssRNA-associated autoantigens have
been reported to activate B cells by combined B-cell antigen
receptor–TLR7 engagement in mice [98].
Endogenous ligands for TLR9
Genomic DNA also triggers the maturation of DCs and macro-
phages. Nonmethylated CpG motifs in bacterial and viral
DNA are recognized by TLR9, but endogenous DNA on its
own is normally inert [99]. The defining difference between
bacterial and endogenous DNA is that bacterial DNA is
unmethylated, while endogenous DNA is 70–80% methylated
[100]. However, cells from autoimmune humans and mice show
decreased CpG methylation [101], yet demethylation of murine
DNA does not enable it to stimulate B cells [102]. Thus, the
mechanism of activation by bacterial and endogenous DNA
appears to be more complex than simply methylation. Given
that TLR9 is capable of recognizing self-DNA (IgG–chroma-
tin) complexes in B cells [24], in situations where necrotic cells
are abundant, the DNA released may form autoantibody
immune complexes that can stimulate TLR9. The discovery of
endogenous TLR ligands described above suggests a possible
role for TLRs in sensing tissue damage and in the generation of
inflammation in autoimmune diseases.
Role of Toll-like receptors in inflammatory diseases
The potential of TLRs to recognize endogenous ligands may
have an effect on the consequent development of autoimmune
disease and chronic sterile inflammatory disorders. Several
studies suggest a role for TLRs in the promotion of systemic
lupus erythematosus (SLE), Crohn’s disease, multiple sclerosis,
Type 1 diabetes, in the repair of lung injuries and in RA
(TABLE 1). Although most studies show a role in disease pro-
gression or development, some TLRs can also facilitate tissue
protection from injury; for example, TLR2 and TLR4 recog-
nize microbes in the gut or hyaluronan degradation products in
the lungs [103,104]. The outcome of TLR activation, be it inflam-
mation or tissue protection, may be dependent on the type of
stimulus encountered.
Evidence for a role for Toll-like receptors in rheumatoid arthritis
TLRs were first suggested to have a role in RA in response to a
pathogen initiating disease [105]. Bacterial TLR ligands have
been detected in human RA synovium [105], but they have also
been found in synovial tissue of healthy donors without any
inflammatory response [106]. B cells, activated by chroma-
tin–IgG complexes binding to the antigen receptor and TLR9,
produce RF independently of T cells. However, reports of
bacterial DNA in the synovium of RA patients [105,107,108] were
called into question by a more specific study detecting the
bacterial marker muramic acid that did not identify any
bacterial components in RA patients [109]. The search for a
pathogenic stimulus initiating RA has proven unsuccessful and
the focus now has turned to the involvement of endogenous
TLR ligands. Possible sources of endogenous TLR ligands
include cell necrosis due to tissue damage or inflammation.
Hyaluronan oligosaccharides, fibronectin fragments, HSPs,
necrotic cells, antibody–DNA complexes and HMGB-1 have
all been identified in the RA joint [110–113].
Several animal models used bacterial cell wall components to
induce experimental arthritis. The injection of streptococcal
cell wall (SCW), containing a peptidoglycan–polysaccharide
fragment, into rats led to a chronic arthritis comparable to
human RA [114]. Similar experiments in mice showed that the
induction of joint inflammation by SCW was dependent on
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TLR2 and MyD88, since TLR2- or MyD88-knockout mice
showed a reduced severity of SCW-induced joint inflamma-
tion [115,116]. In addition, the intra-articular administration of
the TLR2 and NOD2 ligand peptidoglycan also led to the
development of destructive arthritis in mice [117]. As well as
TLR2, there is also evidence for a possible role for TLR4 in
RA [118]. The administration of LPS together with arthrito-
genic serum in IL-1R-deficient mice, but not in MyD88-
deficient mice, resulted in acute paw swelling. Moreover,
serum-transferred arthritis was not sustained in TLR4 mutant
mice compared with controls [118]. Thus, animal disease models
show a possible role for TLR2 and TLR4 in RA.
Expression of TLR2, 3, 4, 7 and 9 has been observed in
human synovial tissue from RA patients [27–29,119,120]. TLR2
expression was identified in synovial fibroblasts, CD16+ mono-
cytes and CD16+ macrophages in the synovium [28,29,121]. Inter-
estingly, expression of TLR2, 3 and 4 is increased in the syno-
vial tissue of RA patients compared with healthy donors or
osteoarthritis (OA) samples used as controls [27,119]. Stimulation
of TLR2- and TLR9-expressing RA synovial fibroblasts with
peptidoglycan, a TLR2 ligand, leads to the expression of MMPs
and secretion of IL-6 and IL-8, while there is no activation in
response to the TLR9 ligand CpG oligodeoxynucleotides [121].
More recently, RNA released from synovial fluid cells, necro-
tized by freeze/thawing, was shown to activate synovial fibro-
blasts via TLR3 [119]. Evidence for a TLR4 ligand in the serum
and synovial fluid of RA patients has been observed. Serum and
synovial fluid from RA patients stimulated TLR4-expressing
Chinese hamster ovary (CHO) cells to upregulate CD25, but
had no effect on untransfected CHO cells [120].
The DNA-binding protein HMGB-1 is released passively
during cell necrosis as well as actively upon LPS, TNF-α or
IL-1 stimulation of macrophages [71,122]. Therefore, it can
function as a mediator of inflammatory responses through
binding to TLR2 and TLR4, the activation of NF-κB and the
induction of proinflammatory cytokines [72,73,75]. A role for
HMGB-1 in RA has been suggested as it was detected in the
synovial fluid of RA patients and Lewis rats with
M. tuberculosis-induced adjuvant arthritis [123]. Moreover,
synovial fibroblasts show higher expression levels of HMGB-1
in RA patients compared with OA patients, which was
suggested to result in the release of proinflammatory
cytokines by RA synovial fibroblasts [113].
Naturally occurring TLR polymorphisms may indicate the rel-
evance of TLR function in human RA. The amino acid sub-
stitution Asp299Gly in the TLR4 gene results in the disruption
of TLR4 signaling and two studies investigating this poly-
morphism found no correlation with susceptibility to RA
[124,125]. Similarly, polymorphisms Arg677Trp and Arg753Gln in
the TLR2 gene and Asp299Gly and Thr399Ile in the TLR4 gene
also showed no association with RA [126]. However, a study by
Radstake and colleagues found a lower susceptibility to RA while
the severity seemed unaffected [127]. The presence of TLRs and
their ligands in RA may indicate a role for these receptors in the
onset and progression of the disease. 
Potential ways to target Toll-like receptor signaling pathways in 
rheumatoid arthritis
The data from murine models and human studies could
suggest that TLRs have a potential role in RA. Ultimately, if
TLRs prove to be functionally linked to inflammation in RA,
inhibitors of TLR-associated signaling pathways will become
attractive candidates for future therapies, offering the poten-
tial of a more target-specific inhibition of inflammation in
RA. Two of the DMARDs used in the clinic may attribute
some of their beneficial action to modulation of TLR signal-
ing. Hydroxychloroquine inhibits endosomal acidification,
thus inhibiting the TLRs that are localized intracellularly, but
would have no effect on those expressed at the cell surface.
Hydroxychloroquine has also been reported to decrease
mRNA expression of TLR4 and TLR9 [128]. However, it also
has many other modes of action that may produce the benefi-
cial effects observed, including inhibition of processing of
pro-TNF-α and thus secretion of the mature form of TNF-α,
as well as inhibition of IL-6 and IL-1β mRNA stability [129].
Glucocorticoids, another treatment used in RA, have recently
been shown to disrupt MyD88-dependent formation of
IRF/p65 complexes [130].
Table 1. Toll-like receptors were shown to be involved in inflammatory diseases and injury. 
Disease/injury Toll-like receptor Potential ligands Ref.
Systemic lupus erythematosis TLR7, TLR8, TLR9 RNA, immune complexes, double-stranded DNA [60,98,172–174]
Atherosclerosis TLR2, TLR4 Fatty acids [175–188]
Diabetes (Type 1) TLR3, TLR7 RNA [189–191]
Multiple sclerosis TLR4, TLR9 ? [192–200]
Crohn’s disease TLR2, TLR5, TLR9 Microbial antigens, bacterial DNA [201–209]
Rheumatoid arthritis TLR2, TLR3, TLR4, TLR9 HMGB-1, RNA, HSP22, bacterial DNA [27–29,64,71–75,105–126,210–218]
Tissue damage TLR2, TLR4 Hyaluronan, microbial antigens [103,104]
HMGB: High-mobility group box; HSP: Heat shock protein; TLR: Toll-like receptor.
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New strategies to inhibit some aspects of the TLR signaling
pathway are already under investigation. For an overview of
TLR signaling, see FIGURE 1. Numerous endogenous negative
regulators of TLR signaling, including single-Ig-IL-1R-related
(SIGIRR) and IRAK-M, have been described (reviewed in
[131,132]), but these proteins would be difficult to administer as
a therapy. NF-κB is a transcription factor with an important
role in regulating inflammatory cytokines and chemokines.
TLR stimulation leads to the nuclear translocation of NF-κB
and the induction of inflammatory genes, including TNF-α
and IL-6, as well as costimulatory molecules and MHC Class
I and II in APCs [133]. NF-κB activation is also involved in
bone resorbtion due to osteoclast maturation [134] and in the
inhibition of chondrocyte differentiation and the repair of
damaged cartilage [135,136]. In addition, increased nuclear
localization of NF-κB has been shown in macrophages and
fibroblast-like synovial cells from RA patients [137–139]. Our
own in vitro studies show that overexpression of inhibitor of
NF-κBα (IκBα) in synovial tissues result in suppression of
proinflammatory cytokines, such as TNF-α [140,141], while
anti-inflammatory mediators, including IL-10, were unaf-
fected [142]. Similar results were obtained in murine models of
RA where NF-κB inhibition resulted in a downregulation of
MMP1 and MMP3 [37,143–145].
A NF-κB inhibitor already approved by the US FDA for the
treatment of multiple myeloma is the proteasome inhibitor
bortezomib (Velcade®; Millenium). By inhibiting the 26S sub-
unit of the proteasome, it prevents the degradation of IκBα and
therefore the translocation of NF-κB to the nucleus. However,
because the proteasome is involved in a great variety of regula-
tory processes, it is currently unclear if the effects observed are
due specifically to inhibition of IκBα degradation. Moreover,
the treatment of chronic inflammatory disease, such as RA,
makes it necessary to administer bortezomib over a long period
of time and thus may lead to unacceptable side effects.
Instead of targeting the proteasome, which is involved in a
number of cellular functions, the inhibition of IKK2, which
phosphorylates IκBα and results in its degradation, is a more
specific approach to block NF-κB. Although major efforts were
undertaken in the development of IKK2 inhibitors, no com-
pound is in further clinical trials, so far [146]. However, initial
experiments showed that the inhibition of IKK2 can reduce the
severity of collagen-induced arthritis, indicating a potential use
in the treatment of inflammatory diseases (for review see [146]).
MAPKs are a family of kinases involved in cellular stress and
TLR signaling pathways. These include p38, p42/44 (extra-
cellular signal-regulated protein kinases [ERK]1/2) and p46/54
(JNK). Signaling via MAPKs leads to activation of the trans-
cription factor activating protein (AP)-1 and the transcription
of proinflammatory cytokines. Although all three MAPKs
appear to be activated in the synovial tissue of RA patients
[147,148], only the inhibition of p38 MAPKs leads to a suppres-
sion of TNF-α production in LPS-stimulated macrophages
[149–151]. Different methods of TNF-α regulation by p38 have
been suggested. In human rheumatoid synovial cells, mRNA
stabilization mediated through p38 was suggested to control
TNF-α production, while, in human macrophages, p38 was
also shown to regulate NF-κB activation and thereby TNF-α
expression [152]. In vivo studies in murine and rat models of
arthritis using the p38 MAPK inhibitors, SB 203580 [153], SB
220025 [154], SB 242235 [155], RWJ 67657 [156] or
PRP200765A [157], showed a reduction in the severity of
arthritis. The major problem of p38 MAPK inhibitors is their
toxicity. However, this seems to be related to unspecific effects
of the inhibitors rather than to p38 inhibition.
Upstream of MAPKs and IKK2 are the family of IRAKs,
consisting of four distinct members, two of which, IRAK-1 and
-4, are involved in signaling from the IL-1R and TLRs. IRAK-1
and -4 are recruited to the receptor by MyD88 where they
become phosphorylated and complex with TRAF-6 (FIGURE 1).
This complex then dissociates from the receptor, activating the
IKK complex, ultimately allowing translocation of NF-κB to
the nucleus. Other IRAK family members include the inactive
kinases IRAK-2 and IRAK-M. IRAK-M is an endogenous
inhibitor of TLR signaling that inhibits the dissociation of
IRAK-1 and -4 from the TLR complex [36]. Patients with
mutated, inactive IRAK-4 suffer from repeated, severe bacterial
infections, are highly susceptible to Gram-positive infections
and exhibit hyporesponsiveness to LPS, IL-1 and IL-18
[158–160]. Although there are endogenous inhibitors of TLR
signaling, such as IRAK-M, these suppressors would be difficult
to administer successfully during treatment. Therefore,
development of inhibitors of IRAK1 and IRAK4 could lead to
IL-1R- and TLR-specific inhibition of NF-κB. This approach
would provide a strategy to inhibit the MyD88-dependent
pathway selectively, leaving the MyD88-independent pathway
intact (FIGURE 1).
A novel inhibitor of TLR signaling pathways is the phyto-
alexin resveratrol found in the skin of red grapes and plums.
Resveratrol is a polyphenol that protects the plant from fungal
infection and a variety of plant diseases [161,162]. In mammalian
models, resveratrol demonstrates anti-inflammatory effects such
as the inhibition of cyclooxygenase (COX)-2 and inducible
nitric oxide synthase (iNOS) [163], and the suppression of
macrophage activation [164]. Initially, these effects were attrib-
uted to inhibition of NF-κB activation and the suppression of
target gene expression, but more recently the direct molecular
targets of resveratrol were shown to be TBK-1 and RIP-1, which
are part of the MyD88-independent pathway (FIGURE 1) [165].
Inhibition of NF-κB and IRF-3 activation by resveratrol seems
to be selective for the MyD88-independent pathway, while the
MyD88-dependent pathway is unaffected [165].
Another plant extract that was shown to inhibit TLR
signaling is ginsan, a polysaccharide found in Panax ginseng.
Mice pretreated with ginsan and consequently challenged with
Staphylococcus aureus showed a lower incidence of septic shock.
This protection against lethal doses of S. aureus seems to be due
to the downregulation of TLR2 and MyD88 and consequently
the inhibition of MAPKs and NF-κB and attenuated cytokine
production [166].
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An immune modulatory role has been suggested for
vitamin D3 [167,168]. Recently, a study found that vitamin D3
downregulated the expression of TLR2 and TLR4 in human
monocytes in response to lipoteichoic acid and LPS, respec-
tively, which led to an inhibition of MAPK and NF-κB and
consequently to the inhibition of TNF-α [169].
The most specific way to target TLR signaling in RA would
be to identify which TLRs are important in inflammatory
signaling and to target these individually at the receptor level.
One approach to inhibit TLR activation is to use TLR neutrali-
zing antibodies that are currently available for some of the
TLRs. However, since different ligands using the same TLR
may bind to different sites on the receptor, a disadvantage of this
approach is that individual blocking antibodies may not work to
inhibit signaling of different ligands sharing the same TLR. Yet
another way to inhibit TLR activation has been demonstrated
for TLR9 by use of immunoregulatory DNA sequences (IRS).
Although the mechanism of these IRS is still unknown, it has
been suggested that the cellular uptake of CpG motifs is unaf-
fected and that the IRS do not compete for binding of the
receptor [170]. This technique has been used to inhibit collagen-
induced arthritis, initiated by bacterial CpG-containing DNA.
In this case, mice treated with IRS before the onset of arthritis
showed decreased production of inflammatory cytokines and
chemokines [171]. These studies suggest that IRS might be a
promising therapeutic agent in the treatment of RA.
Most of the current inhibitors of the TLR signaling pathway,
including the transcription factor NF-κB and p38 MAPK, also
target several other signaling pathways and therefore, their use
as therapeutics may cause major side effects, including hypo-
responsiveness to endotoxin and severe bacterial infections. In
chronic inflammatory disease, such as RA, it is necessary to
administer a drug over a long period of time, making unwanted
side effects particularly unacceptable. Therefore, it is necessary
to develop a more specific inhibition of TLR signaling. An
ideal therapy would be to target individual TLRs, although, at
present, their involvement in RA still needs to be defined.
Identification of the function of TLRs in RA and those that are
actually involved is required before specific therapies can be
developed. It is likely that, in such a complex multicellular
environment, there will be a cocktail of ligands and several
receptors influencing the pathogenesis of RA and thus it is
likely that more than one TLR is involved. The generation of a
specific TLR-targeted therapy could offer benefits of improved
specificity with a reduced impact on the immune system. It is
also likely that different sets of TLRs will influence different
inflammatory diseases.
Expert commentary & five-year view
TLRs have an important role in the innate immune response
recognizing microbial products as well as having a protective
effect in tissue damage. However, the recent recognition that
endogenous ligands for TLRs exist has potentially implicated
these receptors in the pathogenesis of a number of autoimmune
diseases, including RA, and may have a common role in the
initiation of chronic inflammatory conditions. Evidence for a
role of TLRs in RA has come from in vitro studies and murine
models where pathogens are used to induce arthritis. While the
initiating cause of RA still remains elusive, it seems unlikely
that, during chronic inflammation, the TLRs in the joint are
stimulated by a pathogen. A more probable source of TLR
ligands is endogenous molecules released from damaged tissue
and necrotic cells. Necrotic cells are known to induce inflam-
mation and this may be a source of more endogenous TLR
ligands whose release produces a further cycle of inflammation.
In recent years, expression and upregulation of TLRs in the
synovium of RA patients have been observed and evidence for
TLR4 ligands in the synovial fluid of RA patients has been
published. However, a functional link between TLRs and RA
remains still elusive.
Key issues
• Rheumatoid arthritis (RA) affects approximately 0.5–1% of the adult population, making it one of the most prevalent 
autoimmune diseases.
• Toll-like receptors (TLRs) are suggested to have a role in the inflammatory and destructive processes of RA through the recognition 
of endogenous TLR ligands.
• Increasing evidence suggests an involvement of TLRs in other autoimmune disease, such as atherosclerosis, multiple sclerosis and 
Type 1 diabetes.
• Emerging evidence implicates a role for pattern recognition receptors in the pathogenesis of gout, another inflammatory disease of 
the joints.
• Animal models of RA suggest an involvement of TLRs in the disease.
• Endogenous TLR ligands may be released owing to cell necrosis and tissue damage, initiating a cycle of inflammation.
• TLR receptors are expressed in the RA synovium and endogenous TLR3 and TLR4 ligands have been identified in RA synovial fluid.
• Inhibition of TLR signaling is an attractive future therapy for RA. It could provide a more specific effect without globally impairing 
the immune system, making it more suitable for long-term treatment.
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TLRs make attractive candidates for a future therapeutic
target for autoimmune diseases, including RA. Although inhib-
itors targeting some components of the TLR signaling pathway
are available, their actions are often on molecules shared by
other signaling pathways impeding their use in long-term
therapy. In such a complex multicellular environment, it is
plausible that more than one TLR will be involved in the
inflammatory response to endogenous ligands. Inhibition of
combinations of TLRs to suppress the chronic inflammation
observed in RA without affecting other TLRs or immune sig-
naling pathways would be advantageous in dampening down
inflammation in RA, while permitting continued surveillance
of pathogens and tissue damage by other receptors to mount an
immune response. 
Future work will expand our knowledge of TLR expression in
RA and will determine the cell types expressing each TLR and
how expression levels change with disease progression. Further
characterization of the TLRs known to be expressed in the rheu-
matoid synovium, for example, TLR2, 3, 4 and 7 will be intensi-
fied through the use of specific blocking antibodies as well as
emerging technologies, such as short interfering RNA. Further-
more, it will be necessary to consider a dual function of TLRs in
tissue protection as well as inflammation. Studies in mice models
of gut and lung injury support this emerging role for TLRs. Con-
sequently, impairment of TLR signaling may reduce inflamma-
tion in the joint, but may also enable accelerated tissue destruc-
tion. Therefore, further research will be necessary to establish the
role of TLR signaling in the rheumatoid synovium.
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INTRODUCTION
Many anti-inflammatory drugs currently used
in clinical rheumatology are limited by lack of
target specificity and a broad range of side
effects consequent upon this. Thus, there is
much interest in the possibility of developing
improved targeted therapies that will have
greater clinical efficacy combined with a narrower
range of side effects.
The most significant recent advance in the
clinical management of auto-inflammatory con-
ditions including rheumatoid arthritis (RA) has
been the advent of the biopharmaceuticals that
target cytokines. Chief amongst these are the
blockers of tumor necrosis factor (TNF)-α, inflix-
imab (Centocor), a chimeric murine-human anti-
TNF monoclonal antibody (mAb);1 etanercept
(Amgen), a TNF receptor-Fc fusion protein;2 and
adalimumab (Abbott Laboratories), a fully
human anti-TNF mAb.3 In addition, there has
been success with blockade of interleukin (IL)-1
in RA using recombinant IL-1 receptor antago-
nist (IL-1Ra; anakinra, Amgen),4,5 and with
blockade of IL-6 by the humanized anti-IL-6
receptor mAb, tocilizumab (Hoffman-La-Roche).6
However, the biopharmaceuticals have prob-
lems associated with their use including, cost,
route of administration, and side effects.7 They
are also not universally efficacious in all patients.
Thus, there is still a great unmet medical need for
the development of targeted anti-inflammatory
drugs that will overcome some of these problems.
In order to build on the clinical success of the
biopharmaceuticals while circumventing some
of the associated problems, attention has
focused on alternative strategies for inhibiting
cytokine signaling. The transcription factor
nuclear factor-κB (NF-κB) is activated by TNF-α,
IL-6, and IL-1, and these genes are also under
regulation by NF-κB.8 Thus, inhibition of compo-
nents of the NF-κB signaling pathway has come to
be regarded as a promising alternative strategy for
development of novel drugs to block the effects 
of excessive cytokines in auto-inflammatory 
diseases.
As the understanding of pathological cellular
signaling in disease states improves, it is becom-
ing feasible to apply this knowledge to identify
novel drug targets and then seek compounds
that act on these as a route to develop novel
drugs. The efficacy of this approach has already
been demonstrated by the development of the
tyrosine kinase inhibitor imatinib (Novartis)9
that targets constitutive tyrosine kinase signal-
ing in chronic myeloid leukemia. In the future it
is likely that an increasing number of drugs will
be developed in this way.
This chapter discusses evidence that several
anti-inflammatory agents currently in routine
clinical use, in part, owe their anti-inflammatory
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effects to NF-κB inhibition. Current work to
develop more targeted inhibitors will then be
reviewed before discussing potential routes for
the development of novel NF-κB inhibitors in
the future.
THE NF-κB TRANSCRIPTION FACTOR FAMILY
The transcription factor NF-κB is involved in
numerous cellular processes including develop-
ment, inflammation, and immunity.10 It consists
of homo- or hetero-dimers of the subunits, c-Rel
(also known as Rel); RelA (also known as p65
and NF-κB3); RelB, NF-κB1 (also known as p50),
and NF-κB2 (also known as p52). All five sub-
units contain the characteristic Rel homology
domain (RHD), which enables the subunits to
dimerize and to bind to the promoter of target
genes.8
NF-κB signaling is divided into two distinct
signaling pathways, known as the canonical and
the alternative (non-canonical) NF-κB pathways.
Central to the canonical pathway is the formation
of the NEMO (NF-κB essential modulator)/IKK
(inhibitor κB kinase)1/IKK2 complex, the degra-
dation of inhibitor-κB (IκB)α, following its phos-
phorylation, and the translocation of p50/RelA
heterodimers to the nucleus (Figure 47.1). In con-
trast, the alternative pathway is activated by
IKK1 phosphorylating NF-κB2 and marking it for
processing by the proteasome. The processed p52,
dimerized with RelB, subsequently translocates
to the nucleus (Figure 47.1).
The most common dimer in the canonical 
NF-κB pathway, consisting of p50/RelA, is
bound to the inhibitor, IκBα, in the cytosol in the
quiescent state (Figure 47.1). IκBα is the arche-
typical NF-κB inhibitor in an evolutionary con-
served inhibitor family consisting of IκBβ, IκBe,
B cell CLL/lymphoma (Bcl)-3, IκBζ, and IκBNS
as well as IκBγ, which is a degradation product
of NF-κB1 and of NF-κB2.8,11,12 With the excep-
tion of Bcl-3 and IκBζ, these proteins can inhibit
the translocation of NF-κB dimers to the nucleus
by interacting with the RHD and thereby inacti-
vate the nuclear localization signal (NLS). IκBβ
resembles IκBα in its primary as well as tertiary
structure. However, while IκBα degradation
leads to a rapid oscillatory NF-κB activation,
IκBβ degradation results in prolonged NF-κB
activation.8,13,14 This prolonged activation
appears to be required for numerous pathologi-
cal conditions including asthma and cystic fibro-
sis.13,15–21 The oscillatory propensity in the NF-κB
signaling system is counteracted by a negative
feedback mechanism mediated by IκBε, which is
delayed and functions in anti-phase to IκBα.22
This indicates that cells have the capacity to
modulate NF-κB activity depending on cell type
and stimuli. Beside the canonical inhibitors
IκBα, IκBβ, and IκBε, the two IκB family mem-
bers Bcl-3 and IκBζ seem to have a more multi-
faceted role. Bcl-3 specifically interacts with the
intrinsically inactive NF-κB1 and NF-κB2
homodimers in the nucleus and is not degraded
after cellular stimulation.23–26 Depending on its
phosphorylation status it can either act as an
inhibitor, dissociating p50 or p52 homodimers
from DNA, or as a co-activator that is recruited
to the gene promoter by NF-κB1 or NF-κB2
homodimers.23–28 The recently described IκBζ is
highly homologous to Bcl-3. 29–34 Its transcription
is rapidly induced upon stimulation with Toll-like
receptor (TLR) ligands and IL-1. Cells from IκBζ-
deficient mice show a severe impairment of IL-6
production in response to a variety of TLR 
ligands and IL-1 but not in response to TNF-α.35
Similar results were obtained using NF-κB1
knockout mice, which might indicate that IκBζ
specifically interacts with the NF-κB1 subunit.35
On the other hand, IκBNS seems to have the
opposite role to IκBζ, as it was shown to selec-
tively inhibit IL-6 production in response to
lipopolysaccharide (LPS).36 Furthermore, mice
deficient in IκBNS are highly susceptible to LPS-
induced endotoxic shock and intestinal inflam-
mation, most likely due to prolonged activation
of NF-κB.37
In order to allow the release of NF-κB dimers
IκBs need to become phosphorylated by IKKs.38
The IKK complex, inducing the canonical NF-κB
pathway, consists of the regulatory subunit
NEMO and the catalytic subunits IKK1 and
IKK2.39 While NEMO and IKK2 appear to be
essential for NF-κB activation, cells lacking IKK1
still show normal levels of NF-κB DNA binding
activity.40–45 Subsequently, IKK1 kinase activity
was found to be involved in the resolution of
inflammation, induced by NF-κB activation, by
accelerating the turnover of NF-κB and its
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release from the gene promoter.46 In addition,
IKK1 was shown to be an activator of the alter-
native NF-κB pathway47–49 (Figure 47.1). IKK1
homo-dimer complexes induce the processing of
NF-κB1 to p50 and consequently the nuclear
translocation of p50/RelB hetero-dimers. While
the NEMO/IKK1/IKK2 complex is required for
NF-κB activation in response to most NF-κB
stimuli, the role of the two non-canonical IKKs
IKKε (also known as IKKi) and TBK-1 (TNF
receptor associated factor family member-
associated NF-κB activator binding kinase), 
is unclear. Both were shown to be involved in the
induction of interferon (IFN) regulatory factor
(IRF)-3 in response to the TLR4 ligand LPS and the
TLR3 ligand dsRNA.50 Their role in the activation
of NF-κB, however, is still not well understood.
Phosphorylation of IκBα by the IKKs and its
subsequent proteasomal degradation releases 
NF-κB dimers to translocate to the nucleus and
activate target genes.47 However, NF-κB dimers
need to undergo additional post-translational
modifications, including site-specific phosphory-
lation and acetylation to produce a maximal
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Figure 47.1 Illustration of the canonical and alternative NF-κB signaling pathways. The canonical NF-κB is depicted on the left
side of the diagram. It is activated by proinflammatory mediators including TNF-α, IL-1, TLR ligands, and CD40L. Ligand binding
ultimately leads to the activation of the IKK complex consisting of the regulatory subunit NEMO and the catalytic subunits IKK1
and IKK2. The endogenous inhibitor of NF-κB, IκBα, is phosphorylated by the IKK complex, which leads to its ubiquitination and
as a result to its degradation by the proteasome. The released NF-κB dimer translocates to the nucleus where it induces tran-
scription of genes involved in immunity, inflammation, and cell survival. The alternative NF-κB signaling pathway is depicted on
the right. It is induced by lymphotoxin αβ, CD40L, and BLyS. Activation of these receptors leads to the activation of IKK1. IKK1
phosphorylates p100, which becomes degraded to p52 by the proteasome and as a result translocates to the nucleus as a
dimer with RelB. The alternative pathway is involved in the organogenesis of lymphoid organs and in humoral immunity. NF-κB,
nuclear factor-κB; TNF, tumor necrosis factor; IL, interleukin; TLR, Toll-like receptor; IKK, inhibitor of kappa kinase; NEMO, NF-κB
essential modulator; IκBα, inhibitor-κBα; BLyS, B-lymphocyte stimulator.
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transcriptional response.51,52 The most well stud-
ied NF-κB subunit in terms of post-translational
modifications is RelA. Several serine phosphory-
lation sites for RelA have been described includ-
ing serines 276, 311, 529, and 536.51 Kinases
involved in the phosphorylation of these serine
residues include protein kinase A (PKA), mito-
gen- and stress-activated kinase (MSK)-1, protein
kinase C (PKC)ζ, ribosomal subunit kinase
(RSK)-1, glycogen-synthase kinase (GSK)-3β,
and phosphatidylinositol 3-kinase (PI3K), as well
as the canonical IKKs and TBK1.51 The kinases
involved in serine phosphorylation appear to be
stimuli-specific, e.g. PKA phosphorylates serine
276 in response to LPS while TNF-α triggers the
phosphorylation of serine 276 by MSK1.51
Ultimately serine phosphorylation leads to an
enhancement in the overall transcriptional
response. Similarly, acetylation is important for
regulating NF-κB activity. Also, three main
acetylation sites have been identified within
RelA (lysines 218, 221, and 310).53 The acetyl-
transferases p300 and cAMP response element
binding protein (CBP) seem to be involved in
RelA acetylation in vivo53,54 and acetylation of
RelA was reported to be regulated by phospho-
rylation of its serine residues 276 and 536, as
phosphorylation increases the assembly of
phosphoRelA-p300 complexes.55 Acetylation of
RelA results in different outcomes, as acetylation
of lysine 221 enhances DNA binding and
impairs assembly with IκBα, the acetylation of
lysine 310 is required for full transcriptional 
activity of RelA.51
Inhibiting the amplification of NF-κB activity
due to post-translational modification may 
provide a way to dampen the response generated
by proinflammatory stimuli without affecting the
basal activity of NF-κB, which is suggested to be
beneficial by preventing undesired apoptosis.56
Nuclear translocation of NF-κB dimers 
allows their binding to κB sites in the promoter
of the target gene. Several studies have
attempted to identify DNA sequence specificity
of different NF-κB dimers.8,57–63 However, κB
sites display a remarkably variable consensus
sequence.8 The classical κB nucleotide sequence
is G-G-G-R-N-N-Y-Y-C-C8 (where N = any base,
R = purine, and Y = pyrimidine). This may sug-
gest the possibility that the κB site, rather than
determining the ability of a particular dimer to
bind effectively, affects which coactivator forms
productive interactions with the bound NF-κB
dimer. Unpublished results from our group sug-
gest that even greater complexity of regulation
of gene expression by κB sites exists. The κB sites
of the TNF-α gene may be both inhibitory 
and stimulatory under specific conditions. One
possible explanation is that the binding sites
may affect the tertiary structure of the activation
complex.
NF-κB activators and its outputs
The NF-κB pathway described above integrates
signals from a wide range of stimuli and in turn
activates numerous cellular responses.64 This
section will discuss NF-κB activation in the 
context of inflammation.
The canonical pathway is mainly stimulated
by inflammatory signals including TNF-α, 
IL-1, IL-17, and CD40 ligand (CD40L), as well as
pathogen-associated molecular patterns
(PAMPs) recognized by TLRs and nucleotide
oligomerization domain (NOD) receptors.65–68
The activation of NF-κB by these stimuli leads to
the expression of inflammatory mediators such
as cytokines, chemokines, cell adhesion mole-
cules, inducible nitric oxide synthase (iNOS),
anti-apoptotic proteins, costimulatory mole-
cules, matrix metalloproteinases (MMPs), and
cyclooxygenase (COX).69 The canonical NF-κB
pathway leads to the maturation and activation
of macrophages and dendritic cells (DCs) and
consequently to the induction of the innate and
adaptive immune response and inflammation.
In the case of TNF-α-induced signaling, NF-κB
has been shown to be an activator of anti-apoptotic
gene expression.70–73 This outcome of NF-κB sig-
naling has been shown to depend on the termi-
nation of c-Jun N-terminal kinase (JNK)
activation.74,75 Therefore, TNF-α signaling may
result in apoptosis, if JNK is activated, or prolif-
eration, if NF-κB activation prevails.76 This indi-
cates that these signaling pathways are not
strictly linear but that there is cross-talk between
different signaling pathways taking place 
which influences the outcome of receptor stimu-
lation. Therefore, inhibition of one signaling
pathway may also affect the outcome of other
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signaling pathways. In addition, NF-κB exhibits
different activation dynamics depending on the
stimulus. While showing an oscillatory dynamic
when stimulated with TNF-α, this is not observed
when stimulated with the TLR4 ligand LPS.77
These differences are associated with distinct 
signaling pathways induced by those stimuli.
Strong inducers of the alternative NF-κB
pathway are lymphotoxin (LT), CD40L, and 
B-lymphocyte stimulator (BLyS). Unlike the
canonical pathway, activation of the alternative
NF-κB pathway plays a major role in lymphoid
organogenesis and humoral immunity through
inducing B-cell maturation.49
The strong induction of immunity and
inflammatory mediators requires a robust regu-
lation of NF-κB activation. Evidence suggests
that a defect or breakdown of regulatory mecha-
nisms could lead to an exaggerated immune
response and inflammatory diseases.78 Therefore,
NF-κB is a logical target for the treatment of
inflammatory diseases.
INVOLVEMENT OF NF-κB IN 
RHEUMATOLOGICAL DISEASES
Initial evidence for an involvement of NF-κB in
RA originated from the detection of NF-κB
dimers in the nucleus of macrophages and
fibroblast-like synoviocytes of patients with
early and later stage RA.79–81 This observation
has also been made in other inflammatory 
diseases including sarcoidosis.82 Overexpression
of the endogenous NF-κB inhibitor IκBα in dis-
sociated synovial membrane cultures from RA
patients resulted in attenuation of proinflamma-
tory mediators such as TNF-α, IL-1β, IL-6, and
IL-8.83,84 In contrast, expression of the anti-
inflammatory IL-1Ra and IL-10 were unaffected,
further confirming a specific functional role of
NF-κB in driving inflammation in conditions
such as RA84 (Figure 47.2). Similarly, the overex-
pression of IκBα potently inhibited the expres-
sion of MMP-1, -3, and -13, while the expression
of their endogenous inhibitor, tissue inhibitor of
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Figure 47.2 NF-κB activation affects numerous aspects of the disease process of RA. NF-κB activation leads to the expression
of proinflammatory cytokines and chemokines as well as an enhancement of autoantigen presentation by DCs. This leads to
inflammation through further recruitment of T cells and macrophages. The joint destruction observed in RA is also driven by 
NF-κB activation, which induces the expression of MMPs as well as inhibiting the differentiation of chondrocytes and therefore
inhibiting repair of damaged cartilage. A third aspect of RA etiology is the formation of the pannus, which is driven by the induc-
tion of anti-apoptotic genes following NF-κB activation. NF-κB, nuclear factor-κB; RA, rheumatoid arthritis; DC, dendritic cell; MMP,
matrix metalloproteinase.
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metalloproteinase (TIMP)-1, was unaffected.84
Comparable results were obtained in synovial
cells obtained from osteoarthritis (OA) patients.85
Further support for an involvement of NF-κB in
the production of proinflammatory cytokines
and destructive enzymes, such as MMPs,
resulted from experiments using a dominant
negative version of the upstream activator of
NF-κB, IKK2 (IKK2dn). Overexpression of
IKK2dn resulted in a significant inhibition of 
IL-6 and IL-8, as well as MMP-1, -2, -3, and -13.
However, the expression of TNF-α was only
marginally affected.86 These results would sug-
gest different mechanisms of NF-κB-dependent
gene expression. Besides its function as an
inducer of proinflammatory cytokine expression,
NF-κB activation promotes another aspect of
inflammation by up-regulating cell surface mark-
ers important for antigen presentation by DCs
that lead to T-cell activation. This was shown to
depend on the activation of the canonical NF-κB
pathway, as the expression of IKK2dn inhibited
this process.87 Therefore, in the context of RA the
activation of NF-κB could lead to enhanced
autoantigen presentation by DCs (Figure 47.2).
Activation of NF-κB has an important role in
the generation and maturation of osteoclasts,
which are involved in bone resorption while at
the same time inhibiting differentiation of chon-
drocytes that are essential for repair of damaged
cartilage.88–91 This contributes to the bone destruc-
tion observed in RA. Chondrogenesis requires
activation of sex determining region Y-box
(Sox) 9, which is down-regulated by TNF-α and
IL-1 produced in response to NF-κB activation,
thus inhibiting cartilage formation.90 On the
other hand, NF-κB drives synovial proliferation
which leads to the formation of the pannus,
characteristic of RA (Figure 47.2). Synovial tissue
from patients with RA shows a significantly
higher expression of NF-κB1 in cells at the carti-
lage–pannus junction compared with other
areas.92
Animal models support this central role of
NF-κB. Mice deficient in c-Rel or NF-κB1 are
protected from the development of collagen-
induced arthritis (CIA).93 Similarly, transgenic
expression of the constitutively active form of
the inhibitor IκBα (N-terminally truncated from
amino acids 37 to 317) in the T-cell lineage
resulted in a decreased incidence and severity of
CIA.94 Furthermore, the use of decoy oligonu-
cleotides, which obstruct the binding of NF-κB
to the promoter of the target gene, prevented the
recurrence of streptococcal cell wall (SCW)-
induced arthritis as well as CIA, most probably
due to inhibition of TNF-α and IL-1. Inhibition
of IκBα degradation by the proteasome inhibitor
PS-341 after the onset of polyarthritis in rats also
showed beneficial effects as measured by the
Total Arthritis Index.95
The evidence presented here indicates an
involvement of NF-κB in numerous processes
leading to inflammatory diseases and driving their
progression, making NF-κB an attractive target for
the treatment of rheumatological diseases.
NON-SPECIFIC NF-κB INHIBITORS
A number of anti-inflammatory drugs already in
clinical use may produce some of their anti-
inflammatory action by inhibiting components
of the NF-κB signaling pathway. These include
non-steroidal anti-inflammatory drugs (NSAIDs),
sulfasalazine, glucocorticoids, thiazoledine-
diones (TZDs), triptolide, and thalidomide.
However, in the case of all these drugs it must be
emphasized that there is a multiplicity of targets
in addition to NF-κB.
Non-steroidal anti-inflammatory 
drugs and derivatives
The prototypical NSAID is aspirin (aminosali-
cylic acid), the molecular target of which is COX,
which leads to the formation of prostaglandins
that cause inflammation, swelling, pain, and
fever.96 At high doses salicylic acid can also
inhibit IKK2.97 However, this effect is only seen
at very high doses of salicylic acid, higher than
would routinely be used in the treatment of RA.
Sulfasalazine
Sulfasalazine was originally developed in 
the 1940s as a combined antimicrobial/
anti-inflammatory agent containing sulfapyri-
dine and aminosalicylic acid. It is an established
disease-modifying anti-rheumatoid drug
(DMARD) and is also extensively used in the
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management of ankylosing spondylitis.98 Its
anti-inflammatory effects appear to be mediated
through a number of mechanisms including
induction of autocrine adenosine signaling,99
COX inhibition, and inhibition of NF-κB 
signaling.100 Although the endpoint of inhibited
NF-κB signaling is reduced DNA binding (e.g. to
the IL-12 subunit gene, p40-κB site),100 it is not as
yet clear at which exact point(s) along the NF-κB
pathway sulfasalazine mediates its effects.
Glucocorticoids
Glucocorticoids remain among the most com-
monly used anti-inflammatory drugs. Their
numerous anti-inflammatory actions are medi-
ated by the glucocorticoid receptor (GR), a clas-
sical nuclear hormone receptor that dimerizes
upon ligand binding and acts as a ligand-
inducible transcription factor. The anti-inflam-
matory effects of glucocorticoids are mediated
by numerous mechanisms including inhibition
of the transcription factor activating protein-1
(AP-1), induction of lipocortin-1, and inhibition
of NF-κB signaling.101 Inhibition of NF-κB occurs
by at least two distinct mechanisms. Firstly, the
GR reportedly induces expression of the endoge-
nous NF-κB inhibitor IκBα,102,103 which forms a
negative feedback loop inhibiting nuclear
translocation of NF-κB. Secondly, the GR inhibits
expression of NF-κB target genes,104–106 which is
probably mediated by direct protein–protein
interaction between the GR and NF-κB.107
However, glucocorticoids can have significant side
effects including osteoporosis, type 2 diabetes,
hypertension, upper gastrointestinal tract ulcera-
tion, and increased susceptibility to infection.108
Therefore, the challenge is to design compounds
that show comparable anti-inflammatory efficacy
to glucocorticoids without major side effects. 
Other glucocorticoid derivatives with potent 
NF-κB-inhibiting effects but fewer side effects than
traditional glucocorticoids are under develop-
ment, such as the inhaled glucocorticoid derivative
ciclesonide, for the treatment of asthma.109
Thiazoledinediones
The TZDs are synthetic agonists at the peroxi-
some proliferator-activated receptor (PPAR)γ, a
nuclear receptor involved in the regulation of
metabolic function in tissues including liver,
muscle, and adipose.110 This class of drugs was
developed for the treatment of type 2 diabetes
mellitus and includes troglitazone (now with-
drawn due to several cases of liver failure),111
pioglitazone (Takeda),112 and rosiglitazone
(Glaxo Smith Kline).113 In addition to their anti-
diabetic actions, several lines of evidence also
suggest that these drugs have clinically useful
anti-inflammatory properties and these have
now been ascribed, at least in part, to inhibition
of NF-κB signaling. In animal models including
the carrageenin paw edema model of inflamma-
tion, the CIA model of arthritis,114 and the dextran
sodium sulfate (DSS) model of colitis, rosiglita-
zone reduces inflammation. While there are as yet
no clinical trials of TZDs in arthritis, in an open-
label trial of rosiglitazone in patients with ulcera-
tive colitis, 4 mg twice daily led to a reduction of
severity of the colitis.115 Although congestive car-
diac failure may be exacerbated in patients taking
TZDs116 and a small number also develop abnor-
mal liver function tests,117 these drugs are gener-
ally well tolerated and safe for the majority of
patients. Several mechanisms of inhibition of 
NF-κB by TZDs have been hypothesized,118–120
including reduction in RelA expression.118,119
Thalidomide
Thalidomide was originally developed in the
1950s as a treatment for hyperemesis gravi-
darum but was withdrawn in 1961 as its terato-
genic effects became apparent. However, it has
become recognized as an immunomodulatory
agent and has been successfully used in the
treatment of inflammatory conditions including
human immunodeficiency virus (HIV)-associated
aphthous ulceration and inflammatory bowel
disease.121 NF-κB inhibition has been suggested
as a mechanism of action of thalidomide in
inflammation.122,123 In particular, it appears that
thalidomide may inhibit the phosphorylation of
IκBα.124 There are as yet no reported trials 
of thalidomide in RA; however, clinical trials of
thalidomide in inflammatory bowel disease
indicate that not only is it a clinically efficacious
anti-inflammatory agent but it also has an
acceptable safety and side effect profile.125
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Triptolide
The anti-rheumatic properties of extracts of the
Chinese herbal remedy Tripterygium wilfordii
Hook F (thunder god vine, lei gong teng)126 have
been recognized for many years. The active
ingredient has been identified as a diterpene
triepoxide, triptolide (Table 47.1).127 In vitro trip-
tolide inhibits TNF-α- and IL-1β-induced tran-
scription of inflammatory cytokines. Inhibition
occurs after NF-κB DNA-binding, by either
interfering with post-transcriptional modifica-
tions of RelA or interfering with the recruitment
of transcription cofactors.128 Beside the inhibi-
tion of NF-κB, triptolide was also shown to
inhibit the transcription factors, nuclear factor
activating T cells (NF-AT) and AP-1 at the level
of nuclear translocation.128–130 A recent double-
blind placebo-controlled trial of an ethanol/ethyl
acetate extract of Tripterygium wilfordii Hook F in
patients with long-standing RA that was resist-
ant to conventional therapy showed that most
patients achieved an American College of
Rheumatalogists score (ACR) 20% response and
significant improvements in objective markers
of inflammation. No serious side effects were
observed.131
TARGETED THERAPIES
Although a number of anti-inflammatory agents
currently in clinical use may act in part by inhi-
bition of NF-κB, they also have other targets and
are all limited by significant side effects. It is
therefore desirable that drugs with more specific
mechanisms of action are developed providing a
decreased risk of undesirable side effects. In this
section we will therefore review some of the
compounds currently under development that
are designed to inhibit specific components of
the NF-κB signaling pathways.
IKK2 inhibitors
Numerous elements in the activation pathway of
NF-κB are currently under investigation for their
feasibility as therapeutic targets. Inhibitors for the
kinases IKK1 and IKK2 would provide a specific
inhibition of NF-κB activation while leaving other
signaling pathways intact. Therefore, intensive
effort has been made in the development of
these inhibitors (reviewed by Karin et al.).132
Although IKK1 would be an attractive target for
the treatment of autoimmune diseases, no potent
and specific inhibitor has been described so far.
However, several IKK2 inhibitors are in their
preclinical developmental stages and showed an
effect in models of arthritis.
SPC-839 is a quinazoline analog and an ATP-
competitive inhibitor of IKK2.132 It inhibits IKK2
with an IC50 of 62 nM compared with inhibition
of IKK1 with an IC50 of 13 µM.132 Treatment of
rat adjuvant arthritis with SPC-839 led to a
reduction in paw swelling and radiographic
damage.133 An inhibition of NF-κB activation in
LPS-challenged rats was already detectable at a
dose of 10 mg/kg.132 Another well-studied IKK2
inhibitor is BMS-345541. Tested in the human
monocytic cell line THP-1, this compound
blocked the release of LPS-induced TNF-α, 
IL-1β, IL-8, and IL-6 with an IC50 in a range
between 1 and 5 µM.134 More recently, it was
shown that BMS-345541 successfully blocks the
release of MMP-9 in RAW 264.7 cells in response
to the TLR9 ligand CpG DNA.135 Furthermore,
CIA mice treated with BMS-345541 showed signif-
icantly reduced joint inflammation and destruc-
tion.136 However, this effect was only observed if
BMS-345541 was administered prophylactically
before the induction of disease.
A more recently described IKK2 inhibitor is
ML120B, with an IC50 of 60 nM, as evaluated in
an in vitro kinase assay.137 ML120B inhibited the
induction of RANTES (regulated on activation,
normal T-cell expressed and secreted) in TNF-α-
or IL-1β-stimulated human fibroblast-like 
synoviocytes.137 Moreover, the expression of
TNF-α, IL-1β, and IL-6 was also inhibited in
LPS- or peptidoglycan (PGN)-stimulated human
mast cells as well as the expression of MMP-1
and MMP-13 in human chondrocytes stimulated
with IL-1.137 These results suggest that ML120B
is a potent inhibitor of NF-κB in RA-relevant cell
systems. Furthermore, ML120B was shown to
block the differentiation and maturation of T
cells and B cells and to inhibit the expression of
numerous proinflammatory mediators such as
IL-6, IL-8, and RANTES in human airway
smooth muscle cells.138 The inhibition of these
cytokines and chemokines using ML120B was
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Table 47.1 NF-κB targeted anti-inflammatory drugs in current clinical use and undergoing development
Drug Structure Target/mode of action Trials Refs
Triptolide p65 post-transcriptional RA, phase II 127–130,163
modifications
NF-κB co-activator 
recruitment
Sulfasalazine NF-κB DNA binding RA, RCTs 100,164
NFkappaB decoy 5′-CCTTGAAGGGATTT NF-κB DNA binding Phase I in HIV  143,165,
oligo CCCTCC-3′ skin disease, 166,167
(phosphorothioate) phase II in 
atopic 
dermatitis
Steroids, e.g.  Trans-repression of NF-κB RA, RCTs 106,107,168
prednisolone
PPARγ agonists, Trans-repression of DM, RCTs 114
e.g. rosiglitazone NF-κB
SPC-839 IKK2 inhibitor No clinical trial 132,133
data available
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either as effective as or more effective than 
dexamethasone.138
Proteasome inhibitors
Following the phosphorylation and ubiquitination
of IκBα, it is degraded by the proteasome and
releases the NF-κB dimer to translocate to the
nucleus.139 Therefore, targeting the proteasome
could prevent the nuclear translocation of 
NF-κB. A proteasome inhibitor already approved
by the US Food and Drug Administration (FDA)
for the treatment of multiple myeloma is borte-
zomib (Millenium).140 Another proteasome
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Table 47.1 NF-κB targeted anti-inflammatory drugs in current clinical use and undergoing 
development—cont’d
Drug Structure Target/mode of action Trials Refs
BMS-345541 IKK2 inhibitor No clinical trial 134–136,140
data available
ML120B IKK2 inhibitor No clinical trial 138,137
data available
Bortezomib Proteasome inhibitor Approved by 142,141
FDA for 
multiple 
myeloma
NBD C-terminus of IKK1 and IKK2 NF-κB dimerization No clinical 89,152–154
trial data 
available
SN50 NLD of NF-kappaB1 Nuclear localization of No clinical 144–149
NF-kappaB trial data 
available
PTP-p65-P1 Amino acids 271–282 of RelA Transactivation of RelA No clinical 150
trial data 
available
Thalidomide IKK IBD, juvenile 124,169–171
RA, and 
ankylosing 
spondylitis
RCT, randomized controlled trials; IBD, inflammatory bowel disease; CIA, collagen-induced arthritis; IKK2, inhibitor of kappa kinase 2; 
FDA, Federal Drug Authority; NBD, NEMO binding domain; T2DM, type 2 diabetes mellitus; NLD, nuclear localization domain.
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inhibitor currently in clinical trials for multiple
myeloma is PR171 (Proteolix). However,
because the proteasome is involved in a great
variety of regulatory processes, the effects gener-
ated are non-specific. Adverse effects observed
after bortezomib treatment include infections of
the upper respiratory tract, lymphopenia, and
thrombocytopenia.141,142 Because the treatment
of chronic inflammatory diseases such as RA
makes it necessary to administer therapies over
a long period of time, such side effects are likely
to be unacceptable.
NF-κB decoy oligos
Since NF-κB functions by binding specific DNA
sequences in the promoters of target genes,
novel NF-κB targeted anti-inflammatory drugs
utilizing the DNA-binding properties of the 
NF-κB heterodimers may provide future therapies.
One approach to achieve this is the therapeutic
use of phosphothiorate deoxyribonucleic acid
oligomers. Several in vitro experimental models
of this approach have been reported, such as the
use of folate-linked lipid-based nanoparticles to
transfect macrophages with NF-κB decoy
oligos.143 In the RAW264.7 murine macrophage
cell line, these were found to potently inhibit the
translocation of NF-κB from cytoplasm to the
nucleus, following LPS stimulation.143 Such
agents are already in clinical trials for atopic der-
matitis (NIH Clinical Trials Identifier NCT
00125333). These trials are ongoing and no
results are available yet. If it were possible to
safely and effectively deliver such decoy oligos
to the inflamed joint then these would also form
attractive treatments for RA.
NF-κB inhibitory peptides
An alternative approach to inhibit NF-κB activa-
tion is to block the interaction of molecules
involved in NF-κB signaling using short peptide
sequences. The first member of this class of
inhibitors described was SN50, which contained
the nuclear localization domain sequence of 
NF-κB1.144 SN50 was shown to block NF-κB in
numerous cell lines in response to the HIV enve-
lope protein glycoprotein (gp) 120 and staphylo-
coccal enterotoxin B.145,146 Furthermore, SN50
was reported to protect rats from acute pancre-
atitis as well as showing efficacy in the treatment
of corneal alkali burns in mice.147,148 However,
SN50 also affects the nuclear translocation of
STATs (signal transducer and activator of tran-
scription), AP-1, and NF-AT.149 This proof of
principle of inhibiting NF-κB through blocking
specific interaction of signaling components led
to the development of several other inhibitory
peptides. In contrast to SN50, the PTD-p65-P1
peptide was reported to specifically inhibit 
TNF-α-induced NF-κB activation without affect-
ing other transcription factors.150 PTD-p65-P1
corresponds to the amino acid residues 271–282
of RelA. It was reported to block the phosphory-
lation of serines 276, 529, and 536 of RelA,
thereby inhibiting transactivation of RelA with-
out affecting IκBα degradation.150 However, no
in vivo studies confirming the inhibitory effect of
PTD-p65-P1 are available so far. The cell-perme-
able peptide NBD consists of six amino acids
(Leu, Asp, Trp, Ser, Trp, Leu), which correspond
to the C-terminus of IKK1 as well as IKK2 that is
responsible for the association with NEMO.151
Numerous studies have investigated the effect
of NBD administration on NF-κB activation in
models of inflammatory arthritis. The adminis-
tration of NBD to mice before the onset of inflam-
matory arthritis inhibited cytokine-induced
osteoclasts formation and thereby inhibited bone
erosion in the joints of those mice.152 Similarly,
the administration of NBD into mice at the onset
of CIA reduced the severity of the inflammatory
arthritis by impairing the production of TNF-α
and IL-1 and thereby reducing joint swelling and
the destruction of bone and cartilage.89 Also,
NBD given at the onset of carrageenin-induced
paw edema led to a reduction in edema forma-
tion and cellular infiltration into the paws of the
mice.153 In all of the animal studies described
above NBD was administered before or at the
onset of inflammation, therefore, it is unclear if
NBD exhibits an effect on an already established
inflammatory disease. However, initial results
obtained from in vitro studies using fibroblast-
like synoviocytes and macrophages from RA
patients also suggest a positive effect of NBD on
RA treatment in humans.154 When given to ex vivo
cultured RA synovial tissue or RA fibroblast-
like synoviocytes, it inhibited the spontaneous
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release of IL-1β, TNF-α, and IL-6.154 Moreover,
NBD inhibited IL-1β-induced expression of TNF-α
in human macrophages.154 These results indicate
that NBD might be a promising future therapeutic
in rheumatological diseases, which is able to
inhibit NF-κB specifically. However, the use of
peptide drugs is limited by the requirement for a
parenteral route of administration. The ultimate
goal would therefore be to identify pep-
tidometic, orally bioavailable, small molecular
weight compounds to replace such peptides.
POTENTIAL FUTURE TARGETS
In addition to the targets describe above, there
remain a number of targets in the NF-κB signaling
pathway that have so far not been exploited for
development of targeted anti-inflammatory
drugs. In this section, the potential for develop-
ing targeted therapies to inhibit some of these
will be discussed.
Ubiquitin ligase inhibition
Following IκBα phosphorylation by IKKs, E3
ubiquitin ligase targets IκBα for proteasomal
degradation by addition of poly-ubiquitin side
chains. Inhibition of the E3 ligase is therefore 
a potential mechanism for modulating NF-κB
signaling. Such an approach is already being uti-
lized in the oncology field155 by means of high
throughput screening to identify inhibitors of
anaphase promoting complex (APC) E3 ligase.
However, E3 ubiquitin ligases are involved in
numerous cellular processes, therefore, their
inhibition might lead to a broad range of adverse
effects as is observed with proteasome
inhibitors.
Phosphorylation of RelA
Post-translational covalent modification of Rel
family members appears to be a key regulatory
step in NF-κB signaling.46,156 Thus phosphoryla-
tion of serine residues in RelA represents poten-
tial targets. Since kinase inhibition is a well
established route of drug development, such an
approach should be readily amenable to a high
throughput small molecule screening approach
similar to that used in the identification of 
IKK inhibitors.157 Kinases reported to be
involved in serine phosphorylation of RelA
include PKA, MSK-1, PKCζ, RSK-1, GSK-3β,
PI3K, IKK1, IKK2, TBK1,51 and Bruton’s tyrosine
kinase (Btk).156,158 As some of these kinases
appear to be restricted to particular stimuli, their
inhibition raises the prospect of highly specific
future therapies. Moreover, this approach would
potentially have the advantage of inhibiting the
amplification of the stimulated NF-κB signal
while leaving its basal activity unaffected.
Inhibition of translocation
One of the key steps in NF-κB activation is
nuclear translocation. Thus, nuclear–cytoplasmic
shuttling presents an attractive potential target
for inhibition of NF-κB-induced inflammation
and it can be envisaged that drugs to inhibit
transport through the nuclear pore complex
(NPC)159 could be developed. Some interest has
already been shown in this target for drug devel-
opment by researchers in other areas such as
HIV.160,161
Gene therapy
An approach to circumvent potential systemic
toxicity of NF-κB targeted therapies for arthritis
is to administer therapy selectively to the
affected joints by means of gene therapy. A study
of the use of recombinant adeno-associated virus
(rAAV) in the rat adjuvant arthritis model162
showed that a single intra-articular injection of
rAAV encoding IKK2dn produced significant
reductions in paw swelling and production of
IL-6 and TNF-α in the treated joint. Such work
raises the possibility of NF-κB targeted gene
therapy becoming a viable option for the treat-
ment of arthritis in humans. Indeed, a phase II
gene therapy trial sponsored by the Targeted
Genetics Coporation, USA is already recruiting
(clinical trials identifier, NCT00126724) in which
patients with inflammatory arthritis (including
patients who are already on anti-TNF therapy 
or on classical DMARDS) receive repeat 
intra-articular injections of an adeno-associated
vector designed to express human TNF receptor
(TNFR)-immunoglobulin (IgG1) Fc fusion 
protein.
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CONCLUSION
The central role of NF-κB in inflammation and
immunity makes it a legitimate target for the
treatment of inflammatory diseases. In vitro as
well as in vivo studies confirm the central
involvement of NF-κB in rheumatological 
diseases including RA and OA. NF-κB inhibition
causes significant reduction in the disease activity
of CIA and SCW models of RA and the improve-
ment observed in these models of RA appears to
be due to inhibition of NF-κB-dependent expres-
sion of proinflammatory mediators as well as
enzymes including MMPs that are responsible
for joint destruction.
Considerable effort has been made to develop
therapeutically useful inhibitors of NF-κB.
However, the treatment of chronic inflammation
requires a therapy to be administered over a long
period of time, making significant side effects –
as is observed, for example, with proteasome
inhibitors – unacceptable.
The NF-κB pathway shows a high degree of
convergence, whereby signals from a wide range
of receptors are processed through a central sig-
nalling pathway comprising the IKK/IκB/NF-κB
cascade (Figure 47.3). Subsequently, NF-κB 
signaling diverges and results in numerous 
cellular responses due to the induction of a great
variety of genes (Figure 47.3). However, more
recent work is beginning to unveil the complexity
of the NF-κB system and its regulation. For exam-
ple, the discovery of the role of NF-κB transactiva-
tion in ‘fine tuning’ gene induction adds another
layer of complexity to this signaling system.51
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Receptor/receptor proximal
Canonical/alternative
pathway
- IKK inhibitors
- Ubiquitination inhibitors
- Proteasome inhibitors
- Blocking peptides
- IL-1Ra
- Tyrosine kinase
  inhibitors
Receptor
IKK-complex
IκB
NF-κB
Nucleus
- Anti-TNF
- siRNA
NF-κB output
Membrane
Figure 47.3 Possible approaches to inhibit NF-κB signaling. Numerous receptors initiate signaling via the NF-κB pathway.
Signaling then converges through either the canonical or non-canonical pathway before diverging through induction of a wide
range of genes. Examples of classes of compounds that inhibit signaling upstream of the convergence of this pathway
(Receptor/receptor proximal in the diagram) include receptor antagonists (e.g. IL1-Ra). Examples of inhibitors that act on the
canonical and alternative pathways include IKK inhibitors, ubiquitination inhibitors, proteasome inhibitors, and blocking 
peptides. Examples of inhibitors acting after divergence of the pathway (NF-κB output in the diagram) include anti-TNF agents
and siRNA-based therapies. NF-κB, nuclear factor-κB; IL-1Ra, interleukin-1 receptor antagonist; TNF, tumor necrosis factor;
siRNA, small interfering RNA.
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Future therapies based on inhibiting NF-κB
signaling could be divided into three possible
categories (Figure 47.3). Inhibition of the recep-
tor or receptor proximal signal transducers
would be specific for one stimulus; however, it
might affect, several signaling pathways
induced by this receptor. This would be a prom-
ising therapy if the stimulus, responsible for the
condition which is treated, is already identified.
On the other hand, while inhibiting central com-
ponents of the NF-κB pathway (e.g. IKK complex,
IκBα degradation) would exert only limited
effects on other signaling pathways, it may be
expected to produce a more global inhibition of
NF-κB and therefore result in significant adverse
effects. A third possibility would be the target-
ing of specific NF-κB outputs. Anti-TNF therapy
is one such example; in the future siRNA-based
therapies may provide another approach.
However, in addition to mediating pathologi-
cal inflammation, NF-κB is also necessary for
host defense and thus global inhibition of NF-κB
would lead to an unacceptable range of side
effects including serious infections. In order to
utilize the therapeutic potential of NF-κB inhibi-
tion, it will be necessary to further study the 
regulation of NF-κB and its involvement in 
specific conditions including RA and OA. This
knowledge will facilitate future development of
compounds that are more precisely targeted,
thereby giving greater therapeutic efficacy with
fewer side effects.
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